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ABSTRACT 
The work presented herein constitutes the effort of one graduate student to mimic 
the efforts of a small biotech company. To this end, success was had on multiple fronts and 
the author is excited to showcase the data and results obtained on two different projects. 
Both projects focus on different targets of potential male contraceptives: spermiogenesis 
and sperm motility. In chapter one a very brief summary and introduction to the field of 
contraceptive research is presented, serving as an hors d’oeuvre to the main course of 
chapters two through four. 
Chapters two and three detail the efforts towards developing blockers of an 
intriguing calcium ion channel called CatSper. The proper function of this channel is 
required for fertilization, as knockout mice are completely infertile with no deleterious 
phenotypes observed. Inhibitors of this channel are well-suited to applications in non-
hormonal male contraception and two approaches towards developing blockers of this 
channel are described in chapters two and three. 
Chapter two discusses the work done towards converting the endogenous activator 
of the channel, progesterone, into a blocker via systematic modifications to the steroid 
scaffold This approach yielded three compounds able to block the physiologically relevant 
openers of the channel and revealed discrepancies between steroidal blockers and classic 
t-type calcium channel blockers. The discovery, efficacy and discrepancies of and between 
these compounds is discussed at length. 
Chapter three details the hit-to-lead development of two new scaffolds of CatSper 
blockers found via an HTS campaign which finished in 2012. Matrix chemistry was 
 iv 
utilized to generate libraries of focused compounds. The activity of these compounds in a 
developed influx assay could lead to further analog generation and eventually two 
submicromolar blockers of the channel were discovered and characterized. Additionally, 
the first steps of a fragment-inspired approach towards the development of a second 
scaffold is described in the latter half of chapter three. 
Finally, chapter four discusses the efforts of a separate project, focusing on a class 
of molecules termed iminosugars, specifically aminocyclopentitols. These compounds 
strongly modulate glycosphingolipid processing, resulting in infertility from improper 
spermatogenesis. A series of compounds were synthesized and showed potent, and more 
importantly, selective inhibition of the enzyme responsible for degradation of these lipids 
(GBA2). Iminosugars, as a whole, are hindered by species-specific efficacy observations 
and the compounds synthesized and evaluated as part of Chapter 4 could help to illuminate 
these discrepancies in the future, should the desire arise to explore these observations 
further.  
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 Chapter One: Current Scope of Discovery in Male 
Contraception 
Section 1.1 Impact and General Strategies of Research 
The nutritional, economic and social consequences of unwanted pregnancies are 
wide-ranging and a great burden on both families and governments. Every year, worldwide 
there are more than 500 000 deaths from pregnancy-related complications and this figure 
does not include morbidities suffered by women from complications during pregnancy and 
childbirth.2 Additionally, maternal deaths and morbidities associated with pregnancies and 
child birth are as high as 1324 per 100 000 births.3 For these and many other reasons, 
further control over fertility is needed via novel, safe and effect contraceptive methods. 
According to a 2008 report in Contraception, just over 50% of pregnancies in the 
US are unintended.4 This number is decreasing slowly over time as cultural norms change 
but still remains around 50%.5 Given that many women cannot make use of hormonal 
therapies or IUDs, they must instead rely on their partners for contraception, to which the 
only reliable methods are vasectomy or condoms, though the efficacy of these methods is 
questioned.6 To this end, the need for a greater range of male-specific contraceptive options 
Table 1.1. Willingness of men from surveyed countries to utilize a male contraceptive 
If available would you be willing 
to use a new male fertility 
control? 
GER SWE USA ARG BRA MEX INDON 
Willing 69.0 58.1 49.3 44.4 62.7 65.4 28.5 
Uncertain 24.4 17.4 38.4 13.2 12.8 8.9 37.3 
Disapproving 6.6 24.4 12.4 42.3 24.5 25.7 34.2 
GER = Germany, SWE = Sweden, USA = United States of America, ARG = Argentina, 
BRA = Brazil, MEX = Mexico and INDON = Indonesia. Data is adapted from reference.1 
1 
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is great. The discovery of new contraceptive methods for men has been hindered by cultural 
stigmas and social dynamics.7, 8 Fortunately, it appears this outlook on male fertility control 
is finally changing with recent polls and press showing an increasing interest from men 
with respect to male-specific contraceptive methods.9 An acceptability study of over 9000 
men from 9 countries on 4 continents showed that men from all major religions and cultures 
indicated a willingness to use a male contraceptive if proven safe and reversible. 
From a drug development standpoint, the development of an effective, safe and 
reversible male contraceptive is incredibly challenging. Pregnancy, as a medical condition, 
is limited to the female half of any partnership. Societal and moral obligations aside, the 
man in any relationship, however casual or committed, suffers no physical health risks 
from pregnancy. Mental health of both partners in an unwanted pregnancy is obviously at 
risk, however it is the female of a couple who carries the child and suffers the physical 
ailments associated with pregnancy. Because of this, a contraceptive intended for men must 
be exquisitely safe and reversible, unlike in other morbidities in which the standards for 
safety can be reduced, given the state of the physical risk to the patient if left untreated. 
The “patients” taking a male contraceptive therapy are healthy individuals and the course 
of treatment could be many years, rather than months.10 
In general, potential male contraceptives target either spermatogenesis or the 
function of mature spermatozoa.11 Contraceptives affecting either of these categories exist 
as hormonal or non-hormonal therapies. Hormonal therapies were first explored in men, 
given their success in women, however these methods are difficult to achieve success, 
given the complicated hormonal regulation and serious side effects of testosterone 
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imbalance.12 As such, non-hormonal therapies are highly sought after, though it should be 
noted that recent successes of a synthetic androgen have garnered much attention in the 
press.13 This synthetic androgen prodrug successfully reduces levels of testosterone within 
the testes to levels insufficient to support production of sperm, while the concentrations 
circulating in the rest of the body remain nominal, circumventing one of the greatest pitfalls 
of hormonal treatments as discussed below. 
Section 1.2 Hormonal Therapies as Male Contraceptives 
Hormonal therapies as potential male contraceptives have been the first and longest 
studied, given their success in women.14 The studies surrounding hormonal therapies have 
centered on the inhibition of gonadotropin production and the resulting decrease in the 
production of testicular testosterone. Testicular testosterone concentrations are typically 
40- to 100-fold higher than serum levels.15 This high concentration is needed to support 
spermatogenesis and therefore therapies that reduce testicular testosterone levels are able 
to decrease sperm production. This has been proven to be the case in several independent 
studies.16, 17 The problems surrounding these therapies has been an inability to limit the 
reduction of serum testosterone concentrations, thus avoiding several side effects.18 
In all studies except the most recent, serum testosterone levels drop sufficiently low 
to cause a negative feedback to the hypothalamus and pituitary, shutting of secretion of 
luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Diminished levels of 
these hormones reduce testosterone production by the Leydig cells, however concomitant 
drop in serum testosterone levels causes the frequently observed side-effects such as loss 
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of libido and muscle mass.19 If used, these therapies would require androgen replacement 
therapy to restore these functions. 
Progestins have long been used in female contraceptives and are available in a 
variety of formulations, making them great candidates for potential use in men.20, 21 This 
class of hormones has been shown to reduce gonadotropin levels, and by extension, greatly 
diminish sperm counts.22 Their efficacy in vivo, however, has been limited and the focus 
of the field has turned, instead, to androgen-mediated therapies.23 
The parent androgen testosterone is, itself, not available in an oral dosage form and 
hepatotoxicity has been observed in orally bioavailable derivatives.24 Additionally, 
testosterone, as a drug, displays severe side effects given its inability to selectively 
modulate its androgenic (sexual) or anabolic (muscle building) effects.25 As such, synthetic 
derivatives of testosterone able to selectively modulate these functions of testosterone hold 
great promise. These selective androgen receptor modulators, or SARMs, have been the 
pursuit of researchers for over a decade and several synthetic androgens acting as SARMs 
are currently being tested in human patients, showing promise.26, 27 
Figure 1.1 shows the structures of two of the most promising synthetic androgens. 
11-beta-Methylnortestosterone (11β–MNT) and its undecanoate prodrug (11β–MNTD) 
Figure 1.1. Structures of Testosterone and Synthetic Androgens Being Pursued as 
Hormonal Male Contraceptives. 
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have shown efficacy in rabbit models and are currently being tested in healthy human 
males, passing initial safety studies.28 Another synthetic androgen, 7α-
methylnortestosterone (MENT), shows promise since it cannot undergo 5α-reduction and, 
as such, is less likely to show the same side effects observed with testosterone.29 However, 
7α-MENT shows poor bioavailability and as such needs to be delivered continuously via 
an implant.30 A similar application is employed in androgen replacement therapies, and 
therefore an implant requirement is not problematic. The use of implants is also frequently 
used in female contraceptives for continuous release. 
All androgens discussed thus far act by inhibiting sperm production. While 
promising as a means to male contraception, is not without its drawbacks. One drawback 
with respect to these therapies is the time required to sufficiently reduce sperm 
population.31 It takes 12 to 16 weeks of treatment to reduce the sperm count to levels 
deemed contraceptive.32 This is a nontrivial amount of time for a therapy to take effect. 
Furthermore, patient compliance would need to be pristine, as several missed 
administrations could trigger sperm production in Leydig cells, undoing weeks of 
treatment. This of course assumes oral dosing instead of gel patches or subcutaneous 
release mechanisms, which apply a constant dose of would-be contraceptive. 
Another drawback to this approach is the potential need for regular screening to 
ensure sperm production is indeed sustained at a low level. Kits exist for at home use that 
could alleviate this pitfall, however it is nonetheless an extant obstacle. These drawbacks 
assume that the side effects observed with androgen treatment in the past are indeed just 
that: in the past. 
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But the largest drawback for testosterone-modulating contraceptives is that of the 
side effects observed in men dosed with the hormone. The anabolic effects of testosterone 
dosing come first to mind in public – changes in behavior and irritable mood dominate the 
press.33 However even more serious is the uncertainties surrounding the effects of 
testosterone therapy on cardiovascular health of men. One study found that testosterone 
therapy can increase the risk of heath attack, while another showed that it may, in fact, 
lower the risk of cardiovascular disease.34 While the cardiovascular side effects are serious 
and warrant further investigation, other side effects remain including sleep apnea, enlarged 
prostrate (noncancerous) and blood clotting.35 For previously mentioned reasoned, these 
side effects need to be nearly nonexistent for a male contraceptive to be approved by the 
FDA. As such, the field has largely turned to non-hormonal contraceptive options. 
Section 1.3 Nonhormonal Therapies as Male Contraceptives 
Given the challenges surrounding hormonal therapies for male contraception, 
nonhormonal targets have been the subject of intense research in the community. 
Nonhormonal targets include those effecting sperm production, maturation and or 
function.11, 36 While a plethora of targets exist and show promising initial results, the 
challenge remains to ensure the testes-specificity of these compounds. Additionally, 
penetration of the blood-testes barrier presents another hurdle.37 Nonhormonal targets 
include proteins ranging from kinases to ion channels to nuclear receptors. The diversity 
of this class of potential therapies has been the source of extensive and multiple reviews 
and will not be discussed in detail in this thesis, however a brief overview follows.38-40 
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Spermatogenesis is a promising target for contraception, both by hormonal and 
nonhormonal agents. Inhibitors of proteins involved in meiosis prevent spermatogenesis 
by reducing the number of germ cells present, as well as their maturation. Kinases are 
involved in the meiotic process and cyclin-dependent kinase 2 (CDK2) knockout male and 
female mice are infertile.41 
Targeting retinoic acid receptor alpha (RARα) has demonstrated efficacy when 
studied with antagonists thats inhibit spermatogenesis, similar to the aforementioned 
kinases.42 Difficulties in the metabolism of these compounds have limited their 
development, though work is ongoing in several labs.43 At the later stages of 
spermatogenesis, the germ cell must interact with the surrounding Sertoli cells as they 
finish maturation.44, 45 Several classes of compounds have been developed to inhibit this 
Figure 1.2. Structure and Targets for Studied Nonhormonal Contraceptives Affecting 
both Spermatogenesis and Sperm Function. 
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interaction, leading to infertility. Indazole carboxylic acids such as lonidamine,46 adjudin44 
and gamendazole47 (Figure 1.2) disrupt Sertoli cell-germ cell interactions. 
The second chapter of this thesis pertains to a class of compounds referred to as 
iminosugars and their ability to inhibit spermatogenesis by modulating glycoprocessing. 
Specifically, the formation and degradation of glucosylceramide.48 
This class of compounds reversibly induce infertility in C57BL/6 mice but not in 
other mice species, rabbits and humans.49 Further research is required to better understand 
the physiologically relevant targets that these compounds are inhibiting. 
The testes-specific bromodomains (BRDT), an epigenetic regulator, is another 
target regulating spermatogenesis and is the subject of intense study, though selectivity 
over analogous, ubiquitous domains will need to be achieved, given the side effects 
observed with pan bromodomain inhibitors.50-53 
Affecting sperm function once matured is one of the most prevailing strategies 
when for non-hormonal male contraception. Most of the targets currently explored have 
been validated by knockout studies in which the knockout mice showed little effect beyond 
the desired infertility.54 Within this class of potential drug targets, ion channels are 
prominent and include channels specific for calcium55 and potassium56, and as well as 
channels responsible for the regulation of pH, volume and osmolarity (aquaporins).57-60 
Many targets are available for study within this class and noteworthy strides have been 
made in developing inhibitors for the testis-specific Na,K-α4 ATPase exchanger.61 
Analogs of the cardenolide ouabain have proven to be potent and selective inhibitors of the 
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testes-specific isoform α4 with in vivo activity that significantly reduces sperm motility, 
including hyperactivated motility (HAM).62, 63 
In addition to small molecule inhibition of targets responsible for sperm maturation 
and function, effort has been put towards the development of a contraceptive vaccine. 
Immunocontraception involves the use of antigens to target different aspects of gamete 
production.38 Vaccines targeting luteinizing hormone releasing hormone (LHRH) have 
been tested and reduce testosterone production.64 It remains to be seen if these vaccines 
would circumvent the issues observed with hormonal therapies. These therapies would not 
be orally bioavailable and could have difficulty penetrating the blood-testes barrier. 
Nonetheless, efficacy has been shown in male monkeys after injections with human 
recombinant epididymal protease inhibitor (EPPIN), a serine protease inhibitor expressed 
in the testis. Contraceptive vaccines remain an ongoing area of research for several research 
groups.65, 66 
Section 1.4 Summary and Outlook 
Given recent results from the safety studies for 11β-MNTDC male contraception 
may be available to men seeking fertility control in the not-so-distant future. Further 
development of these promising compounds, and indeed, any compound showing efficacy, 
be it hormonal or nonhormonal, will require the involvement of a pharmaceutical 
company.1 This involvement is currently lacking but once a contraceptive has completed 
the rigid clinical trials required of these potential therapies, involvement of a company is 
more likely. Men all over the world, from all walks of life are seeking to carry their weight 
in preventing unplanned pregnancies. The development of a safe, reversible male 
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contraceptive would be a boon to men and women everywhere and this thesis details efforts 
on two fronts: aminocyclopentitols as inhibitors of spermatogenesis and CatSper inhibitors 
which significantly reduce sperm motility. 
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Chapter 2 Discovery and Characterization of Steroidal 
Blockers of the CatSper Complex 
Section 2.1 CatSper Form and Function 
Characterized for the first time in 2001, the cation channel of sperm (CatSper) is 
the foremost entry point of calcium into mature spermatozoa.67, 68 CatSper is a tetrameric, 
strongly voltage-gated ion channel consisting of at least 4 subunits: alpha, beta, delta, 
gamma and zeta and epsilon, though the latter two have only been shown to exist in mice, 
currently.69-72 CatSper is exquisitely testes-specific, demonstrated by Northern blot 
analysis in which it was shown that target mRNA was only present in tissue isolated from 
the testes and nowhere else in the body.68 
Given this specificity, CatSper was immediately implicated in fertility. Mating 
studies with catsper3-/- mice showed that male mice bearing this knockout were completely 
infertile with no other observable phenotypes. Furthermore, it was shown that if any of the 
complex components were knocked out, mice exhibited complete infertility. It should be 
noted that female mice bearing this knockout were completely homologous to their 
wildtype counterparts.55 
The observed infertility was a result of the inability of sperm from knockout mice 
to achieve hyperactivated motility (HAM). HAM is crucial to successful union between 
the sperm and egg and is also required for mature spermatozoa to traverse the upper 
reproductive tract, in which the mucus is quite thick.73 Frequently sperm become 
ensconced in the vascular folds of the endometrium and must release themselves when the 
time comes for the final step of fertilization.74 The egg itself is coated with a thick 
polysaccharide coat known as the zona pellucida.75 This final barrier cannot be penetrated 
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without first achieving HAM.76 As such, CatSper function is vital to successful fertilization 
and is therefore considered to be a promising non-hormonal contraceptive target. 
Endogenously, calcium influx via CatSper is greatly potentiated by the sex 
hormone progesterone and prostaglandin E1 (PGE1, Figure 2.2).77, 78 A large bolus of 
progesterone is released into the upper reproductive tract from the cumulus cells 
surrounding the ovum upon release of an egg.79 This increase in progesterone concentration 
activates CatSper and causes the sperm to release from the endometrium wall and proceed 
towards the released egg. In certain infertility cases, sperm from otherwise healthy men 
failed to respond to a progesterone stimulus.80, 81 Besides giving further credence to 
Figure 2.1. The CatSper Complex is Required for Proper Fertilization. (A) Confocal 
microscopy showing localization of CatSper antibodies to the principal piece of the 
sperm tail. (B) Electrophysiology experiments demonstrating the need for each α-
subunit of the CatSper complex for proper function. (C) Results of mating studies 
between wildtype female and the respective knockout male mice. Images from 54.  
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CatSper as a promising contraceptive target, this observation also directly validated the 
hypothesis that compounds able to prevent the progesterone-induced influx of Ca2+ from 
CatSper could serve as contraceptives. 
While the actions of progesterone on sperm have been known for many decades, it 
is only recently that a detailed characterization was achieved. It was shown in the late 80s 
that progesterone induced calcium influx in sperm, which elicited the aforementioned 
HAM.77 In 2011, electrophysiology experiments by two independent groups demonstrated 
that progesterone activates CatSper.82, 83 And, in 2016, it was reported that rather than 
binding to the CatSper complex, progesterone instead binds to a previously orphaned 
hydrolase called α/β-hydrolase domain containing protein 2 (ABHD2).84 By binding to and 
activating this hydrolase, 2-arachidonoyl glycerol (2-AG) concentrations within the sperm 
plasma membrane drop. Lowering 2-AG concentrations reduces the voltage threshold at 
which CatSper activation occurs, potentiating the inward flux observed in 
electrophysiology experiments.84 What remains to be determined is whether or not the 
other activator of CatSper, PGE1 also activates CatSper via the same mechanism. It has 
been proposed that this is not the case, though the work presented herein will stand in 
contrast to the prevailing views. 
Figure. 2.2. Structures of Progesterone and Prostaglandin E1 (PGE1). 
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CatSper, a validated target for nonhormonal contraception in men, is the subject of 
vigorous study in the field. A compound able to selectively block CatSper activation would 
be an excellent, novel contraceptive method for men. To this end we endeavored to 
discover new CatSper blockers via two distinct strategies. Detailed in this chapter are the 
efforts towards modifying one of the endogenous activators, progesterone, in an attempt to 
change this activator to a blocker of CatSper. 
Section 2.2 The SAR of Progesterone-Induced CatSper Activation 
Section 2.2.1 Study Goal and Overview 
It has been demonstrated that structural modifications to a ligand can lead to drastic 
changes in its activity at a particular target, such as converting agonists to antagonists.85 
To this end, a series of progesterone analogs were purchased, bearing small structural 
changes to the parent steroid in order to thoroughly probe the structure-activity relationship 
(SAR) of this CatSper-activating steroid scaffold as represented by Figure 2.3. 
Additionally, clinically used progestins and anti-progestins were purchased and tested for 
their ability to activate CatSper. Since all steroids share similar scaffolds, we investigated 
additional steroid classes to extend this SAR study. 
Figure 2.3. Sites of Potential Modification to the Progesterone Scaffold. 
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Section 2.2.2 Fluorescence Intensity Plate Reader (FLIPR) Assay for the Measurement of 
Calcium Influx: Development and Validation 
My study began by verifying a previously developed fluorescence intensity plate 
reader (FLIPR) assay by comparing the potency of progesterone to increase [Ca2+]i in 
Figure 2.4. Progesterone and PGE1 Elicit Calcium Influx in Live Human Sperm 
Cells as Monitored in a Representative FLIPR Experiment. Dotted lines representing 
increasing concentrations of test compound as shown. DMSO response is shown as 
solid black line. For both experiments, highest concentration 1 µM (highest RFU) 
down to 0.1 nM (lowest RFU) in 10X dilutions.  
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human sperm cells to the previously published patch-clamp and calcium fluorimetry 
experimental EC50 values of 7.7 ± 1.8 and 42 ± 9.3 nM, respectively. 82, 83 
The FLIPR assay consists of loading live human sperm cells with a calcium-
selective fluorescent dye called Fluo-4-AM.86 Selectively fluorescent in the presence of 
calcium, this dye has long been used to study calcium concentrations in a variety of 
settings. Live human sperm cells are collected and purified via swim up or centrifugation 
procedures, loaded with the dye and transferred to the FLIPR instrument where the 
fluorescence of the cells is monitored in real time. Test compounds to be tested as blockers 
are added to sperm cells in microtiter plates and given 2 min to bind, after which the opener 
relevant to the study is added, and the fluorescence of the well is monitored. DMSO 
Figure 2.5. Dose-Response Curves Confirming Potencies of Progesterone and 
PGE1. The EC50 values compare well with previously reported literature values for 
these compounds. Data are plotted as mean ± standard error, presented as a percent 
response relative to a saturating dose of progesterone (3 µM). Smooth curves 
represent the best fits of a nonlinear regression model to the data for each compound. 
EC50 values determined using Prism v6.05. 
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controls and compounds showing efficacy in the assay show reduced fluorescence as 
displayed in Figure 2.4. 
The observed EC50 value of 7.7 ± 1.4 nM for progesterone agreed with the 
previously reported values. Additionally, the EC50 value for PGE1 was confirmed to be 4.2 
± 0.7 nM, which was sufficiently close to those found previously in the literature.  
Preliminary dose-response experiments with progesterone indicated a 
concentration of 3 µM was sufficient to saturate response in the assay, therefore, 3 µM 
progesterone served as the high control in all subsequent response measurements. 
Section 2.2.2.1 The Characterization of l-Sirenin as a CatSper Activator 
While CatSper channels were originally thought to be animal-specific, it has been 
shown that a CatSper channel complex is present in the basal fungus Allomyces 
macrogynus (A. macrogynus).87 This fungus produces motile gametes that exhibit 
chemotaxis towards their female counterparts. This chemotaxis is driven by the sexual 
pheromone l-sirenin (Figure 2.6).88 
It is not known whether CatSper channels underlie the molecular mechanisms for 
chemotaxis in A. macrogynus, however the mechanism relies on calcium flux.89 We 
hypothesized that l-sirenin may activate fungal CatSper to enable gamete fertilization. 
Figure 2.6. The Chemical Structure of l-Sirenin. 
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Since animals and fungi diverged from a common ancestor over 1 billion years ago, a 
Figure 2.7. Sirenin Activates Catsper in Human Sperm. (A) Raw FLIPR traces 
showing increases in [Ca2+]i elicited by increasing concentrations of synthetic 
sirenin. The sirenin dose-response increases from 10 nM (bottom) to 100 µM 
(top) by 10X fold increases. (B) Concentration-dependent increases in [Ca2+]i 
elicited by sirenin show an EC50 value of 2.9 µM ± 0.7 µM. (C) Sirenin elicits 
the same level of calcium influx as the endogenous activators of CatSper. 
Treatment concentrations (black) were as follows: sirenin – 30 µM, progesterone 
and PGE1 – 1 µM. Pretreatment with 30 µM (grey) reduced the maximum 
efficacy of all openers tested. Data are plotted as mean ± standard error, presented 
as a percent response relative to a saturating dose of progesterone (3 µM) and the 
numbers in parenthesis represent the number of experiments performed. Smooth 
curves represent the best fits of a nonlinear regression model to the data for each 
compound. EC50 values determined using Prism v6.05. 
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compound capable of eliciting a similar response in gametes of both species would serve 
to demonstrate the high degree of conservation thought to govern most reproductive 
signaling.87 As such, we sought to demonstrate that l-sirenin could activate human CatSper 
Figure 2.8. Sirenin Increases Intracellular Calcium in Human Sperm through 
Activation of the CatSper Complex. (A) Representative monovalent ICatSper whole-
cell recordings from human spermatozoa in the absence (blue) or presence of test 
compound. Left panel, 50 µM sirenin (green) or right panel, 1 µM Progesterone 
(red). B) Averaged amplitudes of ICatSper recorded from human spermatozoa in the 
presence of indicated test compound. Potentiation was determined by dividing 
current amplitudes of ICatSper at -80 mV (negative) and +80 mV (positive) by the 
amplitude of ICatSper in the absence of the corresponding compound from the same 
cell. Data are represented as mean ± standard error with n indicating the number 
of individual cells recorded. 
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and cause calcium influx in healthy human sperm cells via our FLIPR assay and subsequent 
electrophysiological confirmation. 
 Sirenin has been an attractive target for the synthetic chemistry community, given 
its compact, complex structure and several total syntheses have been reported.90-95 A 
member of the Georg group, Dr. Syeda, did great work in optimizing the synthesis of this 
compound, further characterizing the side products of several key reactions and ultimately 
improving the synthetic route greatly. The detailed of synthesis of sirenin is not discussed 
here but has been reported.96 The efficacy of the synthesized sirenin acting at the CatSper 
complex was measured in the FLIPR assay. When assayed, the synthetic sirenin produced 
a concentration-dependent rise in [Ca2+]i in human sperm with an EC50 value of 2.9 ± 0.7 
µM. Interestingly, though perhaps not unexpectedly, this potency is greatly attenuated 
compared to the 10 pM concentrations shown to elicit chemotaxis in fungal sperm. This 
reduced potency between the two species is likely the result of the billions of years of 
evolution separating the two species.87 Additionally, the synthetic sirenin was able to elicit 
a maximum response in the assay, though at a reduced potency. Pretreatment with 30 µM 
of the known CatSper blocker mibefradil reduced the sirenin-induced activation 55%. 
These observations indicate that sirenin increases sperm [Ca2+]i by activating the CatSper 
complex. 
To confirm that the sirenin-mediated rise in [Ca2+]i resulted from CatSper 
activation, rather than second messenger pathways or other ion channels present in sperm, 
whole cell patch-clamp electrophysiology experiments were conducted according to 
established methods and are shown in Figure 2.8. ICatSper is a pH-sensitive Ca2+-selective 
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ion current. A step hyperpolarization of the sperm from 0 to – 80 mV followed by a ramp 
depolarization from -80 to +80 mV elicited an inward current followed by an outward 
current mediated by CatSper. Both 10 and 50 µM sirenin potentiated both the inward and 
outward ICatSper currents. This potentiation was blocked by co-application of 30 µM 
mibefradil, further supporting the conclusion that sirenin-induced calcium flux is the result 
of CatSper activation and not that of other channels within the sperm. 
Section 2.2.3 Various Steroids Effectively Activate CatSper 
With the FLIPR assay validated, a general trend of steroid SAR causing calcium 
influx was sought so that compounds exhibiting limited or no activity in the influx assay 
could then be tested for their ability to instead block Ca2+ influx. While testing each 
compound, 30 µM mibefradil co-application was performed concomitantly to ensure any 
observed efficacy was likely due to CatSper activation, given the ability of mibefradil to 
inhibit CatSper. 
In order to assess the effect of substitutions on the northern half of the A ring, 
methylation of the C2 position was sought and achieved via enolate chemistry as shown in 
Scheme 2.1. 
Scheme 2.1. The synthesis of 2,2-Dimethylprogesterone 
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2,2-Dimethylprogesterone (2.4) showed full efficacy when tested in the influx 
assay with an EC50 of 491 nM as shown in Table 2.1. 
TABLE 2.1. The ability of various steroids bearing modifications to the A ring 
and A-B ring fusion to increase [Ca2+]i in a whole cell calcium influx assay with 
and without added mibefradil 
 +30 µM Mibefradil 
Compound Structure EC50, nM[a] Emax, % n EC50, nM[a] Emax, % n 
2.1 
 
7.7 ± 1.4 100 9 5.1 ± 0.6 31 8 
2.2 
 
4.2 ± 0.7 94 9 3.5 ± 1.8 28 8 
2.3 
 
2900 ± 700 99 9 3300 ± 1100 45 6 
2.4 
 
491 ± 95 98 3 ND < 10 3 
2.5 
 
301 ± 79 90 3 349 ± 38 38 3 
2.6 
 
400 ± 18 97 3 291 ± 75 37 3 
2.7 
 
77 ± 9 101 3 82 ± 29 48 4 
2.8 
 
184 ± 38 107 3 106 ± 25 45 4 
2.9 
 
1460 ± 360 107 6 1180 ± 160 17 4 
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2.10 
 
1060 ± 190 108 6 1190 ± 388 23 4 
2.11 
 
77 ± 27 104 5 115 ± 13 46 4 
2.12 
 
159 ± 26 92 5 187 ± 45 18 4 
[a] EC50 values given as the mean ± standard error. ND = not determined 
Next, a thorough examination of the individual rings of the progesterone scaffold 
was undertaken starting with the southern half of the A and B rings and their fusion. In 
general, modification of the A ring is well-tolerated. Compounds containing a reduced C3 
keto group (compounds 2.5–2.12) elicit full response in the influx assay, though at reduced 
potencies varying from 77 to 400 nM. Furthermore, there appears little preference for the 
configuration of the A-B ring fusion, as both 5α-dihydroprogesterone (2.11) and 5β- 
dihydroprogesterone (2.12) display full activity in the assay and lack a significant 
difference in their EC50 values: 77 and 159 nM, respectively. Indeed, all tested compounds 
containing either reduced C4 or, as will be seen, substituted C5 positions show no observed 
preference for a cis vs trans relationship of the A-B ring fusion. Finally, 
tetrahydrodeoxycorticosterones (THDOCs) 2.9 and 2.10, which contain a 21-hydroxyl 
group in addition to a fully reduced A ring, showed a large drop in potency with EC50 
values of 1460 and 1060 nM for the 5β- and 5α-THDOC diastereomers, respectively. 
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Given the attenuated activity of the THDOCs, we next pursued modifications near 
the D-ring despite the known ability of 17α-hydroxyprogesterone (2.13) to evoke calcium 
influx in sperm.77 Table 2.2 shows the results of these modifications and Figure 2.9 shows 
the corresponding dose-response curves. When tested, 2.13 elicited calcium influx with an 
EC50 of 7.2 nM (Figure 2.9, filled squares), equaling the potency of progesterone. Shifting 
the hydroxyl group to the C16 position resulted in a 10-fold loss of activity observed for 
16α-hydroxyprogesterone (2.14). Medroxyprogesterone (2.15), the 6α-methyl analog of 
TABLE 2.2. The effect of C17, C16 and C6 modifications to the progesterone scaffold 
on the ability to increase [Ca2+]i in a whole cell calcium influx assay with and without 
added mibefradil 
 +30 µM Mibefradil 
Compound Structure EC50, nM[a] 
Emax, 
% n 
EC50, 
nM[a] 
Emax, 
% n 
2.13 
 
7.2 ± 0.8 117 3 11 ± 2 59 3 
2.14 
 
190 ± 40 106 3 220 ± 55 53 4 
2.15 
 
480 ± 52 95 3 ND < 10 3 
2.16 
 
> 10 000 ND 3 > 10 000 ND 3 
2.17 
 
> 10 000 ND 8 > 10 000 ND 4 
[a] EC50 values given as the mean ± standard error. ND = not determined 
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2.13 showed over 50-fold loss of activity (Figure 2.9, filled diamonds). The acetylated 
analog of 2.15, medroxyprogesterone acetate (2.16, MPA) showed no ability to increase 
[Ca2+]i up to 10 µM (Figure 2.9, unfilled squares). Interestingly, acetylation alone of the 
17α-hydroxyl group (2.17) was sufficient to almost entirely ablate activity (Figure 2.9, 
filled triangles). 
 
Section 2.2.3.1 Synthesis of Target Steroids 
Given the observed lack of activity of compounds 2.16 (MPA) and 2.17 (17α-
acetoxyprogesterone) in the influx assay, we endeavored to evaluate 6α-
methylprogesterone (2.18) to ascertain the effect on activity of B-ring modifications 
Figure 2.9. Dose-Response Curves Comparing Potencies of Progesterone and 
Several C17 and/or C6-Modified Analogues in Healthy Human Sperm. Data are 
plotted as mean ± standard error, presented as a percent response relative to a 
saturating dose of progesterone (3 µM). The number of separate experiments for 
individual compounds can be found in Table 2.2 along with EC50 and Emax values 
in the presence and absence of mibefradil. Smooth curves represent the best fits 
of a nonlinear regression model to the data for each compound. No fit was 
obtained for MPA and instead a connecting line is shown. 
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without any additional C17 modifications. Synthesis of 2.18 was achieved following 
previously described literature procedures for C6-modified androstanes and is outlined in 
Scheme 2.2.97 The synthesis began via the acid-catalyzed double protection of the C3 and 
C20 ketones of 2.1 furnishing the corresponding ethylene ketal 2.19. Epoxidation of 2.19 
with m-CPBA proceeded in good yield and the two resulting diastereomers were separable 
by column chromatography, revealing 3,3:20,20-bis(ethylenedioxy)-5α,6α-epoxypregnane 
(2.20) as the more polar product. Conditions yielding β-epoxide 2.21 as the sole product 
were successful on small scale, but a lack of solubility greatly hampered scale up. 
Furthermore, while the route to 2.18 could be shortened by alkylation of 2.21, this β-
epoxide proved entirely resistant to ring-opening addition by Grignard reagents or alkyl 
lithium species no matter the conditions used.98 
Scheme 2.2 Synthesis of 6α-Methylprogesterone (2.18) 
 
Proceeding towards target molecule 2.18, Grignard addition into 2.20 proceeded 
smoothly under refluxing conditions and furnished pregnane 2.22. Removal of the ketal 
groups under acidic conditions at elevated temperatures yielded 5α-hydroxy-6β-
methylpregnan-3,20-dione (2.23). Since ketal deprotection conditions proved insufficient, 
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dehydration of the 5α-hydroxy was achieved by treatment with thionyl chloride to provide 
2.24 in good yield. Finally, epimerization of the C6 position to the thermodynamically 
favored 6α epimer gave 6α-methylprogesterone (2.18) in 6 steps and 7% overall yield.  
The epoxidation of 2.19 served as a valuable branching point for the generation of 
additional analogs of the steroid backbone as shown in Scheme 2.3. Compounds 2.20 and 
2.21 were deprotected to give their corresponding epoxyprogesterones 2.25 and 2.26, 
respectively. Additionally, each intermediate along the synthetic route was tested in the 
influx assay and is, as such, included in Table 2.3 which shows the effect of these 
compounds in the calcium influx assay. 
Scheme 2.3 Synthesis of Analogs 2.25 and 2.26 
 
Section 2.2.3.2 Activity of Synthesized Steroids 
Interestingly, every compound tested containing ketalized C3 and C20 positions 
showed no activity in the influx assay (Figure 2.10, open diamonds, representative). The 
corresponding, ketone-containing epoxides (2.25 dose-response in Figure 2.10, filled 
diamonds) showed submicromolar EC50 values. The same pattern is not quite observed 
with 5α-hydroxy-6β-methylprogesterone (2.23) and its analogous ketal 2.22 though the 
compound containing the free ketones is still more potent. 
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With respect to the C6 methyl substitution, there is only a slight difference in 
activity between the two diastereomers 2.24 and 2.18 (Figure 2.10, filled squares vs filled 
triangles). The 6α-methyl substitution found in 2.18 influences activity to a slightly greater 
extent than its 6β-methyl counterpart in 2.24. The 6α-methyl modification of 2.18 caused 
a 93-fold reduction in activity with respect to progesterone activation, a significant 
decrease if not as significant as that of the 17α-acetoxy modification. 
TABLE 2.3. The observed effects on calcium influx with and without added 
mibefradil of synthesized steroids 
 +30 µM Mibefradil 
Compound Structure EC50, nM[a] Emax, % n EC50, nM[a] Emax, % n 
2.19 
 
> 10 000 ND 3 ND < 10 3 
2.20 
 
> 10 000 ND 3 ND < 10 3 
2.21 
 
> 10 000 ND 3 ND < 10 3 
2.22 
 
> 10 000 ND 3 ND < 10 3 
2.23 
 
6390 ± 
1210 ND 3 ND < 10 3 
2.24 
 
267 ± 34 99 3 ND < 10 3 
2.18 
 
720 ± 110 110 3 ND < 10 3 
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2.25 
 
243 ± 61 98 3 ND < 10 3 
2.26 
 
422 ± 30 86 3 ND < 10 3 
[a] EC50 values given as the mean ± standard error. ND = not determined 
Section 2.2.4 Clinically Relevant Steroids Elicit Calcium Influx in Human Sperm 
Given that MPA, a synthetic progestin, was the only compound tested thus far to 
show no activity at high concentrations in the influx assay, a series of clinically relevant 
progestins, anti-progestins and androgens were tested for their ability to increase [Ca2+]i in 
human sperm. As shown in Table 2.4, the progestin activity of MPA is likely not the cause 
Figure 2.10. Dose-Response Curves Comparing Potencies of Progesterone and Select 
Synthesized Compounds in Healthy Human Sperm. Data are plotted as mean ± 
standard error, presented as a percent response relative to a saturating dose of 
progesterone (3 µM). The number of separate experiments for individual compounds 
can be found in Table 2.3 along with EC50 and Emax values in the presence and absence 
of mibefradil. Smooth curves represent the best fits of a nonlinear regression model 
to the data for each compound. 
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of the observed lack of activity, since drospirenone (2.27, Figure 2.11, filled circles), 
another synthetic progestin, displayed an EC50 of 429 nM in the assay. 
However, two other progestins did show little to no ability to cause calcium influx: 
levonorgestrel (LNG, 2.28, Figure 2.11, filled squares) and nestorone (2.29, Figure 2.11, 
upright filled triangles). Intriguingly, both LNG and nestorone contain substitutions at the 
C17 position, bearing an ethynyl and acetoxy group, respectively, adding credence to the 
previous observations that C17 modifications reduce CatSper activity. 
TABLE 2.4. The effects of clinically used steroids on calcium influx with and without 
added mibefradil 
 +30 µM Mibefradil 
Compound Structure EC50, nM[a] Emax, % n EC50, nM
[a] Emax, % n 
2.27 
 
429 ± 
140 104 7 486 ± 180 12 3 
2.28 
 
>> 10 
000 ND 4 ND ND 3 
2.29 
 
≈ 10 000 ND 4 ND ND 3 
2.30 
 
5730 ± 
2030 99 4 ND < 10 3 
2.31 
 
4410 ± 
950 106 5 ND < 10 5 
2.32 
 
>>10 000 ND 3 ND < 10 3 
[a] EC50 values given as the mean ± standard error. ND = not determined 
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Two anti-progestins, mifepristone (2.30, Figure 2.11, downward filled triangles) 
and ulipristal (2.31, Entry 2.29 and Figure 2.11, filled hexagons) were also tested and 
showed very weak activity in the calcium influx assay with EC50 values of 5.7 and 4.4 µM, 
respectively. Again, following the previously observed trend, the 17α-O-acetylated 
ulipristal analog 2.32 showed decreased activity in the influx assay to >>10 µM (Figure 
2.11 unfilled hexagons). 
Additionally, as shown in Table 2.5, the parent estrogen, 17β-estradiol (2.33, Figure 
2.12, circles) was shown to elicit calcium influx in human sperm. Testosterone (2.34, 
Figure 2.12, squares) was shown to cause calcium influx with a potency similar to that of 
the parent estrogen. Another hormone, aldosterone (ALDO, 2.35, Figure 2.12, upward 
Figure 2.11. Dose-Response Curves Comparing Potencies of Clinically Relevant 
Progestins and Antiprogestins. Data are plotted as mean ± standard error, presented as 
a percent response relative to a saturating dose of progesterone (3 µM). The number of 
separate experiments for individual compounds can be found in Table 2.4 along with 
EC50 and Emax values in the presence and absence of mibefradil. Smooth curves 
represent the best fits of a nonlinear regression model to the data for each compound. 
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triangles) was completely inactive in the influx assay. While not bearing any direct C17 
modifications, steric hindrance by the close proximity of the C18 aldehyde and the C21 
hydroxyl group found in the molecule could be responsible for this lack of activity. 
 
Given the activity of testosterone, several synthetic androgens were tested and 
shown to cause a calcium influx. 11β-Methyl-19-nortestosterone (11β-MNT, 2.36, Figure 
TABLE 2.5. The effects of clinically relevant androgens estrogens and 
mineralocorticoids on calcium influx both with and without added mibefradil 
 +30 µM Mibefradil 
Entry Compound EC50, nM[a] Emax, % n EC50, nM
[a] Emax, % n 
2.33 
 
404 ± 92 99 4 302 ± 25 44 3 
2.34 
 
339 ± 22 98 3 433 ± 49 17 3 
2.35 
 
>>10 000 ND 6 ND < 10 3 
2.36 
 
280 ± 36 84 6 344 ± 30 15 3 
2.37 
 
437 ± 144 92 5 520 ± 60 43 3 
2.38 
 
1890 ± 
460 90 9 ND < 10 3 
2.39 
 
4970 ± 
600 32 6 4040 ± 30 30 3 
[a] EC50 values given as the mean ± standard error. ND = not determined 
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2.12, diamonds) was the most potent androgen at 280 nM. Its close analog 7α-methyl-19-
nortestosterone (7α-MNT, 2.37) shows similar activity. Interestingly, both 7α,11β-
dimethylandrolone (2.38) and its diastereomer 7β,11β-dimethylandrolone (2.39, Figure 
2.12, hexagons) showed comparatively diminished potencies at 1890 and 4970 nM, 
respectively. Intriguingly, 7β,11β-dimethylandrolone exhibited a maximum effect (Emax) of 
only 32%, the only such partial activator seen in all of the tested compounds.  
Section 2.3 Characterization of T-type Calcium Blockers Inhibiting 
CatSper 
Section 2.3.1 Mibefradil Blocks All Known CatSper Openers 
As noted previously, in Tables 2.1 – 2.5, 30 µM of the t-type calcium channel 
blocker (CCB) mibefradil (2.40) was included in all influx assays to prove that the induced 
Figure 2.12. Dose-Response Curves Comparing Potencies of 17β-Estradiol, 
Testosterone, Aldosterone and Representative Synthetic Androgens. Data are plotted as 
mean ± standard error, presented as a percent response relative to a saturating dose of 
progesterone (3 µM). The number of separate experiments for individual compounds 
can be found in Table 2.5 along with EC50 and Emax values in the presence and absence 
of mibefradil. Smooth curves represent the best fits of a nonlinear regression model to 
the data for each compound. 
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influx was indeed from CatSper activation, as it has long been known that mibefradil blocks 
Figure 2.13. Inhibition of Progesterone-, PGE1-, l-Sirenin and K+-Induced Calcium 
Influx by Mibefradil. (A) Representative raw FLIPR traces showing dose-dependent 
reduction of progesterone CatSper activation. Cells from DMSO group received neither 
blocker nor progesterone. Data normalized to experiment-specific high (3 µM 
progesterone). (B) Dose-response inhibition curves showing potency of mibefradil 
against progesterone-, PGE1-, sirenin-, or K+-induced calcium influx. In all 
experiments, the concentration of opener used corresponded to an EC80 dose as 
determined from uninhibited dose-response experiments (see text). The data are plotted 
as the mean ± the standard error with the number of repeated experiments and IC50 
values given in Table 2.6. Smooth curves represent the best fits of a nonlinear regression 
model to the data for each compound. 
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CatSper currents.99-101 We sought to validate the influx assay with respect to blocking 
CatSper currents with a control compound before continuing on with testing the inactive 
steroids for their ability to block CatSper currents.  
During the course of the influx assays, the EC80 doses for progesterone, PGE1 and 
sirenin were determined from their nonlinear regressions. These values are 30 nM, 10 nM 
and 1 µM, respectively. These concentrations were used when studying the ability of 
compounds to block each respective opener. CatSper can also be artificially opened by 
introducing the cells to a high pH/ high K+ environment.56 The concentration of K+ used in 
these experiments was 140 mM. 
TABLE 2.6. Inhibition by mibefradil and ML218 of various modes of CatSper 
activation 
Compound Structure Activator IC50, µM[a] Hill Slope[b] n 
2.40 
 
Progesterone 7.5 ± 1.3 –2.3 8 
PGE1 5.8 ± 1.2 –2.6 8 
l-Sirenin 13 ± 4 –1.7 6 
K+/pH 18 ± 2 –1.7 8 
2.41 
 
Progesterone 9.9 ± 0.9 –2.0 5 
PGE1 15 ± 5 –3.6 3 
l-Sirenin 14 ± 3 –2.2 3 
K+/pH 11 ± 3 –2.1 7 
[a] IC50 values given as the mean ± standard error. [b] Hill slope for each compound is 
given. Each opener was dosed at a constant EC80 concentration corresponding to 
concentrations listed in the text. 
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As shown in Figure 2.13 (A) mibefradil displayed a dose-dependent inhibition of 
progesterone-induced calcium influx in the FLIPR assay, as expected. Shown in Table 2.6 
and Figure 2.13 (B), mibefradil inhibits the progesterone-induced influx in the FLIPR assay 
with an IC50 value of 7.5 ± 1.3 µM. This value is higher than that observed in 
electrophysiology experiments in which 1 µM mibefradil was sufficient to ablate all 
CatSper currents. This trend of compounds appearing less potent in the FLIPR assay when 
compared to other assays was observed throughout the course of this study. Not 
unexpectedly, mibefradil was also able to completely block the PGE1-, sirenin, and high 
K+/pH-induced calcium influx, also shown in Table 2.6. 
Figure 2.14. Dose-Response Inhibition Curves Showing the Potency of 
ML218 Against Progesterone-, PGE1-, l-Sirenin-, or K+-Induced Calcium 
Influx. In all experiments, the concentration of opener used corresponded to an 
EC80 dose (see text). The data are plotted as the mean ± the standard error with 
the number of repeated experiments and IC50 values given in Table 2.6. Smooth 
curves represent the best fits of a nonlinear regression model to the data for each 
compound. 
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Section 2.3.2 ML218 also Blocks All Known CatSper Openers 
There have been reports in the past that mibefradil itself causes calcium influx 
above 30 µM in human sperm cells.101 While no mibefradil-induced calcium influx was 
observed in any assay described thus far, another structural class of t-type CCBs capable 
of blocking CatSper activation would be a useful compound to the scientific community. 
To this end we tested whether ML218 (2.41), a t-type CCB that was originally developed 
as a central nervous system probe molecule as an initiative of the molecular libraries 
production center network (MLPCN), is able to block calcium influx caused by CatSper.102 
Originally developed for Cav3.2 and Cav3.3 channels, showing sub-micromolar activity, 
we anticipated this compound might prove to be more potent that the established control 
compounds. 
While ML218 can completely inhibit the progesterone-induced calcium influx 
observed in the FLIPR assay, its potency of 9.9 ± 0.9 µM (Table 2.6 and Figure 2.14) is no 
higher than mibefradil. 
Like mibefradil, ML218 was also able to completely block the signal generated by 
PGE1, sirenin, and high K+/pH (Figure 2.14) with IC50 values given in Table 2.6. In all 
cases, IC50 values between ML218 and mibefradil were not significantly different for any 
method of activation and ML218 did not provoke any signal in the influx assay up to 100 
µM (data not shown). ML218 has a decidedly different structure than mibefradil and 
displays dissimilar selectivity profiles when tested in vivo.102 This compound inhibiting 
CatSper currents provides a second control molecule for researchers studying CatSper 
currents. 
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Section 2.4 The Discovery of Steroidal CatSper Blockers 
Section 2.4.1 The Inactive Steroids Successfully Block CatSper Activation 
Of the 55 compounds tested for their ability to cause calcium influx in human MPA, 
LNG, and ALDO. Having identified these compounds, we sought to determine if they were 
capable of blocking the progesterone-, PGE1-, sirenin-, and high K+/pH-induced activation 
of the CatSper channel, or if they were simply inactive. Cholic acid showed no activation 
when previously tested and also did not block any method of eliciting calcium influx (not 
shown). Therefore, cholic acid was deemed inactive in the assay and was not pursued 
further. Cells treated with increasing concentrations of MPA (2.16), LNG (2.28) and 
ALDO (2.35) showed dose-dependent decreases in the signal elicited by treatment with an 
EC80 dose (30 nM) of progesterone (Figure 2.15, A). The selected steroids not only block 
the CatSper activation via progesterone, but also that of PGE1 (Figure 2.15, B) and sirenin 
(Figure 2.15, C). 
As shown in Figure 2.15 and Table 2.7, MPA (2.16) is the most potent compound 
of the three discovered steroidal blockers, with IC50 values of 9.7 ± 2.9, 9.2 ± 1.6 and 12 ± 
3 µM for the respective activators as shown in Table 2.7. LNG (2.28) blocked each signal 
elicited with IC50 values of 32 ± 6, 20 ± 4 and 81 ± 9 µM, respectively, and ALDO (2.35) 
showed the weakest activity with IC50 values of 43 ± 9, 56 ± 11 and 78 ± 12 µM, 
respectively. 
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Figure 2.15. Dose-Response Inhibition Curves Showing Inhibition of CatSper 
Activation by Selected Steroids. The activator used in each graph is shown in the top 
right. In all experiments, the concentration of the opener used corresponded to an EC80 
dose (see text). The data are plotted as the mean ± the standard error with the number 
of repeated experiments and IC50 values given in Table 2.7. Smooth curves represent 
the best fits of a nonlinear regression model to the data for each compound. 
 40 
Section 2.4.2 The Steroidal Blockers Cannot Inhibit the K+/pH-Induced Calcium Influx 
In general, including the studied t-type CCBs from the previous section, blockers 
most potently inhibit progesterone activation, followed by PGE1 and l-sirenin activation. 
Also, the inhibition curves generated from all compounds except MPA frequently showed 
Hill slopes less than -1.5, whereas those from MPA are closer to -1. 
TABLE 2.7. Inhibition by selected steroids of various modes of CatSper activation 
Compound Structure Activator IC50, µM[a] Hill Slope[b] n 
2.16 
 
Progesterone 9.7 ± 2.9 –1.3 12 
PGE1 9.2 ± 1.6 –1.2 11 
l-Sirenin 13 ± 4 –1.2 9 
2.28 
 
Progesterone 32 ± 6 –2.2 12 
PGE1 20 ± 4 –1.4 6 
l-Sirenin 81 ± 9 –2.8 6 
2.35 
 
Progesterone 43 ± 9 –2.3) 10 
PGE1 56 ± 11 –2.2 10 
l-Sirenin 78 ± 12 –2.3 9 
[a] IC50 values given as the mean ± standard error. [b] Hill slope for each compound 
is given. Each opener was dosed at a constant EC80 concentration corresponding to 
concentrations listed in the text. 
 41 
Figure 2.16 shows the concentration-inhibition curves resulting from high K+/pH-
induced calcium influx in the presence of increasing concentrations of each steroidal 
blocker. From the figure it is clear that the studied steroidal compounds have minimal effect 
on this method of eliciting calcium influx, as the IC50 for each steroid is well above 100 
µM. Conversely, as was seen in the last section, cells treated with increasing concentrations 
of mibefradil and ML218 fail to response to this method of evoking calcium influx, with 
IC50 values for each compound of 18 ± 2 and 11 ± 3 µM, respectively (Table 2.6, K+/pH). 
In order to ensure that the observed discrepancies, and indeed, all the observed 
inhibitory activity, was due to CatSper blockage and not indiscriminate interference of the 
compounds, all studied blockers were tested for their ability to inhibit the diffusion-based 
calcium ionophore, A23187.103 By incubating sperm cells in the presence of 30 µM of each 
Figure 2.16. Dose-Response Inhibition Curves Showing Inability of Selected 
Steroids to Block K+-Induced Calcium Influx. The data are plotted as the mean ± 
the standard error. Experiments were repeated 4 times to ensure results. A smooth 
curve represents the best fits of a nonlinear regression model to the data for ALDO 
and LNG. 
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blocker, then treating with the ionophore and reading fluorescence, it was shown that the 
studied blockers do not indiscriminately reduce fluorescence or interfere with the dye used 
in the assay, Fluo-4-AM. As shown in Figure 2.17, all tested blockers were unable to 
significantly reduce the signal generated by this ionophore that facilitates ion diffusion 
across membranes, serving to validate the results shown previously in this section. 
Section 2.5 Mode of Inhibition Studies of Steroids versus T-type CCBs 
Section 2.5.1 T-type CCBs Display an Insurmountable Block of CatSper Activation 
Figure 2.17. All Studied Blockers Do Not Block the Diffusion-Based Ionophore, 
A23187. The data are plotted as the mean ± the standard error. Experiments were 
repeated 3 times. 
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While screening the purchased and synthesized steroids for their ability to activate 
CatSper, 30 µM mibefradil was included in each assay to ensure that the observed influx 
Figure 2.18. T-type CCBs Cause an Insurmountable Block of Ca2+-Influx in 
Human Sperm. Increasing concentrations of mibefradil and ML218 reduce Emax 
of progesterone (A), PGE1 (B) and l-sirenin (C). The EC50(app) remains 
unchanged from control in each case. Calculated Emax, EC50(app), and the number 
of repeated experiments are given in Table 2.8. The data are plotted as the mean 
± the standard error relative to the signal evoked by 3 µM progesterone. Smooth 
curves represent the best fits of a nonlinear regression model to the data for each 
compound. If Emax < 10%, then a line connecting points is shown instead of best 
fit data. 
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was due to CatSper-specific activation. It was noticed in each case that mibefradil reduced 
the Emax of every effective opener while leaving the EC50 unaffected (Tables 2.1 – 2.5, 
rightmost columns). These results are consistent with insurmountable or non-competitive 
inhibition. To further study and confirm these observations, the mechanism by which t-
type CCBs inhibit the calcium influx caused by the studied openers was examined by 
measuring the effects of fixed concentrations of mibefradil and ML218 on the dose-
response curves of progesterone, PGE1 and sirenin. 
As seen in Table 2.8, the presence of 1, 10, 30, and 100 µM mibefradil or ML218 
reduced Emax while each respective EC50 was insignificantly altered, consistent with non-
competitive inhibition. Furthermore, as seen previously in Tables 2.1–2.5, each studied 
steroid was blocked insurmountably by 30 µM mibefradil corroborating that t-type CCBs 
have binding sites distinct from those of steroids, PGE1 and sirenin. 
Section 2.5.2 The Block Produced by Steroidal Compounds is Surmountable 
Contrary to the non-competitive block caused by the t-type CCBs, the effect of the 
studied steroidal blockers is completely surmountable as shown in Figures 2.19 – 2.21. 
With respect to MPA, increasing concentrations of the progestin caused parallel rightward 
shifts of the progesterone dose-response curves, indicating competitive inhibition (Figure 
2.19, A). 
  Table 2.8. Effects of mibefradil and ML218 on progesterone-, PGE1- and sirenin-induced increase in [Ca2+]i 
in human sperm 
O
pe
ne
r 
   
 Blocker 
Conc. 
(µM) EC50(app)
[a] Emax[b] n EC50(app)[a] Emax[b] n EC50(app)[a] Emax[b] n 
2.40 
 
0 7.7 ± 1.4 100 9 3.1 ± 0.3 94 9 2.9 ± 0.7 99 9 
1 4.1 ± 1.5 92 3 7.4 ± 0.1 84 3 3.8 ± 1.1 88 3 
10 7.9 ± 1.7 80 5 6.7 ± 2.1 50 5 2.8 ± 2.1 58 4 
30 6.6 ± 2.4 22 5 8.6 ± 2.4 9 3 6.7 ± 3.4 21 4 
100 ND 5 4 ND 7 5 ND 9 4 
2.41 
 
0 7.7 ± 1.4 100 9 3.1 ± 0.3 94 9 2.9 ± 0.7 99 9 
1 7.8 ± 1.4 87 3 1.7 ± 0.2 73 3 ND ND – 
10 7.9 ± 2.4 37 3 10 ± 1 48 3 2.9 ± 1.9 66 3 
30 ND 7 3 4.3 ± 1.1 18 3 1.1 ±0.3 31 3 
100 ND 2 3 ND 5 3 ND 2 3 
[a]EC50 values given in nM as the mean ± standard error. [b]Data presented as % of saturating dose of 
progesterone (3 µM). ND = not determined 
  
Competitive inhibition, by definition, signifies that the blocker and opener at least 
partially share a binding site. Interesting, MPA also displays competitive inhibition of the 
signal evoked by PGE1 and l-sirenin (Figure 2.19, B & C, respectively). Pre-incubation of 
cells with 30 µM MPA caused approximately a 10-fold shift in the dose-response curve for 
progesterone giving an EC50(app) of 67 ± 14 nM vs the EC50 of 7.7 ± 1.4 without added 
Figure 2.19. Effects of Increasing Concentrations of Medroxyprogesterone 
Acetate (MPA) on Increase of [Ca2+]i. in Human Sperm. (A-C) Increasing 
concentrations of MPA increase the EC50(app) value of progesterone (A), PGE1 
(B) and l-sirenin (C) while insignificantly affecting Emax, consistent with 
competitive inhibition. Calculated Emax and EC50(app) values, and the number 
of repeated experiments are given in Table 2.9. Data are plotted as the mean 
± the standard error. (D) Representative Schild regression for the competitive 
block of progesterone by MPA. Dose ratios were calculated from EC50 values 
for each curve fitted independently to a non-linear regression model. The line 
was fitted by linear regression with its slope set to unity. KB values for all 
interactions are given in Table 2.10. 
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MPA. Table 2.9 summarizes the interactions of each steroidal blocker with each studied 
opener. 
A similar pattern is observed when cells are treated with increasing concentrations 
of LNG, instead of MPA (Figure 2.20, A–C). LNG displayed a similar effect to those 
observed when cells were treated with MPA, though the effect on the influx evoked by l-
sirenin was diminished at 10 µM, compared the inhibition by MPA. At this concentration, 
LNG was unable to alter the response of cells to l-sirenin. 
Figure 2.20. Effects of Increasing Concentrations of Levonorgestrel (LNG) on 
Increase of [Ca2+]i. in Human Sperm. (A-C) Increasing concentrations of LNG 
increase the EC50(app) value of progesterone (A), PGE1 (B) and l-sirenin (C) while 
insignificantly affecting Emax, consistent with competitive inhibition. Calculated 
Emax and EC50(app) values, and the number of repeated experiments are given in 
Table 2.9. The data are plotted as the mean ± the standard error. (D) Representative 
Schild regression for the competitive block of progesterone by LNG. Dose ratios 
were calculated from EC50 values for each curve fitted independently to a non-
linear regression model. The line was fitted by linear regression with its slope set 
to unity. KB values for all interactions are given in Table 2.10. 
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Finally, Figure 2.21 shows the effect of increasing aldosterone on the signals caused 
by each opener. Again, rightward shifts are observed with increasing concentrations of the  
Table 2.9. Effects of MPA, LNG and ALDO on progesterone-, PGE1- and l-sirenin-
induced increase in [Ca2+]i in human sperm 
O
pe
ne
r 
   
 Blocker 
Conc. (µM) EC50(app), nM[a] Emax
[b] n EC50(app), nM[a] Emax
[b] n EC50(app), µM[a] Emax
[b] n 
2.16 
 
0 7.7 ± 1.4 100 9 3.1 ± 0.3 94 9 2.9 ± 0.7 99 9 
10 28 ± 8 102 3 15 ± 2 101 3 10 ± 1 108 3 
30 67 ± 14 105 3 55 ± 5 108 3 26 ± 5 111 3 
100 234 ± 19 ≥100 3 232 ± 14 ≥100 3 83 ± 6 ≥100 3 
2.28 
 
0 7.7 ± 1.4 100 9 3.1 ± 0.3 94 9 2.9 ± 0.7 99 9 
10 19 ± 6 95 8 15 ± 3 102 4 3.2 ± 0.6 104 4 
30 49 ± 12 102 4 54 ± 4 109 4 10 ± 5 100 4 
100 139 ± 27 ≥100 4 125 ± 7 ≥100 4 32 ± 6 85 4 
2.35 
 
0 7.7 ± 1.4 100 9 3.1 ± 0.3 94 9 2.9 ± 0.7 99 9 
10 28 ± 9 105 4 12 ± 6 105 4 11 ± 2 95 4 
30 84 ± 21 103 4 29 ± 2 104 4 28 ± 5 108 4 
100 253 ± 45 ≥100 4 96 ± 8 96 4 85 ± 7 ≥100 4 
[a]EC50 values given as the mean ± standard error. [b]Data presented as % of saturating 
dose of progesterone (3 µM). A constraint of Emax = 100 was placed on certain curves 
displaying a significant rightward shift and is indicated by a “≥100” for Emax. ND = not 
determined 
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mineralocorticoid while the Emax is unaffected. ALDO, unlike LNG reduced 
EC50(app) of all the studied openers, having the greatest effect at higher concentrations (30 
and 100 µM). 
Given this apparent competitive inhibition, we sought to verify the competitive 
nature of these interactions by performing Schild analysis (Figures 2.19–2.21, D).104 KB 
values (Table 2.10) were determined according to Schild regression experiments and the 
more generalized Leff-Dougall approach.105 There was good agreement between the two 
Figure 2.21. Effects of Increasing Concentrations of Aldosterone (ALDO) on 
Progesterone-Induced Increase of [Ca2+]i. in Human Sperm. (A-C) Increasing 
concentrations of ALDO increase the EC50(app) value of progesterone (A), PGE1 (B) and 
l-sirenin (C) while insignificantly affecting Emax, consistent with competitive 
inhibition. Calculated Emax and EC50(app) values, and the number of repeated experiments 
are given in Table 2.9. The data are plotted as the mean ± the standard error. (D) 
Representative Schild regression for the competitive block of progesterone by ALDO. 
Dose ratios were calculated from EC50 values for each curve fitted independently to a 
non-linear regression model. The line was fitted by linear regression with its slope set 
to unity. KB values for all interactions are given in Table 2.10. 
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methods of analysis and Schild regression plots had slopes of unity within the 95% CI, 
helping to confirm a competitive interaction between the steroidal blockers and 
progesterone, PGE1 and l-sirenin. 
 
Section 2.6 Computer-Aided Sperm Analysis (CASA) as a Confirmatory 
Assay 
Section 2.6.1 CASA as a Technique for Motility Parameter Acquisition 
So far, the data presented, and any conclusions made from it, are derived from the 
results of a single type of assay. While great effort was put towards making this assay as 
reliable as possible (and this was achieved), a secondary assay confirming the observations 
of the first would greatly validate our results. To this end, we turned to computer-aided 
Table 2.10. Calculated dissociation constants for the studied steroidal 
blockers of calcium influx into human sperm 
Opener Blocker 
pKB 
Schild[a] Leff-Dougall[b] 
 
MPA 5.77 5.66 
LNG 5.53 5.14 
ALDO 5.62 5.02 
 
MPA 5.51 5.60 
LNG 5.48 5.26 
ALDO 5.34 4.82 
 
MPA 5.29 4.80 
LNG ND 3.97 
ALDO 5.2 3.98 
[a]For all Schild analyses, the slopes of the regressions used in 
determinations had slopes of unity within a 95% CI. [b]pKB calculated from 
equation presented in ref. 102. ND = not determined 
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sperm analysis (CASA). CASA has been utilized to analyze sperm motility since the late 
80s, when it became readily available commercially. The technique has numerous 
successful studies to its credit in many different species.106, 107 
CASA detects the position of sperm heads and generates tracks relating to sperm 
movement over a short interval. Kinematic parameters (Figure 2.22) can be derived from 
these tracks describing velocities, path curvature, beat cross frequency, and amplitude of 
lateral head displacement (ALH). These parameters are monitored in real time from 
multiple (up to around 60) cells per field of view during short 1 second videos. Cells are 
then sorted into populations of cells including static, weakly motile (slow), motile, and 
progressively motile.108 
Section 2.6.2 CASA as a Technique for Monitoring HAM: Early Studies 
It should be noted here that CatSper function has little effect on these normal 
motility parameters and disruption of channel activity mainly leads to the inability of sperm 
Figure 2.22. The Kinematic Parameters Measured by CASA Systems. VSL, straight 
line velocity; VCL, curvilinear velocity; VAP, average path velocity, ALH; amplitude of 
lateral head displacement; LIN; linearity: the linearity of the curvilinear path (ratio of 
VSL/VCL). 
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to achieve hyperactivated motility (HAM) with only a marginal effect on normal motility 
expected.55 HAM is a complex mode of motility integrally intertwined with the even more 
complex process of capacitation.109 As such, parameters for its detection in CASA 
instruments vary greatly from group to group and are dependent on every aspect of sperm 
cell preparation and isolation including the buffers used, the frame rate of instrument, and 
individual chamber depths.110-113 With this in mind we first set out to ensure we could elicit 
HAM in cells from our various donors involved in the project, while also confirming that 
our core openers in the study had no effect themselves on normal motility parameters. 
First, one of the steps in the procedure for isolating sperm cells can involve a short 
centrifugation step, utilized to ensure consistent concentrations of cells are used in a given 
treatment. This centrifugation step was shown to have no direct effect on observed motility 
of isolated cells and was not taken into any further considerations (data not shown). Next, 
Figure 2.23 shows that up to 10 µM progesterone (A) and PGE1 (B) had no significant 
effect on total or progressive motility in human sperm cells.  
Figure 2.23. Progesterone and PGE1 Show No Effect on Normal Motility Parameters. 
Data are represented as means ± SD and represent at least 6 independent experiments. 
“%” is percent of total cell count. 
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Having shown that progesterone and PGE1 do not affect normal motility 
parameters, we sought conditions to raise the population of cells displaying HAM. Many 
experiments were dedicated to this end and conditions were found in which a 
concentration-depended increase in cells displaying HAM was observed as displayed in 
Figure 2.24. Both progesterone and PGE1, in the presence of 15 mM NaHCO3 and 5% 
(w/v) BSA can successfully and significantly increase the population of cells displaying 
HAM at 100 nM. Furthermore, increases were seen with a concentration as low as 10 nM, 
but these increases were only significant for progesterone.  
Section 2.6.3 Effect of Studied T-Type CCBs on Sperm Motility 
Having established the effect of progesterone and PGE1 on motility, the next 
experiments were carried out to observe the effects of all previously studied blockers on 
Figure 2.24. Progesterone and PGE1 Effectively Increase the Population of Cells 
Displaying HAM in Human Sperm Cells. Data are represented as means ± SD; numbers 
in parentheses indicate the number of experiments; and **P < 0.005, ***P <0.0005. 
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sperm motility, both normal and hyperactivated. It has previously been shown that CatSper 
knockout mice lose motility over time, so blocking CatSper should show a slight drop in 
normal motility parameters with an increased, robust effect on HAM.55 Figure 2.25 shows 
the effects of mibefradil and ML218 on normal motility parameters in sperm. Also included 
is the closely related t-type CCB NNC 55 0396 (NNC). 
As shown in Figure 2.25, the t-type CCBs mibefradil and NNC, have a significant 
effect on motility in human sperm at 10 µM and above, completely reducing total and 
progressive motility to 0% at 30 µM. Only slight motility reduction is observed at 1 µM 
though a pronounced effect can be seen, especially on progressive motility. ML218 shows 
a reduced effect on normal motility compared to mibefradil and NNC, though complete 
Figure 2.25. Effect of T-Type CCBs on Total and Progressive Motility. Data are 
represented as means ± SD; data represent the means of 6 individual experiments in 
all cases; and *P < 0.05, ***P <0.0005, ****P <0.0001. Statistics not performed 
on data showing complete inhibition of motility. 
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ablation of motility is still seen at 30 µM. This reduced effect at 10 µM by ML218 is an 
interesting finding which will be discussed further later in this chapter. 
Section 2.6.4 Steroidal Blockers Show Little Effect on Sperm Motility 
Before determining the effects of the steroidal blockers on HAM, we first sought 
to determine their effects on normal motility parameters. We expected these compounds to 
show a minimal effect on normal motility and this was observed, as shown in Figure 2.26. 
When tested at 1, 10 and 30 µM, only MPA showed any significant effect on total and 
progressive motility. LNG and ALDO did not impact normal motility parameters even at 
the highest concentrations tested, likely reflecting their diminished potencies observed in 
the FLIPR assay. 
Section 2.6.5 Both Classes of Blockers Effectively Reduce HAM 
Figure 2.26. Effect of Steroids on Total and Progressive Motility. Data are represented 
as means ± SD; data represent the means of 8 individual experiments in all cases; and 
*P < 0.05, **P <0.005. 
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With the effects and discrepancies between classes of blockers, the next step in the 
progression of this project was to show the effects of the blockers on HAM specifically. 
Starting with the t-type CCBs, and given their pronounced effect on normal motility, it was 
expected that their effect on HAM would be substantial. Figure 2.27 shows that this is the 
case, with no cells achieving HAM above a concentration of 1 µM. The only exception 
Figure 2.27. Effect of T-Type CCBs on Hyperactivated Motility (HAM). Data are 
represented as means ± SD; data represent the means of four individual experiments in 
all cases; and *P < 0.05, **P <0.005, ***P <0.0005, ****P <0.0001. 
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was ML218 affecting progesterone-evoked HAM, in which a small fraction of cells was 
still able to hyperactivate. The effect of the compounds at 1 µM is pronounced in almost 
all cases. This class of compounds showed little effect on normal motility parameters at 
this concentration. Thus, the observed effect at 1 µM on HAM could point towards the 
efficacy of these compounds inhibiting CatSper specifically. 
Figure 2.28. Effect of MPA, LNG and ALDO on Hyperactivated Motility (HAM). Data 
are represented as means ± SD; data represent the means of six individual experiments 
in all cases; and *P < 0.05, **P <0.005, ***P <0.0005, ****P <0.0001. 
 58 
With respect to the steroidal blockers, the effects on HAM are less pronounced and 
follow the trend observed with normal motility parameters, with MPA proving most 
effective in all cases and both LNG and ALDO providing only weak inhibition of HAM. 
Figure 2.28 shows the effects of the steroidal blockers on HAM. 
MPA at 10 and 30 µM is able to significantly reduce the population of sperm cells 
displaying HAM when both progesterone and PGE1 are used. Like the t-type CCBs, the 
effect from MPA is more potent with respect to HAM, compared to normal motility modes. 
Again, this can point towards CatSper-specific inhibition. Interestingly, LNG and ALDO 
show a reduced ability to inhibit HAM with respect to both studied openers. Both show 
efficacy at 30 µM individually, but neither is consistent across both openers, as either 
steroid shows increased efficacy for only one of the openers studied. 
Section 2.6.6 Recovery of Motility is Only Possible with Steroidal Blockers 
As exhibited in the FLIPR assay, there exists great discrepancies between the two types of 
blockers (Section 2.5) with respect to all methods of opening. To explore this observation 
further, making use of CASA, a simple experiment was envisioned in which the motility 
of cells could be recovered after treatment with a blocker in the presence an opener if that 
block was surmountable in nature. If, in the presence of opener, the motility was recovered 
despite the blocker being present this would indicate surmountable inhibition while, 
insurmountable inhibitors will have their effects unperturbed by the presence of an opener. 
The detailed experiment was only carried out with MPA the steroidal blocker, since 
this compound was the only compound to reduce normal motility parameters. As expected, 
when cells were treated with 30 µM MPA a reduction in total motility was observed 
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consistent with previous results (Figure 2.29, A). When these cells were then challenged 
with 100 nM progesterone significant recovery was observed, even approaching untreated 
levels though falling short marginally. 
Conversely, 100 µM progesterone was unable to increase motility when cells were 
previously dosed with 10 µM mibefradil, consistent with results from the FLIPR studies. 
Unexpectedly, when cells were dosed with 30 µM MPA and then dosed with 100 nM PGE1, 
no recovery of motility was observed. Furthermore, recovery of motility was observed in 
cells pretreated with 10 µM mibefradil, which to this point had only shown insurmountable 
inhibition. The increase in the presence of 100 nM PGE1 was statistically not significant, 
though the trend is undeniable. Further experiments are needed to explore this interesting, 
unexpected discrepancy between the t-type CCBs and the steroidal blockers. 
Figure 2.29. Modulation of Total Motility in the Presence of MPA or Mibefradil by 
Progesterone or PGE1. (A) Progesterone, P, rescues motility when coapplied with 
MPA but not mibefradil. (B) PGE1 is unable to recover motility degraded by steroidal 
blockers but can slightly increase motility in the presence of t-type CCB.  Data are 
represented as means ± SD; data represent the means of three individual experiments 
in all cases; and *P < 0.05. 
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Section 2.7 Discussion of Results 
Section 2.7.1 The CatSper channel is promiscuously activated 
The recent observations that exogenous EDCs and odorants can activate CatSper 
gives credence to the idea that CatSper can be activated by a wide variety of small 
molecules, including several classes of steroids.101 This study corroborates this notion by 
showing that over 30 steroid compounds activate CatSper. The systematic modification of 
the steroid skeleton has led to insights into the activity of steroids acting at CatSper which 
are summarized in Figure 2.30. 
Modifications to the A-ring appear to be well tolerated, with C2 alkylated 2.4 
(Table 2.1), as well as reduction of both the C4,C5-olefin and C3 carbonyl groups 
appearing to have no significant effect on activity (2.5–2.8, Table 2.1). These observations 
correspond well with previous studies showing that an O3-linked BSA-progesterone 
conjugate was still able to activate CatSper.83 The first reductions in potency were seen 
when the C21-hydroxyl bearing THDOCs 2.9 and 2.10 were tested, with EC50 values 
Figure 2.30. Summary of the SAR of Progesterone Activating CatSper. 
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falling above 1 µM for the first time (Table 2.1). This was the first indication that perhaps 
the D-ring of the steroid scaffold could be impactful, with respect to modulating channel 
activity. 
Further exploration of the B ring revealed that alkylations of this area are only 
somewhat well tolerated. Considerably reduced potencies were observed when 
modification of the B-ring is combined with other detrimental modifications, such as C17 
alkylations, like those seen in Table 2.2. An interesting trend was observed with the 
clinically used progestin medroxyprogesterone (2.15), which itself showed a modest 
potency of 480 nM. However, acetylation of the 17α-hydroxyl group to give 2.16 (MPA) 
completely ablated activity. Isolating these modifications, without the accompanying C6 
alkylation gives two compounds of extremely different activities with 17α-
acetoxyprogesterone 2.17 showing almost no ability to activate CatSper while 17α-
hydroxyprogesterone 2.13 is one of the most potent compounds identified at 7.2 nM.  
Whether or not the C6 modifications could also exert this sort of influence over 
activity remained to be seen so the synthesis of 6α-methylprogesterone (2.18) was 
undertaken, generating several additional analogs described in Table 2.3. Testing 2.18 in 
the influx assay revealed it to be a moderately potent activator of CatSper, further pointing 
away from the B-ring and instead towards the D-ring. Two interesting observations came 
from testing these synthesized steroids. First, 5α-hydroxy-6β-methylprogesterone 2.23 
displayed a much lower potency than other, structurally similar, compounds. And second, 
every steroid bearing a C3,C20 ketal rather than the natural ketone was completely inactive 
in the influx assay (2.19–2.22). 
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Several C-ring modified steroids were also tested. Bulky alkylations, such as the 4-
(dimethylamino)phenyl substituent found in the clinically relevant antiprogestins ulipristal 
(2.31), ulipristal acetate (2.32) and mifepristone (2.30) markedly reduce the potency of 
these compounds (Table 2.4). While the potencies of all three were reduced from 
progesterone, 2.31, bearing a 17α—hydroxyl group showed much great efficacy than its 
acetylated counterpart 2.32. Small groups such as hydroxy and methyl substituents were 
tolerated at the C11 position, indicating that large substitutions at this position greatly 
reduce the ability of these compounds to activate CatSper. This agrees nicely with a 
previous study which showed a lack of CatSper activation by a progesterone analog bearing 
a BSA conjugated to the steroid via a C11 hydroxy group.83 
It is worth noting that, while previous studies reported that mifepristone and 
ulipristal acetate were unable to block the progesterone-induced activation of CatSper, this 
is the first time these two compounds have been shown to actually activate the channel, 
albeit at elevated concentrations (EC50 ≈ 5 µM).114 The fact that these nuclear hormone 
receptor antagonists are able to instead activate CatSper serves as a fascinating example 
of the differences between CatSper and the progesterone nuclear hormone receptor. 
Recently, a synthetic androgen, 11β-methyl-19-nortestosterone dodecylcarbonate 
has passed safety trials and is being investigated further as a potential male contraceptive.28 
The free hydroxyl analog of this prodrug was included as a generous gift of synthetic 
androgens from the National Institute of Child Health and Human Development (NICHD) 
and was tested in the influx assay (Table 2.5) 11β-Methyl-19-nortestosterone (2.36) 
activates the CatSper complex with nanomolar efficacy (EC50 = 280 nM). Two of the 
synthetic androgens provided by the NICHD (2.36 and 2.37) displayed submicromolar 
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efficacy and two (2.38 and 2.39) showed micromolar efficacy for activating CatSper. The 
contraceptive efficacy of these compounds has not yet been determined, however if these 
studies were performed, the data presented herein could provide information to be 
considered for clinical trial design. 
In general, modifications to the D-ring of the scaffold produce much greater effects 
on the activity of the tested steroids, leading to the interpretation that this portion of the 
scaffold plays an important role in CatSper activation. This conclusion is strengthened by 
the significant difference in potency observed for 17α-hydroxyprogesterone (2.13) and 
17α-acetoxyprogesterone (2.17) (Table 2.2). It was frequently observed that all of the least 
potent potential activators tested in the influx assay bear acetoxy groups or similar 
hydrophobic substitutions at the C17 position, e.g. ulipristal acetate (2.32), mifepristone 
(2.30), nestorone (2.29),  medroxyprogesterone acetate (2.16), and levonorgestrel (2.28). 
Furthermore, modification of the C18 position produced inactive compounds 
bearing either an ethyl or an aldehyde as seen in 2.28 (LNG) and 2.35 (ALDO), 
respectively, though LNG also bears a C17 modification. All these modifications are 
located in proximity to the D-ring of the scaffold and inhibitor development in the future 
should follow the lead of Strünker et al. in their development of RU1968, shown in Figure 
2.31.115 
Figure 2.31 Structure of RU1968. A cross-species inhibitor of CatSper. 
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Section 2.7.2 ML218 blocks CatSper 
When studying CatSper physiology or pharmacology, investigators have few 
options beyond the published t-type CCBs mibefradil and the structurally similar NNC 55 
0396 (NNC). The mentioned RU1968 serves as another option to investigators but a t-type 
calcium channel showing a distinct structure from mibefradil and NNC would be an 
advantage to the field. In this study, we show for the first time that ML218 (2.41) is able 
to block all methods of evoking calcium influx in sperm, be it progesterone, PGE1, sirenin 
or elevated pH/K+ with IC50 values ranging from 9 to 15 µM depending on mode of 
activation (Table 2.6). For each method, the potency of ML218 was similar to that of 
mibefradil (Table 2.6). Additionally, both these t-type CCBs exhibit Hill slope values well 
below -1.0, pointing to a non-competitive, cooperative inhibition. Additionally, at 
concentrations up to 100 µM, ML218 showed insignificant calcium influx in sperm cells, 
in contrast to previous studies using mibefradil.82 Altogether, ML218 serves as another 
viable option for investigators interested in the pharmacology and physiology of CatSper 
and can be included as a tool compound in future CatSper studies. 
Section 2.7.3 Steroidal blockers of CatSper 
Of the 41 compounds tested for their ability to evoke calcium influx in sperm, four 
compounds showed no activity: cholic acid, MPA, LNG and ALDO. When tested for their 
ability to block the progesterone-induced activation of CatSper, all but cholic acid were 
active (Table 2.7). MPA, LNG and ALDO can now be added to the growing number of 
steroidal inhibitors of the CatSper complex. Furthermore, these compounds were able to 
 65 
prevent the PGE1- and sirenin-induced calcium influx, a first in the field, as no steroidal 
blockers of these modes of activation have been shown previously. 
Of the steroidal blockers, MPA was the most potent across all modes of activation, 
while the IC50 values of ALDO and LNG were below 20 µM. This trend continued for 
PGE1- and sirenin-induced calcium influx. When studied for its ability to effect conception, 
MPA concentrations in the endometrium have been shown to rise towards the IC50 values 
obtained herein.116 This leaves the possibility that MPA could be having contraceptive 
effects by a unique, previously unknown, mechanism. The IC50 values of ALDO and LNG 
are sufficiently high so as to preclude their study of CatSper in vivo. Nevertheless, 
biochemical assays could still make use of these compounds to observe varying effects on 
human sperm function. 
Interestingly, the studied steroids were unable to block the pH/K+-induced calcium 
influx (Figure 2.16) indicating they prevent binding of activators rather than interfering 
with channel shape and function or directly blocking the pore of the channel. Also, given 
that these compounds do not prevent the signal evoked by ionophore A23187 (Figure 2.17), 
they are not non-specifically reducing the signal in the assay. This finding contributes 
further to the idea these compounds are binding and preventing activator binding.  
As mentioned before, the concentrations required for a total block of CatSper within 
these trials is well above those found in individuals taking any of these medications with 
respect to LNG and ALDO.117, 118 Even when taken as a higher dose for emergency 
contraception, LNG concentrations do not approach those corresponding to the IC50 
value.119 That is not to say, however, that the observed effects on motility associated with 
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MPA are not, in small part, due to CatSper activity. Given the intricacies involved in 
gamete transport, a minimal effect on CatSper could have important effects on fertility. 
Section 2.7.4 Mode of inhibition: Steroids vs T-Type CCBs 
Over the course of studying the SAR of steroids activating CatSper, each compound 
was concomitantly blocked with mibefradil to assure its activity was via CatSper 
(rightmost columns of Tables 2.1 – 2.5). In every instance, each tested compound was 
blocked by mibefradil in an apparent insurmountable manner, meaning there was no 
rightward shift in the dose-response curve but Emax was substantially reduced. 
This observation was reinforced by treating cells with increasing doses of 
progesterone, PGE1 and sirenin in the presence of 1, 10, 30 and 100 µM mibefradil or 
ML218 and observing a dose dependent reduction of Emax (Figure 2.18, and Table 2.8). 
These results suggest that mibefradil and ML218, and likely NNC given its structural 
similarity to mibefradil, bind CatSper at a site unique to that of the studied openers. The 
fact that these CCBs can block the ligand-free pH/K+-induced calcium influx suggests they 
alter the conformation of the channel upon binding, closing the pore of CatSper. 
In contrast, cells treated with the studied openers were consistently able to achieve 
maximum efficacy in the influx assay despite treatment with high concentrations (100 µM) 
of steroidal blocker (Figures 2.19 – 2.21). Only an apparent decrease in potency, not 
efficacy, was observed, consistent with competitive inhibition for each steroidal opener. 
(Table 2.9) For competitive inhibition to be observed, an overlap of binding sites is 
required. Given that MPA displays competitive inhibition with respect to both progesterone 
and PGE1, it follows that the binding sites for progesterone and PGE1 are either 
overlapping, the same, or in close proximity.  
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It is not unexpected that MPA and progesterone share a binding site given their 
structural similarity, however that they could also share a site with PGE1, which is perhaps 
more interesting, especially given the previous studies reporting distinct sites for both 
molecules.84 Stranger still is that the action of l-sirenin, a molecule from an entirely 
different species with no human counterpart observed, is also inhibited competitively by 
all three steroidal blockers. Taken together, these observations point to a shared or 
overlapping binding pocket for sirenin, progesterone and PGE1. 
With the identification of ABHD2 as a binding partner for progesterone in 2016, a 
potential explanation for the observed differences between the t-type and steroidal blockers 
of CatSper needs to be considered (Figure 2.32).84 It is possible that the t-type blockers 
Figure 2.32. Graphical Summary of CatSper Activation and Pharmacological 
Interventions. (1) Progesterone binds to and activates the hydrolase ABHD2. (2) 
ABHD2 hydrolyses 2-arachodonyl glycerol (2-AG), decreasing the concentration of 
this lipid in the plasma membrane of sperm. (3) Decreasing 2-AG levels in the 
membrane drastically shift CatSper activation thresholds and allow for potentiation 
of current through the channel. T-type CCBs directly affect CatSper while steroidal 
blockers affect ABHD2. There is insufficient data to conclude with confidence 
where PGE1 binds and exerts its influence. 
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bind to and inhibit the CatSper complex, while the steroidal blockers bind to membrane-
associated ABHD2. Without further studies beyond those conducted here and previously, 
however, the promiscuity with which CatSper is activated will not be fully understood, 
especially given the complexity of CatSper as a whole. 
Section 2.7.5 CASA Studies of Selected Blockers 
To possibly give more credence to these observations, we employed computer-
aided sperm analysis (CASA) to determine the effect of both t-type CCBs and steroidal 
blockers on sperm from healthy men. It was found that the t-type CCBs, mibefradil, ML218 
and NNC 55 0396 have profound effects on normal motility parameters (total and 
progressive motility, Figure 2.25) while also abolishing hyperactivated motility (HAM, 
Figure 2.27). The effect on normal motility versus HAM was not differentiated with this 
class of compounds, meaning the effects on both modes were substantial.  
Contrasting these results, the effects of the steroids on normal motility were 
minimal, with only MPA showing a slight effect on normal motility (Figure 2.26). The 
steroids also showed a diminished effect on HAM (Figure 2.28), with only MPA showing 
significant inhibition. LNG also significantly inhibited HAM at 30 µM, but MPA by far 
showed the most promising inhibition, consistent with its potency in the influx assay 
compared to LNG and ALDO. 
Of note, during the course of these CASA studies, a small percent of the sperm 
population was shown to achieve HAM in the buffers used (Figure 2.27 and 2.28, 
“untreated”). The t-type CCBs completely abolished HAM, reducing the population to zero 
at high concentrations. Conversely, MPA never reduced the population of cells displaying 
HAM to zero, instead only reducing to levels consistent with cells receiving no treatment. 
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This observation shows again the differences between these two classes of blockers. Given 
that the steroids are likely blocking activation via ABHD2 inhibition, a basal level of ICatSper 
is still achievable, leading to these baseline HAM populations. The t-type CCBs block all 
CatSper activation and, as such, abolish all HAM. 
Section 2.8 Summary and Prospects of the Data Presented 
In summary, I have used a calcium influx assay to study the SAR of the 
progesterone activating CatSper through systematic modifications of the steroid scaffold. 
From these experiments, I conclude that the D-ring of the scaffold plays a prominent role 
in CatSper activation while the A, B, and C ring better tolerate modifications, confirming 
observations made from previous work.83 Within these studies, three compounds showed 
negligible influx: medroxyprogesterone acetate (2.16), levonorgestrel (2.28) and 
aldosterone (2.35). 
These compounds were subsequently shown to block not only the progesterone-
induced calcium influx, but also that of PGE1 and sirenin. Furthermore, I showed that these 
steroidal blockers act in a competitive nature with respect to progesterone, PGE1 and 
sirenin, in contrast to the studied t-type CCBs, mibefradil and ML218, which display an 
insurmountable block. This is the first study showing ML218 blocks CatSper activation, 
giving researchers another tool compound beyond mibefradil and NNC55-0396 when 
studying CatSper physiology and pharmacology. Furthermore, the fascinating interplay of 
the steroidal blocks and t-type CCBs was studied in depth, with more questions being raised 
than answered. 
Future work on this project should focus on further studying the potential inhibition 
(or lack thereof) of ABHD2 by relevant compounds. Binding assays, such as those 
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previously reported, should be repeated with UV-probes of PGE1 and, potentially, steroidal 
blockers to gain better insight into this intricate, fascinating system that continues to 
confound the field with its complexity.84  
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Chapter 3: Hit-to-Lead Development of Two Scaffolds 
Discovered via a High Throughput Calcium Influx Assay  
Section 3.1 Introduction 
As presented in the previous chapter, birth control has been available to women 
since the early 1960s.6 Since then research to discover and develop a male equivalent has 
focused on hormonal contraceptives.120 However, no agent has reached the market to date 
due to side effects such as decrease of high-density lipoprotein (HDL), acne, low libido, 
and weight gain.39 Therefore, efforts have centered in recent years on developing non-
hormonal p\harmacological agents that specifically target the testis, the epididymis, or 
sperm. Nonhormonal targets relevant to male contraceptive development are briefly 
outlined in Chapter 1.  
 To date, little progress has been made in developing CatSper-specific blockers or 
antagonists. Along with the previously discussed NNC 55-0396 (3.1)121 and mibefradil 
(3.2),122, 123 limited screening of compounds identified HC-056456 (3.3) and its 
Figure 3.1. Structures of CatSper Blockers Discovered to Date. 
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methylisoxazole analog (3.4) as CatSper blockers (Figure 3.1). Compounds 3.1 and 3.2 are 
both antihypertensive agents showing minimal selectivity for t-type currents over l-type 
currents and have shown cardiotoxicity, leading to their withdrawal from clinical trials.124 
Compounds 3.3 and 3.4 slow the rise of intracellular calcium in sperm and prevent 
hyperactivated motility in the low micromolar range, but contain structural liabilities 
precluding their further development. In the previous chapter we discussed the t-type CCB 
ML218 (3.5, Figure 3.1). This compound is exquisitely selective for t-type currents but its 
safety profile is under explored.102 
As mentioned previously, heterologous expression of a functional CatSper channel 
has not yet been achieved and is likely due to a failure in proper assembly of the CatSper 
complex.125 This issue has hampered traditional drug discovery efforts for this ion channel 
target and thus ex vivo experimentation using live sperm is currently the best method to 
discover modulators of CatSper in a high throughput manner. This chapter describes the 
results of a high throughput screen completed in the fall of 2012 which led to several hit 
compounds which were subsequently verified and elaborated upon. The full scope of this 
screen is beyond the scope of this chapter, but a brief description follows.  
The HTS screen leading to the discovered compounds is found in Figure 3.2. To 
begin, over 36K compounds were screened at 10 µM using elevated potassium/pH 
conditions to elicit calcium influx into human sperm. This resulted in 220 compounds that 
exhibited > 60% inhibition. These 220 compounds were selected for dose response 
experiments in which 104 showed well-defined sigmoidal dose-response curves with IC50 
values below 55 µM.  
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Potency, physiochemical properties and lack of fluorescence interference were 
taken into account to reduce the number of compounds down to 12. These compounds were 
repurchased and verified to be pure by UPLC, then subjected again to the influx assay, only 
now the endogenous activator progesterone was used to elicit influx. Eight compounds 
reconfirmed in this assay and were chosen for further elaboration. One of these compounds 
was the known non-selective dopamine agonist apomorphine. This compound was 
removed from consideration considering its well-defined pharmacology, leaving seven 
scaffolds (3.6 to 3.12, Figure 3.3) for potential elaboration into lead molecules. 
Figure 3.2. CatSper HTS Campaign Workflow. 
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Several rounds of SAR studies were carried out with each confirmed hit using 
commercially available molecules, with data obtained in each round driving the selection 
of successive analogs. Analogs were also selected from the GPHR-library within the ITDD, 
as only a small portion of the library was screened originally. A total of 67 analogs were 
selected for purchase from commercial sources based on structural diversity, high ligand 
efficiencies, and cost/availability. From these purchased compounds, an evaluation of the 
SAR of each scaffold was obtained, though in all cases the most potent compound in the 
FLIPR assay was the original hit compound. 
In an attempt to narrow the number of scaffolds for SAR studies, cytotoxicity 
studies using the AlamarBlue assay were performed. The fibroblast cell line IMR-90 was 
selected as a non-transfected, non-germline control in addition to sperm viability assays. 
From these assays, 3.9 (GPHR-00032750) and 3.12 (GPHR-0036795) showed a complete 
lack of cytotoxicity in both sperm and control cell lines. This fact, coupled with promising 
Figure 3.3. Structures of Screening Hits from HTS Campaign. 
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initial electrophysiology and CASA data, led to the selection of these two scaffolds for a 
comprehensive SAR study. The results of which are described herein. 
Section 3.2 Development of GPHR-00032750 via Matrix Chemistry 
Section 3.2.1 Initial Observations and Retrosynthetic Strategy 
Hit 3.9 was originally found from a library of ChemBridge compounds and 
obtained the designation GPHR-0032750 in the GPHR Library. In the original screen, this 
compound was one of the more potent hits found, with an IC50 value of 4.1 ± 1.2 µM for 
progesterone-induced influx and 9.2 ± 4.0 µM for potassium-mediated influx. 
Additionally, electrophysiology work performed in the lab of Dr. Polina Lishko at UC–
Berkeley showed that the parent compound is a CatSper blocker in healthy human sperm 
(data not shown).  
Based on these results, 3.9 was subjected to further SAR studies. To this end, a 
synthetic chemistry effort utilizing matrix chemistry was undertaken. Matrix chemistry 
allows for the generation of multiple compounds in rapid succession by forming all 
possible iterations of two different reaction partners. With respect to the retrosynthetic 
analysis of scaffold 3.9, the combination of a nucleophile (piperazine) and an electrophile 
(isocyanate) will provide an array of analogs as shown in Scheme 3.1.  
Scheme 3.1 Retrosynthetic approach to analog generation centered on 3.9 
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The chemistry leading to analogs of 3.9 allows for the rapid generation of analogs 
by coupling various piperazines, alcohols, thiols and amines to isocyanates, carboxylic 
acids, sulfonyl and acyl chlorides and others. In this library, every compound was produced 
on a sub 20 mg scale, but sufficient quantities of every compound were purified by flash 
chromatography to properly characterize all synthesized compounds. All compounds were 
verified to be > 85% pure by qNMR before testing in the influx assay. This influx assay is 
the same as described in Chapter 2 and progesterone was utilized to activate CatSper in 
these assays, as it is the more physiologically relevant activator compared to elevated 
potassium/pH. Any compound that proved to be a rather potent analog was resynthesized, 
purified to >95% purity as determined by qNMR and, frequently, though not always, also 
by UPLC.  
 The generation of the focused library and its synthetic efforts follow. 
Section 3.2.2 Initial Synthetic Efforts Towards GPHR-00032750 Analogs 
 Initial forays into the SAR of analogs of 3.9 focused on studying the effect of the 
meta trifluoromethyl groups while varying the internal piperazine moiety in an attempt to 
improve potency. The first compounds synthesized in the first library sought to hold the 
m-trifluoromethyl group of the western phenyl ring relatively constant while varying the 
eastern phenyl ring substituents. The general synthetic scheme for the development of these 
compounds is shown in Scheme 3.2. Mixing of the appropriate piperazine with an 
isocyanate of interest in the presence of a mild base at r.t. was sufficient to obtain target 
molecules in good yield, generating a set of 40 compounds that were assayed for their 
ability to block the progesterone-evoked calcium influx. 
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Scheme 3.2 General reaction scheme for the synthesis of analogs 3.10–3.48 in Table 3.1 
 
Table 3.1. Potency of Piperazinyl Analogs from Scheme 3.2 
Compound R1 R2 IC50[a] 
3.10 H H > 100 
3.11 H 3-Me >100 
3.12 H 3-CF3 >100 
3.13 H 3-CN 25 ± 6 
3.14 H 3-NO2 >100 
3.15 H 3-CO2Me >100 
3.16 3-Me H 69 ± 5 
3.17 3-Me 3-Me 46 ± 11 
3.18 3-Me 3-CF3 9.2 ± 0.8 
3.19 3-Me 3-CN 32 ± 4 
3.20 3-Me 3-NO2 25 ± 2 
3.21 3-Me 3-CO2Me 28 ± 3 
3.22 3-Me 3,5-(CO2Me)2 28 ± 8 
3.23 3-Me 4-Indole >100 
3.24 3-CF3 H 26 ± 5 
3.25 3-CF3 3-Me 9.6 ± 0.4 
3.9 3-CF3 3-CF3 5.2 ± 1.7 
3.26 3-CF3 3,5-(CF3)2 2.9 ± 0.8 
3.27 3-CF3 3-CN >100 
3.28 3-CF3 3-NO2 17 ± 6 
3.29 3-CF3 3-CO2Me 24 ± 6 
3.30 3-CF3 3,5-(CO2Me)2 20 ± 7 
3.31 3-CF3 3-CO2H >100 
3.32 3-CF3 4-Indole 42 ± 9 
3.33 3-CF3 5-Indole 34 ± 3 
3.34 3,5-(CF3)2 H >100 
3.35 3,5-(CF3)2 3-Me 13 ± 4 
3.36 3,5-(CF3)2 3-CF3 4.1 ± 1.2 
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3.37 3,5-(CF3)2 3,5-(CF3)2 >100 
3.38 3,5-(CF3)2 3-CN 13 ± 1 
3.39 3,5-(CF3)2 3-NO2 7.0 ± 1.2 
3.40 3,5-(CF3)2 3-CO2Me 7.5 ± 0.9 
3.41 3,5-(CF3)2 3,5-(CO2Me)2 >100 
3.42 3,5-(CF3)2 3-CO2H >100 
3.43 3,5-(CF3)2 5-Indole 92 ± 9 
3.44 3-CN 3-CF3 8.6 ± 3.3 
3.45 3-CN 3,5-(CF3)2 5.0 ± 1.1 
3.46 3-CN 3-CN >100 
3.47 3-CN 3-NO2 >100 
3.48 3-CN 3-CO2Me >100 
From this initial set of compounds, a series of observations can be made regarding 
SAR patterns. First, the western phenyl group of the scaffold needs to be substituted. The 
type of substitution on this ring is not as important, as a great variety of substitutions retain 
some level of activity, but a phenyl group alone in this region is not sufficient to confer 
activity in the influx assay (compounds 3.10 – 3.15). Building on this observation, the more 
electron withdrawing the substitution, the more likely the compound is to show good 
potency in the assay, in the following order: m-CF3 ≈ m-NO2 > CN > Me. In general, the 
eastern phenyl ring of the scaffold is more tolerant of modifications compared to the 
western ring. A wider variety of substitutions still show activity including indoles (3.32, 
3.33), though potencies are diminished greatly. 
Importantly, included in this set of compounds was the original HTS hit (3.9). 
While this compound had been repurchased from vendors, its resynthesis, purification and 
assay all on site served to validate this series. From the SAR of this library of compounds 
it became apparent that the most potent modifications to the phenyl rings were going to 
remain the m-CF3 groups, though the m-methyl analog 3.17 retained activity, indicating 
that sterics of this group may play a bigger role than electronics. Building on the m-CF3 
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groups, several compounds were synthesized bearing 3,5-bis-CF3 groups. These 
compounds proved rather potent in many cases (3.26, 3.35, 3.36), however 3,5-
disubstitution with CF3 (3.37) and a methyl ester moiety (3.41) on the eastern phenyl ring 
produced inactive compounds. The carboxylic acid-containing compounds 3.31 and 3.42 
showed no activity compared to their ester counterparts 3.29 and 3.40. Presumably, the 
carboxylic acid is preventing cellular penetration.  
Section 3.2.3 Heterocyclic Analogs of Parent Compound Maintain Activity 
Perhaps the most important observation from the SAR study (Table 3.1) is that none 
of the synthesized compounds showed an increase in potency compared to the original hit 
compound 3.9. From Table 3.1 it is apparent that the eastern phenyl ring is more amenable 
to changes than the western phenyl ring. From this we sought to synthesize a small series 
of analogs in which a small heterocyclic group was appended to the eastern ring. In this 
series of analogs, we also investigated N-phenyl piperazines substituted with pyrrole (3.49–
3.51) and N-methylpyrazole (3.52–3.54), pyridine (3.55–3.59) and pyrimidine (3.60) 
moieties.  The results derived from these compounds are shown in Table 3.2. The synthesis 
of these compounds remains unchanged from Scheme 3.2. 
Table 3.2. Potencies of Heterocycles-Containing 
Analogs 3.49–3.60 
 
Compound R1 R2 IC50[a] 
3.49 3-CF3C6H4 
 
19 ± 6 
3.50 3,5-(CF3)2C6H3 
 
5.5 ± 1.8 
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3.51 3-CNC6H4 
 
21 ± 6 
3.52 3-CF3C6H4 
 
11 ± 2 
3.53 3,5-(CF3)2C6H3 
 
4.3 ± 0.9 
3.54 3-CNC6H4 
 
25 ± 5 
3.55 3-py. 3-Me >100 
3.56 3-py. 3-NO2 >100 
3.57 4-py. 3-Me >100 
3.58 4-py. 3-CF3 10 ± 2 
3.59 4-py. 3-NO2 43 ± 22 
3.60 2-pyr. 3-CF3 >100 
[a]Data presented in µM as mean ± SD and 
represent 3 individual experiments in all cases. 
py. = pyridine and pyr. = pyrimidine. 
From the data for these compounds several observations were made. The eastern 
phenyl ring can accept heterocyclic substituents and retain activity, with potencies for 3.50 
and 3.53 that are comparable to the parent compound 3.9. For these compounds, the 
modifications to the western phenyl ring follow the same trend that was observed 
previously, that an increase in electron withdrawing modifications leads to improved 
potency (3.50 > 3.49 > 3.51 and 3.53 > 3.52 > 3.54). Compounds 3.55–3.58 continue the 
trend that the western phenyl ring is less accepting of substitutions, as compounds in which 
the phenyl ring is changed to a pyridine (py) or pyrimidine (pyr), all activity is lost, save 
compound 3.58 which retained activity. 
Section 3.2.4 Analogs with Extended Aryl System Retain Activity 
After analysis of the SAR data for these compounds it became clear that pursuing 
analogs modified at the eastern phenyl ring would be advantageous. Also, since the 
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heterocyclic substituents retained activity, we hypothesized that additional steric bulk 
could be added in this area. As such we expanded the aryl system by adding another ring 
via linkage through an amide bond, making use of the previously synthesized 3.31 and 3.42 
as the starting material. The synthetic scheme leading to these analogs are shown in Scheme 
3.3. 
Scheme 3.3 Synthesis of extended aryl system analogs 
 
 Table 3.3 shows that addition of the extra aryl system to the scaffold is tolerated, 
as evinced by compounds 3.61 and 3.68. Large additions to this phenyl ring are not 
tolerated, however, as shown by compounds 3.66, 3.67, 3.74 and 3.75, smaller groups, such 
as the chloro- groups found in 3.64, 3.65 and 3.72 led to compounds displaying potencies 
slightly better than the parent compound. Conversely, heterocycles are not tolerated at this 
additional phenyl ring (3.76 and 3.77) and when the lipophilicity of the compound is too 
high all activity is lost, demonstrated by the inactive compounds 3.71 and 3.73 through 
3.76. In general, these molecules did not provide significant gains in potency over the 
parent compound and the molecular weights of these compounds were starting to be above 
500. With further modifications needed to improve potency the molecular weight of 
additional analogs would above 550 molecular weight, and therefore a different direction 
was chosen by modifying the central core of the molecule. 
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Section 3.2.5 Modifications to the Piperazinyl Urea Core are not Well Tolerated 
 Having seen little to no improvement in potency when synthesizing targets similar 
in structure to the parent compound, analogs that displayed a greater variety in molecular 
structure were designed and synthesized as shown in Scheme 3.4. 
Table 3.3. Potencies of extended aryl amide analogs 
 
Compound R1 R2 IC50[a] 
3.61 3-CF3 H 13 ± 5 
3.62 3-CF3 4-Cl 13 ± 5 
3.63 3-CF3 4-OMe >100 
3.64 3-CF3 3,4-(Cl)2 2.4 ± 0.7 
3.65 3-CF3 3-Cl 3.2 ± 0.6 
3.66 3-CF3 4-C(CH3)3 >100 
3.67 3-CF3 3-CF3, 4-Cl >100 
3.68 3,5-(CF3)2 H 6.5 ± 2.4 
3.69 3,5-(CF3)2 4-Cl >100 
3.70 3,5-(CF3)2 4-OMe >100 
3.71 3,5-(CF3)2 3,4-Cl >100 
3.72 3,5-(CF3)2 3-Cl 3.8 ± .3 
3.73 3,5-(CF3)2 4-NMe2 >100 
3.74 3,5-(CF3)2 4-C(CH3)3 >100 
3.75 3,5-(CF3)2 3-CF3, 4-Cl >100 
3.76 3,5-(CF3)2 4-py. >100 
3.77 3,5-(CF3)2 3-py. >100 
3.78 3,5-(CF3)2 4-CF3 7.1 ± 3.1 
[a]Data presented in µM as mean ± SD and represent 3 individual 
experiments in all cases. Py. = pyridine with numbering representing the 
position of endocyclic nitrogen. 
 83 
Scheme 3.4 The synthesis of ring opened analogs of 3.9 via EDC coupling or isocyanate 
chemistry 
 
Modifications to the scaffold included removal of the eastern nitrogen of the urea 
linker, replacing it with a methylene group or simply removing the spacer all together, 
resulting in several compounds with an aryl ketone rather than the usual aniline.  
Table 3.4. Activities of Ring-Opened Analogs of 3.9 
 
Compound R1 R2 X Y n IC50[a] 
3.79 3-CF3, 4-Cl 3-CF3 NH CH2 1 6.4 ± 1.4 
3.80 3-CF3, 4-Cl 3-CN NH – 0 26 ± 1 
3.81 3-CF3, 4-Cl 3,5-CF3 NH – 0 >100 
3.82 3-CF3, 6-Cl 3-CF3 S CH2 1 29 ± 6 
3.83 3-CF3, 6-Cl 3-Me S NH 1 >100 
3.84 3-CF3 3-Me S NH 1 39 ± 11 
3.85 3-CF3 3-CN S NH 1 >100 
3.86 3-CF3 3-CO2Me S NH 1 32 ± 2 
3.87 3-CF3 3,5-(CO2Me)2 S NH 1 25 ± 8 
3.88 3-CF3 4-Indole S NH 1 15 ± 3 
[a]Data presented in µM as mean ± SD and represent 3 individual experiments in all 
cases. “–“ represents nonexistent site 
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In all synthesized compounds, the piperazine ring was opened to give either 
diamide linkers or carbamothioic esters in place of the normal urea. The activity of the 
resulting compounds is described in Table 3.4. 
As observed in Table 3.4, opening the ring to a more flexible linking moiety 
resulted in compounds that retained activity in the assay, but displayed diminished 
activities. In almost all cases double digit micromolar inhibitors were observed except for 
compound 3.79 whose potency matched that of the parent compound. No discernable 
trends were observed with these compounds regarding thiol linkers over amide linkers or 
how ring opening affected phenyl substitution patterns, but the fact that these compounds 
retained activity prompted further exploration of ring-opened analogs. Scheme 3.5 shows 
the additional analogs synthesized, centered on a commercially available azaindole 
methylamine nucleophile 3.89. 
Scheme 3.5 The synthesis of additional ring opened analogs of 3.9 
 
When first tested, these compounds appeared to be submicromolar inhibitors in the 
FLIPR assay. Closer inspection of the data, however, revealed these compounds 
substantially interfered with the fluorescent readings of the assay (not shown), prompting 
their removal from consideration and truncating their testing at n =2.  
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Table 3.5. Potencies of Analogs Using 3.89 as Nucleophile 
 
 
 
 Compound R1 n IC50[a]  
 3.90 3-CF3 0 >100  
 3.91 3,5-(CF3)2 0 >100  
 3.92 3-CN 0 >100  
 3.93 4-CN 1 >100  
 3.94 3-CF3, 6-Cl 0 >100  
 3.95 
 
0 >100  
 3.96 
  
>100  
[a]Data presented in µM as mean ± SD and represent 2 individual experiments in all cases. 
For R1, when drawn, eastern phenyl group is replaced by entire drawing. 
Section 3.2.6 Sulfonamide Analogs of 3.9 Are Completely Inactive Save One Compound 
With the lackluster potencies seen in all ring-opened compounds the decision was 
made to stop drastically altering the piperazinyl core and instead, and change the urea 
linking group to improve potency. Sulfonamides retain many of the physicochemical 
properties of amides and ureas and, as such, were sought as potential analogs. Synthesis 
and testing of compound 3.97 showed that the sulfonamide analog corresponding to parent 
substitution pattern of 3.9 retained activity. With this knowledge, a series of sulfonamides 
were synthesized and assayed in the FLIPR assay. The synthesis of these compounds is 
shown in Scheme 3.6, though the chemistry is identical to the previously discussed 
isocyanate couplings. 
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Scheme 3.6 Synthesis of sulfonamide derivatives of 3.9 
 
As can be seen in Table 3.6, while analog 3.97 retained activity in the influx assay, 
almost every other sulfonamide synthesized showed no ability to block the progesterone-
mediated calcium influx in human sperm.  
Table 3.6. Potencies of Sulfonamide Derivatives 
 
Compound R1 R2 IC50[a] 
3.97 3-CF3 3-CF3 7.4 ± 0.9 
3.98 H H >100 
3.99 H 3-Me >100 
3.100 H 2-CF3 >100 
3.101 H 3-CF3 >100 
3.102 H 4-CF3 >100 
3.103 H 3,5-(CF3)2 >100 
3.104 3-Me H >100 
3.105 3-Me 2-CF3 >100 
3.106 3-Me 3-CF3 >100 
3.107 3-Me 4-CF3 >100 
3.108 3-Me 3,5-(CF3)2 >100 
3.109 3-CF3 H >100 
3.110 3-CF3 3-Me >100 
3.111 3-CF3 4-CF3 52 ± 9 
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3.112 3-CF3 3,5-(CF3)2 >100 
3.113 3-CN H 19 ± 4.4 
3.114 3-CN 3-Me >100 
3.115 3-CN 3-CF3 >100 
3.116 3,5-(CF3)2 H 76 ± 32 
3.117 3,5-(CF3)2 3-Me >100 
3.118 3,5-(CF3)2 2-CF3 >100 
3.119 3,5-(CF3)2 3-CF3 59 ± 7 
3.120 3,5-(CF3)2 4-CF3 2.2 ± 0.4 
[a]Data presented in µM as mean ± SD and represent 2 individual 
experiments. In cases where an IC50 value < 100 µM is observed,  
3 experiments were performed. 
 
A disappointing result to be sure, given the initial success of 3.97. This series of 
compounds was the first to introduce an o-CF3 group into any analog, though in all cases 
this substitution was inactive and not pursued in additional analogs. Compound 3.120 bears 
a p-CF3 group and is the most potent sulfonamide tested, though only moderately more 
potent than 3.97 and hit compound 3.9. 
Section 3.2.7 Exploration of the Nitrogen Spacer Reveals Promising Results 
Having synthesized and tested over 100 compounds to this point, several 
observations were used to drive further analog synthesis. First, the electron deficiency of 
both phenyl rings is crucial for retention of activity, with very few analogs showing activity 
independent of –CF3 groups. Second, the piperazine ring should be kept if possible, as most 
ring opened compounds showed reduced activity. Finally, the urea moiety is amenable to 
alteration only if the western nitrogen of this group is maintained, and it absolutely should 
not be changed to a sulfonamide. 
Scheme 3.7 EDC-mediated couplings leading to varied spacer analogs 
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Throughout the tested analogs there exist several examples in which the NH group 
of the urea linker is changed to a methylene linker (see compounds 3.79 and 3.97). Also, 
compound 3.80 retains some potency with a truncated spacer, keeping just an aryl amide 
rather than a full urea. We next sought to explore the need for this spacer by synthesizing 
compounds according to Scheme 3.7, in which zero or one methylene groups or nitrogen 
atoms could modulate potency in the influx assay. 
 As seen in Table 3.7, most of the compounds in which n = 0, leaving an aryl amide, 
show little reduced potency in the influx assay, with several showing no activity 
whatsoever (3.121, 3.124 and 3.125). These compounds closely resemble the parent 
compound, so their lack activity reflects the need for this spacer region to exist. Further 
validating the need for this spacer are compounds 3.126 and 3.127, which retain activity 
and are the same as the parent compound except the urea NH group is a methylene linker. 
These two compounds are less potent then their urea counter parts (see 3.126 vs 3.9 and 
3.127 vs 3.36). 
Table 3.7 Potency of truncated or methylene-containing compounds 
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 Compound R1 R2 n IC50[a]  
3.121 3-CF3 3-CF3 0 >100 
3.122 3-CF3 3,5-(CF3)2 0 26 ± 3 
3.123 3,5-(CF3)2 3-CF3 0 11 ± 1 
3.124 3,5-(CF3)2 3,5-(CF3)2 0 >100 
3.125 3,5-(CF3)2 3-CN 0 >100 
3.126 3-CF3 3-CF3 1 9.8 ± 0.2 
3.127 3,5-(CF3)2 3-CF3 1 7.7 ± 0.7 
3.128 3-CN 3-CF3 0 17 ± 2 
3.129 3-CN 3,5-(CF3)2 0 26 ± 6 
3.130 3-CN 3-CN 0 64 ± 1 
[a]Data presented in µM as mean ± SD and represent 3 individual experiments in all cases. 
Having explored truncated linkers with respect to the urea portion of the molecule, 
we next set out to increase the linker length. Having demonstrated with compounds 3.126 
and 3.127 that a methylene is tolerated at this position, we sought to explore whether 
potency could be gained via alkylation of this methylene group. We also utilized a phenoxy 
linker in these compounds to explore the effect of this change on compound potency. 
Scheme 3.8 Synthesis of phenoxy derivatives with alkylated linker regions 
 
Table 3.8. Potency of phenoxymethylene derivatives with and without alkylated 
linker regions 
 
 
 
 Compound R1 R2 R3 R4 IC50[a]  
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3.131 3-CF3 H H 3-CF3 6.9 ± 1.6 
3.132 3,5-(CF3)2 H H 3-CF3 4.7 ± 0.9 
3.133 3-CN H H 3-CF3 15 ± 4 
3.134 3-CF3 H H 3,4-F2 8.6 ± 1.2 
3.135 3,5-(CF3)2 H H 3,4-F2 7.5 ± 1.3 
3.136 3-CN H H 3,4-F2 66 ± 13 
3.137 3-CF3 H Me 3-CF3 9.6 ± 0.5 
3.138 3,5-(CF3)2 H Me 3-CF3 10 ± 4 
3.139 3-CN H Me 3-CF3 20 ± 4 
3.140 3-CF3 Me Me 3-CF3 5.2 ± 0.9 
3.141 3,5-(CF3)2 Me Me 3-CF3 43 ± 26 
3.142 3-CN Me Me 3-CF3 12 ± 4 
[a]Data presented in µM as mean ± SD and represent 3 individual experiments in all 
cases. 
From Table 3.8 there are several observations that can be made starting with the 
fact that, for the first time, all compounds in a synthesized set retained activity. This 
phenoxymethylene linker present in each of these compounds is an accepted change to the 
scaffold. Compounds 3.131, 3.132, 3.134, 3.135, and 3.140 display potencies equal to the 
parent compound. Though no significant increases in potency were observed, these results 
indicate a positive trend.  
Also, the need for an electron withdrawing groups continues as previously observed 
trends continue to be seen, with 3,5-CF3 > 3-CF3 > 3-CN (see compounds 3.132 vs 3.131 
vs 3.133. The new substitution pattern of 3,4-difluorophenyl seen in compounds 3.134 – 
3.136 retained activity, prompting the synthesis of future compounds that to explore 
monofluorinated phenyl ring systems. Finally, in general, it appears alkylation of this 
methylene linker is not beneficial, as methyl and gem-dimethyl variants did not show an 
increased potency in the influx assay as seen with compound 3.131 vs 3.137 vs 3.140. 
While the alkylated derivatives did not lose activity, they did not gain any. 
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Section 3.2.8 Further Exploration of Spacer Region Results in Most Potent Compounds 
Discovered to Date 
With the phenoxymethylene linker-containing compounds proving efficacious in 
the influx assay, we sought to further explore compounds of a similar nature by changing 
the phenoxy moiety to an aniline, more closely resembling the parent compound. 
Furthermore, the spacer was elongated in some cases to two methylene groups and 
monofluorinated phenyl substitution patterns were included given the success of 
compounds 3.134 – 3.136. The synthesis of one of the final libraries of compounds is 
shown in Scheme 3.9 and follows the same EDC-mediated amide formations prevalent 
through earlier sections. 
Scheme 3.9 Synthesis of anilino derivatives with methylene and ethyl linkers 
 
Table 3.9. Synthesis of anilino derivatives with methylene and ethyl linkers 
 
 
 
 Compound R1 R2 n IC50[a]  
3.143 3-CF3 3-CF3 1 5.9 ± 1.7 
3.144 3,5-(CF3)2 
3-CF3 1 1.9 ± 0.5 
3.145 3-CF3 2,4-F2 1 8.3 ± 1.2 
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The synthesized compounds were tested for their ability to inhibit progesterone-
induced calcium influx as per our standard protocol. These compounds were expected to 
be rather potent based on the compounds found in Table 3.8, and this is indeed the case 
with the two most potent compounds to date being found within this library: 3.147 and 
3.148. These two compounds are fluorinated anilines with a methylene spacer between the 
piperazinylamide and the eastern aryl group. 
It is perhaps not surprising that these compounds have a m-CF3 group on the 
western phenyl ring. Nonetheless, these compounds are the first submicromolar inhibitors 
discovered in this campaign and consistently displayed a potent block in our FLIPR assay 
as shown in Figure 3.4. Other very potent compounds are seen in Table 3.9 including 3.144 
and 3.160. Of particular interest is 3.160, since this compound was one of only two 
compounds with an ethyl linker to show activity in the assay, see compounds 3.153 – 3.159. 
3.146 3-CF3 4-Cl 1 4.6 ± 0.6 
3.147 3-CF3 2-F 1 0.51 ± 0.12 
3.148 3-CF3 4-F 1 0.46 ± 0.03 
3.149 3-Me 2,4-F2 1 5.9 ± 1.0 
3.150 3-Me 4-Cl 1 11 ± 1.7 
3.151 3-Me 2-F 1 6.6 ± 1.4 
3.152 3-Me 4-F 1 5.1 ± 0.2 
3.153 H H 2 >100 
3.154 3-Me H 2 >100 
3.155 3-CF3 H 2 >100 
3.156 H 2-NO2, 4-CF3 2 >100 
3.157 3-Me 2-NO2, 4-CF3 2 >100 
3.158 3-CF3 2-NO2, 4-CF3 2 >100 
3.159 H 3-F 2 >100 
3.160 3-Me 3-F 2 2.9 ± 0.3 
3.161 3-CF3 3-F 2 5.5 ± 2.1 
[a]Data presented in µM as mean ± SD and represent 3 individual experiments in all cases. 
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Compound 3.161 was the other active ethyl linker analog. Interestingly, 3.160 is the more 
potent of the compounds, yet bears a m-methyl substitution, while 3.161 has the typically 
more potent m-CF3 substitution. An interesting deviation from a consistent trend. 
Section 3.2.9 Probing the Piperazinyl Nitrogen via Heterocyclic and CH Replacement  
In an attempt to possibly find yet more potent compounds, an additional small 
collection of compounds was synthesized as shown in Scheme 3.10. 
Scheme 3.10 Synthesis of pyrimidinylpiperazine analogs 
 
Combining the potent carboxylic acids from Scheme 3.9 with the underutilized 
pyrimidinylpiperazine, it was hypothesized that this combination could potentially lead to 
Figure 3.4. Dose-Response Curves of 3.147 and 3.148 from influx assay. Data are 
plotted as mean ± standard error, presented as a percent response relative to an EC50 
dose of progesterone (30 nM). Smooth curves represent the best fits of a nonlinear 
regression model to the data for each compound. IC50 values determined using Prism 
v8.02. 
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potent compounds. As seen in Table 3.10, this was not the case. Previously, compound 
3.60 was the only compound with a pyrimidinylpiperazine moiety and was totally inactive 
in the assay. Optimism winning out, 5 compounds were synthesized and tested. One of the 
compounds did show activity in the assay though the potency left much to be desired. 
Table 3.10. Potencies of synthesized pyrimidinylpiperazine analogs 
 
 
 
Compound R1 IC50[a] 
3.162 3-CF3 >100 
3.163 2,4-(F)2 >100 
3.164 4-Cl >100 
3.165 2-F 22 ± 2 
3.166 4-F >100 
[a]Data represented as mean ± SD and represent 2 individual experiments in all cases except 
where activity was observed, then 3 replicates were performed. 
While synthesizing the various analogs of 3.9, the obvious electronic contributions 
of the western phenyl ring were observed consistently, with electron withdrawing groups 
seemingly required. As a final experiment a piperidine analog was synthesized, in which 
the Western nitrogen of the piperazine ring is replaced by a carbon. meta Electron 
withdrawing groups will lower the electron density of the piperazinyl nitrogen, raising its 
pKa. Given that this nitrogen is less likely to be protonated at relevant pHs, the activity of 
the parent compound should be “protonated nitrogen” agnostic. This is indeed the case, 
Figure 3.5 shows that piperidine compound 3.167, having a -CH- group in place of the 
anilinic nitrogen, is just as potent as 3.9. While not conclusive, this result suggests future 
analogs of this scaffold need not contain this potential metabolic liability. 
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Section 3.2.10 Verifying Synthesized Compounds Via CASA 
 As described before, CASA is computer-aided sperm analysis and measures the 
motility of live human sperm cells by tracking key kinematic parameters such as velocity 
and the amplitude of lateral head displacement. Having synthesized and tested over 160 
compounds in the FLIPR assays, validation of the two submicromolar compounds in a 
secondary assay was sought. The secondary assay used was CASA. Figure 3.6 summarizes 
the effect of compounds 3.9 (initial hit), 3.147, and 3.148. 
All the tested compounds affect normal motility at the concentrations tested to a 
significant degree. The parent compound 3.9 was tested at higher concentrations than the 
synthesized compounds due to the discrepancies in potency between the compounds. The 
Figure 3.5. A Piperazinyl Nitrogen is not Needed for Activity of Analogs. (A) 
Structures of 3.9 and 3.167 with circle highlighting difference in structure. (B) Dose-
response curves of piperidine-containing 3.167 and piperazine-containing 3.9. Data are 
plotted as mean ± standard error, presented as a percent response relative to an EC50 
dose of progesterone (30 nM). Smooth curves represent the best fits of a nonlinear 
regression model to the data for each compound. IC50 values determined using Prism 
v8.02. 
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two synthesized compounds effectively reduce motility in human sperm at 0.1 and 1 µM. 
Compound 3.148 is especially potent, showing only 33% remaining motility at 0.1 µM.  
It would be expected that a CatSper inhibitor would have minimal effect on normal 
motility parameters, however as observed in Chapter 2, the known t-type CCBs mibefradil 
and NNC 55 0396 have potent effects on normal motility in human sperm, indicating 
precedence for the observed effects these synthesized analogs are having on normal 
motility parameters. 
With respect to HAM, the synthesized compounds drastically impact HAM evoked 
by both PGE1 (Figure 3.7) and progesterone (Figure 3.8). At 100 nM 3.147 is able to 
effectively prevent cells from achieving HAM and at 1 µM both compounds are able to 
completely ablate the population of cells displaying HAM to zero or near zero.  
Figure 3.6. Compound 3.9 and Derivatives 3.147 and 3.148 Reduce both Total (black) 
and Progressive (gray) Motility in Human Sperm. Data are plotted as mean ± standard 
error, representing the mean of 4 replicate experiments, and *P < 0.05, **P < 0.005, 
***P < 0.0005, ****P < 0.0001. 
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The three compounds all show an improved efficacy with respect to inhibiting 
HAM over normal motility. For instance, at 1 µM parent compound 3.9 shows little effect 
on normal motility, but significantly impacts HAM. The same can be said for 3.147, which 
has limited impact on normal motility at 100 nM, yet nearly completely knocks down HAM 
at this concentration. Compound 3.148 is a bit of a stranger case in that it shows a 
pronounced effect on normal motility even at 100 nM, but, at this concentration, has a 
negligible effect on HAM elicited by both PGE1 and progesterone, though complete 
inhibition of HAM at 1 µM is seen. This oddity requires further investigation and the 
recruitment of additional progesterone-sensitive donors to fully elucidate this interaction. 
Section 3.3 Fragment-Inspired Approach towards Development of 
GPHR-00213869  
Section 3.3.1 Initial Observations and Retrosynthetic Strategy 
Figure 3.7. Effect of compound 3.9 and Derivatives 3.147 and 3.148 on HAM Induced 
by Treatment with 100 nM PGE1. Data are represented as means ± SD; data represent 
the means of 4 individual experiments in all cases; and ***P < 0.0005. 
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While the development of hit compound 3.9 was ongoing, forays into the 
development of 3.12 were planned and begun. Hit compound 3.12 was found, perhaps 
unsurprisingly given its structure, from a kinase inhibitor library. Showing an initial IC50 
value of 21 ± 2 µM and 10 ± 2 µM for progesterone- and K+-induced calcium influx 
respectively, this hit compound was chosen for further development based on promising 
electrophysiology data in human sperm and a lack of cytotoxicity in both sperm and 
somatic cells up to 100 µM. 
  
Figure 3.8. Effect of Compound 3.9 and its Synthesized Derivatives 3.147 and 3.148 
on HAM Induced by Treatment with 100 nM Progesterone (P). Data are represented as 
means ± SD; data represent the means of 4 individual experiments in all cases; and *P 
< 0.05, **P < 0.005. 
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Scheme 3.11 Retrosynthetic analysis of hit compound 3.12 
 
Hit compound 3.12 has a more complicated structure than 3.9, containing a 
triazolopyridine core with a piperidine linker tying into an amide side chain. Scheme 3.11 
shows the retrosynthetic analysis for synthesis of target molecule 3.12. Disconnecting the 
side chain in the northeastern quadrant of the molecule and subsequent decoupling of the 
piperidine linker from the aromatic heterocycle gives a core heterocycle which can be 
disconnected to reveal 3-hydrazinylpyridazine and anhydrides as the starting materials. 
While compound 3.9 lent itself to the rapid generation of analogs via matrix 
chemistry, it would not be prudent to undertake the same strategy with 3.12. Requiring four 
steps to complete the synthesis, though rather abridged, would still give an exceedingly 
high number of analogs if each modification were to be explored in full. As such, a 
fragment-inspired approach to the development of 3.12 was undertaken and the description 
of the preliminary results follow. 
Section 3.3.2 General Strategy Towards Potent Analogs of GPHR-00213869 (3.12) 
As can be seen clearly in Scheme 3.11, the first step of the synthesis towards 3.12 
is a condensation cyclization reaction akin to those pioneered by Bischler and Napieralski. 
This robust chemistry allows for the electrophilic intramolecular formation of the triazolo 
or imidazole cores found in many natural products and drug molecules. For our efforts, this 
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chemistry allowed us to synthesize a series of compounds with varying nitrogen 
compositions. While varying the anhydride partner used in the reaction, a series a low 
molecular weight fragments could be envisioned as shown in Scheme 3.12. 
Scheme 3.12 General synthesis of southwestern fragments 
 
 
The starting material for this chemistry was affordable and the reactions were quite 
robust, as will be described. This chemistry was used to generate a focused library of 
fragments containing 64 compounds all of which were tested in the influx assay at two 
concentrations for their ability to inhibit calcium influx. The synthesis and testing of these 
analogs are described below. 
Section 3.3.3 Synthesis and Evaluation of 1,2,4-triazolo[4,3-b]pyridazine Core-
Containing Fragments 
The fragment library containing all four nitrogen atoms present in parent compound 
3.12 constitute 16 of the 64 compounds synthesized and bears a triazolopyridazine core. 
Interestingly, it was found that the phosphorous (IV) oxychloride usually required for these 
intramolecular cyclization chemistries to function was not needed, with the reaction 
proceeding smoothing in toluene under reflux as shown in Scheme 3.13 below. 
Scheme 3.13 Synthesis of [1,2,4]-triazolo[4,3-b]pyridazine heterocycles 
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Table 3.11. Percent inhibition of triazolopyridazine core compounds 
 
Compound R %Inhibition (30 µM) %Inhibition (100 µM) 
3.168 H 65 ± 12 65 ± 16 
3.169 3-Me 54 ± 10 53 ± 19 
3.170 3-CF3 50 ± 12 42 ± 14 
3.171 4-Me 55 ± 17 63 ± 20 
3.172 4-CF3 43 ± 21 22 ± 6 
3.173 4-OMe 44 ± 10 37 ± 11 
3.174 4-F 35 ± 19 49 ± 14 
3.175 4-Cl 53 ± 17 50 ± 20 
3.176 3-py. 22 ± 22 41 ± 23 
3.177 3,4-Cl 15 ± 9 34 ± 21 
3.178 4-C(CH3)3 61 ± 11 43 ± 13 
 
3.179 Me 29 ± 17 61 ± 8 
3.180 n-Butyl 51 ± 12 50 ± 20 
3.181 C(CH3)3 35 ± 18 31 ± 15 
3.182 CF3 49 ± 17 48 ± 13 
3.183 CCl3 72 ± 7 58 ± 15 
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 The substitution pattern stemming from the variable group on the symmetric 
anhydride were selected with inspirations taken from the work of Topliss, featuring 
different hydrophobicity constants (π) and substituent constants (electronics, σ) among all 
analogs synthesized.126 As mentioned, the synthesized compounds were tested for their 
ability to inhibit the progesterone-mediated calcium influx in our FLIPR assay. Given the 
low molecular weight of the compounds, and the desire to keep the number of assays to a 
minimum, the compounds were screened initially at two concentrations of 100 and 30 µM. 
The results of these assays are provided in Table 3.11. 
From Table 3.11 it is apparent that a rather narrow SAR is observed, with all 
compounds showing some level of activity, but no compound displaying markedly 
increased potency over the rest. Since potencies were similar across the tested compounds, 
favor was given to those compounds which showed a good dose-dependent action. Many 
of the compounds displayed the same levels of inhibition at both concentrations, so the 
compounds showing good potency while also showing a reasonable improvement of 
potency at 100 µM over 30 µM (3.171, 3.174, 3.179) were marked as targets for resynthesis 
and retesting.  
Data represented as mean ± SD and represent 3 individual experiments. In all cases, 
signal evoked by 30 nM progesterone. py. = Pyridine with numbering representing 
the position of endocyclic nitrogen. 
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The m-Me substitution pattern found in compound 3.169 performed well, showing 
some of the better potency, though a dose-dependent effect was not observed. Interestingly, 
the unmodified phenyl substitute found in compound 3.168 proved to be quite a potent 
compound in the assay. Furthermore, bulky aliphatic groups, such as those seen in 3.178 
and 3.181 did not perform well, neither did heterocyclic replacements (3.176) nor 
trihalomethyl groups that were appended to phenyl rings (3.182, 3.183). Figure 3.8 shows 
the graphs associated with the data from Table 3.11. 
Section 3.3.4 Compounds containing a [1,2,4]triazolo[4,3-a]pyridine as Additional 
Fragments 
Scheme 3.14 Synthesis of [1,2,4]-triazolo[4,3-a]pyridine heterocycles 
 
Figure 3.8. Activity of Triazolopyridazine Library in a Calcium Influx Assay. Data are 
plotted as mean ± standard deviation, representing the mean of 3 replicate experiments. 
Compounds tested at 30 µM (dark grey) and 100 µM (light grey) against 30 nM 
progesterone.  
 104 
As part of generating the fragment library, the systematic removal of the endocyclic 
nitrogen atoms of the southwestern ring system was planned. As such, the next series of 
compounds from which a library was synthesized removed one of the pyridazinyl nitrogen 
atoms, giving a triazolopyridine core. The chemistry used to synthesize this library is 
shown in Scheme 3.14 but is unchanged from Scheme 3.13. Again, the need for POCl3 was 
not observed, with refluxing conditions in toluene sufficient to induce the intramolecular 
cyclization. 
The synthesis of this class of fragment proceeded smoothly and 13 fragments were 
added to the library. The activity of these compounds is shown in Figure 3.9. Again, these 
compounds were tested at two concentrations to minimize the number of assays run and 
the data is presented as %remaining activity of a 30 nM dose of progesterone. 
 In general, removal of the superfluous nitrogen atoms (with respect to the 
chemistry) improved the activity of the compounds slightly, indicating that this extra 
Figure 3.9. Activity of Triazolopyridine Library in a Calcium Influx Assay. Data are 
plotted as mean ± standard deviation, representing the mean of 3 replicate experiments. 
Compounds tested at 30 µM (dark grey) and 100 µM (light grey) against 30 nM 
progesterone.  
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nitrogen atom is not needed for activity. Indeed, the fact that all the compounds showed 
activity aids this point. The percent remaining activity of each compound is given in Tables 
3.12 for the phenyl and alkyl derivatives, respectively. 
Table 3.12. Percent inhibition data for triazolopyridine core compounds 
 
Compound R %Inhibition (30 µM) %Inhibition (100 µM) 
3.184 H 33 ± 8 45 ± 12 
3.185 3-Me 34 ± 11 34 ± 13 
3.186 3-CF3 41 ± 12 29 ± 9 
3.187 4-Me 40 ± 10 34 ± 10 
3.188 4-CF3 46 ± 10 40 ± 9 
3.189 4-OMe 51 ± 11 38 ± 11 
3.190 4-F 55 ± 16 52 ± 13 
3.191 4-Cl 28 ± 4 29 ± 14 
3.192 3,4-Cl 26 ± 10 21 ± 10 
 
3.193 3-py. 46 ± 9 51 ± 10 
3.194 n-Butyl 30 ± 9 39 ± 11 
3.195 C(CH3)3 37 ± 9 50 ± 8 
3.196 3-CF3 42 ± 9 49 ± 11 
Data represented as mean ± SD and represent 3 individual experiments. In all cases, 
signal evoked by 30 nM progesterone. py. = Pyridine with numbering representing 
the position of endocyclic nitrogen. 
Similar trends were observed between the triazolopyridine and triazolopyridazine 
libraries. To start, the unsubstituted phenyl analog 3.184 shows similar activity to its 
triazolopyridazine counterpart 3.168 though its potency is reduced (68 vs 35% remaining 
activity). There is no significant trend between closely related analogs of the first two 
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libraries. That is to say not all triazolopyridazines are more/less potent than there 
triazolopyridine counterparts. That said, several compounds from this library showed good 
inhibition of the progesterone-induced influx, especially the lower molecular weight alkyl 
derivatives from Table 3.12 (3.194 – 3.196). 
Section 3.3.5 Generation of a Fragment Library with Compounds Containing an 
Imidazo[1,5-a]pyridine Core 
The last library systematically modifying the endocyclic nitrogen atoms of the 
southwestern fragment was a collection of compounds containing an imidazopyridine core. 
The synthesis of these compounds followed that of the previous libraries, though in this 
case the POCl3 was needed for the intramolecular cyclization to proceed. DCE was needed 
to access temperatures high enough to breach the activation energy of the reaction; DCM 
proved insufficient. 
Scheme 3.15 Synthesis of imidazo[1,5-a]pyridine heterocycles 
 
The synthesis of a small library of imidazopyridine core compounds was completed 
in short time and these compounds were assayed in the influx assay previously described. 
The results of these assays are shown in Table 3.13 and Figure 3.10. In general, the 
imidazopyridine library contained compounds showing the best potency of all compounds 
tested. In particular, compounds 3.198–3.200 are the most potent fragments with nearly 
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70% inhibition at 30 µM and near complete inhibition at 100 µM. Unfortunately, @ 100 
µM 3.198 affected the signal of the assay to such a degree that a reliable IC50 value could 
not be obtained. Nonetheless its potency at 30 µM was quite promising. 
Table 3.13. Percent inhibition data for triazolopyridine core compounds 
 
Compound R %Inhibition (30 µM) %Inhibition (100 µM) 
3.197 H 65 ± 11 48 ± 14 
3.198 3-Me 72 ± 6 ND 
3.199 3-CF3 61 ± 9 98 ± 2 
3.200 4-Me 70 ± 6.8 91 ± 12 
3.201 4-CF3 37 ± 9 62 ± 5 
3.202 4-F 53 ± 7 36 ± 8 
3.203 4-Cl 62 ± 10 44 ± 5 
 
3.204 3-py. 63 ± 9 61 ± 10 
3.205 Me 45 ± 8 42 ± 15 
3.206 n-Butyl 49 ± 11 57 ± 9 
Data represented as mean ± SD and represent 3 individual experiments. In all cases, 
signal evoked by 30 nM progesterone. py. = Pyridine with numbering representing 
the position of endocyclic nitrogen. ND = not determined. 
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 Yet again, as in all libraries synthesized so far, the phenyl derivative 3.197 shows 
good potency at 30 µM, it its activity at 100 µM is lower. The p-CF3 group found in 3.201 
confers good potency at 30 µM, like its m-CF3 counterpart in compound 3.199, however 
the activity at 100 µM was not increased compared to 30 µM, so this compound was not 
pursued further. Compound 3.204 is one of the first heterocyclic substitutions to show good 
activity at 30 µM, though at 100 µM no increase is observed. 
Section 3.3.6 Further Amide Fragments from Imidazo[1,5-a]pyridine Core Library 
The final library to be discussed resulted from a mistake by an undergraduate 
research assist who was working in the lab at the time. As can be seen in Scheme 3.15, the 
solvent for the intramolecular cyclization needed to be DCE to access higher temperatures. 
Figure 3.10. Activity of imidazopyridine library in a calcium influx assay. Data 
presented as percent remaining activity compared to signal evoked by 30 nM 
progesterone. Compounds tested at 30 µM (dark grey) and 100 µM (light grey). Data 
are plotted as mean ± standard deviation, representing the mean of 3 replicate 
experiments. No data for 100 µM 3.198 was obtained. 
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However, the researcher misread the lab notebook and used DCM in its place. In this 
solvent, only the initial addition product is observed as shown in Scheme 3.16. 
Scheme 3.16 Synthesis of an amide library 
 
Several analogs corresponding to these ring-opened amides were isolated before 
this oversight could be remedied. However, given the nature of the project, these 
compounds were simply treated as additional, easily accessible compounds. 
Table 3.14. Percent inhibition data for amide library 
 
Compound R %Inhibition (30 µM) %Inhibition (100 µM) 
3.207 H 32 ± 18 63 ± 8 
3.208 3-Me 37 ± 14 60 ± 12 
3.209 4-Me 33 ± 19 66 ± 21 
3.210 4-CF3 49 ± 18 72 ± 19 
3.211 4-OMe 58 ± 17 41 ± 4 
3.212 4-F 53 ± 17 45 ± 8 
3.213 4-Cl 57 ± 25 47 ± 11 
3.214 3,5-Cl 30 ± 23 89 ± 25 
3.215 4-C(CH3)3 50 ± 15 83 ± 22 
 
3.216 3-py. 67 ± 19 52 ± 18 
3.216 Me 25 ± 5 66 ± 17 
3.217 n-Butyl 42 ± 5 60 ± 14 
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Data represented as mean ± SD and represent 3 individual experiments. In all cases, 
signal evoked by 30 nM progesterone. py. = Pyridine with numbering representing 
the position of endocyclic nitrogen. 
 
 A small library of amides resulted and these compounds were tested as previously 
described. Of note, while POCl3 was added to the first few reactions, once it was decided 
to synthesize the remaining analogs, this step was obviously not performed. 
As shown in Table 3.14, some of these serendipitous fragments are actually quite 
potent inhibitors of the progesterone-induced calcium influx, showing that methylamine 
derivatives can be used in the future development of this compound in addition to the 
cyclized products. In general, the same trends observed with the ring-closed analogs 
continue with this library of amides, with phenyl (3.207), m-Me (3.208) and CF3 groups 
(3.210) presenting the most active compounds. The 3,5-dichlorophenyl derivative 3.214 
Figure 3.11. Activity of Ring-Opened Amide Fragment Library in the Calcium Influx 
Assay. Data presented as percent remaining activity of signal evoked by 30 nM 
progesterone. Compounds tested at 30 µM (dark grey) and 100 µM (light grey). Data 
are plotted as mean ± standard deviation, representing the mean of 3 replicate 
experiments. 
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showed a great dose response, however solubility issues prevented this compound from 
being pursued further.  
Section 3.3.7 Validating the Fragment-Based Approach Via Synthesis and Evaluation of 
Test Compounds 
During the course of generating and evaluating the discussed libraries, a valid 
question was raised: What percent of a particular compound’s activity is derived from the 
omnipresent halogen? This halogen was included on each molecule because it serves as the 
handle for second step chemistries involving either SNAr displacements or Buchwald-
Hartwig couplings. This handle was kept on the tested analogs in an attempt to save costs 
and time, as not all compound was used in to assay activity and remaining powder could 
be taken into these next steps immediately. 
That said, as a control, several dehalogenated analogs were synthesized and tested 
for their ability to inhibit calcium influx in human sperm. Comparing their activities to 
their halogenated counterparts would presumably show activity caused by the halogen. It 
Figure 3.12 Comparison of Test Compounds with or without an Aryl Halide. Data 
presented as percent of signal evoked by 30 nM Progesterone. Compounds tested at 30 
µM (dark grey) and 100 µM (light grey). Data are plotted as mean ± standard deviation, 
representing the mean of 3 replicate experiments. 
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was expected that the dehalogenated compounds would be slightly less potent than their 
halogenated partners, but that activity profiles would remain similar. If this were the case, 
then the strategy used so far would be legitimized. 
The synthesis of these control compounds is identical to that of their halogenated 
derivatives in the relevant schemes shown previously. Figure 3.12 shows the results of this 
test to be positive. 
 In both tested compounds, the dehalogenated derivative 3.218 and 3.219 show 
sufficiently similar activity to that of the originally tested compound (3.168 and 3.184) so 
as to not induce doubt in the previously reported data. While not conclusive, this 
experiment helps to show that the activity observed in the assay is almost certainly from 
the other molecular features present on the tested molecules and not that of the halogen. 
Section 3.3.8 Fragment Library Part Two: Confirming Activity of Most Potent Fragments 
in Influx Assay 
In the synthesis and characterization of the four focused libraries, 51 compounds 
were generated and tested in the influx assay. Of these 51 compounds several showed a 
promising ability to inhibit the progesterone-mediated calcium influx in human sperm. 
Before continuing with the next step of the synthetic route (transition-metal couplings or 
SNAr displacements), verification of a select few compounds and subsequent selection of 
a few key fragments was desired. To this end, as shown in Table 3.15, a small cohort of 
promising fragments, as determined by their initial results, were resynthesized, verified 
pure by qNMR and UPLC and assayed again in the influx assay. This time, given their 
already promising activity, the compounds were assayed at lower concentrations, being 10 
and 30 µM, rather than 30 and 100 µM. 
 113 
Table 3.15. Resynthesized compounds and their potencies at lower 
concentrations 
 
Compound R X Y Z %Inhibition 
(10 µM) 
%Inhibition 
(30 µM) 
3.220 (3.198) 3-Me CH CH Br 31 ± 10 52 ± 5 
3.221 (3.199) 3-CF3 CH CH Br 30 ± 9 62 ± 5 
3.222 (3.200) 4-Me CH CH Br 15 ± 6 33 ± 8 
3.223 (3.168) H N N Cl 9 ± 2 30 ± 5 
3.224 (3.169) 3-Me N N Cl 26 ± 6 15 ± 5 
3.225 (3.171) 4-Me N N Cl 8 ± 2 29 ± 3 
3.226 (3.174) 4-F N N Cl 16 ± 7 29 ± 3 
 
3.227 (3.210) 4-CF3 CH2 CH Br 17 ± 13 23 ± 2 
3.228 (3.216) 4-C(CH3)3 CH2 CH Br 9 ± 4 26 ± 10 
Data represented as mean ± SD and represent 3 individual experiments. 
Compound number in parenthesis corresponds to previously synthesized 
compound number. 30 nM Progesterone was used to evoke signal in all assays. 
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As can be seen from Table 3.15 and Figure 3.13, the resynthesized compounds 
retained activities close their original levels of inhibition, a promising observation. For the 
sake of comparison, the original compound number for the first iteration of synthesis if 
provided in parenthesis in the table. Compounds 3.223 – 3.228 show around 70% 
remaining activity when retested at these lower concentrations. These values are similar to 
those previously seen with these compounds. Moreover, a dose response is seen in all 
compounds except 3.224 which showed equal inhibition at both concentrations tested. 
Figure 3.13. Activity of Resynthesized Compounds in a Calcium Influx Assay. Data 
presented as percent remaining activity compared to signal evoked by 30 nM 
Progesterone. Compounds tested at 10 µM (dark grey) and 30 µM (light grey). Data are 
plotted as mean ± standard deviation, representing the mean of 3 replicate experiments. 
Figure 3.14. Structures of Chosen Fragments from Synthesized Fragment 
Libraries. 
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In general, the fact that the compounds inhibited the influx at these lower 
concentrations, given their low molecular weights, is a promising result. However only 
three compounds were chosen for further elaboration. The compounds 3.220, 3.221 and 
3.222 are shown in Figure 3.14 that showed the best potency of all the retested fragments. 
Section 3.3.9 Ongoing Work: Towards Larger Molecular Weight Fragments of GPHR-
00213869 
The chosen fragments from Figure 3.14 are to be elaborated upon as shown in 
Scheme 3.17. It should be noted that, while not discussed, the 3-Me triazolopyridazine-
containing fragment, bearing the same substitution pattern seen in 3.12, will also be 
subjected to coupling reactions to synthesize a small number of compounds bearing this 3-
Me triazolopyridazine southwestern fragment. This small subset of compounds can serve 
as a pseudo control set, since their substitution pattern will eventually result in the 
resynthesis of the parent compound. Increases in potency from the novel analogs would be 
desired over the parent substitution pattern. 
The chemistries currently being utilized are meant to explore the linking of the 
piperidine ring found in 3.12. Modifications to this ring include ring expansions and 
contractions to both the corresponding homo-piperidine and pyrrolidine (Scheme 3.17, top 
reaction). Further nitrogen-containing rings are being pursued including piperazine, homo-
piperazine as well as pyrrole linkers. Fourteen commercially available nitrogen coupling 
partners have been purchased and will be coupled to each of the fragments by Buchwald-
Hartwig chemistry. Additionally, Suzuki-Miyaura reactions can be utilized to introduce 
aryl-aryl linkages via the corresponding pinacol boronic esters (Scheme 3.17, bottom 
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reaction). A series of 15 boronic esters and acids have been purchased and will be coupled 
to the chosen fragments to generate libraries of compounds for testing. 
 Each potential analog building off the southwestern heterocycle contains a methyl 
ester group, so as to standardize this group’s reactivity, much like the halogens in the 
discussed libraries. By holding this group constant, increases/decreases in activity can be 
correlated to the other introduced molecular features. After completion of this linker region 
library of compounds, compounds can be chosen in a manner similar to that described in 
this section. Then this methyl ester can be hydrolyzed using LiOH·2H2O (Scheme 3.18) 
and further analogs can be generated via EDC couplings to generate a large variety of 
analogs. Fischer esterification could also be utilized to explore the activity of esters at this 
position. Though, given their metabolic instabilities, it is perhaps merited to explore amides 
Scheme 3.17 Current and future reactions exploring linker region of 3.12 (inset) 
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to a greater degree. Preliminary SAR by commerce explored this modification and 
therefore it is known that amide formation is a viable approach to generate active analogs. 
Section 3.4 Discussion and Overarching Observations from Hit-to-Lead 
Development Endeavors 
After the preliminary work of Dr. Francis revealed narrow SAR patterns for all the 
HTS hit compounds, the best indicators for which of the hits should be developed further 
came from electrophysiology data provided by the Lishko lab at UC–Berkeley. This data 
showed the two compounds GPHR-00032750 (3.9) and GPHR-00213869 (3.12) were able 
to fully block the progesterone-mediated current in human sperm at 1µM. From this, the 
development of these two compounds was undertaken and some amount of success was 
achieved with respect to both of them. It should be said that the development of both these 
inhibitors is still ongoing and the work discussed in this chapter constitutes only a portion 
of an ongoing story. 
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Section 3.4.1 The Development of GPHR-00032750 
 The development of GPHP-00032750 (3.9) was begun in earnest in early 2015. The 
biphenylpiperazine scaffold lent itself to the rapid generation of analogs via facile 
chemistries. As such, the first library of compounds synthesized sought to explore the two 
phenyl ring substitutions present in the molecule via basic modifications probing the 
electronics of the two phenyl rings. In this library it was shown for the first, though not the 
last, that EWGs at the meta position are highly coveted and bring about the best activity, 
especially when comparing compounds 3.9 to 3.17. From this library, and confirmed in 
subsequent libraries, the general trend of –CF3 = –NO2 > Me >> Ph was found. With respect 
to the western phenyl ring, substitutions at the meta position were the only which retained 
activity. 
As seen from the data for this library heterocyclic appendages to the eastern phenyl 
ring seen in compounds 3.32 and 3.33 retained activity, indicating a tolerance in this area 
for bulkier substitutions. So, a series of compounds in which the eastern phenyl ring was 
substituted with heteroaromatic groups was synthesized (Table 3.2, compounds 3.49 – 
3.54). These compounds further showed the tolerance of this eastern phenyl ring for bulky 
substitutions, so analogs in which an additional aryl system was appended were synthesized 
and assayed. As seen in Table 3.3, these extended analogs retained activity in many cases, 
but given the quickly rising molecular weights and lipophilicity of these compounds, a turn 
in strategy was taken.127  
Given the lack of success in modifying the two phenyl rings, alterations of the core 
of the molecule, such as probing the piperazinylurea moiety was sought. The piperazine 
ring was opened to give diamide-containing analogs or thiocarbamoic esters and the urea 
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group was replaced with a sulfonamide in several analogs (Tables 3.4 – 3.6). This strategy 
failed to yield compounds with improved activity, ultimately leading to a great majority of 
inactive compounds. 
Knowing now that modification of the piperazine, and furthermore the western 
phenyl group, was not likely to increase potency, the spacing group adjacent to the eastern 
phenyl group was explored. Analogs were synthesized in which the urea group was 
replaced with an aryl ketone (3.121–3.125 and 3.128–3.130). These compounds were 
largely inactive, leading to the conclusion that the aniline moiety of the phenyl urea was 
needed, or perhaps at least a methylene to serve as a spacer between the eastern phenyl ring 
and the urea since compounds 3.126 and 3.127 retained activity. 
Extending this spacer group to phenoxymethylene linkers seen in Table 3.8 started 
to show promising results, with every compound showing potency equal to the parent 
compound. Also, now that this spacer was extend by a carbon, an additional point of 
modification (the methylene carbon) became possible. However, alkylation of this carbon 
did not significantly increase potency as demonstrated by compounds 3.136–3.142 and was 
abandoned. 
With momentum turning in our favor we sought to further explore analogs of 
similar structure to those compounds in Table 3.8. It was promising that compounds 
showing submicromolar inhibition in our calcium influx assay were achieved by changing 
of the phenoxy group to an aniline while making use of less bulky, still electron 
withdrawing o- and p-fluoro substitutions. Compounds 3.147 and 3.148 show 
submicromolar IC50 values and constitute the most potent CatSper blockers observed to 
date (Figure 3.4).  
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These compounds were subjected to CASA to evaluate their abilities to reduce 
sperm motility (both normal and hyperactivated) characterized. Both compounds show an 
impressive ability to reduce both normal and hyperactivated motility (Figures 3.6 – 3.8). 
Compound 3.147 is able to significantly diminish the population of cells displaying HAM 
at 100 nM and at 1 µM completely ablates this population. Analog 3.148 had a diminished 
effect on HAM at 100 nM but also shows complete reduction of HAM at 1 µM. These 
compounds both significantly reduce normal motility parameters at both concentrations 
tested. 
Going forward, further analogs of 3.147 and 3.148 should focus on removing the 
anilines from the compound while maintaining potency, since this group can be a metabolic 
liability. Further work should confirm that these compounds do indeed inhibit CatSper and 
not the recently characterized activity of the ubiquitously expressed ABHD2.128 
Confirmation of the activity of these compounds via electrophysiology is ongoing and will 
serve as the final test for these potent inhibitors of this intriguing channel. 
Section 3.4.2 Fragment-Inspired Development of GPHR-00213869 
 As mentioned previously, 3.12 or GPHR-00213869 is a more drug-like hit 
compound compared to 3.9. This compound, however, requires more synthetic steps to 
generate analogs. To avert this set back, a fragment-inspired approach was taken towards 
the development of this compound, with optimization of the southwestern heterocycle and 
adjacent phenyl system serving as a starting point. 
 Four libraries of compounds are described in Sections 3.3.3 through 3.3.6. These 
libraries focused on discerning the need for the individual nitrogen atoms of the original 
triazolopyridazine core. It was found that not all nitrogen atoms are necessary for the 
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Bischler-Napieralski chemistry to function and could be removed and fragments with good 
potency could still be obtained as exemplified by compounds 3.220 and 3.221. Compounds 
containing more than the two necessary nitrogen atoms were still effective inhibitors, but 
the imidazopyridine fragments were the best performing compounds.  
 The phenyl ring adjacent to this heterocyclic core was also explored at great length, 
with substitution patterns being heavily influenced by Topliss considerations surrounding 
lipophilicity and substituent constants.126 A great variety of both hydrophilic vs 
hydrophobic along with EWG vs EDG were synthesized. In general, as for 3.9, EWGs were 
favored, with –CF3 groups predominating the list of most active compounds as 
demonstrated with analog 3.199. Several analogs were synthesized in which the entirety of 
the phenyl ring was removed, replaced by alkyl chains of varying length and configuration. 
These compounds retained a modicum of activity but were usually less active than their 
phenyl counterparts (see 3.198 vs 3.205).  
Given that each fragment tested thus far contained an aryl halogen, effort was put 
towards ensuring the activity of the synthesized compounds was derived from molecular 
features which would be present in the final molecules, rather than a halogen. To this end, 
test compounds 3.218 and 3.219 were synthesized and their activities compared to their 
halogenated counterparts. As seen in Figure 3.12, the phenyl and halogenated derivatives 
displayed similar levels of activity, helping to prove that the pertinent molecular features 
of the synthesized fragments were the cause of activity, though further testing would be 
needed for conclusive assertions. 
 In total, 51 fragments were synthesized and three were chosen after a series of 
compounds were resynthesized and retested at lower concentrations (Section 3.3.8). These 
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three compounds (3.220, 3.221 and 3.222) will be taken forward into subsequent 
chemistries to explore the next fragment of the molecules, being the piperidine linker. 
Work is ongoing and several SNAr reactions have been completed to generate an initial 
library with these three chosen fragments being coupled to a series of commercially 
available nitrogen nucleophiles. Generation of additional analogs via Suzuki and Buchwald 
chemistry is planned and following subsequent testing and confirmation of activity, a series 
of EDC reactions will generate a final library of compounds resembling very closely 3.12, 
though hopefully optimized for CatSper inhibition. If all goes to plan, potent compounds 
resembling 3.12 should result from these synthetic efforts with only around 150 compounds 
being synthesized rather than the over 10K possible analogs. 
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Chapter 4: Structure-Activity Studies of Aminocyclopentitols: 
Discovery of Potent and Selective Inhibitors of GBA1 and 
GBA2 
Section 4.1 Project Aim and Background 
Found widespread in plants and bacteria, iminosugars are compounds in which the 
endocyclic oxygen of the sugar is replaced by a nitrogen atom.129 While minimally 
changing the overall structure of the compound, this substitution results in different 
biological properties. Comparing the amine to the ether moiety, the differences in the 
electrostatic properties of these two functional groups become apparent (Figure 4.1). As 
such, the protonated amine 4.1 found in iminosugars make them excellent modulators of 
Figure 4.1. Iminosugars as a Molecular Class of Compounds. (A) Representation of 
protonated amine 4.1 versus oxocarbenium ion transition state 4.2 found in carbohydrate 
processing enzymes. (B) Structures of example iminosugars. Including approved drugs 
NB-DNJ 4.3 and miglitol (4.5). 
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carbohydrate processing enzymes, mimicking intermediate oxocarbenium ion 4.2 found in 
enzymatic catabolism of glycosidic linkages.130, 131 
Iminosugars have been tested as potential therapeutics for numerous indications. 
Given their similarity to carbohydrates, saccharide processing deficiencies and lysosomal 
storage disorders were the first disease states that are treated with iminosugars.132, 133 In 
2002 and 2003, respectively, miglustat (N-butyl deoxy-nojirimycin, NB-DNJ, 4.3) was 
approved as an orphan drug by the Federal Drug Administration and the European 
Medicines Evaluation Agency for the treatment of type 1 Gaucher disease.134 Also, miglitol 
(4.5) is an approved treatment for type 2 diabetes.135 Moreover, iminosugars have shown 
several other properties including antiviral,136 and, antibacterial137 activity. More recently, 
Figure 4.2. Inhibitory Effects on CGT, GBA1 and GBA2. These enzymes are 
responsible for the synthesis (A) and degradation (B) of glycosphingolipids, 
respectively. The IC50 values for NB-DNJ inhibition are shown in light grey. CGT = 
ceramide-specific glucosyltransferase. GBA1 = Glucocerebrosidase 1 (lysosomal) 
GBA2 = Glucosylceramidase 2 (non-lysosomal) Figure and IC50 values adapted from 
previous reports. 141 
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iminosugars have been reported as cystic fibrosis transmembrane conductance (CFTR) 
correctors.138, 139 Several examples are shown at the bottom of Figure 4.1. 
The biological activities of iminosugars are extensive but of relevance to this work 
is the ability of these compounds to modulate the glycosphingolipid metabolic pathway. 
Figure 4.2 illustrates this pathway containing several key enzymes that are inhibited by 
NB-DNJ and its diastereomer N-butyldeoxy-galactonojirimycin (4.4, NB-DGJ). These 
compounds can inhibit the enzymes responsible for both the formation and degradation of 
glucosylceramide: ceramide-specific glucosyltransferase (CGT) and β-glucosidase 1 
(lysosomal) and 2 (non-lysosomal).140-143 
 In 2002, it was shown that inhibition of these two enzymes can cause reversible 
loss of fertility in C57BL/6 mice.144 The study showed that these compounds affected 
formation of the acrosome, resulting in decreased motility and abnormal sperm 
morphology. However, these results could not be reproduced in humans, nor other species 
such as rats, rabbits and even different strains of mice.49, 145, 146 The discrepancies in these 
results among species as well as strains of mice is an ongoing area of research.147 
Figure 4.3. SAR of Six-Membered Iminosugars with Respect to CGT Inhibition. Figure 
adapted from reference 138. 
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The six-membered iminosugars NB-DNJ (4.3) and NB-DGJ (4.4) inhibit GBA1 
and GBA2 more effectively than CGT. This observation served as evidence that inhibition 
of GBA2 rather than CGT is responsible for the male contraceptive effects.148 Furthermore, 
it was shown later that GBA2 knockout mice were infertile.149 The SAR of the six-
membered iminosugars acting at these enzymes is well known with many studies seeking 
to improve both potency and selectivity of the scaffold for aforementioned reasons. The 
known SAR is shown in Figure 4.3. Any substitution to the C2 position of the ring, as well 
as alkylation of the C4 hydroxyl group completely ablates activity. The adjacent 
stereocenter at the C5 position can be either in alpha or beta orientation. Ring size of the 
glucose scaffold can vary greatly while retaining activity with analogs comprising 4- to 8-
membered rings.150 
Perhaps the most studied structural modification is the alkylation of the endocyclic 
nitrogen that generate N-alkyl iminosugar analogs.143 Studies have shown the inhibitory 
activity of compounds bearing hydrophobic alkyl groups at this nitrogen directly correlate 
with hydrophobicity.48 The most potent 6-membered iminosugar inhibitor of CGT, GBA1 
and GBA2 bears a [(5-adamantan-1-yl-methoxy)pentyl] group off the nitrogen. This 
compound, AMP-DNJ (Figure 4.1, 4.7) displays selective inhibitory activity for GBA2.151 
In an effort to further improve selectivity and potency for GBA2 we turned towards 
another class of iminosugars known as aminocyclopentitols.152 These compounds are 
known inhibitors of glucosidases but had not yet been tested as inhibitors of CGT, GBA1 
or GBA2.153 Aminocyclopentitols bear an exocyclic amine that is protonated at relevant 
pH values, which mimics the oxocarbenium intermediate in the same manner as their 6-
membered iminosugar counterparts. Previous work from the Georg group had shown that 
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monoalkylated aminocyclopentitols bearing butyl and nonyl alkyl chains were potent 
inhibitors of GBA1 and GBA2, with little to no effect on CGT.143 Thus, the work discussed 
herein attempted to further improve the activity of this aminocyclopentitol scaffold at 
GBA1 and GBA2 by synthesizing dialkylated compounds similar to those previously 
synthesized, hypothesizing that the increased hydrophobicity of analogs would further 
increase activity. The synthesis and biological characterization of these compounds 
follows. 
Section 4.2 Synthesis of Aminocyclopentitol Targets 
The synthesis of aminocyclopentitol derivatives up to the late stage alkylation 
precursor 4.15 is shown in Scheme 4.1. Starting the synthetic route from methyl-alpha-D-
glucopyranoside (4.8), the primary alcohol was protected as the tert-butyl silyl ether to 
form trihydroxy compound 4.9. Subsequent protection of the remaining secondary alcohols 
was achieved with benzyl bromide and resulted in the fully protected pyranoside 4.10.  
Scheme 4.1 Synthesis of benzylated aminocyclopentitol alkylation precursor 4.15 
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Deprotection of the primary alcohol under acidic conditions provided compound 
4.11, which was converted to the corresponding iodide compound using 
triphenylphosphine and molecular iodine to give Vasella fragmentation precursor 4.12.154 
The aforementioned chemistry was used to open acetal 4.12 to the primary aldehyde while 
concomitantly converting the primary iodide to the olefin 4.13. This aldehyde, after 
reaction with hydroxylamine hydrochloride, formed an intermediate oxime, which 
underwent 1,3-dipole cycloaddtion in toluene to furnish the [4:2] bicyclic system 4.14. 
Cleavage of the N-O bond proceeded under reductive conditions to reveal the primary 
amine 4.15, which was the precursor for the final steps of the reaction. 
Before proceeding onto the final steps of target molecule synthesis, one of the side 
chains desired was an adamantyl ether side chain that required a five-step synthesis.155 As 
described previously, this adamantyl sidechain was desired based on glucose mimic 4.7 
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which bears this modification and displays great activity. Scheme 4.2 shows the synthesis 
of the adamantyl aldehyde 4.20, that later served as the coupling partner with 4.15, 
beginning from 1,5-pentanediol. 
Scheme 4.2 Synthesis of target adamantyl aldehyde 4.20 
 
Monotosylation of 1,5-pentanediol gave tosylate 4.16, which after Parikh-Doering 
oxidation of the alcohol was converted to aldehyde 4.17. Subsequent protection of this 
aldehyde as the corresponding acetal 4.18, followed by SN2 displacement of the tosyl group 
by deprotonated 1-adamantylmethanol furnished compound 4.19. This reaction required 
elevated temperatures and would not proceed under 40 °C. Finally, deprotection of the 
acetal under acidic conditions proceeded smoothly and gave the desired aldehyde 4.20 in 
a 2% overall yield due to a disappointing yield in the initial monotosylation. However, 1,5–
pentanediol is inexpensive and therefore scale-up of the first step to accommodate this low 
yield is not cost prohibitive. 
With the required synthesis of the adamantyl aldehyde accomplished, the synthetic 
route could be completed, and target molecules 4.24–4.26 were obtained (Scheme 4.3). 
Previous work on this project subjected the benzylated primary amine to reductive 
amination conditions after forming the HCl salt of the primary amine. Since dibenzylated 
derivatives were the targets, the reaction conditions leading to the alkylated debenzylation 
precursors were modified to the conditions shown in Scheme 4.3.  
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Scheme 4.3 Completion of synthetic route and acquisition of target aminocyclopentitols 
 
Dialkylation of the primary amine was achieved using sodium 
triacetoxyborohydride (STAB) in dichloroethane (DCE) at elevated temperature and 
provided the benzylated compounds 4.21–4.23. From here two different methods were 
employed to deprotect the three hydroxyl groups. In situ generation of H2 via 
decomposition of ammonium formate in the presence of palladium on carbon was 
sufficient for the deprotection of 4.21 and 4.23. However, this reaction was sluggish with 
respect to benzylated dinonyl compound 4.22. As such, Birch conditions were utilized to 
deprotect this lipophilic molecule. In the end, target aminocyclopentitols 4.24, 4.25, and 
4.26 were obtained in either 10 linear steps for 4.24 and 4.26 or 15 steps for 4.25. 
Section 4.3 Biological Evaluation of Synthesized Aminocyclopentitols 
 Until work performed by another student in the Georg group, no 
aminocyclopentitol derivatives had been tested for their ability to inhibit CGT. As such, 
novel analogs 4.24–4.26 were assayed for CGT, as well as GBA2 inhibitory activities.48 
The full details on the assays used to determine CGT, GBA1 and GBA2 activities have 
been reported.48  
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Briefly, for CGT, a HEPES-buffered solution containing UDP-glucose, target 
iminosugar, and microsomes isolated from either C57BL/6 mice or LE rats were incubated 
for 30 min in the presence of a BODIPY-tagged ceramide. Enzymatic activity transfers a 
glucose molecule to this fluorescent ceramide. The product resulting from CGT activity is 
determined by elution on a TLC plate and the fluorescent product is quantified in a 
transilluminator. For GBA1 and GBA2, a fluorescence-based assay utilizing 4-
methylumbelliferyl β-D-glucoside (MUG) was used. Iminosugar dilutions are combined 
with testicular microsomes from the species of interest. GBA1 or GBA2 activity leads to 
the hydrolysis of the MUG probe, releasing the umbelliferone thereby increasing 
fluorescence. 
Table 4.1 shows the testing results for these compounds as inhibitors of GBA2 and 
CGT. NB-DNJ (4.3) was used as a reference compound in these assays and showed an IC50 
value of 48 and 7.4 µM for GBA2 and CGT, respectively. (Table 4.1) These results 
corroborate previous studies and highlight the lack of selectivity of this compound.48, 156 
Dibutyl derivative 4.24 showed a modest potency of 95 µM (Entry 4.2) when 
assayed for GBA2 inhibition but displayed no inhibition of CGT up to 1 mM. Compound 
4.24 is less potent than the monoalkylated derivative previously synthesized during the 
course of this project (3.3 µM, data not shown) with respect to GBA2 inhibition.143 The 
monoalkylated butyl analog also showed no inhibition of CGT up to 1 mM (data not 
shown).143 Continuing this trend, dinonyl aminocyclopentitol 4.26 was also less potent than 
its monoalkylated counterpart, which inhibited GBA2 with an IC50 value of 0.043 µM. 
However, compound 4.26 still shows a potent inhibition of GBA2 at 0.89 µM with no 
inhibition of CGT up to 1000 mM. Interestingly, shown in Entry 4.4, compound 4.25 
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showed 100% inhibition in the assay, even at concentrations as low as 1 pM. No inhibition 
CGT was observed up to 1 mM with 4.25. 
Table 4.1. Inhibitory activity of synthesized Iminosugars on enzymes of 
interest[a] 
 
Compound 
Ki (µM)  
GBA2 CGT 
 
4.3 48 7.4[b] 
 
4.24 95 >1000 
 
4.26 0.89 >1000 
 
4.25 << 1 nM > 1000 
[a]The details and procedures of the enzyme inhibition assay for GBA and CGT 
are reported.48 [b Value taken from previous reports.48 GBA2, β-glucosidase 2; 
CGT, ceramide-specific glucosyltransferase. Data presented as mean of 3 
experiments. 
Effort was then undertaken to deduce the cause of this exquisitely potent 
compound. The assay was functioning properly, as the controls worked well, and 4.25 itself 
was not interfering with the fluorescence of the assay. It was eventually reasoned that the 
sample sent for testing was contaminated with chelated palladium from the final 
deprotection step. To remedy this setback, the altered synthetic route displayed in Scheme 
4.4 was devised in which the debenzylation was moved up in the reaction sequence. It 
should be noted that this redefined scheme was needed because 4.25 proved unstable in the 
presence of a trimercaptotriazine resin meant to sequester palladium out of solutions. 
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Scheme 4.4 Altered synthetic route to avert palladium contamination  
 
Resynthesis of the target compound commenced and the alternative scheme was 
used for the final steps towards the synthesis of 4.25. Deprotection of benzylated 
aminocyclopentitol core 4.15 via in situ generation of H2 in the presence of palladium 
afforded the aminocyclopentitol 4.27, which was stable in the presence of the TMT resin. 
Compound 4.27 could then be subjected to the previously optimized reductive alkylation 
conditions to afford 4.25 after purification. qICP analysis performed by the UMN core 
facilities revealed only trace amounts of palladium, as well as other heavy metals. This 
compound was then retested and performed similarly to expected efficacy for the 
compounds of this class. 
Table 4.2 Inhibitory activity of resynthesized adamantyl compound on enzymes 
of interest[a] 
 
Compound 
Ki (µM)  
GBA1 GBA2 CGT 
 
4.25a ≤0.016[b] 0.014 ≈1000 
[a]The details and procedures of the enzyme inhibition assay for GBA and CGT are 
reported previously.48 [b]Below limit of detection in assay. Data presented as mean 
of three independent trials. 
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As shown in Table 4.2, 4.25 displayed a much more realistic IC50 value of 14 nM 
in the GBA2 assay. This updated IC50 value aligns with expected values, given previous 
results with monoalkylated aminocyclopentitols. That said, the resynthesized iminosugar 
shows an excellent selectivity for GBA1 and GBA2 over CGT (> 10,000). This is 
promising since NB-DNJ inhibits all three enzymes with nearly equal potency, with IC50 
values of 34, 38 and 7.4 µM for GBA1, GBA2 and CGT, respectively (Table 4.1, GBA1 
data not shown). 
The synthesized aminocyclopentitols described here inhibit GBA1 and GBA2 to a 
much greater extent than CGT. As expected, compounds bearing alkyl chains of increasing 
length showed concomitant increase in GBA inhibition, as demonstrated by the inhibitory 
trend observed in compounds 4.24 (butyl, 95 µM) versus 4.26 (nonyl, 0.89 µM). As 
mentioned, these dialkylated analogs are less potent than their previously synthesized 
mono-alkylated derivatives, indicating that there is a limit to the correlation of 
hydrophobicity with activity at these enzymes. Indeed, the cLogP of these dialkylated 
compounds is above 6 and solubility is likely an issue, especially at the higher 
concentrations. 
Furthermore, it is possible that only secondary amines display full activity and that 
a hydrogen bond donor is a necessary molecular feature of the GBA2 pharmacophore. 
However, despite their reduced activity, the selectivity profile for these compounds is still 
exquisite and future studies would do well to utilize these compounds. 
Section 4.4 Species-Dependent Action of Iminosugar Activity 
As discussed previously, differences in the efficacy between species has been 
observed with respect to iminosugars and infertility.144, 146, 157 Compound 4.3 (NB-DNJ) 
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inhibits CGT, GBA1 and GBA2 in vitro and in vivo with similar efficacies. Also, though 
4.3 was shown to be an effective and reversible oral male contraceptive agent when tested 
in C57BL/6 mice, the same level of efficacy was not observed in several other species, 
including rabbit, human and other mouse strains. In C57BL/6 mice, however, reversible 
inhibition of fertility was observed three weeks after daily oral administration of 15 mg/kg 
NB-DNJ, with return to normal parameters observed after three weeks of cessation of 
treatment. 144 Separately, glucosylceramide levels were elevated in the testes, brain and 
spleen of mice treated with these iminosugars, indicating the enzymes responsible for the 
breakdown of glucosylceramide, i.e. GBA2, are more pertinent to contraceptive effects 
observed in vivo.158 
It has been shown that NB-DGJ (4.4) can disrupt spermiogenesis in C57BL/6 mice 
and does so at much lower concentrations than NB-DNJ (4.3) .144 Furthermore, NB-DGJ 
has shown efficacy in species that remain fertile after treatment with NB-DNJ.159 The 
observed discrepancies between the two diastereomers could be caused by differences in 
their ADMET properties. To address this, a pharmacokinetic study with the two 
diastereomers was planned in an attempt to determine if plasma levels of 4.3 and 4.4 were 
significantly different, and thus a possible cause for the observed differences. 
Section 4.4.1 Synthesis of NB-DGJ and NB-DNJ 
Since 4.4 is not commercially available, its synthesis was carried out according to 
known procedures from the literature (Scheme 4.5).160 The four-step synthetic route begins 
with an LAH-mediated reductive ring opening of tetra-O-benzyl-D-glucopyranose 4.28 to 
reveal diol 4.29. Swern oxidation of 4.29 formed the intermediate ketoaldehyde that after 
double reductive amination reformed the six-membered ring observed in 4.30, now 
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containing the alkylated endocyclic nitrogen. Finally, debenzylation of this compound gave 
target molecule NB-DGJ (4.4) in 53% overall yield.  
Scheme 4.5 Gram-scale synthesis of NB-DGJ (4.4) 
 
While NB-DNJ is commercially available, purchasing the amount needed for even 
this small PK study was cost prohibitive. Therefore, we synthesized the amounts needed 
using the same route as shown in Scheme 4.3 but starting from the glucopyranoside. In 
short, we obtained sufficient amounts so as to perform the study with both compounds. 
Section 4.4.2 Bioavailability Determinations of NB-DNJ and NB-DGJ in Male CD Rats 
Per our original aim, we sought to correlate observed in vivo activity with the 
bioavailability of NB-DGJ, and perhaps discrepancies would be observed when compared 
to NB-DNJ. Previously, a study in collaboration between the Tash group at the University 
of Kansas Medical Center and the Georg group showed that NB-DGJ inhibits GBA2 from 
CD rats at 10 µM (unpublished results). This study also showed that NB-DJG was capable 
of causing a reversible contraceptive effect in vivo, while NB-DNJ showed no efficacy 
(unpublished results). To evaluate if bioavailability could be the cause of these 
discrepancies a small PK study was performed in which plasma levels following a single 
bolus oral dose of 150 mg/kg of either NB-DNJ or NB-DGJ were examined. Male CD rats 
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were orally dosed with the synthesized compounds by gavage (n=4) and at various 
timepoints following dosing, blood was taken. The resulting plasma was analyzed by 
LC/MS/MS.  
As seen in Figure 4.4, oral dosing of NB-DGJ resulted in a t1/2 of 6.5 hr and a Cmax 
of 11,0167 ng/mL. These results agree with previously reported literature values for the 
compound.161 Unfortunately, these data show no significant difference between NB-DNJ 
and NB-DGJ, indicating some other cause of the species-specific differences causing 
infertility. Based on this study we are confident that the variation of efficacies for these 
compounds is not due to differences in the metabolism of the compounds in this strain of 
rat. 
Figure 4.4 Pharmacokinetics of NB-DGJ and NB-DNJ in Male CD Rats. Rats with in-
dwelling jugular vein cannulas were orally dosed with compound (150 mg/kg) and at 
various times (0.083, 0.25, 0.5, 1, 2, 4, 8, 12, 24 and 48 h) afterwards, approximately 
0.1 ml whole blood was collected from each animal. Target compound was quantified 
in the resulting plasma using LC/MS/MS. Data represent the mean plasma levels ± SD 
and are the average of 4 independent experiments.  
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Section 4.5 Discussion and Summary of Aminocyclopentitol Work 
Herein, the synthesis and biological evaluation of several novel iminosugars of a 
sub classed known as aminocyclopentitols are reported. Previously, monoalkylated 
derivatives of this compound had been synthesized and been tested for their inhibition of 
GBA1 and GBA2. Using known trends in the SAR of this class of molecules affecting the 
enzymes, the hydrophobicity of the amine substitution was increased by dialkylation with 
alkyl chains of increasing length. 
Similar to their previously synthesized monoalkylated derivatives, the dialkylated 
aminocyclopentitols described here display increasing activity with alkyl chain length, 
though the dialkylated compounds proved less potent than their monoalkylated 
counterparts. 
One compound, 4.25, bearing an adamantyl chain was found to be a 14 nM inhibitor 
of GBA2, while showing only a slight inhibition of CGT (IC50 = 1000 µM). When first 
assayed this compound showed complete inhibition at 1 pM, but a redesigned synthesis 
allowed for us to obtain compound free of this metal contaminant and reliable assay results 
were achieved. 
Compound 4.25 is the most selective iminosugar for GBA2 vs CGT published to 
date and could serve as a future tool molecule for studying glucosidase inhibition-derived 
infertility, a field that is plagued by species-dependent results. Previous studies used a tool 
compound, NB-DNJ (4.3), which displays poor selectivity amongst GBA1, GBA2 and 
CGT.145 Therefore, molecules that selectively inhibit any one enzyme of the group would 
be preferred for future studies and these aminocyclopentitols fill a much-needed niche. 
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Finally, a portion of this project was dedicated to the synthesis and subsequent 
study of NB-DGJ (4.4), the galactose epimer of NB-DNJ (4.3). Compound 4.4 has shown 
efficacy in species outside the originally studied C57BL/6 mice, the only species in which 
4.3 has shown efficacy.159, 162, 163 We hypothesized that discrepancies in metabolism of 
these two compounds could be the cause for the differences in efficacy. Therefore, we 
synthesized both diastereomers of the compound of interest in gram quantity and dosed LE 
rats orally to observe any differences in the pharmacokinetic properties of 4.4 as compared 
to published values for 4.3. Unfortunately, the clearance and t1/2 of the two analogs were 
nearly identical, pointing to other causes for the observed species-dependent infertility 
results. Further pharmacological work is needed to understand the discrepancies in results 
between species and the synthesized aminocyclopentitols could serve as useful tool 
compounds in such studies.  
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Experimental Data and Procedures 
General Synthetic Considerations 
All chemicals and reagents were purchased from commercial sources and used directly 
without further purification. Solvents were dried using standard procedures. All non-
aqueous reactions were performed under an atmosphere of nitrogen in flame-dried 
glassware. Reaction progress was monitored by thin layer chromatography using silica gel 
plates (silica gel 60 F254) and eluted TLC plates were visualized with UV light (254 nm) 
and developing the plate with either KMnO4 or Ce(SO4)2 stain. Reaction products were 
isolated by silica gel flash column chromatography. NMR experiments were performed on 
a 400/100 MHz Bruker instrument (unless noted otherwise). NMR spectra were processed 
through MestReNova 9.0 (Mestrelab Research). Chemical shifts are reported as ppm 
relative to CDCl3 (7.26 ppm for 1H, 77.0 ppm for 13C) or CD3OD (3.33 ppm for 1H, 49.0 
ppm for 13C). 1H NMR coupling constants (J) are expressed in Hz, and multiplicity is 
described as follows: s = singlet; d = doublet; t = triplet; q = quartet; quin = quintet; sext = 
sextet; br = broad resonance; m = multiplet. Mass spectrometry experiments were recorded 
with APCI unless noted otherwise. Melting points, when present, were determined with 
Electrothermal Digital Mel-Temp 3.0 melting point apparatus and are uncorrected. For 
compounds centered on the GPHR-00032750 and GPHR-00213869 scaffolds, yields are 
not reported, as only a small fraction of the compound was collected after chromatography 
to ensure purity of the to-be-tested compound. 
Protocol for the Isolation of Motile Human Sperm 
Semen is collected from healthy male donors (IRB: 1102M96152) and allowed to liquify 
at 37 °C for at least 40 min. Concomitantly, for each mL of semen sample, a canonical tube 
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containing 5 mL of HAMs-F10 is prepared and allowed to warm to 37 ˚C at a 45 degree 
angle. After liquefaction, 1 mL of sample is layered beneath the buffer in each tube. The 
tubes are then left to incubate at 37 °C in a 5% CO2 environment for 1 h. After this 1 h, the 
top 2 mL of the buffer is siphoned off and combined among the different tubes. The 
concentration of this combined population is then determined through use of a 
hemocytometer and if a concentration of 10x106 cell/mL is not achieved the sample is 
centrifuged at 400 x g for 7 min. Post centrifugation, the supernatant is discarded and the 
pelleted cells are resuspended in an appropriate buffer, using a volume sufficient to achieve 
10x106 cells/mL. Note: it is crucial to ensure no loss of motility is observed due to the 
centrifugation. It is recommended that additional motility data is obtained post 
centrifugation to ensure cell health. If an experiment requires capacitation, cells (post swim 
up and concentration) are suspended in HAM’s-F10 containing 5% (w/v) BSA and 15 mM 
NaHCO3 and left to incubate for 3.5 h at 37 ˚C in an atmosphere of 5% CO2 either in the 
presence of compound or a DMSO vehicle. 
Calcium Influx Assay and the Isolation of Sperm for this Assay 
Semen from healthy human donors (IRB: 1102M96152) is collected and incubated in a 
shaker at 37 ˚ C until complete liquefaction is observed (no longer than 1 hr post collection). 
The sample is diluted to 50 mL in low pH/low K+ buffer (lo/lo buffer) containing (in mM): 
101 NaCl, 4.69 KCl, 0.2 MgSO4, 0.36 KH2PO4, 25 NaHCO3, 0.32 sodium pyruvate, 2.78 
glucose, 94 sodium lactate, 0.2 CaCl2, pH 6.7 adjusted with 1 M HCl. The sample is then 
centrifuged at 800 x g for 10 min at RT followed by aspiration of the supernatant; this 
centrifugation is repeated an additional time. Following this second centrifugation, the 
pellet was resuspended in 10 mL lo/lo buffer containing 10 µg/mL Fluo-4-AM (Life 
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Technologies, Grand Island, NY) and 1 mM probenicid After, incubation for 30 min at 37 
˚C (caution: light sensitive!), the sample was again diluted to 50 mL with low pH/low K+ 
buffer, centrifuged, and the supernatant aspirated to remove extracellular dye. The pellet 
was then resuspended in ca. 8 mL lo/lo buffer. Dye-loaded sperm were plated into black 
clear-bottom 384-well assay plates (Corning Inc, Tewksbury, MA) and transferred to the 
FLIPR® Tetra platform (Molecular Devices, Sunnyvale, CA). The calcium-induced 
fluorescence signal was continuously monitored for 7 min at 2 s intervals. When tested, 
blocking compound was added after a 10 s delay and allowed a 2 min binding period prior 
to opener addition. The signal was monitored for 5 min after opener addition. Opening of 
the channel was afforded by either 3 µM progesterone in lo/lo buffer or an activation buffer 
containing (in mM): 10 NaCl, 140 KCl, 0.198 MgSO4 · 7 H2O, 0.36 KH2PO4, 24.99 
NaHCO3, 0.32 sodium pyruvate, 2.78 glucose, 94.08 sodium lactate, CaCl2 · 2 H2O. 
Sperm Motility Analysis 
Viable human spermatozoa were selected by swim-up, and a subset of cells was allowed 
to capacitate at 37°C in normal capacitation media for 3.5 h. Sperm motility was analyzed 
by computer-assisted semen analysis (CASA, HTM-IVOS sperm analysis system, version 
12.3, Hamilton Thorne Biosciences, Beverly, MA) system that measured average path 
velocity (VAP, µm/s), straight-line velocity (VSL, µm/s,) and curvilinear velocity (VCL, 
µm/s). From these measurements, we can determine linearity of progression [LIN = 
(VSL/VCL) × 100], and straightness [STR = ( VSL/VAP) × 100]. Data were normalized 
to vehicle matched controls and presented as the average of (n) individual experiments ± 
S.E.M. For all experimental conditions, a minimum of 10 fields of view was analyzed 
containing at least 200 cells total, and all experiments were performed at 37°C. 
 143 
Data Analysis 
Data were analyzed in Prism 8.0.2 (GraphPad Software, Inc, San Diego, CA, USA). 
Statistical data were calculated and represented everywhere in the text as the mean ± S.E.M 
or S.D where applicable, and (n) indicates the number of repeated experiments. 
Throughout, statistical significance is indicated by *P < 0.05, **P < 0.005, ***P < 0.0005 
and ****P < 0.0001. 
Synthesized Steroids 
2,2-Dimethylprogesterone (2.4)  
 
Progesterone (500 mg, 1.59 mmol) was dissolved in anhydrous diethylether (50 mL) and 
chilled to -78 °C followed by dropwise addition of n-butyllithium (1.74 mmol) as a 2.5 M 
solution in hexanes. The solution was stirred for 30 min followed by dropwise addition of 
methyliodide (4.77 mmol, 0.296 mL) after which the temperature of the reaction was 
allowed to raise to room temperature and stirred for 24 hr. A saturated solution of NH4Cl 
(5 mL) was used to quench excess alkyllithium reagent. After quenching, the contents of 
the flask were transferred to a separatory funnel and the organics were extracted with 
EtOAc (2 x 100 mL). The combined organics were washed with a saturated solution of 
NaCl (2 x 100 mL) and dried over Na2SO4, after which the solvent was removed in vacuo 
to afford an off white, viscous oil as the crude product. Purification by silica gel flash 
column chromatography (0 to 50% EtOAc in hexanes, followed by a second column at 0 
to 20% EtOAc) yielded target compound as a clear oil in 3.6% yield (26% BRSM). 1H 
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NMR (400 MHz, CDCl3) δ 5.56 (dd, J1 = 2.45, J2 = 5.14, 1H), 2.52 (m, 3H), 2.13 (s, 3H), 
1.23 (s, 3H), 0.86 (s, 6H), 0.64 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 216.5, 209.4, 149.8, 
119.7, 63.6, 56.9, 48.8, 48.7, 44.0, 38.8, 37.1, 33.7, 32.1, 31.6, 31.5, 31.2, 30.2, 27.3, 24.49, 
22.9, 21.3, 19.3, 13.3; HRMS (APCI-TOF) m/z calcd for C23H38NO2+ [M + NH4]+ 
360.2897, found 360.2903. 
 
3,3:20,20-bis(Ethylenedioxy)-pregn-5-ene (2.19)  
 
Progesterone (5 g, 15 mmol) was dissolved in toluene (250 mL) containing a catalytic 
amount of p-toluenesulfonic acid (172 mg, 0.9 mmol). To this mixture was added ethylene 
glycol (40 mL) followed by attachment of a Dean-Stark trap and heating of the reaction to 
145 °C held for 24 h. At this time, the reaction was cooled to room temperature and 
concentrated under reduced pressure to ca 25% of its original volume and then was 
transferred to a separatory funnel. A saturated solution of sodium bicarbonate was added 
to the separatory funnel and the crude product was extracted with EtOAc (3 x 100 mL). 
The organic layers were then combined, dried with Na2SO4 and concentrated under reduced 
pressure to give crude product as an off-white solid which was then purified silica gel 
column chromatography (5 to 30% EtOAc in hexanes), affording 4.5 g (86% yield) of the 
desired bis-ketal as a white solid. mp 166-169 °C; 1H NMR (400 MHz, CDCl3) δ 5.35 (td, 
J1 = 1.95, J2 = 1.95, J3 = 4.46, 1H), 4.02-3.83 (m, 8H), 2.56 (ddd, J1 = 2.89, J2 = 5.51, J3 
= 14.10, 1H), 2.11 (dd, J1 = 2.86, J2 = 14.19j, 1H), 2.06 (dt, J1 = 3.90, J2 = 3.90, J3 = 12.85 
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1H), 1.96 (dddd, J1 = 2.96, J2 = 5.19, J3 = 5.19, J4 = 17.51, 1H), 1.30 (s, 3H), 1.03 (s, 3H), 
0.78 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 140.2, 122.1, 112.0, 109.5, 65.2, 64.5, 64.24, 
63.3, 58.2, 56.6, 49.7, 41.8, 39.4, 36.7, 36.4, 31.7, 31.5, 31.1, 24.6, 23.9, 23.0, 20.9, 18.9, 
12.9; HRMS (APCI-TOF) m/z calcd for C25H39O4+ [M + H]+ 403.2843, found 403.2860. 
 
3,3:20,20-bis(Ethylenedioxy)-5,6-epoxypregnane 
 
m-Chloroperoxybenzoic acid (mCPBA, 1.84 g, 10 mmol, accounting for 77% purity of 
mCPBA), was added at room temperature to a foiled flask containing 1.01 g of 2 (2.5 
mmol) and 0.630 g NaHCO3 (7 mmol) dissolved in 200 mL anhydrous DCM. The reaction 
was stirred for 2 hr after which time 100 mL of sat. NaHCO3 solution was added. The 
contents were transferred to a separatory funnel where the layers were separated and the 
organics were washed twice more with 75 mL sat. NaHCO3. The combined organics were 
washed with brine, dried over Na2SO4 and concentrated in vacuo to afford crude product 
as a white solid. Purification by silica gel flash column chromatography (5% to 30% EtOAc 
in hexanes) gave 837 mg (80% yield) of 5α,6α-epoxide as a white solid, the more polar 
diastereomer (Rf = 0.15 @ 30% EtOAc) compared to 167 mg (16% yield) of the 5β,6β-
epoxide (Rf = 0.30 @ 30% EtOAc in hexanes) which was also a white solid. 
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3,3:20,20-bis(Ethylenedioxy)-5α,6α-epoxypregnane (2.20) 
mp 175-178 °C; 1H NMR (400 MHz, CDCl3) δ 3.93 (m, 8H), 2.81 (d, J1 = 
4.22, 1H) 2.37 (d, J1 = 13.99, 1H), 1.99 (dd, J1 = 3.14, J2 = 11.62, 1H), 1.92 
(ddd, J1 = 4.59, J2 = 6.61, J3 = 15.15, 1H), 1.27 (s, 3H), 1.07 (s, 3H), 0.71 
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 112.1, 109.1, 65.3, 64.9, 64.7, 64.2, 
63.4, 58.03, 57.6, 56.9, 42.3, 42.0, 39.3, 39.2, 35.2, 31.5, 31.1, 29.5, 28.6, 
24.7, 23.7, 23.0, 20.6, 15.8, 13.0; (APCI-TOF) m/z calcd for C25H39O5+ [M 
+ H]+ 419.2792, found 419.2803. 
 
 
3,3:20,20-bis(Ethylenedioxy)-5β,6β-epoxypregnane (2.21): 
mp 132-134 °C; 1H NMR (400 MHz, CDCl3) δ 3.92 (m, 8H), 3.06 (d, J1 = 
1.99, 1H), 2.33 (d, J1 = 14.02, 1H), 2.04 (ddt, J1 = 3.18, J2 = 3.18, J3 = 14.46, 
J4 = 26.30, 2H), 1.28 (s, 3H), 1.00 (s, 3H), 0.74 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 111.9, 108.9, 65.1, 64.7, 64.6, 64.1, 63.2, 57.9, 57.4, 56.7, 
42.2, 41.8, 39.1, 39.1, 35.1, 31.3, 31.0, 29.4, 28.4, 24.5, 23.6, 22.8, 20.4, 
15.7, 12.9; HRMS (ESI-TOF) m/z calcd for C50H76NaO10 [Dimer + Na]+ 
859.5331, found 859.5319. 
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3,3:20,20-bis(Ethylenedioxy)-5α-hydroxy-6β-methylpregnane (2.22) 
 
To a solution of 3,3:20,20-bis(ethylenedioxy)-5α,6α-epoxypregnane (71 mg, 0.17 mmol) 
dissolved in 5 mL THF was added MeMgBr (1.3 mL, 20 equiv, 3.4 mmol) as a 3 M solution 
in THF. The solution was then brought to reflux for 18 hr, after which it was cooled to 
room temperature and excess Grignard reagent was quenched with 3 mL of a saturated 
NH4Cl solution. Organics were then extracted with EtOAc (3 X 25 mL) and the organics 
were combined, washed with a saturated NaCl solution and dried over Na2SO4, then 
concentrated in vacuo to afford crude product as a clear, viscous oil. Purification by 
chromatography (0 to 20% EtOAc in hexanes) yielded 33 mg (45%, 75% based on RSM) 
of 5 as a white powder. mp 187-189; 1H NMR (400 MHz, CDCl3) δ 4.25 (s, 1H), 3.92 (m, 
8H), 2.20 (d, J1 = 14.04, 1H), 1.29 (s, 3H), 1.02 (s, 3H), 0.98 (d, J1 = 7.8, 3H), 0.77 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 112.02, 110.18, 76.33, 65.19, 64.35, 63.85, 63.19, 58.36, 
55.71, 45.63, 42.15, 40.43, 39.66, 39.51, 33.03, 32.56, 31.13, 30.14, 24.57, 23.82, 22.93, 
20.90, 18.15, 17.18, 13.19; HRMS (APCI-TOF) m/z calcd for C26H43O5+ [M + H]+ 
435.3105, found 435.3127. 
 
 148 
5α-Hydroxy-6β-methylpregnan-3,20-dione (2.23) 
 
To a stirring solution of 3,3:20,20-bis(ethylenedioxy)-5α-hydroxy-6β-methylpregnane (96 
mg, 0.221 mmol) in 2 mL THF was added 1 mL 3 M HCl. The reaction was stirred at room 
temperature for 3 hr, after which it was diluted with 50 mL of EtOAc and neutralized with 
a saturated solution of NaHCO3. The layers were separated and the organic layer was 
washed with brine, dried over Na2SO4 and then concentrated in vacuo. Silica gel flash 
column chromatography (0 to 40% EtOAc in hexanes) afforded 39 mg (51% yield) of 6 as 
a white solid. mp 227-229; 1H NMR (400 MHz, CDCl3) δ 3.01 (d, J1 = 14.7, 1H), 2.55 (t, 
J1 = 8.97, 1H), 2.36 (t, J1 = 6.29, 1H), 2.34 (d, J1 = 4.78, 1H) 2.13 (s, 3H), 1.25 (s, 3H), 
1.09 (d, J1 = 7.49, 3H), 0.66 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 211.4, 209.5, 80.0, 
63.8, 56.0, 50.6, 46.4, 44.3, 42.0, 40.0, 39.0, 38.0, 35.7, 33.4, 31.6, 30.6, 29.7, 24.6, 22.8, 
21.4, 17.9, 13.6; HRMS (ESI-TOF) m/z calcd for C44H68NaO6 [Dimer + Na]+ 715.4908, 
found 715.4861. 
 
6β-Methylprogesterone (2.24) 
 
Thionyl chloride (310 µL, 0.04 mmol) was added to a stirring solution of 3,3:20,20-
bis(ethylenedioxy)-5,6-epoxypregnane (20 mg, 0.058 mmol) in pyridine (1 mL) at 0 °C. 
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After 5 minutes, 5 mL of ice water was added to the reaction and organics were extracted 
2 X 10 mL EtOAc. The combined organics were then washed with brine (20 mL), dried 
over Na2SO4 and concentrated in vacuo. Purification by silica gel column chromatography 
(0 to 30 % EtOAc in hexanes) afforded 11 mg (60% yield) of 7 as a white solid. mp; 171-
172; 1H NMR (400 MHz, CDCl3) δ 5.76 (s, 1H), 2.65 (p, J1 = 7.01, 1H), 2.50 (m, 2H), 2.36 
(ddd, J1 = 2.68, J2 = 3.84, J3 = 17.45, 1H), 2.12 (s, 3H), 1.26 (s, 3H), 1.22 (d, J1 = 7.57, 
3H), 0.69 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 209.3, 199.8, 175.3, 125.2, 63.6, 56.1, 
53.2, 44.0, 38.7, 38.4, 38.3, 37.7, 37.4, 34.1, 31.5, 30.3, 24.5, 23.1, 22.8, 21.1, 20.4, 13.4; 
mp; 171-172; HRMS (APCI-TOF) m/z calcd for C22H33O2+ [M + H]+ 329.2475, found 
329.2483. 
 
6α-Methylprogesterone (2.18) 
 
After 6β-methylprogesterone (11 mg, 0.033 mmol) was dissolved in ethanol (95%, 1 mL) 
with sonication, 0.1 mL of 1 M HCl was added and the reaction was stirred under reflux 
for 2 hr. The reaction was cooled and concentrated under reduced pressure. The resulting 
slurry was diluted with sodium bicarbonate (10 mL) and extracted with EtOAc (2 X 10 
mL). The combined organic layers were washed with brine (15 mL), dried over Na2SO4 
and concentrated in vacuo. Purification by silica gel column chromatography (0 to 30% 
EtOAc in hexanes) and HPLC (50% to 95% MeCN in H2O over 20 min) afforded 6α-
methylprogesterone (10.5 mg, 95%) as a white powder. mp 116-119 °C; 1H NMR (400 
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MHz, CDCl3) δ 5.80 (s, 1H), 2.53 (t, J1 = 9.02, 1H), 2.12 (s, 3H), 1.85 (td, J1 = 3.95, J2 = 
12.70, 1H), 1.19 (s, 3H), 1.07 (d, J1 = 6.40, 3H), 0.67 (s, 3H); 13C NMR (100 MHz, CDCl3) 
δ 209.3, 199.8, 174.1, 121.3, 63.5, 55.9, 53.9, 44.0, 40.9, 38.9, 38.7, 36.0, 35.4, 33.9, 33.7, 
31.5, 24.3, 22.9, 21.2, 18.4, 18.3, 13.4; HRMS (APCI-TOF) m/z calcd for C22H33O2+ [M + 
H]+ 329.2475, found 329.2484. 
 
5α,6α-Epoxypregnan-3,20-dione (2.25) 
 
To a stirring solution of 3,3:20,20-bis(ethylenedioxy)-pregn-5-ene (alpha isomer, 27 mg, 
0.065 mmol) in 1 mL THF was added 0.7 mL 3 M HCl. The reaction was stirred at room 
temperature for 3 hr, after which it was diluted with 40 mL of EtOAc and neutralized with 
a saturated solution of NaHCO3. The layers were separated and the organic layer was 
washed with brine, dried over Na2SO4 and then concentrated in vacuo. Silica gel column 
chromatography (0 to 40% EtOAc in hexanes) afforded deprotected product as a white 
powder in 70% yield. mp 193-195 °C; 1H NMR (400 MHz, CDCl3) δ 3.82 (m, 1H), 3.37 
(d, J1 = 15.49, 1H), 2.54 (t, J1 = 8.94, 1H), 2.13 (s, 3H), 1.45 (s, 3H), 0.69 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 210.5, 209.3, 78.7, 63.6, 63.4, 55.4, 50.7, 45.6, 44.2, 39.2, 
38.8, 37.8, 35.3, 34.8, 31.5, 30.1, 24.4, 22.8, 21.3, 17.8, 13.5; HRMS (APCI-TOF) m/z 
calcd for C21H34NO3+ [M + NH4]+ 348.2533, found 348.2534. 
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5β,6β-Epoxypregnan-3,20-dione (2.26) 
 
To a stirring solution of 3,3:20,20-bis(ethylenedioxy)-pregn-5-ene (beta-isomer, 16.8 mg, 
0.04 mmol) in 1 mL THF was added 0.7 mL 3 M HCl. The reaction was stirred at room 
temperature for 3 hr, after which it was diluted with 40 mL of EtOAc and neutralized with 
a saturated solution of NaHCO3. The layers were separated and the organic layer was 
washed with brine, dried over Na2SO4 and then concentrated in vacuo. Silica gel column 
chromatography (0 to 40% EtOAc in hexanes) afforded 7.3 mg of deprotected product as 
a white powder in 58% yield. mp 154-152 °C; 1H NMR (400 MHz, CDCl3) δ 2.18 (s, 3H), 
0.96 (s, 3H), 0.65 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 211.08, 208.99, 208.52, 63.30, 
57.49, 56.61, 53.30, 46.38, 44.34, 41.14, 38.38, 38.08, 37.79, 37.35, 36.96, 31.48, 24.18, 
22.78, 21.62, 13.41, 12.60; HRMS (CI-TOF) m/z calcd for C21H34NO3+ [M + NH4]+ 
348.2533, found 348.2538. 
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GPHR-00032750 Analogs 
N,4-Diphenylpiperazine-1-carboxamide (3.10)  
 
To a stirring solution of 1-phenylpiperazine (30 mg, 0.18 mmol, 1.0 equiv), triethylamine 
(1.9 µL, 0.018 mmol, 0.1 equiv) in DCM (5 mL) was added isocyanatobenzene (27 mg, 
0.21 mmol, 1.2 equiv) and the solution was stirred for 30 min at RT. After confirming 
consumption of limiting reagent by TLC, 3 mL of distilled water was added to the reaction 
vial. The organic layer was separated and removed under reduced atmosphere. Column 
chromatography (0 to 50% EtOAc/Hex) on silica gel was used to purify sufficient amounts 
of the target molecule for biological testing and characterization. LRMS (APCI - quad) m/z 
cal’d forC17H20N3O+ [M+H+], 282.3665 found 284. 1H NMR (400 MHz, CD3OD) δ 7.37 
(d, J = 8.6 Hz, 2H), 7.30 - 7.23 (m, 4H), 7.06 - 7.00 (m, 3H), 6.88 (t, J = 7.3 Hz, 1H), 3.74 
- 3.66 (m, 4H), 3.25 - 3.18 (m, 4H). 
 
4-Phenyl-N-(m-tolyl)piperazine-1-carboxamide (3.11)  
 
To a stirring solution of 1-phenylpiperazine (30 mg, 0.18 mmol, 1.0 equiv), triethylamine 
(1.9 µL, 0.018 mmol, 0.1 equiv) in DCM (5 mL) was added 1-isocyanato-3-methylbenzene 
(29 mg, 0.21 mmol, 1.2 equiv) and the solution was stirred for 30 min at RT. After 
confirming consumption of limiting reagent by TLC, 3 mL of distilled water was added to 
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the reaction vial. The organic layer was separated and removed under reduced atmosphere. 
Column chromatography (0 to 50% EtOAc/Hex) on silica gel was used to purify sufficient 
amounts of the target molecule for biological testing and characterization. LRMS (APCI - 
quad) m/z cal’d C18H22N3O+ [M+H+], 296.3935 found 297. 1H NMR (400 MHz, CD3OD) 
δ 7.26 (t, J = 7.4 Hz, 2H), 7.21 (s, 1H), 7.19 - 7.12 (m, 2H), 7.02 (d, J = 7.6 Hz, 2H), 6.92 
- 6.84 (m, 2H), 3.72 - 3.65 (m, 4H), 3.23 - 3.17 (m, 4H), 2.32 (s, 3H).  
 
4-Phenyl-N-(3-(trifluoromethyl)phenyl)piperazine-1-carboxamide (3.12)  
 
To a stirring solution of 1-phenylpiperazine (20 mg, 0.13 mmol, 1.0 equiv), triethylamine 
(1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added 1-isocyanato-3-
(trifluoromethyl)benzene (27 mg, 0.16 mmol, 1.2 equiv) and the solution was stirred for 
30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of distilled 
water was added to the reaction vial. The organic layer was separated and removed under 
reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was 
used to purify sufficient amounts of the target molecule for biological testing and 
characterization.  LRMS (APCI - quad) m/z cal’d for C18H19F3N3O+ [M+H+], 350.36 found 
360. 1H NMR (400 MHz, CDCl3) δ 7.68 (s, 1H), 7.60 (d, J = 8.1 Hz, 1H), 7.41 (t, J = 7.9 
Hz, 1H), 7.35 - 7.24 (m, 3H), 7.01 - 6.91 (m, 3H), 6.59 (br, 1H), 3.75 - 3.68 (m, 4H), 3.30 
- 3.23 (m, 4H). 
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N-(3-Cyanophenyl)-4-phenylpiperazine-1-carboxamide (3.13)  
 
To a stirring solution of 1-phenylpiperazine (30 mg, 0.18 mmol, 1.0 equiv), triethylamine 
(1.9 µL, 0.018 mmol, 0.1 equiv) in DCM (5 mL) was added 3-isocyanatobenzonitrile (32 
mg, 0.21 mmol, 1.2 equiv) and the solution was stirred for 30 min at RT. After confirming 
consumption of limiting reagent by TLC, 3 mL of distilled water was added to the reaction 
vial. The organic layer was separated and removed under reduced atmosphere. Column 
chromatography (0 to 50% EtOAc/Hex) on silica gel was used to purify sufficient amounts 
of the target molecule for biological testing and characterization. LRMS (APCI - quad) m/z 
cal’d for C18H19N4O+  [M+H+], 307.3765 found 307. 1H NMR (400 MHz, CD3OD) δ 7.85 
(s, 1H), 7.69 (d, J = 7.4 Hz, 1H), 7.45 (t, J = 7.9 Hz, 1H), 7.36 (d, J = 7.6 Hz, 1H), 7.27 (t, 
J = 7.5 Hz, 2H), 7.02 (d, J = 8.2 Hz, 1H), 6.68 (t, J = 7.3 Hz, 1H), 3.77 - 3.64 (m, 4H), 3.27 
- 3.17 (m, 4H). 
 
N-(3-Nitrophenyl)-4-phenylpiperazine-1-carboxamide (3.14)  
 
To a stirring solution of 1-phenylpiperazine (20 mg, 0.12 mmol, 1.0 equiv), triethylamine 
(1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added 1-isocyanato-3-nitrobenzene 
(24 mg, 0.16 mmol, 1.2 equiv) and the solution was stirred for 30 min at RT. After 
confirming consumption of limiting reagent by TLC, 3 mL of distilled water was added to 
the reaction vial. The organic layer was separated and removed under reduced atmosphere. 
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Column chromatography (0 to 50% EtOAc/Hex) on silica gel was used to purify sufficient 
amounts of the target molecule for biological testing and characterization. LRMS (APCI - 
quad) m/z cal’d for C17H19N4O3+ [M+H+], 327.36 found 328. 1H NMR (400 MHz, CDCl3) 
δ 8.24 (t, J = 2.2 Hz, 1H), 7.89 (dd, J1 = 2.1, J2 = 8.1 Hz, 1H), 7.84 (dd, J1 = 2.1, J2 = 8.2 
Hz, 1H), 7.45 (t, J = 8.2 Hz, 1H), 7.31 (t, J = 7.2 Hz, 2H), 7.01 - 6.91 (m, 3H), 6.77 (br, 
1H), 3.77 - 3.70 (m, 4H), 3.31 - 3.25 (m, 4H).   
 
Methyl 3-(4-phenylpiperazine-1-carboxamido)benzoate (3.15)  
 
To a stirring solution of 1-phenylpiperazine (30 mg, 0.18 mmol, 1.0 equiv), triethylamine 
(1.9 µL, 0.018 mmol, 0.1 equiv) in DCM (5 mL) was added methyl 3-isocyanatobenzoate 
(39 mg, 0.21 mmol, 1.2 equiv) and the solution was stirred for 30 min at RT. After 
confirming consumption of limiting reagent by TLC, 3 mL of distilled water was added to 
the reaction vial. The organic layer was separated and removed under reduced atmosphere. 
Column chromatography (0 to 50% EtOAc/Hex) on silica gel was used to purify sufficient 
amounts of the target molecule for biological testing and characterization. LRMS (APCI - 
quad) m/z cal’d for C19H22N3O3+  [M+H+], 340.4025 found 340. 1H NMR (400 MHz, 
CD3OD) δ 8.09 (s, 1H), 7.74 - 7.63 (m, 3H), 7.45 - 7.36 (m, 1H), 7.27 (t, J = 7.3 Hz, 1H), 
7.02 (d, J = 7.2 Hz, 1H), 6.87 (t, J = 7.0 Hz, 1H), 3.93 - 3.87 (m, 5H), 3.74 - 3.68 (m, 4H), 
3.24 - 3.17 (m, 4H). 
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N-Phenyl-4-(m-tolyl)piperazine-1-carboxamide (3.16)  
 
To a stirring solution of 1-(m-tolyl)piperazine (30 mg, 0.14 mmol, 1.0 equiv), triethylamine 
(1.7 µL, 0.14mmol, 0.1 equiv) in DCM (5 mL) was added isocyanatobenzene (25 mg, 0.17 
mmol, 1.2 equiv) and the solution was stirred for 30 min at RT. After confirming 
consumption of limiting reagent by TLC, 3 mL of distilled water was added to the reaction 
vial. The organic layer was separated and removed under reduced atmosphere. Column 
chromatography (0 to 50% EtOAc/Hex) on silica gel was used to purify sufficient amounts 
of the target molecule for biological testing and characterization.  LRMS (APCI - quad) 
m/z cal’d C18H22N3O+ [M+H+], 296.3935 found 297. 1H NMR (400 MHz, CD3OD) δ 7.37 
(d, J = 8.6 Hz, 2H), 7.28 (t, J = 7.7 Hz, 2H), 7.14 (t, J = 7.8 Hz, 1H), 7.03 (t, J = 7.2 Hz, 
1H), 6.86 - 6.79 (m, 2H), 6.72 (d, J = 7.4 Hz, 1H), 3.72 - 3.65 (m, 4H), 3.22 - 3.15 (m, 4H), 
2.31 (s, 3H). 
 
N,4-di-m-Tolylpiperazine-1-carboxamide (3.17)  
 
To a stirring solution of 1-(m-tolyl)piperazine (30 mg, 0.15 mmol, 1.0 equiv), triethylamine 
(1.8 µL, 0.015 mmol, 0.1 equiv) in DCM (5 mL) was added 1-isocyanato-3-methylbenzene 
(27 mg,  0.18 mmol, 1.2 equiv) and the solution was stirred for 30 min at RT. After 
confirming consumption of limiting reagent by TLC, 3 mL of distilled water was added to 
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the reaction vial. The organic layer was separated and removed under reduced atmosphere. 
Column chromatography (0 to 50% EtOAc/Hex) on silica gel was used to purify sufficient 
amounts of the target molecule for biological testing and characterization. LRMS (APCI - 
quad) m/z cal’d C19H24N3O+ [M+H+], 310.4205 found 310. 1H NMR (400 MHz, CD3OD) 
δ 7.21 (s, 1H), 7.18 - 7.11 (m, 3H), 6.88 - 6.83 (m, 2H), 6.80 (dd, J1 = 2.4, J2 = 8.1 Hz, 
1H), 6.72 (d, J = 7.4 Hz, 1H), 3.72 - 3.64 (m, 4H), 3.21 - 3.13 (m, 4H), 2.31 (s, 6H). 
 
4-(m-Tolyl)-N-(3-(trifluoromethyl)phenyl)piperazine-1-carboxamide (3.18)  
 
To a stirring solution of 1-(m-tolyl)piperazine (20 mg, 0.11 mmol, 1.0 equiv), triethylamine 
(1.8 µL, 0.011 mmol, 0.1 equiv) in DCM (5 mL) was added 1-isocyanato-3-
(trifluoromethyl)benzene (25 mg, 0.14 mmol, 1.2 equiv) and the solution was stirred for 
30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of distilled 
water was added to the reaction vial. The organic layer was separated and removed under 
reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was 
used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C19H21F3N3O+ [M+H+], 364.39 found 
365. 1H NMR (400 MHz, CDCl3) δ 7.68 (s, 1H), 7.59 (d, J = 8.2 Hz, 1H), 7.41 (t, J = 7.9 
Hz, 1H), 7.30 (d, J = 8.1 Hz, 1H), 7.20 (t, J = 7.8 Hz, 1H), 6.84 - 6.73 (m, 3H), 3.71 (br, 
4H), 3.29 - 3.23 (m, 4H), 2.34 (s, 3H). 13C NMR (176 MHz, CDCl3) δ 154.6, 139.5, 139.2, 
131.2 (q, J = 33 Hz), 129.4, 129.2, 123.9 (q, J = 272 Hz), 123.0, 119.8 (d, J = 4 Hz), 117.7, 
116.6 (d, J = 4 Hz), 113.9, 49.6, 44.0, 21.8.  
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N-(3-Cyanophenyl)-4-(m-tolyl)piperazine-1-carboxamide (3.19) 
 
To a stirring solution of 1-(m-tolyl)piperazine (30 mg, 0.17 mmol, 1.0 equiv), triethylamine 
(1.8 µL, 0.017 mmol, 0.1 equiv) in DCM (5 mL) was added 3-isocyanatobenzonitrile (29 
mg, 0.20 mmol, 1.2 equiv) and the solution was stirred for 30 min at RT. After confirming 
consumption of limiting reagent by TLC, 3 mL of distilled water was added to the reaction 
vial. The organic layer was separated and removed under reduced atmosphere. Column 
chromatography (0 to 50% EtOAc/Hex) on silica gel was used to purify sufficient amounts 
of the target molecule for biological testing and characterization. LRMS (APCI - quad) m/z 
cal’d for C19H21N4O+  [M+H+], 321.4035 found 322. 1H NMR (400 MHz, CD3OD) δ 7.84 
(s, 1H), 7.68 (d, J = 8.4 Hz, 1H), 7.45 (t, J = 7.8 Hz, 1H), 7.35 (d, J = 6.4 Hz, 1H), 7.14 (t, 
J = 7.8 Hz, 1H), 6.85 (s, 1H), 6.81 (d, J = 8.1 Hz, 1H), 6.72 (d, J = 7.5 Hz, 1H), 3.73 - 3.67 
(m, 4H), 3.24 - 3.15 (m, 4H), 2.31 (s, 3H). 
 
N-(3-Nitrophenyl)-4-(m-tolyl)piperazine-1-carboxamide (3.20)  
 
To a stirring solution of 1-(m-tolyl)piperazine (20 mg, 0.11 mmol, 1.0 equiv), triethylamine 
(1.8 µL, 0.011 mmol, 0.1 equiv) in DCM (5 mL) was added 1-isocyanato-3-nitrobenzene 
(22 mg, 0.16 mmol, 1.2 equiv) and the solution was stirred for 30 min at RT. After 
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confirming consumption of limiting reagent by TLC, 3 mL of distilled water was added to 
the reaction vial. The organic layer was separated and removed under reduced atmosphere. 
Column chromatography (0 to 50% EtOAc/Hex) on silica gel was used to purify sufficient 
amounts of the target molecule for biological testing and characterization. LRMS (APCI - 
quad) m/z cal’d for C18H21N4O3+ [M+H+], 341.39 found 342. 1H NMR (400 MHz, CDCl3) 
δ 8.24 (t, J = 2.2 Hz, 1H), 7.89 (dd, J1 = 2.2, J2 = 8.2 Hz, 1H), 7.84 (dd, J1 = 2.2, J2 = 8.2 
Hz, 1H), 7.45 (t, J = 8.2 Hz, 1H), 7.20 (t, J = 7.7 Hz, 1H), 6.85 - 6.74 (m, 3H), 3.74 (m, 
4H), 3.30 - 3.24 (m, 4H), 2.34 (s, 3H). 
 
Methyl 3-(4-(m-tolyl)piperazine-1-carboxamido)benzoate (3.21)  
 
To a stirring solution of 1-(m-tolyl)piperazine (30 mg, 0.17 mmol, 1.0 equiv), triethylamine 
(1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added methyl 3-isocyanatobenzoate 
(36 mg, 0.20 mmol, 1.2 equiv) and the solution was stirred for 30 min at RT. After 
confirming consumption of limiting reagent by TLC, 3 mL of distilled water was added to 
the reaction vial. The organic layer was separated and removed under reduced atmosphere. 
Column chromatography (0 to 50% EtOAc/Hex) on silica gel was used to purify sufficient 
amounts of the target molecule for biological testing and characterization. LRMS (APCI - 
quad) m/z cal’d for C20H24N3O3+  [M+H+], 354.4295 found 354. 1H NMR (400 MHz, 
CD3OD) δ 8.09 (s, 1H), 7.75 - 7.62 (m, 3H), 7.45 - 7.35 (m, 1H), 7.14 (t, J = 7.8 Hz, 1H), 
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6.85 (s, 1H), 6.81 (d, J = 8.2 Hz, 1H), 6.72 (d, J = 7.4 Hz, 1H), 3.91 (s, 3H), 3.75 - 3.65 
(m, 4H), 3.23 - 3.16 (m, 4H), 2.32 (s, 3H).  
 
Dimethyl 5-(4-(m-tolyl)piperazine-1-carboxamido)isophthalate (3.22)  
 
To a stirring solution of 1-(m-tolyl)piperazine (30 mg, 0.17 mmol, 1.0 equiv), triethylamine 
(1.8 µL, 0.017 mmol, 0.1 equiv) in DCM (5 mL) was added dimethyl 5-
isocyanatoisophthalate (48 mg, 0.20 mmol, 1.2 equiv) and the solution was stirred for 30 
min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of distilled 
water was added to the reaction vial. The organic layer was separated and removed under 
reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was 
used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C22H26N3O5+  [M+H+], 412.4655 
found 412. 1H NMR (400 MHz, CD3OD) δ 8.34 (s, 2H), 8.28 (s, 1H), 7.14 (t, J = 7.8 Hz, 
1H), 6.85 (s, 1H), 6.81 (d, J = 8.2 Hz, 1H), 6.72 (d, J = 7.4 Hz, 1H), 3.94 (s, 6H), 3.75 - 
3.68 (m, 4H), 3.23 - 3.16 (m, 4H), 2.32 (s, 3H). 
 
N-(1-Methyl-1H-indol-4-yl)-4-(m-tolyl)piperazine-1-carboxamide (3.23)  
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To a stirring solution of 1-(m-tolyl)piperazine (30 mg, 0.17 mmol, 1.0 equiv), triethylamine 
(1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added 4-isocyanato-1-methyl-1H-
indole (35 mg, 0.20 mmol, 1.2 equiv) and the solution was stirred for 30 min at RT. After 
confirming consumption of limiting reagent by TLC, 3 mL of distilled water was added to 
the reaction vial. The organic layer was separated and removed under reduced atmosphere. 
Column chromatography (0 to 50% EtOAc/Hex) on silica gel was used to purify sufficient 
amounts of the target molecule for biological testing and characterization. LRMS (APCI - 
quad) m/z cal’d for C18H19N4O+  [M+H+], 307.3765 found 307. 1H NMR (400 MHz, 
CD3OD) δ 7.22 - 7.10 (m, 4H), 7.06 (d, J = 7.4 Hz, 1H), 6.86 (s, 1H), 6.83 (d, J = 8.0 Hz, 
1H), 6.72 (d, J = 7.5 Hz, 1H), 6.47 (d, J = 3.1 Hz, 1H), 3.80 (s, 3H), 3.77 - 3.69 (m, 4H), 
3.30 - 3.18 (m,4 H), 2.32 (s, 3H). 
 
N-Phenyl-4-(3-(trifluoromethyl)phenyl)piperazine-1-carboxamide (3.24)  
 
To a stirring solution of 1-(3-(trifluoromethyl)phenyl)piperazine (30 mg, 0.12 mmol, 1.0 
equiv), triethylamine (1.8 µL, 0.012 mmol, 0.1 equiv) in DCM (5 mL) was added 
isocyanatobenzene (19 mg, 0.15 mmol, 1.2 equiv) and the solution was stirred for 30 min 
at RT. After confirming consumption of limiting reagent by TLC, 3 mL of distilled water 
was added to the reaction vial. The organic layer was separated and removed under reduced 
atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was used to 
purify sufficient amounts of the target molecule for biological testing and characterization. 
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LRMS (APCI - quad) m/z cal’d C18H19F3N3O+ [M+H+], 350.3647 found 351. 1H NMR 
(400 MHz, CD3OD) δ 7.42 (t, J = 7.8 Hz, 1H), 7.40 - 7.36 (m, 2H), 7.31 - 7.25 (m, 2H), 
7.25 - 7.20 (m, 2H), 7.12 (d, J = 7.7 Hz, 1H), 7.03 (t, J = 6.4 Hz, 1H), 3.74 - 3.67 (m, 4H), 
3.34 - 3.26 (m, 4H). 
 
N-(m-Tolyl)-4-(3-(trifluoromethyl)phenyl)piperazine-1-carboxamide (3.25)  
 
To a stirring solution of 1-(m-tolyl)piperazine (30 mg, 0.11 mmol, 1.0 equiv), triethylamine 
(1.6 µL, 0.011 mmol, 0.1 equiv) in DCM (5 mL) was added 1-isocyanato-3-methylbenzene 
(27 mg, 0.14 mmol, 1.2 equiv) and the solution was stirred for 30 min at RT. After 
confirming consumption of limiting reagent by TLC, 3 mL of distilled water was added to 
the reaction vial. The organic layer was separated and removed under reduced atmosphere. 
Column chromatography (0 to 50% EtOAc/Hex) on silica gel was used to purify sufficient 
amounts of the target molecule for biological testing and characterization. LRMS (APCI - 
quad) m/z cal’d C19H21F3N3O+ [M+H+], 364.3917 found 365. 1H NMR (400 MHz, 
CD3OD) δ 7.43 (t, J = 7.9 Hz, 1H), 7.25 - 7.09 (m, 6H), 6.87 (d, J = 6.2 Hz, 1H), 3.73 - 
3.68 (m, 4H), 3.34 - 3.25 (m, 4H), 2.32 (s, 3H). 13C NMR (176 MHz, CDCl3) δ 155.0, 
151.0, 138.9, 138.6, 131.6 (q, J = 31 Hz), 129.7, 128.7, 124.3, 124.0 (d, J = 272 Hz), 120.8, 
119.1, 117.1, 116.5 (d, J = 4 Hz), 112.5 (d, J = 4 Hz), 48.6, 43.8, 21.5. 
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N,4-bis(3-(Trifluoromethyl)phenyl)piperazine-1-carboxamide (3.9).  
 
To a stirring solution of 1-(3-triflouromethylphenyl)piperazine (30 mg, 0.13 mmol, 1.0 
equiv), triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added 3-
trifluoromethylphenylisocyanate (29 mg, 0.15 mmol, 1.2 equiv) and the solution was 
stirred for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL 
of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C19H18F6N3O+ [M+H+] 418.36, 
found 418. 1H NMR (400 MHz, CDCl3) δ 7.66 (s, 1H), 7.58 (d, J = 8.2 Hz, 1H), 7.39 (q, 
J = 7.2 Hz, 2H), 7.30 (d, J = 7.8 Hz, 1H), 7.14 (d, J = 7.8 Hz, 1H), 7.12 (s, 1H), 7.07 (d, J 
= 8.4 Hz, 1H), 6.69 (s, 1H), 3.69 (t, J = 13.1 Hz, 4H), 3.29 (t, J = 5.2 Hz, 4H). 13C NMR 
(176 MHz, CDCl3) δ 160.4, 154.9 (d, J = 11 Hz), 154.8 (d, J = 11 Hz), 150.9, 139.5 (d, J 
= 9 Hz), 131.6 (d, J = 29 Hz), 131.2 (d, J = 36 Hz), 129.8, 129.4, 124.7 (d, J = 46 Hz), 
123.5, 123.2 (d, J = 27 Hz), 119.8, 119.2, 117.0, 116.6, 112.6, 48.6, 43.8. 
 
N-(3,5-Bis(trifluoromethyl)phenyl)-4-(3-(trifluoromethyl)phenyl)piperazine-1-
carboxamide (3.26)  
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To a stirring solution of 1-(3-(trifluoromethyl)phenyl)piperazine (30 mg, 0.13 mmol, 1.0 
equiv), triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added dimethyl 
1-isocyanato-3,5-bis(trifluoromethyl)benzene (40 mg, 0.16 mmol, 1.2 equiv) and the 
solution was stirred for 30 min at RT. After confirming consumption of limiting reagent 
by TLC, 3 mL of distilled water was added to the reaction vial. The organic layer was 
separated and removed under reduced atmosphere. Column chromatography (0 to 50% 
EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for C20H17F9N3O+ 
[M+H+], 486.3611 found 486. 1H NMR (400 MHz, CD3OD) δ 8.10 (s, 2H), 7.55 (s, 1H), 
7.44 (t, J = 7.9 Hz, 1H), 7.26 - 7.22 (m, 2H), 7.13 (d, J = 7.6 Hz, 1H), 3.81 - 3.69 (m, 4H), 
3.38 - 3.30 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 153.9, 150.8, 140.3, 132.2 (q, J = 34 
Hz), 131.7 (q, J = 32 Hz), 129.8, 123.9 (d, J = 272 Hz), 123.1 (d, J = 273 Hz), 119.4, 119.3, 
116.9 (d, J = 4 Hz), 116.5, 112.8 (d, J = 4 Hz), 48.7, 43.9. 
 
N-(3-Cyanophenyl)-4-(3-(trifluoromethyl)phenyl)piperazine-1-carboxamide (3.27) 
 
To a stirring solution of 1-(3-(trifluoromethyl)phenyl)piperazine (30 mg, 0.13 mmol, 1.0 
equiv), triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added 3-
isocyanatobenzonitrile (22 mg, 0.16 mmol, 1.2 equiv) and the solution was stirred for 30 
min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of distilled 
water was added to the reaction vial. The organic layer was separated and removed under 
reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was 
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used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C19H18F3N4O+ [M+H+], 375.3747 
found 375. 1H NMR (400 MHz, CD3OD) δ 7.85 (s, 1H), 7.69 (d, J = 9.6 Hz, 1H), 7.48 - 
7.40 (m, 2H), 7.35 (d, J = 7.7 Hz, 1H), 7.26 - 7.20 (m, 2H), 7.12 (d, J = 7.7 Hz, 1H), 3.77 
- 3.70 (m, 4H), 3.36 - 3.30 (m, 4H). 
 
N-(3-Nitrophenyl)-4-(m-tolyl)piperazine-1-carboxamide (3.28)  
 
To a stirring solution of 1-(3-(trifluoromethyl)phenyl)piperazine (20 mg, 0.09 mmol, 1.0 
equiv), triethylamine (1.8 µL, 0.009 mmol, 0.1 equiv) in DCM (5 mL) was added 1-
isocyanato-3-nitrobenzene (16 mg, 0.12 mmol, 1.2 equiv) and the solution was stirred for 
30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of distilled 
water was added to the reaction vial. The organic layer was separated and removed under 
reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was 
used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C18H21N4O3+ [M+H+], 341.39 found 
342. 1H NMR (400 MHz, CDCl3) δ 8.23 (t, J = 2.2 Hz, 1H), 7.89 (dd, J1 = 2.1, J2 = 8.1 
Hz, 1H), 7.84 (dd, J1 = 2.1, J2 = 8.1 Hz, 1H), 7.46 (t, J = 8.1 Hz, 1H), 7.40 (t, J = 8.0 Hz, 
1H), 7.19 - 7.14 (m, 2H), 7.11 (d, J = 8.4 Hz, 1H), 6.79 (br, 1H), 3.79 - 3.70 (m, 4H), 3.37 
- 3.30 (m, 4H). 
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Methyl 3-(4-(3-(trifluoromethyl)phenyl)piperazine-1-carboxamido)benzoate (3.29)  
 
To a stirring solution of 1-(3-(trifluoromethyl)phenyl)piperazine (30 mg, 0. 13 mmol, 1.0 
equiv), triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added methyl 
3-isocyanatobenzoate (28 mg, 0.16 mmol, 1.2 equiv) and the solution was stirred for 30 
min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of distilled 
water was added to the reaction vial. The organic layer was separated and removed under 
reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was 
used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C20H21F3N3O3+ [M+H+], 408.4007 
found 408. 1H NMR (400 MHz, CD3OD) δ 8.14 (s, 1H), 7.75 - 7.67 (m, 2H), 7.49 - 7.40 
(m, 2H), 7.29 - 7.24 (m, 2H), 7.16 (d, J = 7.6 Hz, 1H), 3.94 (s, 3H), 3.81 - 3.73 (m, 4H), 
3.39 - 3.30 (m, 4H). 
 
Dimethyl 5-(4-(3-(trifluoromethyl)phenyl)piperazine-1-carboxamido)isophthalate 
(3.30) 
 
To a stirring solution of 1-(3-(trifluoromethyl)phenyl)piperazine (30 mg, 0.13 mmol, 1.0 
equiv), triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added dimethyl 
5-isocyanatoisophthalate (36 mg, 0.16 mmol, 1.2 equiv) and the solution was stirred for 30 
min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of distilled 
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water was added to the reaction vial. The organic layer was separated and removed under 
reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was 
used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C22H23F3N3O5+ [M+H+], 466.4367 
found 466. 1H NMR (400 MHz, CD3OD) δ 8.44 - 8.18 (m, 2H), 7.45 (s, 1H), 7.34 - 7.04 
(m, 2H), 4.13 (br, 2H), 4.03 - 3.63 (m, 7H). 
 
3-(4-(3-(Trifluoromethyl)phenyl)piperazine-1-carboxamido)benzoic Acid (3.31) 
 
A solution of methyl 3-(4-(3-(trifluoromethyl)phenyl)piperazine-1-carboxamido)benzoate 
(EJC-3-136, 483 mg, 1.18 mmol, 1.0 equiv) was dissolved in a H2O/THF cosolvent system 
(1:5, H2O to THF) at rt. To the reaction was added LiOH·H2O (442 mg, 5.88 mmol, 5 
equiv) and the reaction was left to stir overnight. After confirming consumption of starting 
material by TLC, the THF was removed under reduced pressure and the resulting slurry 
was taken up in EtOAc and washed several times (2x25 mL) with 0.1 N HCl. The organic 
layer was separated and removed under reduced atmosphere. Column chromatography (0 
to 100% EtOAc/Hex) resulted in target molecule as a white powder in moderate yield (202 
mg, 47%). LRMS (APCI - quad) m/z cal’d C19H19F3N3O3+ [M+H+], 394.3737 found 395. 
1H NMR (400 MHz, CDCl3) δ 7.97 (t, J = 2.0 Hz, 1H), 7.59 (td, J1 = 1.3, J2 = 7.7 Hz, 1H), 
7.55 (ddd, J1 = 1.0, 2.3, 8.2 Hz, 1H), 7.33 (t, J = 7.9 Hz, 1H), 7.28 (t, J = 7.9 Hz, 1H), 7.16 
- 7.10 (m, 2H), 7.01 (d, J = 7.6 Hz, 1H), 3.66 - 3.59 (m, 4H), 3.27 - 3.17 (m, 4H). 
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N-(1-Methyl-1H-indol-4-yl)-4-(3-(trifluoromethyl)phenyl)piperazine-1-carboxamide 
(3.32)  
 
To a stirring solution of 1-(3-(trifluoromethyl)phenyl)piperazine (30 mg, 0.13 mmol, 1.0 
equiv), triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added 4-
isocyanato-1-methyl-1H-indole (27 mg, 016 mmol, 1.2 equiv) and the solution was stirred 
for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of 
distilled water was added to the reaction vial. The organic layer was separated and removed 
under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel 
was used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C21H22F3N4O+ [M+H+], 403.4287 
found 404. 1H NMR (400 MHz, CD3OD) δ 7.33 (t, J = 7.9 Hz, 1H), 7.18 - 7.11 (m, 2H), 
7.10 - 7.04 (m, 2H), 7.03 - 7.00 (m, 2H), 6.96 (d, J = 7.3 Hz, 1H), 6.36 (d, J = 3.2 Hz, 1H), 
3.69 (s, 3H), 3.68 - 3.63 (m, 4H). 
 
N-(1-Methyl-1H-indol-5-yl)-4-(3-(trifluoromethyl)phenyl)piperazine-1-carboxamide 
(3.33)  
 
To a stirring solution of 1-(3-(trifluoromethyl)phenyl)piperazine (30 mg, 0.13 mmol, 1.0 
equiv), triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added 5-
isocyanato-1-methyl-1H-indole (27 mg, 0.16 mmol, 1.2 equiv) and the solution was stirred 
for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of 
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distilled water was added to the reaction vial. The organic layer was separated and removed 
under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel 
was used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C21H22F3N4O+ [M+H+], 403.4287 
found 403. 1H NMR (400 MHz, CD3OD) δ 8.12 (d, J = 11 Hz, 1H), 7.51 (d, J = 2.0 Hz, 
1H), 7.44 (t, J = 7.9 Hz, 1H), 7.31 (d, J = 8.8 Hz, 1H), 7.28 - 7.21 (m, 1H), 7.16 - 7.10 (m, 
3H), 6.38 (d, J = 3.1 Hz, 1H), 3.79 (s, 3H), 3.75 - 3.70 (m, 4H). 
 
4-(3,5-bis(Trifluoromethyl)phenyl)-N-phenylpiperazine-1-carboxamide (3.34)  
 
To a stirring solution of 1-(3,5-bis(trifluoromethyl)phenyl)piperazine (30 mg, 0.09 mmol, 
1.0 equiv), triethylamine (1.5 µL, 0.009 mmol, 0.1 equiv) in DCM (5 mL) was added 
isocyanatobenzene (15 mg, 0.11 mmol, 1.2 equiv) and the solution was stirred for 30 min 
at RT. After confirming consumption of limiting reagent by TLC, 3 mL of distilled water 
was added to the reaction vial. The organic layer was separated and removed under reduced 
atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was used to 
purify sufficient amounts of the target molecule for biological testing and characterization. 
LRMS (APCI - quad) m/z cal’d C19H18F6N3O+ [M+H+], 418.3629 found 419. 1H NMR 
(400 MHz, CD3OD) δ 7.46 - 7.36 (m, 4H), 7.32 - 7.25 (m, 4H), 7.03 (q, J = 6.4 Hz, 2H), 
3.76 - 3.70 (m, 4H), 3.43 - 3.39 (m, 4H). 
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4-(3,5-bis(Trifluoromethyl)phenyl)-N-(m-tolyl)piperazine-1-carboxamide (3.35)  
 
To a stirring solution of 1-(3,5-bis(trifluoromethyl)phenyl)piperazine (30 mg, 0.09 mmol, 
1.0 equiv), triethylamine (1.5 µL, 0.009 mmol, 0.1 equiv) in DCM (5 mL) was added 1-
isocyanato-3-methylbenzene (16 mg, 0.11 mmol, 1.2 equiv) and the solution was stirred 
for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of 
distilled water was added to the reaction vial. The organic layer was separated and removed 
under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel 
was used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d C20H20F6N3O+ [M+H+], 432.3899 found 
433. 1H NMR (400 MHz, CD3OD) δ 7.44 (s, 2H), 7.31 (s, 1H), 7.26 - 7.12 (m, 4H), 6.89 
- 6.82 (m, 1H), 3.75 - 3.68 (m, 4H), 3.44 - 3.35 (m, 4H), 2.31 (s, 3H). 
 
4-(3,5-bis(Trifluoromethyl)phenyl)-N-(3-(trifluoromethyl)phenyl)piperazine-1-
carboxamide (3.36).  
 
To a stirring solution of 1-(3,5-bis-triflouromethylphenyl)piperazine (30 mg, 0.10 mmol, 
1.0 equiv), triethylamine (1.8 µL, 0.01 mmol, 0.1 equiv) in DCM (5 mL) was added 3-
trifluoromethylphenylisocyanate (29 mg, 0.12 mmol, 1.2 equiv) and the solution was 
stirred for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL 
of distilled water was added to the reaction vial. The organic layer was separated and 
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removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C20H17F9N3O+ [M+H+] 486.36, 
found 487. 1H NMR (400 MHz, CDCl3) δ 7.67 (s, 1H), 7.58 (t, J = 8.2 Hz, 1H), 7.42 (t, J 
= 8.0 Hz, 1H), 7.36 (s, 1H), 7.32 (d, J = 7.5 Hz, 1H), 6.57 (s, 1H), 3.74 (t, J = 5.1 Hz, 4H), 
3.40 (t, J = 5.4 Hz, 4H). 13C NMR (176 MHz, CDCl3) δ 154.5, 151.1, 139.1, 132.6 (d, J 
= 33 Hz) 131.4 (d, J = 32 Hz), 129.5, 124.2, 123.2, 122.7, 120.1, 116.8, 115.0, 112.9, 100.0, 
47.9, 43.6. 
 
N,4-bis(3,5-bis(Trifluoromethyl)phenyl)piperazine-1-carboxamide (3.37)  
 
To a stirring solution of 1-(3,5-bis(trifluoromethyl)phenyl)piperazine (30 mg, 0.11 mmol, 
1.0 equiv), triethylamine (1.7 µL, 0.011 mmol, 0.1 equiv) in DCM (5 mL) was added 1-
isocyanato-3,5-bis(trifluoromethyl)benzene (30 mg, 0.13 mmol, 1.2 equiv) and the solution 
was stirred for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 
mL of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C23H22F6N3O5+ [M+H+], 
534.4349 found 534. 1H NMR (400 MHz, CD3OD) δ 8.10 (s, 2H), 7.54 (s, 1H), 7.46 (s, 
2H), 7.31 (s, 1H), 3.38 - 3.69 (m, 4H), 3.50 - 3.38 (m, 4H). 
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4-(3,5-bis(Trifluoromethyl)phenyl)-N-(3-cyanophenyl)piperazine-1-carboxamide 
(3.38)  
 
To a stirring solution of 1-(3,5-bis(trifluoromethyl)phenyl)piperazine (30 mg, 0.11 mmol, 
1.0 equiv), triethylamine (1.7 µL, 0.011 mmol, 0.1 equiv) in DCM (5 mL) was added 3-
isocyanatobenzonitrile (17 mg, 0.14 mmol, 1.2 equiv) and the solution was stirred for 30 
min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of distilled 
water was added to the reaction vial. The organic layer was separated and removed under 
reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was 
used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C20H17F6N4O+ [M+H+], 443.3729 
found 443. 1H NMR (400 MHz, CDCl3) δ 7.86 (s, 1H), 7.69 (d, J = 6.3 Hz, 1H), 7.48 - 
7.42 (m, 3H), 7.36 (d, J = 7.7 Hz, 1H), 7.31 (s, 1H), 3.79 - 3.71 (m, 4H), 3.47 - 3.39 (m, 
4H). 
 
4-(3,5-bis(Trifluoromethyl)phenyl)-N-(3-nitrophenyl)piperazine-1-carboxamide 
(3.39) 
 
To a stirring solution of 1-(3,5-bis(trifluoromethyl)phenyl)piperazine (30 mg, 0.09 mmol, 
1.0 equiv), triethylamine (1.6 µL, 0.009 mmol, 0.1 equiv) in DCM (5 mL) was added 1-
isocyanato-3-nitrobenzene (20 mg, 0.11 mmol, 1.2 equiv) and the solution was stirred for 
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30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of distilled 
water was added to the reaction vial. The organic layer was separated and removed under 
reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was 
used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d C19H17F6N4O3+ [M+H+], 463.3599 found 
464. 1H NMR (400 MHz, CDCl3) δ 8.24 (t, J = 2.2 Hz, 1H), 7.91 (dd, J1 = 2.3, J2 = 8.3 
Hz, 1H), 7.83 (dd, J1 = 2.3, J2 = 8.2 Hz, 1H), 7.47 (t, J = 8.2 Hz, 1H), 7.37 (s, 1H), 7.28 (s, 
2H), 6.70 (s, 1H), 3.81 - 3.74 (m, 4H), 3.45 - 3.39 (m, 4H). 
 
Methyl 3-(4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-carboxamido)benzoate 
(3.40)  
 
To a stirring solution of 1-(3,5-bis(trifluoromethyl)phenyl)piperazine (30 mg, 0.11 mmol, 
1.0 equiv), triethylamine (1.7 µL, 0.011 mmol, 0.1 equiv) in DCM (5 mL) was added 
methyl 3-isocyanatobenzoate (20 mg, 0.14 mmol, 1.2 equiv) and the solution was stirred 
for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of 
distilled water was added to the reaction vial. The organic layer was separated and removed 
under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel 
was used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C21H20F6N3O3+ [M+H+], 476.3989 
found 477. 1H NMR (400 MHz, CD3OD) δ 8.10 (s, 1H), 7.72 - 7.64 (m, 2H), 7.46 (s, 2H), 
7.40 (t, J = 7.9 Hz, 1H), 7.31 (s, 1H), 3.91 (s, 3H), 3.79 - 3.72 (m, 4H), 3.46 - 3.40 (m, 4H). 
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13C NMR (101 MHz, CDCl3) δ 166.8, 154.6, 151.2, 138.9, 132.5 (q, J = 33 Hz), 130.9, 
129.1, 124.6, 124.5, 123.5 (q, J = 273 Hz), 120.8, 114.9, 112.7, 52.2, 47.9, 43.6. 
 
Dimethyl 5-(4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-
carboxamido)isophthalate (3.41)  
 
To a stirring solution of 1-(3,5-bis(trifluoromethyl)phenyl)piperazine (30 mg, 0.11 mmol, 
1.0 equiv), triethylamine (1.7 µL, 0.011 mmol, 0.1 equiv) in DCM (5 mL) was added 
dimethyl 5-isocyanatoisophthalate (28 mg, 0.14 mmol, 1.2 equiv) and the solution was 
stirred for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL 
of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C23H22F6N3O5+ [M+H+], 
534.4349 found 534. 1H NMR (400 MHz, CD3OD) δ 8.34 (s, 2H), 8.29 (s, 1H), 7.47 (s, 
2H), 7.32 (s, 1H), 4.59 (br, 3H), 3.94 (s, 6H), 3.81 - 3.71 (m, 4H), 3.50 - 3.37 (m, 4H). 13C 
NMR (176 MHz, CDCl3) δ 165.9, 157.9, 150.9, 132.0 (q, J = 32 Hz), 131.5 (q, J = 32 Hz), 
130.3, 129.8, 124.0 (dq, J1 = 70, J2 = 273 Hz), 119.4, 118.5 (d, J = 4 Hz), 117.8, 116.9 (d, 
J = 4 Hz), 112.8 (d, J = 5 Hz), 111.8 (d, J = 4 Hz), 67.5, 49.3, 48.8, 45.1, 41.2. 
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3-(4-(3,5-bis(Trifluoromethyl)phenyl)piperazine-1-carboxamido)benzoic Acid (3.42)  
 
A solution of methyl 3-(4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-
carboxamido)benzoate (EJC-3-137, 499 mg, 1.05 mmol, 1.0 equiv) was dissolved in a 
H2O/THF cosolvent system (1:5, H2O to THF) at rt. To the reaction was added LiOH·H2O 
(210 mg, 5.25 mmol, 5 equiv) and the reaction was left to stir overnight. After confirming 
consumption of starting material by TLC, the THF was removed under reduced pressure 
and the resulting slurry was taken up in EtOAc and washed several times (2x25 mL) with 
0.1 N HCl. The organic layer was separated and removed under reduced atmosphere. 
Column chromatography (0 to 100% EtOAc/Hex) resulted in target molecule as a white 
powder in moderate yield (327 mg, 68%). LRMS (APCI - quad) m/z cal’d C20H18F6N3O3+ 
[M+H+], 462.3719 found 463. 1H NMR (400 MHz, CDCl3) δ 7.97 (t, J = 1.9, 1H), 7.60 
(td, J1 = 1.3, J2 = 7.8 Hz, 1H), 7.56 (ddd, J1 = 1.0, J2 = 2.2, J3 = 8.2 Hz, 1H), 7.35 (s, 2H), 
7.28 (t, J = 7.9 Hz, 1H), 7.20 (s, 1H), 3.68 - 3.59 (m, 4H), 3.36 - 3.28 (m, 4H). 
 
4-(3,5-bis(Trifluoromethyl)phenyl)-N-(1-methyl-1H-indol-6-yl)piperazine-1-
carboxamide (3.43)  
 
To a stirring solution of 1-(3,5-bis(trifluoromethyl)phenyl)piperazine (30 mg, 0.11 mmol, 
1.0 equiv), triethylamine (1.7 µL, 0.011 mmol, 0.1 equiv) in DCM (5 mL) was added 4-
isocyanato-1-methyl-1H-indole (21 mg, 0.14 mmol, 1.2 equiv) and the solution was stirred 
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for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of 
distilled water was added to the reaction vial. The organic layer was separated and removed 
under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel 
was used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C22H21F6N4O+ [M+H+], 471.4269 
found 472. 1H NMR (400 MHz, CD3OD) δ 7.51 (d, J = 1.9 Hz, 1H), 7.46 (s, 2H), 7.33 - 
7.28 (m, 2H), 7.17 - 7.10 (m, 2H), 6.38 (d, J = 3.1 Hz, 1H), 3.79 (s, 3H), 3.77 - 3.71 (m, 
4H), 3.46 - 3.39 (m, 4H). 
 
4-(3-Cyanophenyl)-N-(3-(trifluoromethyl)phenyl)piperazine-1-carboxamide (3.44).  
 
To a stirring solution of 1-(3-cyanophenyl)piperazine (30 mg, 0.16 mmol, 1.0 equiv), 
triethylamine (1.8 µL, 0.016 mmol, 0.1 equiv) in DCM (5 mL) was added 3-
trifluoromethylphenylisocyanate (29 mg, 0.18 mmol, 1.2 equiv) and the solution was 
stirred for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL 
of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C19H18F3N4O+ [M+H+] 375.37, 
found 375. 1H NMR (400 MHz, CDCl3) δ 7.67 (s, 1H), 7.59 (d, J = 8.1 Hz, 1H), 7.41 (t, 
J = 7.8 Hz, 1H), 7.36 (t, J = 8.7 Hz, 1H), 7.30 (d, J = 7.8 Hz, 1H), 7.16 (d, J = 7.0 Hz, 1H), 
7.12 (s, 1H),  6.71 (s, 1H), 3.70 (t, J = 5.1 Hz, 4H),  3.29 (t, J = 5.2 Hz, 4H). 13C NMR 
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(176 MHz, CDCl3) δ 154.7, 150.8, 139.5, 131.2, 130.1, 129.4, 123.7 (q, J = 274 Hz), 123.3, 
123.2, 120.3, 119.8, 119.8, 119.3, 118.7, 116.8, 113.0, 100.0, 48.2, 43.7. 
 
N-(3,5-bis(Trifluoromethyl)phenyl)-4-(3-cyanophenyl)piperazine-1-carboxamide 
(3.45)  
 
To a stirring solution of 3-(piperazin-1-yl)benzonitrile (30 mg, 0.16 mmol, 1.0 equiv), 
triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added 1-isocyanato-
3,5-bis(trifluoromethyl)benzene (30 mg, 0.19 mmol, 1.2 equiv) and the solution was stirred 
for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of 
distilled water was added to the reaction vial. The organic layer was separated and removed 
under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel 
was used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C20H17F6N4O+ [M+H+] 443.3729, 
found 443. 1H NMR (400 MHz, CDCl3) δ 7.90 (s, 2H), 7.52 (s, 1H), 7.37 (t, J = 7.8 Hz, 
1H), 7.19 - 7.10 (m, 3H), 6.97 (s, 1H), 3.83 - 3.61 (m, 4H), 3.36 - 3.22 (m, 4H). 13C NMR 
(101 MHz, CDCl3) δ 154.5, 150.8, 139.3, 131.2 (q, J = 33 Hz), 130.1, 129.5, 125.3, 123.3, 
123.0, 122.6, 120.3, 119.9 (q, J = 4 Hz), 119.1, 118.7, 116.6 (q, J = 4 Hz), 113.2, 48.2, 
43.7.  
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N,4-bis(3-Cyanophenyl)piperazine-1-carboxamide (3.46)  
 
To a stirring solution of 3-(piperazin-1-yl)benzonitrile (30 mg, 0.16 mmol, 1.0 equiv), 
triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added 3-
isocyanatobenzonitrile (28 mg, 0.19 mmol, 1.2 equiv) and the solution was stirred for 30 
min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of distilled 
water was added to the reaction vial. The organic layer was separated and removed under 
reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was 
used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C19H18N5O+ [M+H+] 332.3865, found 
332. 1H NMR (400 MHz, CDCl3) δ 7.76 (s, 1H), 7.62 (d, J = 7.2 Hz, 1H), 7.43 - 7.32 (m, 
3H), 7.18 - 7.11 (m, 3H), 6.62 (s, 1H), 3.74 - 3.66 (m, 4H), 3.35 - 3.29 (m, 4H). 
 
4-(3-Cyanophenyl)-N-(3-nitrophenyl)piperazine-1-carboxamide (3.47)  
 
To a stirring solution of 3-(piperazin-1-yl)benzonitrile (30 mg, 0.16 mmol, 1.0 equiv), 
triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added 1-isocyanato-3-
nitrobenzene (32 mg, 0.19 mmol, 1.2 equiv) and the solution was stirred for 30 min at RT. 
After confirming consumption of limiting reagent by TLC, 3 mL of distilled water was 
added to the reaction vial. The organic layer was separated and removed under reduced 
atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was used to 
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purify sufficient amounts of the target molecule for biological testing and characterization. 
LRMS (APCI - quad) m/z cal’d C18H18N5O3+ [M+H+], 352.3735 found 354. 1H NMR (400 
MHz, CDCl3) δ 8.20 (s, 2H), 7.89 (d, J = 8.3, 1H), 7.82 (d, J = 8.1 Hz, 1H), 7.45 (t, J = 7.4 
Hz, 1H), 6.93 (s, 1H), 3.67 (br, 4H), 3.07 (br, 4H). 
 
Methyl 3-(4-(3-cyanophenyl)piperazine-1-carboxamido)benzoate (3.48)  
 
To a stirring solution of 3-(piperazin-1-yl)benzonitrile (30 mg, 0.16 mmol, 1.0 equiv), 
triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added methyl 3-
isocyanatobenzoate (34 mg, 0.19 mmol, 1.2 equiv) and the solution was stirred for 30 min 
at RT. After confirming consumption of limiting reagent by TLC, 3 mL of distilled water 
was added to the reaction vial. The organic layer was separated and removed under reduced 
atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was used to 
purify sufficient amounts of the target molecule for biological testing and characterization. 
LRMS (APCI - quad) m/z cal’d for C20H21N4O3+ [M+H+] 365.4125, found 365. 1H NMR 
(400 MHz, CDCl3) δ 7.94 (s, 1H), 7.74 - 7.67 (m, 2H), 7.40 - 7.30 (m, 2H), 7.16 - 7.08 (m, 
3H), 6.86 (s, 1H), 3.88 (s, 3H), 3.70 - 3.64 (m, 4H), 3.28 - 3.22 (m, 4H). 
 
N-(3-(1H-Pyrrol-1-yl)phenyl)-4-(3-(trifluoromethyl)phenyl)piperazine-1-
carboxamide (3.49) 
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To a stirring solution of 1-(3-triflouromethylphenyl)piperazine (31 mg, 0.13 mmol, 1.0 
equiv), triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added 1-(3-
isocyanatophenyl)-1H-pyrrole (30 mg, 0.15 mmol, 1.2 equiv) and the solution was stirred 
for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of 
distilled water was added to the reaction vial. The organic layer was separated and removed 
under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel 
was used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C22H22F3N4O+ [M+H+] 415.44, found 
416. 1H NMR (400 MHz, CDCl3) δ 7.59 (t, J = 2.1 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.32 
(t, J = 8.1 Hz, 1H), 7.19 - 7.11 (m, 3H), 7.11 - 7.06 (m, 3H), 6.61 (br, 1H), 6.32 (t, J = 2.1 
Hz, 2H), 3.69 (t, J = 5.1 Hz, 4H), 3.28 (t, J = 5.2 Hz, 4H). 
 
 
N-(3-(1H-Pyrrol-1-yl)phenyl)-4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-
carboxamide (3.50) 
 
To a stirring solution of 1-(3,5-bis-triflouromethylphenyl)piperazine (40 mg, 0.13 mmol, 
1.0 equiv), triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added 3,5-
bistrifluoromethylphenylisocyanate (30 mg, 0.015 mmol, 1.2 equiv) and the solution was 
stirred for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL 
of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
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silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C23H21F6N4O+ [M+H+] 483.44, 
found 484. 1H NMR (400 MHz, CDCl3) δ 7.57 (t, J = 2.0 Hz, 1H), 7.36 - 7.30 (m, 2H), 
7.23 (s, 2H), 7.16 (d, J = 8.0 Hz, 1H), 7.12 - 7.05 (m, 3H), 3.70 (t, J = 4.9 Hz, 4H), 3.33 (t, 
J = 5.3 Hz, 4H) 
 
N-(3-(1H-Pyrrol-1-yl)phenyl)-4-(3-cyanophenyl)piperazine-1-carboxamide (3.51) 
 
To a stirring solution of 1-(3-cyanophenyl)piperazine (30 mg, 0.16 mmol, 1.0 equiv), 
triethylamine (1.8 µL, 0.016 mmol, 0.1 equiv) in DCM (5 mL) was added 1-(3-
isocyanatophenyl)-1H-pyrrole (29 mg, 0.19 mmol, 1.2 equiv) and the solution was stirred 
for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of 
distilled water was added to the reaction vial. The organic layer was separated and removed 
under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel 
was used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C22H22N5O+ [M+H+] 372.45, found 
372. 1H NMR (400 MHz, CDCl3) δ 7.60 (t, J = 2.2 Hz, 1H), 7.38 (t, J = 8.6 Hz, 1H), 7.33 
(t, J = 7.8 Hz, 1H), 7.21-7.14 (m, 4H), 7.10 (t, J = 2.4 Hz, 3H), 6.49 (br, 1H), 6.33 (t, J = 
2.2 Hz, 2H), 3.74 (t, J = 5.2 Hz, 4H), 3.32 (t, J = 5.4 Hz, 4H). 
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N-(3-(1-Methyl-1H-pyrazol-5-yl)phenyl)-4-(3-(trifluoromethyl)phenyl)piperazine-1-
carboxamide (3.52) 
 
To a stirring solution of 1-(3-triflouromethylphenyl)piperazine (28 mg, 0.12 mmol, 1.0 
equiv), triethylamine (1.8 µL, 0.012 mmol, 0.1 equiv) in DCM (5 mL) was added 5-(3-
isocyanatophenyl)-1-methyl-1H-pyrazole (30 mg, 0.14 mmol, 1.2 equiv) and the solution 
was stirred for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 
mL of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C22H23F3N5O+ [M+H+] 430.45, 
found 431. 1H NMR (400 MHz, CDCl3) δ 7.54 - 7.51 (m, 2H), 7.41 - 7.35 (m, 3H), 7.16 - 
7.07 (m, 4H), 6.71 (br, 1H), 6.32 (d, J = 1.9 Hz, 1H), 3.92 (s, 3H), 3.72 (t, J = 5.3 Hz, 4), 
3.31 (t, J = 5.3 Hz, 4H),   
 
4-(3,5-bis(Trifluoromethyl)phenyl)-N-(3-(1-methyl-1H-pyrazol-5-
yl)phenyl)piperazine-1-carboxamide (3.53) 
 
To a stirring solution of 1-(3,5-bis-triflouromethylphenyl)piperazine (37 mg, 0.12 mmol, 
1.0 equiv), triethylamine (1.8 µL, 0.012 mmol, 0.1 equiv) in DCM (5 mL) was added 5-(3-
isocyanatophenyl)-1-methyl-1H-pyrazole (30 mg, 0.14 mmol, 1.2 equiv) and the solution 
was stirred for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 
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mL of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex)) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C23H22F6N5O+ [M+H+] 498.45, 
found 499. 1H NMR (400 MHz, CDCl3) δ 7.54 - 7.51 (m, 2H), 7.43 - 7.38 (m, 2H), 7.34 
(br, 1H), 7.15 - 7.07 (m, 1H), 6.69 (br, 1H), 6.33 (d, J = 1.5 Hz, 1H), 3.93 (s, 3H), 3.75 (t, 
J = 5.0 Hz, 4H), 3.40 (t, J = 5.3 Hz, 4H). 13C NMR (176 MHz, CDCl3) δ 154.8, 151.2, 
143.3, 139.0, 138.5, 132.7, 132.5, 131.4, 129.3, 124.2, 123.7, 122.7, 121.1, 120.4, 120.0, 
115.0, 112.8, 106.1, 48.0, 43.6, 37.6. 
 
4-(3-Cyanophenyl)-N-(3-(1-methyl-1H-pyrazol-5-yl)phenyl)piperazine-1-
carboxamide (3.54) 
 
To a stirring solution of 1-(3-cyanophenyl)piperazine (30 mg, 0.16 mmol, 1.0 equiv), 
triethylamine (1.8 µL, 0.016 mmol, 0.1 equiv) in DCM (5 mL) was added 1-(3-
isocyanatophenyl)-1H-pyrrole (29 mg,  0.19 mmol, 1.2 equiv) and the solution was stirred 
for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of 
distilled water was added to the reaction vial. The organic layer was separated and removed 
under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex)) on silica gel 
was used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C22H23N6O+ [M+H+] 387.47, found 
387. 1H NMR (400 MHz, CDCl3) δ 7.55 (br, 1H), 7.53 (d, J = 2.0 Hz, 1H), 7.41 - 7.33 (m, 
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3H), 7.18 - 7.09 (m, 4H), 6.69 (1H), 6.33 (d, J = 2.0 Hz, 1H), 3.94 (s, 3H), 3.72 (t, J = 5.0 
Hz, 4H), 3.31 (t, J = 5.3 Hz, 4H). 13C NMR (176 MHz, CDCl3) δ 154.7, 151.1, 141.4, 
139.9, 132.8, 132.6, 132.4, 132.3, 129.9, 124.2, 122.7, 119.3, 116.9, 115.3, 115.0, 112.7, 
112.2, 110.5, 47.9, 43.6. 
 
4-(Pyridin-3-yl)-N-(m-tolyl)piperazine-1-carboxamide (3.55)  
 
To a stirring solution of 1-(pyridin-3-yl)piperazine (30 mg, 0.18 mmol,  1.0 equiv), 
triethylamine (1.9 µL, 0.018 mmol, 0.1 equiv) in DCM (5 mL) was added 1-isocyanato-3-
methylbenzene (29 mg, 0.21 mmol, 1.2 equiv) and the solution was stirred for 30 min at 
RT. After confirming consumption of limiting reagent by TLC, 3 mL of distilled water was 
added to the reaction vial. The organic layer was separated and removed under reduced 
atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was used to 
purify sufficient amounts of the target molecule for biological testing and characterization. 
LRMS (APCI - quad) m/z cal’d for C17H21N4O+ [M+H+], 297.38 found 299. 1H NMR (400 
MHz, CDCl3) δ 8.31 (dd, J1 = 1.6, J2 = 5.0 Hz, 2H), 7.23 (s, 1H), 7.18 (t, J = 7.8 Hz, 1H), 
7.14 - 7.10 (m, 1H), 6.88 (d, J = 8.8 Hz, 1H), 6.70 - 6.63 (m, 2H), 6.41 (br, 1H), 3.72 - 3.64 
(m, 4H), 3.48 - 3.40 (m, 4H), 2.33 (s, 3H). 
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N-(3-Nitrophenyl)-4-(pyridin-3-yl)piperazine-1-carboxamide (3.56)  
 
To a stirring solution of 1-(pyridin-3-yl)piperazine (30 mg, 0.18 mmol, 1.0 equiv), 
triethylamine (1.9 µL, 0.018 mmol, 0.1 equiv) in DCM (5 mL) was added 1-isocyanato-3-
nitrobenzene (29 mg, 0.21 mmol, 1.2 equiv) and the solution was stirred for 30 min at RT. 
After confirming consumption of limiting reagent by TLC, 3 mL of distilled water was 
added to the reaction vial. The organic layer was separated and removed under reduced 
atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was used to 
purify sufficient amounts of the target molecule for biological testing and characterization. 
LRMS (APCI - quad) m/z cal’d for C17H21N4O+ [M+H+], 297.38 found 299. 1H NMR (400 
MHz, CDCl3) δ 8.33 (dd, J1 = 1.7, J2 = 5.0 Hz, 2H), 8.23 (t, J = 2.2 Hz, 1H), 7.91 (ddd, J1 
= 1.0, J2 = 2.2, J3 = 8.2 Hz, 1H), 7.82 (ddd, J1 = 0.8, J2 = 2.2, J3 = 8.2 Hz, 1H), 7.47 (t, J = 
8.2 Hz, 1H), 6.71 - 6.65 (m, 3H), 3.77 - 3.70 (m, 4H), 3.52 - 3.44 (m, 4H). 
 
4-(Pyridin-4-yl)-N-(m-tolyl)piperazine-1-carboxamide (3.57)  
 
To a stirring solution of 1-(pyridin-4-yl)piperazine (30 mg, 0.18 mmol, 1.0 equiv), 
triethylamine (1.9 µL, 0.018 mmol, 0.1 equiv) in DCM (5 mL) was added 1-isocyanato-3-
methylbenzene (29 mg, 0.21 mmol, 1.2 equiv) and the solution was stirred for 30 min at 
RT. After confirming consumption of limiting reagent by TLC, 3 mL of distilled water was 
added to the reaction vial. The organic layer was separated and removed under reduced 
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atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was used to 
purify sufficient amounts of the target molecule for biological testing and characterization. 
LRMS (APCI - quad) m/z cal’d for C17H21N4O+ [M+H+], 297.38 found 298. 1H NMR (400 
MHz, CDCl3) δ 8.32 (t, J = 1.9 Hz, 1H), 8.15 (t, J = 2.9 Hz, 1H), 7.24 (s, 1H), 7.22 - 7.19 
(m, 2H), 7.17 (d, J = 7.5 Hz, 1H), 7.15 - 7.11 (m, 1H), 6.88 (d, J = 7.3 Hz, 1H), 6.45 (br, 
1H), 3.72 - 3.62 (m, 4H), 3.29 - 3.21 (m, 4H), 2.33 (s, 3H). 
 
4-(Pyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)piperazine-1-carboxamide (3.58)  
 
To a stirring solution of 1-(pyridin-4-yl)piperazine (30 mg, 0.18 mmol, 1.0 equiv), 
triethylamine (1.9 µL, 0.018 mmol, 0.1 equiv) in DCM (5 mL) was added 1-isocyanato-3-
(trifluoromethyl)benzene (41 mg, 0.21 mmol, 1.2 equiv) and the solution was stirred for 
30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of distilled 
water was added to the reaction vial. The organic layer was separated and removed under 
reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was 
used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C17H18F3N4O+ [M+H+], 351.35 found 
352. 1H NMR (400 MHz, CDCl3) δ 8.31 (t, J = 2.0 Hz, 1H), 8.15 (t, J = 3.1 Hz, 1H), 7.66 
(t, J = 2.0 Hz, 1H), 7.58 (dd, J1 = 2.1, J2 = 8.0 Hz, 1H), 7.39 (t, J = 7.9 Hz, 1H), 7.29 (d, J 
= 7.8 Hz, 1H), 7.22 - 7.19 (m, 2H), 6.89 (br, 1H), 3.75 - 3.64 (m, 4H), 3.30 - 3.22 (m, 4H). 
 
 187 
N-(3-Nitrophenyl)-4-(pyridin-4-yl)piperazine-1-carboxamide (3.59)  
 
To a stirring solution of 1-(pyridin-4-yl)piperazine (30 mg, 0.18 mmol, 1.0 equiv), 
triethylamine (1.9 µL, 0.018 mmol, 0.1 equiv) in DCM (5 mL) was added 1-isocyanato-3-
nitrobenzene (29 mg, 0.21 mmol, 1.2 equiv) and the solution was stirred for 30 min at RT. 
After confirming consumption of limiting reagent by TLC, 3 mL of distilled water was 
added to the reaction vial. The organic layer was separated and removed under reduced 
atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was used to 
purify sufficient amounts of the target molecule for biological testing and characterization. 
LRMS (APCI - quad) m/z cal’d for C17H21N4O+ [M+H+], 297.38 found 299. 1H NMR (400 
MHz, CDCl3) δ 8.32 (t, J = 2.0 Hz, 1H), 8.22 (t, J = 2.2 Hz, 1H), 8.16 (t, J = 2.6 Hz, 1H), 
7.88 (ddd, J1 = 1.0, J2 = 3.2, J3 = 8.2 Hz, 1H), 7.83 (ddd, J1 = 1.0, J2 = 3.2, J3 = 8.2 Hz, 
1H), 7.45 (t, J = 8.2, 1H), 7.23 - 7.20 (m, 2H), 6.97 (br, 1H), 3.77 - 3.68 (m, 4H), 3.34 - 
3.24 (m, 4H). 
 
4-(Pyrimidin-2-yl)-N-(3-(trifluoromethyl)phenyl)piperazine-1-carboxamide (3.60)  
 
To a stirring solution of 2-(piperazin-1-yl)pyrimidine (30 mg, 0.11 mmol, 1.0 equiv), 
triethylamine (1.8 µL, 0.011 mmol, 0.1 equiv) in DCM (5 mL) was added 1-isocyanato-3-
(trifluoromethyl)benzene (41 mg, 0.14 mmol, 1.2 equiv) and the solution was stirred for 
30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of distilled 
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water was added to the reaction vial. The organic layer was separated and removed under 
reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was 
used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C16H17F3N5O+ [M+H+], 352.34 found 
353. 1H NMR (400 MHz, CDCl3) δ 8.33 (d, J = 4.8 Hz, 2H), 7.67 (s, 1H), 7.59 (d, J = 8.2 
Hz, 1H), 7.40 (t, J = 7.9 Hz, 1H), 7.29 (d, J = 7.8 Hz, 1H), 6.63 (br, 1H), 6.56 (t, J = 4.7 
Hz, 1H), 3.98 - 3.86 (m, 4H), 3.66 - 3.58 (m, 4H). 
 
N-(3-(Phenylcarbamoyl)phenyl)-4-(3-(trifluoromethyl)phenyl)piperazine-1-
carboxamide (3.61)  
 
To a stirring solution of 3-(4-(3-(trifluoromethyl)phenyl)piperazine-1-
carboxamido)benzoic acid (20 mg, 0.05 mmol, 1 equiv) in DCM (5 mL) was added EDC 
(21 mg, 0.1 mmol, 2.0 equiv) and DMAP (0.085 mg, 0.005 mmol, 0.01 equiv). A small 
amount of DMF was needed for complete dissolution of the acid. This solution was stirred 
for 10 min before addition of aniline(7 mg, 0.075 mmol, 1.5 equiv). The reaction slurry 
was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics 
were separated and the solvent was removed under reduced pressure. Column 
chromatography (0 to 100% (EtOAc/Hex) on silica gel was used to purify sufficient 
amounts of the target molecule for biological testing and characterization. LRMS (APCI - 
quad) m/z cal’d C25H24F3N4O2+ [M+H+], 469.4877 found 470. 1H NMR (400 MHz, 
CDCl3) δ 8.01 (s, 1H), 7.87 (t, J = 2.0, 1H), 7.67 - 7.60 (m, 3H), 7.51 (d, J = 7.9 Hz, 1H), 
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7.42 - 7.32 (m, 3H), 7.18 - 7.10 (m, 2H), 7.08 (d, J = 8.2 Hz, 1H), 6.81 (br, 1H), 3.72 - 3.64 
(m, 4H), 3.32 - 3.22 (m, 4H). 
 
N-(3-((4-Chlorophenyl)carbamoyl)phenyl)-4-(3-(trifluoromethyl)phenyl)piperazine-
1-carboxamide (3.62)  
 
To a stirring solution of 3-(4-(3-(trifluoromethyl)phenyl)piperazine-1-
carboxamido)benzoic acid (20 mg, 0.05 mmol, 1 equiv) in DCM (5 mL) was added EDC 
(21 mg, 0.1 mmol, 2.0 equiv) and DMAP (0.085 mg, 0.005 mmol0.01 equiv). A small 
amount of DMF was needed for complete dissolution of the acid. This solution was stirred 
for 10 min before addition of 4-chloroaniline (6 mg, 0.075 mmol, 1.5 equiv). The reaction 
slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). 
Organics were separated and the solvent was removed under reduced pressure. Column 
chromatography (0 to 100% (EtOAc/Hex) on silica gel was used to purify sufficient 
amounts of the target molecule for biological testing and characterization. LRMS (APCI - 
quad) m/z cal’d C25H23ClF3N4O2+ [M+H+], 503.9297 found 504. 1H NMR (400 MHz, 
CDCl3) δ 8.12 (s, 1H), 7.87 (s, 1H), 7.62 - 7.54 (m, 3H), 7.50 (d, J = 7.8 Hz, 1H), 7.42 - 
7.35 (m, 2H), 7.31 (d, J = 8.8 Hz, 2H), 7.15 (d, J = 7.8 Hz, 1H), 7.12 (s, 1H), 7.07 (d, J = 
8.3 Hz, 1H), 6.75 (br, 1H), 3.74 - 3.62 (m, 4H), 3.35 - 3.21 (m, 4H). 
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N-(3-((4-Methoxyphenyl)carbamoyl)phenyl)-4-(3-
(trifluoromethyl)phenyl)piperazine-1-carboxamide (3.63)  
 
To a stirring solution of 3-(4-(3-(trifluoromethyl)phenyl)piperazine-1-
carboxamido)benzoic acid (20 mg, 0.05 mmol, 1 equiv) in DCM (5 mL) was added EDC 
(21 mg, 0.1 mmol, 2.0 equiv) and DMAP (0.085 mg, 0.005 mmol, 0.01 equiv). A small 
amount of DMF was needed for complete dissolution of the acid. This solution was stirred 
for 10 min before addition of 4-methoxyaniline (7 mg, 0.075 mmol, 1.5 equiv). The 
reaction slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 
mL). Organics were separated and the solvent was removed under reduced pressure. 
Column chromatography (0 to 100% (EtOAc/Hex) on silica gel was used to purify 
sufficient amounts of the target molecule for biological testing and characterization. LRMS 
(APCI - quad) m/z cal’d C26H26F3N4O3+ [M+H+], 499.5137 found 500. 1H NMR (400 
MHz, CDCl3) δ 7.91 (t, J = 2.0 Hz, 1H), 7.77 - 7.71 (m, 2H), 7.43 - 7.36 (m, 2H), 7.18 - 
7.09 (m, 2H), 6.52 (br, 1H), 3.91 (s, 3H), 3.75 - 3.68 (m, 4H), 3.36 - 3.29 (m, 4H). 
 
N-(3-((3,4-Dichlorophenyl)carbamoyl)phenyl)-4-(3-
(trifluoromethyl)phenyl)piperazine-1-carboxamide (3.64)  
 
To a stirring solution of 3-(4-(3-(trifluoromethyl)phenyl)piperazine-1-
carboxamido)benzoic acid (20 mg, 0.05 mmol, 1 equiv) in DCM (5 mL) was added EDC 
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(21 mg, 0.1 mmmol, 2.0 equiv) and DMAP (0.085 mg, 0.005 mmol, 0.01 equiv). A small 
amount of DMF was needed for complete dissolution of the acid. This solution was stirred 
for 10 min before addition of 3,4-dichloroaniline (8 mg, 0.075 mmol, 1.5 equiv). The 
reaction slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 
mL). Organics were separated and the solvent was removed under reduced pressure. 
Column chromatography (0 to 100% (EtOAc/Hex) on silica gel was used to purify 
sufficient amounts of the target molecule for biological testing and characterization. LRMS 
(APCI - quad) m/z cal’d C25H22Cl2F3N4O2+ [M+H+], 538.3717 found 540. 1H NMR (400 
MHz, CDCl3) δ 8.35 (br, 1H), 7.89 (d, J = 2.5 Hz, 1H), 7.83 (t, J = 2.0 Hz, 1H), 7.52 - 7.43 
(m, 3H), 7.42 - 7.29 (m, 3H), 7.15 (d, J = 7.8 Hz, 1H), 7.13 (s, 1H), 7.09 (d, J = 8.3 Hz, 
1H), 6.80 (br, 1H), 3.76 - 3.61 (m, 4H), 3.35 - 3.22 (m, 4H). 
 
N-(3-((3-Chlorophenyl)carbamoyl)phenyl)-4-(3-(trifluoromethyl)phenyl)piperazine-
1-carboxamide (3.65)  
 
To a stirring solution of 3-(4-(3-(trifluoromethyl)phenyl)piperazine-1-
carboxamido)benzoic acid (20 mg, 0.05 mmol, 1 equiv) in DCM (5 mL) was added EDC 
(21 mg, 0.10 mmol, 2.0 equiv) and DMAP (0.085 mg, 0.005 mmol, 0.01 equiv). A small 
amount of DMF was needed for complete dissolution of the acid. This solution was stirred 
for 10 min before addition of 3-chloroaniline (7 mg, 0.075 mmol, 1.5 equiv). The reaction 
slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). 
Organics were separated and the solvent was removed under reduced pressure. Column 
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chromatography (0 to 100% (EtOAc/Hex) on silica gel was used to purify sufficient 
amounts of the target molecule for biological testing and characterization. LRMS (APCI - 
quad) m/z cal’d C25H23ClF3N4O2+ [M+H+], 503.9297 found 505. 1H NMR (400 MHz, 
CDCl3) δ 8.26 (s, 1H), 7.83 (t, J = 2.0 Hz, 1H), 7.77 (t, J = 2.1 Hz, 1H), 7.56 (d, J = 8.0, 
1H), 7.50 - 7.44 (m, 2H), 7.42 - 7.31 (m, 2H), 7.26 (t, J = 7.0 Hz, 1H), 7.19 - 7.08 (m, 4H), 
6.91 (s, 1H), 3.74 - 3.64 (m, 4H), 3.32 - 3.24 (m, 4H). 
 
N-(3-((4-(tert-Butyl)phenyl)carbamoyl)phenyl)-4-(3-
(trifluoromethyl)phenyl)piperazine-1-carboxamide (3.66)  
 
To a stirring solution of 3-(4-(3-(trifluoromethyl)phenyl)piperazine-1-
carboxamido)benzoic acid (20 mg, 0.05 mmol, 1 equiv) in DCM (5 mL) was added EDC 
(21 mg, 0.1 mmol, 2.0 equiv) and DMAP (0.085 mg, 0.005 mmol, 0.01 equiv). A small 
amount of DMF was needed for complete dissolution of the acid. This solution was stirred 
for 10 min before addition of 4-(tert-butyl)aniline (8 mg, 0.075 mmol, 1.5 equiv). The 
reaction slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 
mL). Organics were separated and the solvent was removed under reduced pressure. 
Column chromatography (0 to 100% (EtOAc/Hex) on silica gel was used to purify 
sufficient amounts of the target molecule for biological testing and characterization. LRMS 
(APCI - quad) m/z cal’d C29H32F3N4O2+ [M+H+], 525.5957 found 527. 1H NMR (400 
MHz, CDCl3) δ 7.92 (s, 1H), 7.87 (t, J = 1.9 Hz, 1H), 7.66 (d, J = 9.9 Hz, 1H), 7.58 - 7.49 
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(m, 2H), 7.44 - 7.35 (m, 3H), 7.19 - 7.08 (m, 2H), 6.72 (br, 1H), 3.78 - 3.65 (m, 4H), 3.36 
- 3.24 (m, 4H).  
 
N-(3-((4-Chloro-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-4-(3-
(trifluoromethyl)phenyl)piperazine-1-carboxamide (3.67)  
 
To a stirring solution of 3-(4-(3-(trifluoromethyl)phenyl)piperazine-1-
carboxamido)benzoic acid (20 mg, 0.05 mmol, 1 equiv) in DCM (5 mL) was added EDC 
(21 mg, 0.10 mmol, 2.0 equiv) and DMAP (0.085 mg, 0.005 mmol, 0.01 equiv). A small 
amount of DMF was needed for complete dissolution of the acid. This solution was stirred 
for 10 min before addition of 4-chloro-3-(trifluoromethyl)aniline (10 mg, 0.075 mmol, 1.5 
equiv). The reaction slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl 
solution (3 mL). Organics were separated and the solvent was removed under reduced 
pressure. Column chromatography (0 to 100% (EtOAc/Hex) on silica gel was used to 
purify sufficient amounts of the target molecule for biological testing and characterization. 
LRMS (APCI - quad) m/z cal’d C26H22ClF6N4O2+ [M+H+], 571.9279 found 572. 1H NMR 
(400 MHz, CDCl3) δ 8.41 (s, 1H), 8.00 (d, J = 2.5 Hz, 1H), 7.93 (t, J = 1.9 Hz, 1H), 7.89 
(dd, J1 = 2.6, J2 = 8.8 Hz, 1H), 7.54 (d, J = 7.6 Hz, 1H), 7.51 - 7.45 (m, 2H), 7.43 - 7.36 
(m, 2H), 7.19 - 7.09 (m, 2H), 6.68 (br, 1H), 3.79 - 3.65 (m, 4H), 3.36 - 3.26 (m, 4H). 
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4-(3,5-bis(Trifluoromethyl)phenyl)-N-(3-(phenylcarbamoyl)phenyl)piperazine-1-
carboxamide (3.68)  
 
To a stirring solution of 3-(4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-
carboxamido)benzoic acid (20 mg, 0.05 mmol, 1 equiv) in DCM (5 mL) was added EDC 
(13 mg, 0.1 mmol, 2.0 equiv) and DMAP (0.052 mg, 0.005 mmol, 0.01 equiv). A small 
amount of DMF was needed for complete dissolution of the acid. This solution was stirred 
for 10 min before addition of aniline (6 mg, 0.075 mol, 1.5 equiv). The reaction slurry was 
brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics were 
separated and the solvent was removed under reduced pressure. Column chromatography 
(0 to 100% (EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target 
molecule for biological testing and characterization. LRMS (APCI - quad) m/z cal’d 
C26H23F6N4O2+ [M+H+], 537.4859 found 537. 1H NMR (400 MHz, CDCl3) δ 7.94 (s, 1H), 
7.90 (t, J = 2.0 Hz, 1H), 7.69 - 7.60 (m, 3H), 7.54 (d, J = 7.7 Hz, 1H), 7.46 - 7.36 (m, 4H), 
7.16 (t, J = 7.4 Hz, 1H), 6.69 (br, 1H), 3.79 - 3.68 (m, 4H), 3.43 - 3.35 (m, 4H). 
 
4-(3,5-bis(Trifluoromethyl)phenyl)-N-(3-((4-
chlorophenyl)carbamoyl)phenyl)piperazine-1-carboxamide (3.69)  
 
To a stirring solution of 3-(4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-
carboxamido)benzoic acid (20 mg, 0.05 mmol, 1 equiv) in DCM (5 mL) was added EDC 
 195 
(13 mg, 0.1 mmol, 2.0 equiv) and DMAP (0.052 mg, 0.005 mmol, 0.01 equiv). A small 
amount of DMF was needed for complete dissolution of the acid. This solution was stirred 
for 10 min before addition of 4-chloroaniline (8 mg, 0.075 mmol, 1.5 equiv). The reaction 
slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). 
Organics were separated and the solvent was removed under reduced pressure. Column 
chromatography (0 to 100% (EtOAc/Hex) on silica gel was used to purify sufficient 
amounts of the target molecule for biological testing and characterization. LRMS (APCI - 
quad) m/z cal’d C26H22ClF6N4O2+ [M+H+], 571.9279 found 572. 1H NMR (400 MHz, 
CDCl3) δ 8.02 (s, 1H), 7.93 (s, 1H), 7.65 - 7.52 (m, 3H), 7.43 (t, J = 7.8 Hz, 1H), 7.39 - 
7.30 (m, 2H), 6.63 (br, 1H), 3.82 - 3.67 (m, 4H), 3.47 - 3.33 (m, 4H). 
 
4-(3,5-bis(Trifluoromethyl)phenyl)-N-(3-((4-
methoxyphenyl)carbamoyl)phenyl)piperazine-1-carboxamide (3.70)  
 
To a stirring solution of 3-(4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-
carboxamido)benzoic acid (20 mg, 0.05 mmol, 1 equiv) in DCM (5 mL) was added EDC 
(13 mg, 0.1 mmol, 2.0 equiv) and DMAP (0.052 mg, 0.005 mmol, 0.01 equiv). A small 
amount of DMF was needed for complete dissolution of the acid. This solution was stirred 
for 10 min before addition of 4-methoxyaniline (8 mg, 0.075 mmol, 1.5 equiv). The 
reaction slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 
mL). Organics were separated and the solvent was removed under reduced pressure. 
Column chromatography (0 to 100% (EtOAc/Hex) on silica gel was used to purify 
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sufficient amounts of the target molecule for biological testing and characterization. LRMS 
(APCI - quad) m/z cal’d C27H25F6N4O3+ [M+H+], 567.5119 found 567. 1H NMR (400 
MHz, CDCl3) δ 7.88 (s, 1H), 7.81 (s, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.58 - 7.49 (m, 3H), 
7.43 (t, J = 7.9 Hz, 1H), 7.35 (s, 1H), 6.91 (d, J = 8.8 Hz, 2H), 6.55 (br, 1H), 3.82 (s, 3H), 
3.77 - 3.69 (m, 4H), 3.45 - 3.36 (m, 4H). 
 
4-(3,5-bis(Trifluoromethyl)phenyl)-N-(3-((3,4-
dichlorophenyl)carbamoyl)phenyl)piperazine-1-carboxamide (3.71)  
 
To a stirring solution of 3-(4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-
carboxamido)benzoic acid (20 mg, 0.05 mmol, 1 equiv) in DCM (5 mL) was added EDC 
(13 mg, 0.1 mmol, 2.0 equiv) and DMAP (0.052 mg, 0.005 mmol, 0.01 equiv). A small 
amount of DMF was needed for complete dissolution of the acid. This solution was stirred 
for 10 min before addition of 3,4-dichloroaniline (11 mg, 0.075 mmol, 1.5 equiv). The 
reaction slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 
mL). Organics were separated and the solvent was removed under reduced pressure. 
Column chromatography (0 to 100% (EtOAc/Hex) on silica gel was used to purify 
sufficient amounts of the target molecule for biological testing and characterization. LRMS 
(APCI - quad) m/z cal’d C26H21Cl2F6N4O2+ [M+H+], 606.3699 found 607. 1H NMR (400 
MHz, CDCl3) δ 8.83 (s, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.84 (s, 1H), 7.56 - 7.44 (m, 3H), 
7.42 - 7.32 (m, 3H), 7.27 (s, 1H), 6.84 (br, 1H), 3.80 - 3.65 (m, 4H), 3.43 - 3.29 (m, 4H). 
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4-(3,5-bis(Trifluoromethyl)phenyl)-N-(3-((3-
chlorophenyl)carbamoyl)phenyl)piperazine-1-carboxamide (3.72)  
 
To a stirring solution of 3-(4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-
carboxamido)benzoic acid (20 mg, 0.05 mmol, 1 equiv) in DCM (5 mL) was added EDC 
(13 mg, 0.1 mmol, 2.0 equiv) and DMAP (0.052 mg, 0.005 mmo, 0.01 equiv). A small 
amount of DMF was needed for complete dissolution of the acid. This solution was stirred 
for 10 min before addition of 3,4-dichloroaniline (8 mg, 0.075 mmol, 1.5 equiv). The 
reaction slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 
mL). Organics were separated and the solvent was removed under reduced pressure. 
Column chromatography (0 to 100% (EtOAc/Hex) on silica gel was used to purify 
sufficient amounts of the target molecule for biological testing and characterization. LRMS 
(APCI - quad) m/z cal’d C26H22ClF6N4O2+ [M+H+], 571.9279 found 572. 1H NMR (400 
MHz, CDCl3) δ 8.07 (s, 1H), 7.88 (t, J = 2.0 Hz, 1H), 7.78 (t, J = 2.1 Hz, 1H), 7.60 (d, J = 
8.0 Hz, 1H), 7.54 - 7.46 (m, 2H), 7.41 (t J = 7.9 Hz, 1H), 7.36 (s, 1H), 7.29 (d, J = 8.1 Hz, 
1H), 7.13 (ddd, J1 = 1.0, J2 = 3.0, J3 = 8.0 Hz, 1H), 6.71 (br, 1H), 3.83 - 3.66 (m, 4H), 3.46 
- 3.30 (m, 4H). 
 
4-(3,5-bis(Trifluoromethyl)phenyl)-N-(3-((4-(dimethylamino)phenyl)-
carbamoyl)phenyl)piperazine-1-carboxamide (3.73)  
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To a stirring solution of 3-(4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-
carboxamido)benzoic acid (20 mg, 0.05 mmol, 1 equiv) in DCM (5 mL) was added EDC 
(13 mg, 0.1 mmol, 2.0 equiv) and DMAP (0.052 mg, 0.005 mmol, 0.01 equiv). A small 
amount of DMF was needed for complete dissolution of the acid. This solution was stirred 
for 10 min before addition of N1,N1-dimethylbenzene-1,4-diamine (9 mg, 0.075 mmol, 
1.5 equiv). The reaction slurry was brought to 37 ˚C for 12 h before quenching with 1 N 
HCl solution (3 mL). Organics were separated and the solvent was removed under reduced 
pressure. Column chromatography (0 to 100% (EtOAc/Hex) on silica gel was used to 
purify sufficient amounts of the target molecule for biological testing and characterization. 
LRMS (APCI - quad) m/z cal’d C28H28F6N5O2+ [M+H+], 580.5549 found 580. 1H NMR 
(400 MHz, CDCl3) δ 7.91 (s, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.58 - 7.50 (m, 2H), 7.40 (t, J 
= 8.0 Hz, 1H), 7.34 (s, 1H), 7.25 (s, 1H), 3.80 - 3.65 (m, 4H), 3.42 - 3.33 (m, 4H), 2.98 (s, 
6H). 
 
4-(3,5-bis(Trifluoromethyl)phenyl)-N-(3-((4-(tert-
butyl)phenyl)carbamoyl)phenyl)piperazine-1-carboxamide (3.74)  
 
To a stirring solution of 3-(4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-
carboxamido)benzoic acid (20 mg, 0.05 mmol, 1 equiv) in DCM (5 mL) was added EDC 
(13 mg, 0.1 mmol, 2.0 equiv) and DMAP (0.052 mg, 0.005 mmol, 0.01 equiv). A small 
amount of DMF was needed for complete dissolution of the acid. This solution was stirred 
for 10 min before addition of 4-(tert-butyl)aniline (10 mg, 0.075 mmol, 1.5 equiv). The 
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reaction slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 
mL). Organics were separated and the solvent was removed under reduced pressure. 
Column chromatography (0 to 100% (EtOAc/Hex) on silica gel was used to purify 
sufficient amounts of the target molecule for biological testing and characterization. LRMS 
(APCI - quad) m/z cal’d C30H31F6N4O2+ [M+H+], 593.5939 found 594. 1H NMR (400 
MHz, CDCl3) δ 7.91 - 7.83 (m, 2H), 7.68 (d, J = 8.5 Hz, 1H), 7.57 - 7.51 (m, 3H), 7.47 - 
7.33 (m, 4H), 6.61 (br, 1H), 3.78 - 3.69 (m, 4H), 3.45 - 3.35 (m, 4H), 1.32 (s, 9H). 
 
4-(3,5-bis(Trifluoromethyl)phenyl)-N-(3-((4-chloro-3-
(trifluoromethyl)phenyl)carbamoyl)phenyl)piperazine-1-carboxamide (3.75)  
 
To a stirring solution of 3-(4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-
carboxamido)benzoic acid (20 mg, 0.05 mmol, 1 equiv) in DCM (5 mL) was added EDC 
(13 mg, 0.1 mmol, 2.0 equiv) and DMAP (0.052 mg, 0.005 mmol, 0.01 equiv). A small 
amount of DMF was needed for complete dissolution of the acid. This solution was stirred 
for 10 min before addition of 4-chloro-3-(trifluoromethyl)aniline (13 mg, 0.075 mmol, 1.5 
equiv). The reaction slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl 
solution (3 mL). Organics were separated and the solvent was removed under reduced 
pressure. Column chromatography (0 to 100% (EtOAc/Hex) on silica gel was used to 
purify sufficient amounts of the target molecule for biological testing and characterization. 
LRMS (APCI - quad) m/z cal’d C27H21ClF9N4O2+ [M+H+], 639.9261 found 695. 1H NMR 
(400 MHz, CDCl3) δ 8.34 (s, 1H), 7.99 (d, J = 2.5 Hz, 1H), 7.93 (s, 1H), 7.88 (dd, J1 = 2.6, 
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J2 = 8.8 Hz, 1H), 7.57 - 7.45 (m, 3H) 7.41 (t, J = 7.8 Hz, 1H), 7.36 (s, 1H), 7.27 (s, 2H), 
6.67 (br, 1H), 3.79 - 3.71 (m, 4H), 3.44 - 3.35 (m, 4H). 
 
4-(3,5-bis(Trifluoromethyl)phenyl)-N-(3-(pyridin-4-ylcarbamoyl)phenyl)piperazine-
1-carboxamide (3.76)  
 
To a stirring solution of 3-(4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-
carboxamido)benzoic acid (20 mg, 0.05 mmol, 1 equiv) in DCM (5 mL) was added EDC 
(13 mg, 0.1 mmol, 2.0 equiv) and DMAP (0.052 mg, 0.005mmol, 0.01 equiv). A small 
amount of DMF was needed for complete dissolution of the acid. This solution was stirred 
for 10 min before addition of pyridin-4-amine (6 mg, 0.075 mmol, 1.5 equiv). The reaction 
slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). 
Organics were separated and the solvent was removed under reduced pressure. Column 
chromatography (0 to 100% (EtOAc/Hex) on silica gel was used to purify sufficient 
amounts of the target molecule for biological testing and characterization. LRMS (APCI - 
quad) m/z cal’d C25H22F6N5O2+ [M+H+], 538.4739 found 539. 1H NMR (400 MHz, 
CDCl3) δ 8.54 (d, J = 5.4 Hz, 1H) 8.03 - 7.89 (m, 2H), 7.64 (d, J = 6.5 Hz, 1H), 7.55 (t, J 
= 6.9 Hz, 1H), 7.46 - 7.32 (m, 3H), 6.70 (br, 1H), 3.80 - 3.66 (m, 4H), 3.45 - 3.32 (m, 4H). 
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4-(3,5-bis(Trifluoromethyl)phenyl)-N-(3-(pyridin-3-ylcarbamoyl)phenyl)piperazine-
1-carboxamide (3.77)  
 
To a stirring solution of 3-(4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-
carboxamido)benzoic acid (20 mg, 0.05 mmol, 1 equiv) in DCM (5 mL) was added EDC 
(13 mg, 0.1 mmol, 2.0 equiv) and DMAP (0.052 mg, 0.01 equiv). A small amount of DMF 
was needed for complete dissolution of the acid. This solution was stirred for 10 min before 
addition of pyridin-3-amine (6 mg, 0.075 mmol, 1.5 equiv). The reaction slurry was 
brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics were 
separated and the solvent was removed under reduced pressure. Column chromatography 
(0 to 100% (EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target 
molecule for biological testing and characterization. LRMS (APCI - quad) m/z cal’d 
C25H22F6N5O2+ [M+H+], 538.4739 found 539. 1H NMR (400 MHz, CDCl3) δ 11.1 (s, 1H), 
9.37 (s, 1H), 9.14 (s, 1H), 8.29 (br, 1H), 8.16 (d, J = 5.6 Hz, 1H), 8.11 (br, 1H), 7.70 (s, 
1H), 7.63 (d, J = 8.2, 1H), 7.58 (d, J = 7.8 Hz, 1H), 7.32 (s, 1H), 7.21 (s, 2H), 7.10 (t, J = 
7.8 Hz, 1H), 3.76 (br, 4H), 3.29 (br, 4H). 
 
4-(3,5-bis(Trifluoromethyl)phenyl)-N-(3-((4-
(trifluoromethyl)phenyl)carbamoyl)phenyl)piperazine-1-carboxamide (3.78)  
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To a stirring solution of 3-(4-(3,5-bis(trifluoromethyl)phenyl)piperazine-1-
carboxamido)benzoic acid (20 mg, 0.05 mmol, 1 equiv) in DCM (5 mL) was added EDC 
(13 mg, 0.1 mmol, 2.0 equiv) and DMAP (0.052 mg, 0.005 mmol, 0.01 equiv). A small 
amount of DMF was needed for complete dissolution of the acid. This solution was stirred 
for 10 min before addition of 4-(trifluoromethyl)aniline (10 mg, 0.075 mmol, 1.5 equiv). 
The reaction slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution 
(3 mL). Organics were separated and the solvent was removed under reduced pressure. 
Column chromatography (0 to 100% (EtOAc/Hex) on silica gel was used to purify 
sufficient amounts of the target molecule for biological testing and characterization. LRMS 
(APCI - quad) m/z cal’d C27H22F9N4O2+ [M+H+], 605.4841 found 606. 1H NMR (400 
MHz, CDCl3) δ 8.18 (s, 1H), 7.96 (s, 1H), 7.79 (d, J = 8.3 Hz, 2H), 7.63 (d, J = 8.2 Hz, 
2H), 7.57 (d, J = 7.5 Hz, 1H), 7.48 -7.37 (m, 2H), 7.19 - 7.06 (m, 2H), 6.58 (br, 1H), 3.73 
(br, 4H), 3.33 (br, 4H). 
 
N-(4-Chloro-3-(trifluoromethyl)phenyl)-2-(2-(3-
(trifluoromethyl)phenyl)acetamido)acetamide (3.79) 
 
To a stirring solution of 2-amino-N-(4-chloro-3-(trifluoromethyl)phenyl)acetamide (38 
mg, 0.14 mmol, 1.0 equiv), triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) 
was added 2-(3-(trifluoromethyl)phenyl)acetyl chloride (40 mg, 0.17 mmol,1.2 equiv) and 
the solution was stirred for 30 min at RT. After confirming consumption of limiting reagent 
by TLC, 3 mL of distilled water was added to the reaction vial. The organic layer was 
separated and removed under reduced atmosphere. Column chromatography (0 to 50% 
 203 
EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C18H14ClF6N2O2+ [M+H+] 439.7619, found 439. 1H NMR (400 MHz, CDCl3) δ 8.86 (s, 
1H), 7.85 (d, J = 2.6 Hz, 1H), 7.61 - 7.53 (m, 3H), 7.51 - 7.46 (m, 2H), 7.39 (d, J = 8.8 Hz, 
1H), 6.52 (s, 1H), 4.11 (d, J = 5.3 Hz, 2H), 3.72 (s, 4H). 
 
N-(4-Chloro-3-(trifluoromethyl)phenyl)-2-(3-(3-cyanophenyl)ureido)acetamide 
(3.80) 
 
To a stirring solution of 3-cyanobenzoic acid (15 mg, 0.12 mmol, 1 equiv) in DCM (5 mL) 
was added EDC (32 mg, 0.24 mmol, 2.0 equiv) and DMAP (32 mg, 0.30 mmol, 2.5 equiv). 
This solution was stirred for 10 min before addition of 2-amino-N-(4-chloro-3-
(trifluoromethyl)phenyl)acetamide (40 mg, 0.16 mmol,1.5 equiv). The reaction slurry was 
brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics were 
separated and the solvent was removed under reduced pressure. Column chromatography 
(0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target 
molecule for biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C17H13ClF3N4O2+ [M+H+] 397.7617, found 398. 1H NMR (400 MHz, CD3OD) δ 8.14 (t, J 
= 1.7 Hz, 1H), 8.08 (td, J1 = 1.4, J2 = 6.6 Hz, 1H), 8.0 (d, J = 2.6 Hz, 1H), 7.82 (td, J1 = 
1.4, J2 = 7.8 Hz, 1H), 7.69 (dd, J1 = 2.6, J2 = 8.8 Hz, 1H), 7.58 (t, J = 7.8 Hz, 1H), 7.43 (d, 
J = 8.7 Hz, 1H), 4.12 (s, 2H). 
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2-(3-(3,5-bis(Trifluoromethyl)phenyl)ureido)-N-(4-chloro-3-
(trifluoromethyl)phenyl)acetamide (3.81) 
 
To a stirring solution of 3,5-bistrifluoromethylbenzoic acid (27 mg, 0.12 mmol, 1 equiv) 
in DCM (5 mL) was added EDC (32 mg, 0.24 mmol, 2.0 equiv) and DMAP (32 mg, 0.30 
mmol, 2.5 equiv). This solution was stirred for 10 min before addition of 2-amino-N-(4-
chloro-3-(trifluoromethyl)phenyl)acetamide (40 mg, 0.16 mmol,1.5 equiv). The reaction 
slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). 
Organics were separated and the solvent was removed under reduced pressure. Column 
chromatography (0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient amounts 
of the target molecule for biological testing and characterization. LRMS (APCI - quad) m/z 
cal’d for C18H12ClF9N3O2+ [M+H+] 508.7481, found 509. 1H NMR (400 MHz, CD3OD) δ 
8.58 (s, 2H), 8.20 (s, 1H), 8.13 (d, J = 2.6 Hz, 1H), 7.82 (dd, J1 = 2.6, J2 = 8.8 Hz, 1H), 
7.56 (d, J = 8.8 Hz, 1H), 4.27 (s, 3H). 
 
S-(2-((2-Chloro-5-(trifluoromethyl)phenyl)amino)-2-oxoethyl) 2-(3-
(Trifluoromethyl)phenyl)ethanethioate (3.82) 
 
To a stirring solution of N-(2-chloro-5-(trifluoromethyl)phenyl)-2-mercaptoacetamide (40 
mg, 0.15 mmol, 1.0 equiv), triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) 
was added 2-(3-(trifluoromethyl)phenyl)acetyl chloride (40 mg, 0.18 mmol, 1.2 equiv) and 
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the solution was stirred for 30 min at RT. After confirming consumption of limiting reagent 
by TLC, 3 mL of distilled water was added to the reaction vial. The organic layer was 
separated and removed under reduced atmosphere. Column chromatography (0 to 50% 
EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C18H14ClF6N2O2+ [M+H+] 439.7619, found 440. 1H NMR (400 MHz, CDCl3) δ 8.67 (d, J 
= 2.0 Hz, 1H), 8.53 (br, 1H), 7.62 - 7.56 (m, 2H), 7.52 - 7.45 (m, 3H), 7.29 (dd, J1 = 2.1, 
J2 = 8.4 Hz, 1H), 4.01 (s, 2H), 3.75 (s, 2H). 
 
S-(2-((2-Chloro-5-(trifluoromethyl)phenyl)amino)-2-oxoethyl) m-
tolylcarbamothioate (3.83)  
 
To a stirring solution of N-(2-chloro-5-(trifluoromethyl)phenyl)-2-mercaptoacetamide (30 
mg, 0.10 mmol, 1.0 equiv), triethylamine (1.7 µL, 0.01 mmol, 0.1 equiv) in DCM (5 mL) 
was added 1-isocyanato-3-methylbenzene (20 mg, 0.12 mmol, 1.2 equiv) and the solution 
was stirred for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 
mL of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d C17H15ClF3N2O2S+ [M+H+], 
403.8237 found 404. 1H NMR (400 MHz, CD3OD) δ 8.49 (s, 1H), 7.64 (d, J = 8.4 Hz, 
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1H), 7.43 (dd, J1 = 2.1, J2 = 8.4 Hz, 1H), 7.36 - 7.29 (m, 2H), 7.18 (t, J = 7.7 Hz, 1H), 6.93 
(d, J = 7.6 Hz, 1H), 3.89 (s, 2H), 2.32 (s, 3H). 
 
S-(2-Oxo-2-((3-(trifluoromethyl)phenyl)amino)ethyl) m-tolylcarbamothioate (3.84) 
 
To a stirring solution of 2-mercapto-N-(3-(trifluoromethyl)phenyl)acetamide (30 mg, 0.10 
mmol, 1.0 equiv), triethylamine (1.7 µL, 0.010 mmol, 0.1 equiv) in DCM (5 mL) was 
added 1-isocyanato-3-methylbenzene (20 mg, 0.12 mmol, 1.2 equiv) and the solution was 
stirred for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL 
of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d C17H16F3N2O2S+ [M+H+], 369.3817 
found 370. 1H NMR (400 MHz, CD3OD) δ 8.04 (s, 1H), 7.77 (br, 1H), 7.51 (d, J = 8.4 Hz, 
1H), 7.40 (d, J = 7.6 Hz, 1H), 7.34 - 7.25 (m, 2H), 7.18 (t, J = 7.8 Hz, 1H), 6.92 (d, J = 7.4 
Hz, 1H) 3.38 (s, 2H), 2.32 (s, 3H). 
 
S-(2-Oxo-2-((3-(trifluoromethyl)phenyl)amino)ethyl) (3-
cyanophenyl)carbamothioate (3.85) 
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To a stirring solution of 2-mercapto-N-(3-(trifluoromethyl)phenyl)acetamide (36 mg, 0.15 
mmol, 1.0 equiv), triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was 
added 3-cyanophenylisocyanate (40 mg, 0.18 mmol, 1.2 equiv) and the solution was stirred 
for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL of 
distilled water was added to the reaction vial. The organic layer was separated and removed 
under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel 
was used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C17H13F3N3O2S+ [M+H+] 380.3647, 
found 381. 1H NMR (400 MHz, CD3OD) δ 7.93 (br, 1H), 7.85 (t, J = 1.9 Hz, 1H), 7.68 - 
7.62 (m, 2H), 7.44 - 7.27 (m, 4H), 3.80 (s, 2H). 
 
Methyl 3-((((2-oxo-2-((3-
(trifluoromethyl)phenyl)amino)ethyl)thio)carbonyl)amino)benzoate (3.86) 
 
To a stirring solution of 2-mercapto-N-(3-(trifluoromethyl)phenyl)acetamide (36 mg, 0.15 
mmol, 1.0 equiv), triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was 
added 4-isocyanato-1-methyl-1H-indole (40 mg, 0.19 mmol, 1.2 equiv) and the solution 
was stirred for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 
mL of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C18H16F3N2O4S+ [M+H+] 
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413.3907, found 414. 1H NMR (400 MHz, CD3OD) δ 8.08 (s, 1H), 7.92 (s, 1H), 7.70 - 
7.60 (m, 3H), 7.40 (t, J = 8.0 Hz, 1H), 7.33 - 7.25 (m, 2H), 3.79 (s, 3H), 3.78 (s, 2H). 
 
Dimethyl 5-((((2-oxo-2-((3-
(trifluoromethyl)phenyl)amino)ethyl)thio)carbonyl)amino)isophthalate (3.87) 
 
To a stirring solution of 2-mercapto-N-(3-(trifluoromethyl)phenyl)acetamide (36 mg, 0.15 
mmol, 1.0 equiv), triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was 
added 4-isocyanato-1-methyl-1H-indole (43 mg, 0.19 mmol, 1.2 equiv) and the solution 
was stirred for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 
mL of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C20H18F3N2O6S+ [M+H+] 
471.4267, found 471. 1H NMR (400 MHz, CD3OD) δ 8.30 (d, J = 1.4 Hz, 2H), 8.22 (s, 
1H), 7.93 (s, 1H), 7.68 (d, J = 8.2 Hz, 1H), 7.41 (t, J = 8.0 Hz, 1H), 7.29 (d, J = 7.7 Hz, 
1H), 3.83 (s, 6H), 3.81 (s, 2H). 
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S-(2-Oxo-2-((3-(trifluoromethyl)phenyl)amino)ethyl) (1-methyl-1H-indol-4-
yl)carbamothioate (3.88) 
 
To a stirring solution of 2-mercapto-N-(3-(trifluoromethyl)phenyl)acetamide (36 mg, 0.15 
mmol, 1.0 equiv), triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was 
added 4-isocyanato-1-methyl-1H-indole (42 mg, 0.18 mmol, 1.2 equiv) and the solution 
was stirred for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 
mL of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C19H17F3N3O2S+ [M+H+] 
408.4187, found 408. 1H NMR (400 MHz, CD3OD) δ 7.94 (s, 1H), 7.66 (d, J = 4.3 Hz, 
1H), 7.39 (t, J = 7.96, 1H), 7.31 - 7.19 (m, 2H), 7.11 (d, J = 8.2 Hz, 1H), 7.05 - 6.99 (m, 
2H), 6.46 (d, J = 3.2 Hz, 1H), 3.76 (s, 2H), 3.68 (s, 3H). 
 
3-(Trifluoromethyl)-N-((5-(trifluoromethyl)-1H-benzo[d]imidazol-2-
yl)methyl)benzamide (3.90) 
 
To a stirring solution of 3-(trifluoromethyl)benzoic acid (20 mg, 0.11 mmol, 1 equiv) in 
DCM (5 mL) was added EDC (36 mg, 0.22 mmol, 2.0 equiv) and DMAP (35 mg, 0.26 
mmol, 2.5 equiv). This solution was stirred for 10 min before addition of (5-
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(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)methanamine (30 mg, 0.16 mmol, 1.5 equiv). 
The reaction slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution 
(3 mL). Organics were separated and the solvent was removed under reduced pressure. 
Column chromatography (0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient 
amounts of the target molecule for biological testing and characterization. LRMS (APCI - 
quad) m/z cal’d for C17H12F6N3O+ [M+H+] 388.2929, found 388. 1H NMR (400 MHz, 
CD3OD) δ 8.98 (s, 1H), 8.23 (s, 1H), 8.12 (d, J = 7.8 Hz, 1H), 7.83 (s, 1H), 7.77 (d, J = 7.8 
Hz, 1H), 7.66 - 7.47 (m, 3H), 4.89 (d, J = 5.7 Hz, 2H).  
 
3,5-bis(Trifluoromethyl)-N-((5-(trifluoromethyl)-1H-benzo[d]imidazol-2-
yl)methyl)benzamide (3.91) 
 
To a stirring solution of 3,5-bis(trifluoromethyl)benzoic acid (20 mg, 0.11 mmol, 1 equiv) 
in DCM (5 mL) was added EDC (36 mg, 0.22 mmol, 2.0 equiv) and DMAP (35 mg, 0.26 
mmol, 2.5 equiv). This solution was stirred for 10 min before addition of (5-
(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)methanamine (30 mg, 0.16 mmol, 1.5 equiv). 
The reaction slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution 
(3 mL). Organics were separated and the solvent was removed under reduced pressure. 
Column chromatography (0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient 
amounts of the target molecule for biological testing and characterization. LRMS (APCI - 
quad) m/z cal’d for C18H11F9N3O+ [M+H+] 456.2911, found 456. 1H NMR (400 MHz, 
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CDCl3) δ 8.49 (br, 1H), 8.42 (s, 1H), 8.05 (s, 1H), 7.87 (s, 1H), 7.64 (d, J = 7.9 Hz, 1H), 
7.54 (d, J = 7.8 Hz, 1H), 4.89 (d, J = 5.7 Hz, 2H). 
 
3-Cyano-N-((5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)methyl)benzamide (3.92) 
 
To a stirring solution of 3-cyanobenzoic acid (20 mg, 0.11 mmol, 1 equiv) in DCM (5 mL) 
was added EDC (36 mg, 0.22 mmol, 2.0 equiv) and DMAP (35 mg, 0.26 mmol, 2.5 equiv). 
This solution was stirred for 10 min before addition of (5-(trifluoromethyl)-1H-
benzo[d]imidazol-2-yl)methanamine (30 mg, 0.16 mmol, 1.5 equiv). The reaction slurry 
was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics 
were separated and the solvent was removed under reduced pressure. Column 
chromatography (0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient amounts 
of the target molecule for biological testing and characterization. LRMS (APCI - quad) m/z 
cal’d for C17H12F3N4O+ [M+H+] 345.3047, found 346. 1H NMR (400 MHz, CDCl3) δ 8.58 
(t, J = 5.9 Hz, 1H), 8.25 (s, 1H), 8.16 (d, J = 7.9 Hz, 1H), 7.82 (d, J = 7.7 Hz, 1H), 7.59 (d, 
J = 7.9 Hz, 1H), 7.54 (t, J = 8.7 Hz, 1H), 4.87 (d, J = 5.7 Hz, 2H). 
 
2-(4-Cyanophenyl)-N-((5-(trifluoromethyl)-1H-benzo[d]imidazol-2-
yl)methyl)acetamide (3.93) 
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To a stirring solution of 2-(4-cyanophenyl)acetic acid (20 mg, 0.11 mmol, 1 equiv) in DCM 
(5 mL) was added EDC (36 mg, 0.22 mmol, 2.0 equiv) and DMAP (35 mg, 0.20 mmol, 
2.5 equiv). This solution was stirred for 10 min before addition of (5-(trifluoromethyl)-1H-
benzo[d]imidazol-2-yl)methanamine (30 mg, 0.16 mmol, 1.5 equiv). The reaction slurry 
was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics 
were separated and the solvent was removed under reduced pressure. Column 
chromatography (0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient amounts 
of the target molecule for biological testing and characterization. LRMS (APCI - quad) m/z 
cal’d for C18H14F3N4O+ [M+H+] 359.3317, found 359. 1H NMR (400 MHz, CDCl3) δ 10.43 
(br, 1H), 7.64 (d, J = 8.2 Hz, 2H), 7.52 (s, 1H), 7.38 (d, J = 8.1 Hz, 2H), 6.81 (br, 1H), 4.62 
(d, J = 5.9 Hz, 2H), 3.69 (s, 2H). 
 
N-((5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)methyl)-2-(3-
(trifluoromethyl)phenoxy)acetamide (3.94) 
 
To a stirring solution of 2-(3-(trifluoromethyl)phenoxy)acetic acid (20 mg, 0.11 mmol, 1 
equiv) in DCM (5 mL) was added EDC (36 mg, 0.22 mmol, 2.0 equiv) and DMAP (35 mg, 
0.26 mmol, 2.5 equiv). This solution was stirred for 10 min before addition of (5-
(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)methanamine (30 mg, 0.16 mmol, 1.5 equiv). 
The reaction slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution 
(3 mL). Organics were separated and the solvent was removed under reduced pressure. 
Column chromatography (0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient 
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amounts of the target molecule for biological testing and characterization. LRMS (APCI - 
quad) m/z cal’d for C18H14F6N3O2+ [M+H+] 418.3189, found 419. 1H NMR (400 MHz, 
CDCl3) δ 10.94 (br, 1H), 8.09 (s, 1H), 7.95 (br, 1H), 7.74 (br, 1H), 7.51 (s, 1H), 7.39 (t, J 
= 8.0 Hz, 1H), 7.09 (s, 1H), 7.03 (d, J = 8.2, 1H), 4.77 (d, J = 6.1, 2H), 4.58 (s, 3H).  
 
5,5,8,8-Tetramethyl-N-((5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)methyl)-
5,6,7,8-tetrahydronaphthalene-2-carboxamide (3.95)  
 
To a stirring solution of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carboxylic 
acid (41 mg, 0.11 mmol, 1 equiv) in DCM (5 mL) was added EDC (36 mg, 0.22 mmol, 2.0 
equiv) and DMAP (35 mg, 0.20 mmol, 2.5 equiv). This solution was stirred for 10 min 
before addition of (5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)methanamine (30 mg, 
0.16 mmol, 1.5 equiv). The reaction slurry was brought to 37 ˚C for 12 h before quenching 
with 1 N HCl solution (3 mL). Organics were separated and the solvent was removed under 
reduced pressure. Column chromatography (0 to 45% (EtOAc/Hex) on silica gel was used 
to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C24H27F3N3O+ [M+H+] 430.4947, 
found 431. 1H NMR (400 MHz, CDCl3) δ 8.00 (t, J = 8.0 Hz, 1H), 7.86 (d, J = 1.9 Hz, 
2H), 7.60 (dd, J1 = 2.1, J2 = 8.3 Hz, 2H), 7.50 (d, J = 8.6 Hz, 1H), 7.35 (d, J = 8.2 Hz, 1H), 
4.87 (d, J = 5.9 Hz, 2H), 1.68 (s, 6H), 1.37 - 1.23 (m, 16H). 
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2-Chloro-N-((5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)methyl)isonicotinamide 
(3.96)  
 
To a stirring solution of 2-chloroisonicotinic acid (28 mg, 0.11 mmol, 1 equiv) in DCM (5 
mL) was added EDC (36 mg, 0.22 mmol, 2.0 equiv) and DMAP (35 mg, 0.20 mmol, 2.5 
equiv). This solution was stirred for 10 min before addition of (5-(trifluoromethyl)-1H-
benzo[d]imidazol-2-yl)methanamine (30 mg, 0.16 mmol, 1.5 equiv). The reaction slurry 
was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics 
were separated and the solvent was removed under reduced pressure. Column 
chromatography (0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient amounts 
of the target molecule for biological testing and characterization. LRMS (APCI - quad) m/z 
cal’d for C15H11ClF3N4O+ [M+H+] 355.7247, found 356. 1H NMR (400 MHz, CDCl3) δ 
8.88 (br, 1H), 8.52 (dd, J1 = 0.7, J2, = 5.2 Hz, 1H), 7.86 (s, 2H), 7.71 (dd, J1 = 1.5, J2 = 5.2 
Hz, 1H), 7.64 (d, J = 8.5 Hz, 1H), 7.55 (d, J = 8.5 Hz, 1H), 4.85 (d, J = 5.7 Hz, 2H). 
 
1-((3-(Trifluoromethyl)benzyl)sulfonyl)-4-(3-(trifluoromethyl)phenyl)piperazine 
(3.97)  
 
A stirring solution of 1-(3-(trifluoromethyl)phenyl)piperazine (20 mg, 0.09 mmol, 1 equiv) 
in DCM (3 mL) was chilled to 0 °C and to this solution was added pyridine (21 mg, 0.27 
mmol, 3 equiv) and (3-(trifluoromethyl)phenyl)methanesulfonyl chloride (22 mg, 0.11 
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mmol, 1.2 equiv). The ice bath was removed and after confirming consumption of limiting 
reagent by TLC, 2 mL of distilled water was added to the reaction vial. The organic layer 
was separated and removed under reduced atmosphere. Column chromatography (0 to 50% 
EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C19H19F6N2O2S+ [M+H+] 453.4229, found 453. 1H NMR (400 MHz, CDCl3) δ 7.70 -7.61 
(m, 3H), 7.54 (t, J = 7.6 Hz, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.14 (d, J = 7.6 Hz, 1H), 7.08 (s, 
1H), 7.03 (d, J = 8.64, 1H), 4.29 (s, 2H), 3.36 - 3.28 (m, 4H), 3.23 - 3.14 (m, 4H). 13C 
NMR (176 MHz, CDCl3) δ 150.9, 134.1, 131.4 (ddd, J1 = 32, J2 = 48, J3 = 64), 129.8, 
129.7, 129.4, 127.5 (d, J = 4 Hz), 125.7 (d, J = 4 Hz), 123.9 (dq, J1 = 72, J2 = 273 Hz), 
119.7, 117.2, 113.2, 56.4, 49.4, 45.9. 
 
1-(Benzylsulfonyl)-4-phenylpiperazine (3.98) 
 
A stirring solution of 1-phenylpiperazine (20 mg, 0.18 mmol, 1 equiv) in DCM (3 mL) was 
chilled to 0 °C and to this solution was added pyridine (21 mg, 0.56 mmol, 3 equiv) and 
phenylmethanesulfonyl chloride (28 mg, 0.21 mmol, 1.2 equiv). The ice bath was removed 
and after confirming consumption of limiting reagent by TLC, 2 mL of distilled water was 
added to the reaction vial. The organic layer was separated and removed under reduced 
atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was used to 
purify sufficient amounts of the target molecule for biological testing and characterization. 
LRMS (APCI - quad) m/z cal’d for C17H21N2O2S+ [M+H+], 317.4265 found 318. 1H NMR 
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(400 MHz, CDCl3) δ 7.38 - 7.28 (m, 4H), 7.23 - 7.15 (m, 4H), 6.86 - 6.77 (m, 2H), 4.19 (s, 
2H), 3.25 - 3.15 (m, 4H), 3.08 - 3.00 (m, 4H). 13C NMR (176 MHz, CDCl3) δ 165.9, 
157.8, 151.2, 132.5 (q, J = 33 Hz), 132.0 (q, J = 33 Hz), 130.3, 123.5 (dq, J1 = 60, J2 = 272 
Hz), 118.5 (d, J = 3 Hz), 117.8, 115.3 (d, J = 4 Hz), 113.0, 111.8 (d, J = 4 Hz), 67.6, 48.6, 
48.2, 44.8, 41.6. 
 
1-((3-Methylbenzyl)sulfonyl)-4-phenylpiperazine (3.99)  
 
A stirring solution of 1-phenylpiperazine (20 mg, 0.12 mmol, 1 equiv) in DCM (3 mL) was 
chilled to 0 °C and to this solution was added pyridine (21 mg, 0.36 mmol, 3 equiv) and 
m-tolylmethanesulfonyl chloride (30 mg, 0.15 mmol, 1.2 equiv). The ice bath was removed 
and after confirming consumption of limiting reagent by TLC, 2 mL of distilled water was 
added to the reaction vial. The organic layer was separated and removed under reduced 
atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was used to 
purify sufficient amounts of the target molecule for biological testing and characterization. 
LRMS (APCI - quad) m/z cal’d for C18H23N2O2S+ [M+H+], 331.4535 found 331. 1H NMR 
(400 MHz, CDCl3) δ 7.35 - 7.15 (m, 6H), 6.94 - 6.85 (m, 3H), 4.22 (s, 2H), 3.33 - 3.22 (m, 
4H), 3.15 - 3.09 (m, 4H), 2.37 (s, 3H). 
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1-Phenyl-4-((2-(trifluoromethyl)benzyl)sulfonyl)piperazine (3.100)  
 
A stirring solution of 1-phenylpiperazine (20 mg, 0.18 mmol, 1 equiv) in DCM (3 mL) was 
chilled to 0 °C and to this solution was added pyridine (21 mg, 0.56 mmol, 3 equiv) and 
(2-(trifluoromethyl)phenyl)methanesulfonyl chloride (38 mg, 0.21 mmol, 1.2 equiv). The 
ice bath was removed and after confirming consumption of limiting reagent by TLC, 2 mL 
of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C18H20F3N2O2S+ [M+H+], 
385.4247 found 386. 1H NMR (400 MHz, CDCl3) δ 7.85 (d, J = 7.8 Hz, 1H), 7.73 (dd, J1 
= 1.3, J2 = 8.0 Hz, 1H), 7.60 (t, J = 7.6 Hz, 1H), 7.49 (t, J = 7.6 Hz, 1H), 7.31 - 7.24 (m, 
2H), 6.95 - 6.68 (m, 3H), 4.44 (s, 2H), 3.41 - 3.34 (m, 4H), 3.21 - 3.12 (m, 4H). 
 
1-Phenyl-4-((3-(trifluoromethyl)benzyl)sulfonyl)piperazine (3.101)  
 
A stirring solution of 1-phenylpiperazine (20 mg, 0.18 mmol, 1 equiv) in DCM (3 mL) was 
chilled to 0 °C and to this solution was added pyridine (21 mg, 056 mmol, 3 equiv) and (3-
(trifluoromethyl)phenyl)methanesulfonyl chloride (38 mg, 0.21 mmol, 1.2 equiv). The ice 
bath was removed and after confirming consumption of limiting reagent by TLC, 2 mL of 
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distilled water was added to the reaction vial. The organic layer was separated and removed 
under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel 
was used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C18H20F3N2O2S+ [M+H+], 385.4247 
found 386. 1H NMR (400 MHz, CDCl3) δ 7.71 - 7.61 (m, 3H), 7.53 (t, J = 7.7 Hz, 1H), 
7.31 - 7.26 (m, 2H), 6.95 - 6.86 (m, 3H), 4.27 (s, 2H), 3.36 - 3.29 (m, 4H), 3.18 - 3.11 (m, 
4H). 
 
1-Phenyl-4-((4-(trifluoromethyl)benzyl)sulfonyl)piperazine (3.102)  
 
A stirring solution of 1-phenylpiperazine (20 mg, 0.18 mmol, 1 equiv) in DCM (3 mL) was 
chilled to 0 °C and to this solution was added pyridine (21 mg, 0.56 mmol, 3 equiv) and 
(4-(trifluoromethyl)phenyl)methanesulfonyl chloride (38 mg, 0.21 mmol, 1.2 equiv). The 
ice bath was removed and after confirming consumption of limiting reagent by TLC, 2 mL 
of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C18H20F3N2O2S+ [M+H+], 
385.4247 found 387. 1H NMR (400 MHz, CDCl3) δ 7.66 (d, J = 8.1 Hz, 2H), 7.56 (d, J = 
8.0 Hz, 2H), 7.31 - 7.26 (m, 2H), 6.94 - 6.87 (m, 2H), 4.26 (s, 2H), 3.35 - 3.30 (m, 4H), 
3.19 - 3.14 (m, 4H). 
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1-((3,5-bis(Trifluoromethyl)benzyl)sulfonyl)-4-phenylpiperazine (3.103)  
 
A stirring solution of 1-phenylpiperazine (20 mg, 0.18 mmol, 1 equiv) in DCM (3 mL) was 
chilled to 0 °C and to this solution was added pyridine (21 mg, 0.52 mmol, 3 equiv) and 
(3,5-bis(trifluoromethyl)phenyl)methanesulfonyl chloride (48 mg, 0.21 mmol, 1.2 equiv). 
The ice bath was removed and after confirming consumption of limiting reagent by TLC, 
2 mL of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C19H19F6N2O2S+ [M+H+], 
453.4229 found 453. 1H NMR (400 MHz, CDCl3) δ 7.31 - 7.26 (m, 2H), 7.02 - 6.95 (m, 
2H), 6.95 - 6.88 (m, 3H), 6.85 (dddd, J1 = 2.4, J2 = 4.8, J3 = 8.9, J4 = 11.2 Hz, 1H), 4.19 
(s, 2H), 3.40 - 3.31 (m, 4H), 3.22 - 3.11 (m, 4H). 
 
1-(Benzylsulfonyl)-4-(m-tolyl)piperazine (3.104)  
 
A stirring solution of 1-(m-tolyl)piperazine (20 mg, 0.18 mmol, 1 equiv) in DCM (3 mL) 
was chilled to 0 °C and to this solution was added pyridine (21 mg, 0.56 mmol, 3 equiv) 
and phenylmethanesulfonyl chloride (26 mg, 0.2 mmol, 1.2 equiv). The ice bath was 
removed and after confirming consumption of limiting reagent by TLC, 2 mL of distilled 
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water was added to the reaction vial. The organic layer was separated and removed under 
reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel was 
used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C18H23N2O2S+ [M+H+], 331.4535 
found 331. 1H NMR (400 MHz, CDCl3) δ 7.44 - 7.37 (m, 4H), 7.15 (t, J = 7.7 Hz, 1H), 
6.76 - 6.66 (m, 3H), 4.26 (s, 2H), 3.30 - 3.22 (m, 4H), 3.14 - 3.08 (m, 4H), 2.31 (s, 3H). 
 
1-(m-Tolyl)-4-((2-(trifluoromethyl)benzyl)sulfonyl)piperazine (3.105)  
 
A stirring solution of 1-(m-tolyl)piperazine (20 mg, 0.18 mmol, 1 equiv) in DCM (3 mL) 
was chilled to 0 °C and to this solution was added pyridine (21 mg, 0.56 mmol, 3 equiv) 
and (2-(trifluoromethyl)phenyl)methanesulfonyl chloride (35 mg, 0.21 mmol, 1.2 equiv). 
The ice bath was removed and after confirming consumption of limiting reagent by TLC, 
2 mL of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C19H22F3N2O2S+ [M+H+], 
399.4517 found 400. 1H NMR (400 MHz, CDCl3) δ 7.85 (d, J = 7.8 Hz, 1H), 7.73 (d, J = 
8.0 Hz, 1H), 7.61 (t, J = 7.7 Hz, 1H), 7.49 (t, J = 7.7 Hz, 1H), 7.16 (t, J = 7.7 Hz, 1H), 6.76 
- 6.67 (m, 3H), 4.44 (s, 2H), 3.41 - 3.33 (m, 4H), 3.20 - 3.12 (m, 4H), 2.32 (s, 3H). 
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1-(m-Tolyl)-4-((3-(trifluoromethyl)benzyl)sulfonyl)piperazine (3.106)  
 
A stirring solution of 1-(m-tolyl)piperazine (20 mg, 0.18 mmol, 1 equiv) in DCM (3 mL) 
was chilled to 0 °C and to this solution was added pyridine (21 mg, 0.27 mmol, 3 equiv) 
and (3-(trifluoromethyl)phenyl)methanesulfonyl chloride (35 mg, 0.21 mmol, 1.2 equiv). 
The ice bath was removed and after confirming consumption of limiting reagent by TLC, 
2 mL of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C19H22F3N2O2S+ [M+H+], 
399.4517 found 399. 1H NMR (400 MHz, CDCl3) δ 7.71 - 7.58 (m, 3H), 7.53 (t, J = 7.7 
Hz, 1H), 7.16 (t, J = 7.7 Hz, 1H), 6.76 - 6.66 (m, 3H), 4.27 (s, 2H), 3.36 - 3.28 (m, 4H), 
3.17 - 3.09 (m, 4H), 2.31 (s, 3H). 
 
1-(m-Tolyl)-4-((4-(trifluoromethyl)benzyl)sulfonyl)piperazine (3.107)  
 
A stirring solution of 1-(m-tolyl)piperazine (20 mg, 0.18 mmol, 1 equiv) in DCM (3 mL) 
was chilled to 0 °C and to this solution was added pyridine (21 mg, 0.56 mmol, 3 equiv) 
and (4-(trifluoromethyl)phenyl)methanesulfonyl chloride (35 mg, 0.21 mmol, 1.2 equiv). 
The ice bath was removed and after confirming consumption of limiting reagent by TLC, 
2 mL of distilled water was added to the reaction vial. The organic layer was separated and 
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removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C19H22F3N2O2S+ [M+H+], 
399.4517 found 400. 1H NMR (400 MHz, CDCl3) δ 7.67 (d, J = 8.1 Hz, 2H), 7.55 (d, J = 
8.1 Hz, 2H), 7.16 (t, J = 7.6 Hz, 1H), 6.77 - 6.64 (m, 3H), 4.28 (s, 2H), 3.35 - 3.25 (m, 4H), 
3.17 - 3.10 (m, 4H), 2.31 (s, 3H). 
 
1-((3,5-bis(Trifluoromethyl)benzyl)sulfonyl)-4-(m-tolyl)piperazine (3.108)  
 
A stirring solution of 1-(m-tolyl)piperazine (20 mg, 0.18 mmol, 1 equiv) in DCM (3 mL) 
was chilled to 0 °C and to this solution was added pyridine (21 mg, 0.56 mmol, 3 equiv) 
and (3,5-bis(trifluoromethyl)phenyl)methanesulfonyl chloride (44 mg, 0.21 mmol, 1.2 
equiv). The ice bath was removed and after confirming consumption of limiting reagent by 
TLC, 2 mL of distilled water was added to the reaction vial. The organic layer was 
separated and removed under reduced atmosphere. Column chromatography (0 to 50% 
EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C20H21F6N2O2S+ [M+H+], 467.4499 found 468. 1H NMR (400 MHz, CDCl3) δ 7.18 (s, 
1H), 7.09 (t, J = 7.7 Hz, 1H), 6.95 - 6.87 (m, 2H), 6.86 (tt, J1 = 2.3, J2 = 8.8 Hz, 1H), 6.70 
- 6.61 (m, 2H), 4.11 (s, 2H), 3.30 - 3.21 (m, 4H), 3.13 - 3.04 (m, 4H), 2.25 (s, 3H). 
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1-(Benzylsulfonyl)-4-(3-(trifluoromethyl)phenyl)piperazine (3.109)  
 
A stirring solution of 1-(3-(trifluoromethyl)phenyl)piperazine (20 mg, 0. 09 mmol, 1 equiv) 
in DCM (3 mL) was chilled to 0 °C and to this solution was added pyridine (21 mg, 0.27 
mmol, 3 equiv) and phenylmethanesulfonyl chloride (19 mg, 0.11 mmol, 1.2 equiv). The 
ice bath was removed and after confirming consumption of limiting reagent by TLC, 2 mL 
of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C18H20F3N2O2S+ [M+H+] 
385.4247, found 386. 1H NMR (400 MHz, CDCl3) δ 7.46 - 7.32 (m, 6H), 7.13 (d, J = 7.6 
Hz, 1H), 7.06 (s, 1H), 7.01 (d, J = 8.3 Hz, 1H), 4.28 (s, 2H), 3.30 - 3.23 (m, 4H), 3.18 - 
3.12 (m, 4H). 
 
1-((3-Methylbenzyl)sulfonyl)-4-(3-(trifluoromethyl)phenyl)piperazine (3.110) 
 
A stirring solution of 1-(3-(trifluoromethyl)phenyl)piperazine (20 mg, 0.09 mmol, 1 equiv) 
in DCM (3 mL) was chilled to 0 °C and to this solution was added pyridine (21 mg, 0.27 
mmol, 3 equiv) and m-tolylmethanesulfonyl chloride (18 mg, 0.11 mmol, 1.2 equiv). The 
ice bath was removed and after confirming consumption of limiting reagent by TLC, 2 mL 
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of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C19H22F3N2O2S+ [M+H+] 
399.4517, found 399. 1H NMR (400 MHz, CDCl3) δ 7.35 (t, J = 8.0 Hz, 1H), 7.30 - 7.26 
(m, 1H), 7.25 - 7.16 (m, 3H), 7.13 (d, J = 7.7 Hz, 1H), 7.06 (s, 1H), 7.02 (d, J = 8.8 Hz, 
1H), 4.23 (s, 2H), 3.32 - 3.24 (m, 4H), 3.22 - 3.13 (m, 4H), 2.36 (s, 3H). 
 
1-((4-Methylbenzyl)sulfonyl)-4-(3-(trifluoromethyl)phenyl)piperazine (3.111)  
 
A stirring solution of 1-(3-(trifluoromethyl)phenyl)piperazine (20 mg, 0.09 mmol, 1 equiv) 
in DCM (3 mL) was chilled to 0 °C and to this solution was added pyridine (21 mg, 0.27 
mmol, 3 equiv) and 4-methylphenylmethanesulfonyl chloride (18 mg, 0.11 mmol, 1.2 
equiv). The ice bath was removed and after confirming consumption of limiting reagent by 
TLC, 2 mL of distilled water was added to the reaction vial. The organic layer was 
separated and removed under reduced atmosphere. Column chromatography (0 to 50% 
EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C19H22F3N2O2S+ [M+H+] 399.4517, found 399. 1H NMR (400 MHz, CDCl3) δ 7.66 (d, J 
= 8.1 Hz, 2H), 7.55 (d, J = 8.1 Hz, 2H), 7.37 (t, J = 7.96 Hz, 1H), 7.15 (d, J = 7.7 Hz, 1H), 
7.09 (s, 1H), 7.03 (d, J = 8.3 Hz, 1H), 4.29 (s, 2H), 3.38 - 3.29 (m, 4H), 3.25 - 3.17 (m, 
4H).  
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1-((3,5-bis(Trifluoromethyl)benzyl)sulfonyl)-4-(3-
(trifluoromethyl)phenyl)piperazine (3.112)  
 
A stirring solution of 1-(3-(trifluoromethyl)phenyl)piperazine (20 mg, 0.8 mmol, 1 equiv) 
in DCM (3 mL) was chilled to 0 °C and to this solution was added pyridine (21 mg, 0.24 
mmol, 3 equiv) and (3,5-bis(trifluoromethyl)phenyl)methanesulfonyl chloride (34 mg, 
0.11 mmol, 1.2 equiv). The ice bath was removed and after confirming consumption of 
limiting reagent by TLC, 2 mL of distilled water was added to the reaction vial. The organic 
layer was separated and removed under reduced atmosphere. Column chromatography (0 
to 50% EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target 
molecule for biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C20H18F9N2O2S+ [M+H+], 521.4211 found 521. 1H NMR (400 MHz, CDCl3) δ 7.37 (t, J = 
8.0 Hz, 1H), 7.15 (d, J = 7.6 Hz, 1H), 7.09 (s, 1H), 7.04 (dd, J1 = 2.5, J2 = 8.3 Hz, 1H), 
7.02 - 6.95 (m, 2H), 6.86 (tt, J1 = 2.3, J2 = 8.8 Hz, 1H), 4.20 (s, 2H), 3.39 - 3.32 (m, 4H), 
3.25 - 3.18 (m, 4H). 
 
3-(4-(Benzylsulfonyl)piperazin-1-yl)benzonitrile (3.113)  
 
A stirring solution of 3-(piperazin-1-yl)benzonitrile (30 mg, 0.09 mmol, 1 equiv) in DCM 
(3 mL) was chilled to 0 °C and to this solution was added pyridine (21 mg, 0.27 mmol, 3 
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equiv) and phenylmethanesulfonyl chloride (20 mg, 0.11 mmol, 1.2 equiv). The ice bath 
was removed and after confirming consumption of limiting reagent by TLC, 2 mL of 
distilled water was added to the reaction vial. The organic layer was separated and removed 
under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel 
was used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C18H20N3O2S+ [M+H+] 342.4365, 
found 342. 1H NMR (400 MHz, CDCl3) δ 7.45 - 7.37 (m, 4H), 7.32 (t, J = 7.6 Hz, 1H), 
7.22 (d, J = 7.6 Hz, 1H), 7.14 (d, J = 6.7 Hz, 1H), 7.09 - 7.04 (m, 2H), 4.28 (s, 2H), 3.30 - 
3.19 (m, 4H), 3.18 - 3.08 (m, 4H). 
 
3-(4-((3-Methylbenzyl)sulfonyl)piperazin-1-yl)benzonitrile (3.114)  
 
A stirring solution of 3-(piperazin-1-yl)benzonitrile (30 mg, 0.09 mmol, 1 equiv) in DCM 
(3 mL) was chilled to 0 °C and to this solution was added pyridine (21 mg, 0.11 mmol, 
0.27 mmol, 3 equiv) and m-tolylmethanesulfonyl chloride (20 mg, 1.2 equiv). The ice bath 
was removed and after confirming consumption of limiting reagent by TLC, 2 mL of 
distilled water was added to the reaction vial. The organic layer was separated and removed 
under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on silica gel 
was used to purify sufficient amounts of the target molecule for biological testing and 
characterization. LRMS (APCI - quad) m/z cal’d for C19H22N3O2S+ [M+H+] 356.4635, 
found 356. 1H NMR (400 MHz, CDCl3) δ 7.33 (dt, J1 = 2.0, J2 = 7.4 Hz, 1H), 7.30 - 7.26 
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(m, 1H), 7.23 (s, 1H), 7.19 (d, J = 8.3 Hz, 2H), 7.15 (d, J = 8.0 Hz, 1H), 7.09 - 7.04 (m, 
2H), 4.23 (s, 2H), 3.29 - 3.23 (m, 4H), 3.17 - 3.10 (m, 4H), 2.37 (s, 3H). 
 
3-(4-((3-(Trifluoromethyl)benzyl)sulfonyl)piperazin-1-yl)benzonitrile (3.115)  
 
A stirring solution of 3-(piperazin-1-yl)benzonitrile (30 mg, 0.09 mmol, 1 equiv) in DCM 
(3 mL) was chilled to 0 °C and to this solution was added pyridine (21 mg, 0.27 mmol, 3 
equiv) and (3-(trifluoromethyl)phenyl)methanesulfonyl chloride (20 mg, 0.11 mmol, 1.2 
equiv). The ice bath was removed and after confirming consumption of limiting reagent by 
TLC, 2 mL of distilled water was added to the reaction vial. The organic layer was 
separated and removed under reduced atmosphere. Column chromatography (0 to 50% 
EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C19H19F3N3O2S+ [M+H+] 410.4347, found 411. 1H NMR (400 MHz, CDCl3) δ 7.67 (d, J 
= 8.1 Hz, 2H), 7.56 (d, J = 8.0 Hz, 2H), 7.34 (t, J = 7.9 Hz, 1H), 7.17 (d, J = 6.4 Hz, 1H), 
7.11 - 7.07 (m, 2H), 4.30 (s, 2H), 3.35 - 3.30 (m, 4H), 3.21 - 3.15 (m, 4H). 
 
1-(Benzylsulfonyl)-4-(3,5-bis(trifluoromethyl)phenyl)piperazine (3.116)  
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A stirring solution of 1-(3,5-bis(trifluoromethyl)phenyl)piperazine (20 mg, 0.09 mmol, 1 
equiv) in DCM (3 mL) was chilled to 0 °C and to this solution was added pyridine (21 mg, 
0.27 mmol, 3 equiv) and phenylmethanesulfonyl chloride (15 mg, 0.11 mmol, 1.2 equiv). 
The ice bath was removed and after confirming consumption of limiting reagent by TLC, 
2 mL of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C19H19F6N2O2S+ [M+H+] 
453.4229, found 455. 1H NMR (400 MHz, CDCl3) δ 7.45 -7.37 (m, 5H), 7.33 (s, 1H), 7.19 
(s, 1H), 4.29 (s, 2H), 3.29 - 3.23 (m, 4H), 3.23 - 3.18 (m, 4H). 
 
1-(3,5-bis(Trifluoromethyl)phenyl)-4-((3-methylbenzyl)sulfonyl)piperazine (3.117)  
 
A stirring solution of 1-(3,5-bis(trifluoromethyl)phenyl)piperazine (20 mg, 0.09 mmol, 1 
equiv) in DCM (3 mL) was chilled to 0 °C and to this solution was added pyridine (21 mg, 
0.27 mmol, 3 equiv) and m-tolylmethanesulfonyl chloride (16 mg, 0.11 mmol, 1.2 equiv). 
The ice bath was removed and after confirming consumption of limiting reagent by TLC, 
2 mL of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C20H21F6N2O2S+ [M+H+] 467.45, 
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found 468. 1H NMR (400 MHz, CDCl3) δ 7.33 (br, 1H), 7.30 - 7.23 (m, 2H), 7.22 - 7.18 
(m, 4H), 4.26 (s, 2H), 3.30 - 3.20 (m, 8H), 2.36 (s, 3H). 
 
1-(3,5-bis(Trifluoromethyl)phenyl)-4-((2-
(trifluoromethyl)benzyl)sulfonyl)piperazine (3.118)  
 
A stirring solution of 1-(3,5-bis(trifluoromethyl)phenyl)piperazine (30 mg, 0.11 mmol, 1 
equiv) in DCM (3 mL) was chilled to 0 °C and to this solution was added pyridine (21 mg, 
0.33 mmol, 3 equiv) and (2-(trifluoromethyl)phenyl)methanesulfonyl chloride (31 mg, 
0.14 mmol, 1.2 equiv). The ice bath was removed and after confirming consumption of 
limiting reagent by TLC, 2 mL of distilled water was added to the reaction vial. The organic 
layer was separated and removed under reduced atmosphere. Column chromatography (0 
to 50% EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target 
molecule for biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C20H18F9N2O2S+ [M+H+], 521.4211 found 521. 1H NMR (400 MHz, CDCl3) δ 7.86 (d, J 
= 7.7 Hz, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.62 (t, J = 7.5, 1H), 7.51 (t, J = 7.7 Hz, 1H), 7.34 
(s, 1H), 7.21 (s, 2H), 4.17 (s, 2H), 3.40 - 3.34 (m, 4H), 3.29 - 3.25 (m, 4H). 
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1-(3,5-bis(Trifluoromethyl)phenyl)-4-((3-
(trifluoromethyl)benzyl)sulfonyl)piperazine (3.119)  
 
A stirring solution of 1-(3,5-bis(trifluoromethyl)phenyl)piperazine (20 mg, 0.9 mmol, 1 
equiv) in DCM (3 mL) was chilled to 0 °C and to this solution was added pyridine (21 mg, 
0.27 mmol, 3 equiv) and (3-(trifluoromethyl)phenyl)methanesulfonyl chloride (21 mg, 
0.11 mmol, 1.2 equiv). The ice bath was removed and after confirming consumption of 
limiting reagent by TLC, 2 mL of distilled water was added to the reaction vial. The organic 
layer was separated and removed under reduced atmosphere. Column chromatography (0 
to 50% EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target 
molecule for biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C20H18F9N2O2S+ [M+H+] 521.4211, found 522. 1H NMR (400 MHz, CDCl3) δ 7.69 - 7.62 
(m, 3H), 7.55 (t, J = 8.0 Hz, 1H), 7.35 (s, 1H), 7.21 (s, 2H), 4.30 (s, 2H), 3.38 - 3.28 (m, 
4H), 3.27 - 3.19 (m, 4H). 
 
1-(3,5-bis(Trifluoromethyl)phenyl)-4-((4-
(trifluoromethyl)benzyl)sulfonyl)piperazine (3.120)  
 
A stirring solution of 1-(3,5-bis(trifluoromethyl)phenyl)piperazine (20 mg, 0.09 mmol, 1 
equiv) in DCM (3 mL) was chilled to 0 °C and to this solution was added pyridine (21 mg, 
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0.27 mmol, 3 equiv) and (4-(trifluoromethyl)phenyl)methanesulfonyl chloride (21 mg, 
0.11 mmol, 1.2 equiv). The ice bath was removed and after confirming consumption of 
limiting reagent by TLC, 2 mL of distilled water was added to the reaction vial. The organic 
layer was separated and removed under reduced atmosphere. Column chromatography (0 
to 50% EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target 
molecule for biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C20H18F9N2O2S+ [M+H+] 521.4211, found 521. 1H NMR (400 MHz, CDCl3) δ 7.77 (d, J 
= 8.1 Hz, 2H), 7.56 (d, J = 8.0, 2H), 7.36 (s, 1H), 7.22 (s, 2H), 4.31 (s, 2H), 3.37 - 3.30 (m, 
4H), 3.28 - 3.22 (m, 4H). 
 
(3-(Trifluoromethyl)phenyl)(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)methanone 
(3.121) 
 
To a stirring solution of 3-trifluoromethylbenzoic acid (22 mg, 0.12 mmol, 1 equiv) in 
DCM (5 mL) was added EDC (36 mg, 0.24 mmol, 2.0 equiv) and DMAP (35 mg, 0.30 
mmol, 2.5 equiv). This solution was stirred for 10 min before addition of 1-(3-
(trifluoromethyl)phenyl)piperazine (40 mg, 0.17 mmol, 1.5 equiv). The reaction slurry was 
brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics were 
separated and the solvent was removed under reduced pressure. Column chromatography 
(0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target 
molecule for biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C19H17F6N2O+ [M+H+] 403.3479, found 404. 1H NMR (400 MHz, CD3OD) δ 7.74 - 7.68 
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(m, 2H), 7.67 - 7.56 (m, 2H), 7.32 (t, J = 7.7 Hz, 1H), 7.16 - 7.09 (m, 2H), 7.01 (d, J = 7.6 
Hz, 1H), 3.84 (br, 2H), 3.50 (br, 2H), 3.26 (br, 2H), 3.15 (br, 2H). 
 
(3,5-bis(Trifluoromethyl)phenyl)(4-(3-(trifluoromethyl)phenyl)piperazin-1-
yl)methanone (3.122) 
 
To a stirring solution of 3,5-bistrifluoromethylbenzoic acid (16 mg, 0.12 mmol, 1 equiv) 
in DCM (5 mL) was added EDC (36 mg, 0.24 mmol, 2.0 equiv) and DMAP (35 mg, 0.30 
mmol, 2.5 equiv). This solution was stirred for 10 min before addition of 1-(3-
(trifluoromethyl)phenyl)piperazine (40 mg, 0.17 mmol, 1.5 equiv). The reaction slurry was 
brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics were 
separated and the solvent was removed under reduced pressure. Column chromatography 
(0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target 
molecule for biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C20H16F9N2O+ [M+H+] 471.3461, found 471. 1H NMR (400 MHz, CD3OD) δ 8.14 (s, 1H), 
8.13 (s, 2H), 7.44 (t, J = 8.0 Hz, 1H), 7.27 - 7.22 (m, 2H), 7.14 (d, J = 7.6 Hz, 1H), 3.98 
(br, 2H), 3.61 (br, 2H), 3.41 (br, 2H), 3.28 (br, 2H). 
 
(4-(3,5-bis(Trifluoromethyl)phenyl)piperazin-1-yl)(3-
(trifluoromethyl)phenyl)methanone (3.123) 
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To a stirring solution of 3-trifluoromethylbenzoic acid (16 mg, 0.12 mmol, 1 equiv) in 
DCM (5 mL) was added EDC (36 mg, 0.24 mmol, 2.0 equiv) and DMAP (35 mg, 0.30 
mmol, 2.5 equiv). This solution was stirred for 10 min before addition of 1-(3,5-
bis(trifluoromethyl)phenyl)piperazine (40 mg, 0.18 mmol, 1.5 equiv). The reaction slurry 
was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics 
were separated and the solvent was removed under reduced pressure. Column 
chromatography (0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient amounts 
of the target molecule for biological testing and characterization. LRMS (APCI - quad) m/z 
cal’d for C20H16F9N2O+ [M+H+] 471.3461, found 471. 1H NMR (400 MHz, CD3OD) δ 
7.85 - 7.79 (m, 2H), 7.76 - 7.70 (m, 2H), 7.46 (s, 2H), 7.32 (s, 1H), 3.96 (br, 2H), 3.63 (br, 
2H), 3.48 (br, 2H), 3.37 (br, 2H). 
 
(3,5-bis(Trifluoromethyl)phenyl)(4-(3,5-bis(trifluoromethyl)phenyl)piperazin-1-
yl)methanone (3.124) 
 
To a stirring solution of 3,5-bis(trifluoromethyl)benzoic acid acid (22 mg, 0.08 mmol, 1 
equiv) in DCM (5 mL) was added EDC (36 mg, 0.16 mmol, 2.0 equiv) and DMAP (35 mg, 
0.20 mmol, 2.5 equiv). This solution was stirred for 10 min before addition of 1-(3,5-
bis(trifluoromethyl)phenyl)piperazine (40 mg, 0.13 mmol, 1.5 equiv). The reaction slurry 
was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics 
were separated and the solvent was removed under reduced pressure. Column 
chromatography (0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient amounts 
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of the target molecule for biological testing and characterization. LRMS (APCI - quad) m/z 
cal’d for C21H15F12N2O+ [M+H+] 539.3443, found 539. 1H NMR (400 MHz, CD3OD) δ 
8.15 - 8.12 (m, 3H), 7.46 (s, 2H), 7.32 (s, 1H), 3.98 (br, 2H), 3.62 (br, 2H), 3.51 (br, 2H), 
3.39 (br, 2H). 
 
3-(4-(3,5-bis(Trifluoromethyl)phenyl)piperazine-1-carbonyl)benzonitrile (3.125) 
 
To a stirring solution of 3-cyanobenzoic acid acid (13 mg, 0.08 mmol, 1 equiv) in DCM (5 
mL) was added EDC (36 mg, 0.16 mmol, 2.0 equiv) and DMAP (35 mg, 0.20 mmol, 2.5 
equiv). This solution was stirred for 10 min before addition of 1-(3,5-
bis(trifluoromethyl)phenyl)piperazine (40 mg, 0.13 mmol, 1.5 equiv). The reaction slurry 
was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics 
were separated and the solvent was removed under reduced pressure. Column 
chromatography (0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient amounts 
of the target molecule for biological testing and characterization. LRMS (APCI - quad) m/z 
cal’d for C20H16F6N3O+ [M+H+] 428.3579, found 429. 1H NMR (400 MHz, CD3OD) δ 
7.92 - 7.84 (m, 2H), 7.79 (td, J1 = 1.5, J2 = 7.8 Hz, 1H), 7.48 - 7.39 (m, 2H), 7.33 (s, 2H), 
7.23 (d, J = 8.1 Hz, 1H), 3.95 (br, 2H), 3.62 (br, 2H), 3.49 (br, 2H), 3.38 (br, 2H). 
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2-(3-(Trifluoromethyl)phenyl)-1-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethan-
1-one (3.126) 
 
To a stirring solution of 1-(3-(trifluoromethyl)phenyl)piperazine (34 mg, 0.15 mmol, 1.0 
equiv), triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added 2-(3-
(trifluoromethyl)phenyl)acetyl chloride (40 mg, 0.18 mmol, 1.2 equiv) and the solution 
was stirred for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 
mL of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C20H19F6N2O+ [M+H+] 417.3749, 
found 417. 1H NMR (400 MHz, CDCl3) δ 7.56 - 7.50 (m, 2H), 7.47 - 7.44 (m, 2H), 7.36 
(t, J = 8.0 Hz, 1H), 7.13 (d, J = 7.7 Hz, 1H), 7.08 (s, 1H), 7.04 (dd, J1 = 2.5, J2 = 8.4 Hz, 
1H), 3.85 - 3.81 (m, 4H), 3.67 - 3.61 (m, 2H), 3.22 - 3.19 (m, 2H), 3.13 - 3.10 (m, 2H). 
13C NMR (176 MHz, CDCl3) δ 168.9, 150.9, 135.7, 132.3, 131.5 (q, J = 32 Hz), 131.0 (q, 
J = 28), 129.8, 129.2, 125.6 (d, J = 4 Hz), 124.1 (dq, J1 = 29, J2 = 273 Hz), 293.2 (d, J = 4 
Hz), 119.3, 116.7 (d, J = 4 Hz), 112.9 (d, J = 4 Hz), 49.0, 48.7, 45.7, 41.6, 40.2. 
 
1-(4-(3,5-bis(Trifluoromethyl)phenyl)piperazin-1-yl)-2-(3-
(trifluoromethyl)phenyl)ethan-1-one (3.127) 
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To a stirring solution of 1-(3,5-bis(trifluoromethyl)phenyl)piperazine (44 mg, 0.15 mmol, 
1.0 equiv), triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added 2-(3-
(trifluoromethyl)phenyl)acetyl chloride (40 mg, 0.18 mmol, 1.2 equiv) and the solution 
was stirred for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 
mL of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C21H18F9N2O+ [M+H+] 485.3731, 
found 386. 1H NMR (400 MHz, CDCl3) δ 7.57 - 7.50 (m, 2H), 7.48 - 7.45 (m, 2H), 7.33 
(s, 1H), 7.22 (s, 2H), 3.88 - 3.81 (m, 4H), 3.69 - 3.63 (m, 2H), 3.32 - 3.25 (m, 2H), 3.23 - 
3.15 (m, 2H). 13C NMR (176 MHz, CDCl3) δ 168.9, 151.2, 135.5, 132.5 (q, J = 33 Hz), 
132.3, 131.1 (q, J = 32 Hz), 129.3, 125.6, 123.9 (q, J = 272 Hz), 124.0 (d, J = 4 Hz), 123.4 
(q, J = 273 Hz), 115.2 (d, J = 4 Hz), 112.9, 48.3, 48.2, 45.5, 41.4, 40.3. 
 
3-(4-(3-(Trifluoromethyl)benzoyl)piperazin-1-yl)benzonitrile (3.128)  
 
To a stirring solution of 3-trifluoromethylbenzoic acid (20 mg, 0.12 mmol, 1 equiv) in 
DCM (5 mL) was added EDC (36 mg, 0.24 mmol, 2.0 equiv) and DMAP (35 mg, 0.30 
mmol, 2.5 equiv). This solution was stirred for 10 min before addition of 3-(piperazin-1-
yl)benzonitrile (30 mg, 0.16 mmol, 1.5 equiv). The reaction slurry was brought to 37 ˚C 
for 12 h before quenching with 1 N HCl solution (3 mL). Organics were separated and the 
solvent was removed under reduced pressure. Column chromatography (0 to 45% 
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(EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for C19H17F3N3O+ 
[M+H+], 360.3597 found 362. 1H NMR (400 MHz, CDCl3) δ 7.75 - 7.68 (m, 2H), 7.65 - 
7.57  (m, 2H), 7.36 (dd, J1 =7.3, J2 = 7.6 Hz, 1H), 7.19 - 7.10 (m, 3H), 3.94 (br, 2H), 3.61 
(br, 2H), 3.24 (br, 4H). 
 
3-(4-(3,5-bis(Trifluoromethyl)benzoyl)piperazin-1-yl)benzonitrile (3.129)  
 
To a stirring solution of 3,5-bis(trifluoromethyl)benzoic acid (27 mg, 0.12 mmol, 1 equiv) 
in DCM (5 mL) was added EDC (36 mg, 0.24 mmol, 2.0 equiv) and DMAP (35 mg, 0.30 
mmol, 2.5 equiv). This solution was stirred for 10 min before addition of 3-(piperazin-1-
yl)benzonitrile (30 mg, 0.16 mmol, 1.5 equiv). The reaction slurry was brought to 37 ˚C 
for 12 h before quenching with 1 N HCl solution (3 mL). Organics were separated and the 
solvent was removed under reduced pressure. Column chromatography (0 to 45% 
(EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for C20H16F6N3O+ 
[M+H+], 428.3579 found 427. 1H NMR (400 MHz, CDCl3) δ 7.97 (s, 1H), 7.90 (s, 2H), 
7.37 (dd, J1 = 4.6, J2 = 7.6 Hz, 1H), 7.17 (d, J = 6.5 Hz, 1H), 7.15 - 7.10 (m, 2H), 3.96 (br, 
2H), 3.60 (br, 2H), 3.28 (br, 4H). 
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3-(4-(3-Cyanobenzoyl)piperazin-1-yl)benzonitrile (3.130)  
 
To a stirring solution of 3-cyanobenzoic acid (15 mg, 0.12 mmol, 1 equiv) in DCM (5 mL) 
was added EDC (36 mg, 0.24 mmol, 2.0 equiv) and DMAP (35 mg, 0.30 mmol, 2.5 equiv). 
This solution was stirred for 10 min before addition of 3-(piperazin-1-yl)benzonitrile (30 
mg, 0.16 mmol, 1.5 equiv). The reaction slurry was brought to 37 ˚C for 12 h before 
quenching with 1 N HCl solution (3 mL). Organics were separated and the solvent was 
removed under reduced pressure. Column chromatography (0 to 45% (EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C19H17N4O+ [M+H+], 317.3715 
found 317. 1H NMR (400 MHz, CDCl3) δ 7.76 - 7.72 (m, 2H), 7.68 (d, J = 7.8 Hz, 1H), 
7.58 (t, J = 7.9 Hz, 1H), 7.36 (dd, J1 = 5.0, 7.7 Hz, 1H), 7.16 (d, J = 7.6 Hz, 1H), 7.14 - 
7.10 (m, 2H), 3.93 (br, 2H), 3.59 (br, 2H), 3.25 (br, 4H). 
 
2-(3-(Trifluoromethyl)phenoxy)-1-(4-(3-(trifluoromethyl)phenyl)piperazin-1-
yl)ethan-1-one (3.131) 
 
To a stirring solution of 2-(3-(trifluoromethyl)phenoxy)acetic acid (19 mg, 0.12 mmol, 1 
equiv) in DCM (5 mL) was added EDC (36 mg, 0.24 mmol, 2.0 equiv) and DMAP (35 mg, 
0.30mmol, 2.5 equiv). This solution was stirred for 10 min before addition of 1-(3-
(trifluoromethyl)phenyl)piperazine (40 mg, 0.17 mmol, 1.5 equiv). The reaction slurry was 
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brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics were 
separated and the solvent was removed under reduced pressure. Column chromatography 
(0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target 
molecule for biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C20H19F6N2O2+ [M+H+] 433.3739, found 433. 1H NMR (400 MHz, CD3OD) δ 7.49 (t, J = 
8.1 Hz, 1H), 7.43 (t, J = 7.8 Hz, 1H), 7.30 - 7.23 (m, 3H), 7.13 (d, J = 7.7 Hz, 1H), 4.97 (s, 
2H), 3.83 - 3.72 (m, 4H), 3.30 - 3.23 (m, 4H). 
 
1-(4-(3,5-bis(Trifluoromethyl)phenyl)piperazin-1-yl)-2-(3-
(trifluoromethyl)phenoxy)ethan-1-one (3.132) 
 
To a stirring solution of 2-(3-(trifluoromethyl)phenoxy)acetic acid (19 mg, 0.08 mmol, 1 
equiv) in DCM (5 mL) was added EDC (36 mg, 0.16 mmol, 2.0 equiv) and DMAP (35 mg, 
0.2 mmol, 2.5 equiv). This solution was stirred for 10 min before addition of 1-(3,5-
bis(trifluoromethyl)phenyl)piperazine (31 mg, 0.13mmol, 1.5 equiv). The reaction slurry 
was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics 
were separated and the solvent was removed under reduced pressure. Column 
chromatography (0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient amounts 
of the target molecule for biological testing and characterization. LRMS (APCI - quad) m/z 
cal’d for C21H18F9N2O2+ [M+H+] 501.3721, found 501. 1H NMR (400 MHz, CD3OD) δ 
7.50 (t, J = 8.0 Hz, 1H), 7.47 (s, 2H), 7.33 (s, 1H), 7.39 (s, 2H), 7.27 (d, J = 8.8 Hz, 1H), 
4.99 (s, 2H), 3.85 - 3.76 (m, 4H), 3.48 - 3.43 (m, 2H), 3.34 - 3.36 (m, 2H). 
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3-(4-(2-(3-(Trifluoromethyl)phenoxy)acetyl)piperazin-1-yl)benzonitrile (3.133)  
 
To a stirring solution of 2-(3-(trifluoromethyl)phenoxy)acetic acid (23 mg, 0.12 mmol, 1 
equiv) in DCM (5 mL) was added EDC (36 mg, 0.24 mmol, 2.0 equiv) and DMAP (35 mg, 
0.30 mmol, 2.5 equiv). This solution was stirred for 10 min before addition of 3-(piperazin-
1-yl)benzonitrile (30 mg, 0.16 mmol, 1.5 equiv). The reaction slurry was brought to 37 ˚C 
for 12 h before quenching with 1 N HCl solution (3 mL). Organics were separated and the 
solvent was removed under reduced pressure. Column chromatography (0 to 45% 
(EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for C20H19F3N3O2+ 
[M+H+], 390.3857 found 391. 1H NMR (400 MHz, CDCl3) δ 7.41 (t, J = 8.0 Hz, 1H), 7.34 
(dd, J1 = 4.6, J2 = 7.6 Hz, 1H), 7.28 - 7.24 (m, 1H), 7.19 (s, 1H), 7.14 (d, J = 7.9 Hz, 2H), 
7.13 - 7.08 (m, 2H), 4.78 (s, 2H), 3.83 - 3.71 (m, 4H), 3.27 - 3.16 (m, 4H). 
 
2-((3,4-Difluorophenyl)amino)-1-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethan-
1-one (3.134) 
 
To a stirring solution of (3,4-difluorophenyl)glycine (30 mg, 0.13 mmol, 1 equiv) in DCM 
(5 mL) was added EDC (44 mg, 0.26 mmol, 2.0 equiv) and DMAP (1.9 mg, 0.013 mmol,  
0.1 equiv). This solution was stirred for 10 min before addition of 1-(3-
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trifluoromethylphenyl)-piperazine (55 mg, 0.19 mmol, 1.5 equiv). The reaction slurry was 
brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics were 
separated and the solvent was removed under reduced pressure. Column chromatography 
(0 to 45% (EtOAc/Hex)) on silica gel was used to purify sufficient amounts of the target 
molecule for biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C19H18F5N2O2+ [M+H+] 401.36, found 402. 1H NMR (400 MHz, CDCl3) δ 738 (t, J = 8.4 
Hz, 1H), 7.15 (d, J = 8.0 Hz, 1H), 7.11 (br, 1H), 7.11 - 7.04 (m, 2H), 6.81 (ddd, J1 = 3.44, 
J2 = 6.5, J3 = 9.4 Hz, 1H), 6.68 (dddd, J1 = 1.8, J2 = 3.2, J3 = 6.4, J4 = 9.1 Hz, 1H), 4.70 (s, 
2H), 3.80 (t, J = 5.2, 2H), 3.75 (t, J = 5.1 Hz, 2H), 3.26 - 3.19 (m, 4H). 13C NMR (176 
MHz, CDCl3) δ 165.9, 153.9 (d, J = 11 Hz), 151.2 (d, J = 14 Hz), 150.8, 149.8 (d, J = 13 
Hz), 149.8 (d, J = 13 Hz), 144.9 (d, J = 13 Hz), 131.2 (q, J = Hz), 129.8, 124 (d, J = 272 
Hz), 119.4, 117.5 (d, J = 18 Hz), 116.9 (d, J = 4 Hz), 112.9 (d, J = 4 Hz), 109.9 (dd, J1 = 4 
Hz, J2 = 6 Hz), 104.7 (d, J = 20 Hz), 68.2, 49.3, 48.9, 45.1, 41.8. 
 
1-(4-(3,5-bis(Trifluoromethyl)phenyl)piperazin-1-yl)-2-((3,4-
difluorophenyl)amino)ethan-1-one (3.135) 
 
To a stirring solution of (3,4-difluorophenyl)glycine (30 mg, 0.13 mmol, 1 equiv) in DCM 
(5 mL) was added EDC (44 mg, 0.26 mmol, 2.0 equiv) and DMAP (1.9 mg, 0.013 mmol, 
0.1 equiv). This solution was stirred for 10 min before addition of 1-(3,5-
bistrifluoromethylphenyl)-piperazine (71 mg, 0. 20 mol, 1.5 equiv). The reaction slurry 
was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics 
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were separated and the solvent was removed under reduced pressure. Column 
chromatography (0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient amounts 
of the target molecule for biological testing and characterization. LRMS (APCI - quad) m/z 
cal’d for C20H17F8N2O2+ [M+H+] 469.3547, found 470. 1H NMR (400 MHz, CDCl3) δ 
7.36 (s, 1H), 7.25 (s, 2H), 7.08 (q, J = 9.4 Hz, 1H), 6.81 (ddd, J1 = 3, J2 = 6.4, J3 = 9.4 Hz, 
1H), 6.71 - 6.65 (m, 1H), 4.71 (s, 2H), 3.82 (t, J = 5.2 Hz, 2H), 3.78 (t, J = 5.1 Hz, 2H), 
3.35 - 3.26 (m, 4H). 13C NMR (176 MHz, CDCl3) δ 166.0, 153.9 (d, J = 10 Hz), 151.2, 
149.8 (d, J = 14 Hz), 146.4 (d, J = 13 Hz), 145.0 (d, J = 13 Hz), 132.5 (q, J = 33 Hz), 123.3 
(q, J = 272 Hz), 117.6 (d, J = 19 Hz), 115.3, 113.1, 109.8 (dd, J1 = 4, J2 = 6 Hz), 104.6 (d, 
J = 21 Hz), 68.3, 48.7, 48.2, 44.6, 41.6.  
 
3-(4-((3,4-Difluorophenyl)glycyl)piperazin-1-yl)benzonitrile (3.136) 
 
To a stirring solution of (3,4-difluorophenyl)glycine (30 mg, 0.16 mmol, 1 equiv) in DCM 
(5 mL) was added EDC (44 mg, 0.32 mmol, 2.0 equiv) and DMAP (1.9 mg, 0.016 mmol, 
0.1 equiv). This solution was stirred for 10 min before addition of 3-(piperazin-1-
yl)benzonitrile (44 mg, 0.24 mmol, 1.5 equiv). The reaction slurry was brought to 37 ˚C 
for 12 h before quenching with 1 N HCl solution (3 mL). Organics were separated and the 
solvent was removed under reduced pressure. Column chromatography (0 to 45% 
(EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for C19H18F2N3O2+ 
[M+H+] 358.3683, found 358. 1H NMR (400 MHz, CDCl3) δ 7.36 (dd, J1 = 7.6, J2 = 9.24, 
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1H), 7.17 (d, J = 7.6, 1H), 7.13 - 7.05 (m, 3H), 6.81 (ddd, J1 = 3, J2 = 6.4, J3 = 9.4 Hz, 1H), 
6.68 (dddd, J1 = 1.8, J2 = 3.2, J3 = 6.4, J4 = 9.1 Hz, 1H), 4.70 (s, 2H), 3.80 (t, J = 5.2 Hz, 
2H), 3.75 (t, J = 5.0 Hz, 2H), 3.25 - 3.16 (m, 4H). 
 
2-(3-(Trifluoromethyl)phenoxy)-1-(4-(3-(trifluoromethyl)phenyl)piperazin-1-
yl)propan-1-one (3.137) 
 
To a stirring solution of 2-(3-(trifluoromethyl)phenoxy)propanoic acid (30 mg, 0.13 mmol, 
1 equiv) in DCM (5 mL) was added EDC (40 mg, 0.26 mmol, 2.0 equiv) and DMAP (1.2 
mg, 0.1 equiv). This solution was stirred for 10 min before addition of 1-(3-
trifluoromethylphenyl)-piperazine (44 mg, 0.19 mmol, 1.5 equiv). The reaction slurry was 
brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics were 
separated and the solvent was removed under reduced pressure. Column chromatography 
(0 to 45% (EtOAc/Hex)) on silica gel was used to purify sufficient amounts of the target 
molecule for biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C21H21F6N2O2+ [M+H+] 447.40, found 447. 1H NMR (400 MHz, CDCl3) δ 7.38 (app. qt, 
2H), 7.24 (d, J = 7.7 Hz, 1H), 7.17 - 7.06 (m, 4H), 7.04 (d, J = 8.0 Hz, 1H), 5.04 (q, J = 
6.9 Hz, 1H), 3.89 - 3.73 (m, 4H), 3.26 - 3.16 (m, 2H), 3.16 - 3.07 (m, 1H), 3.07 - 2.99 (m, 
1H), 1.67 (d, J = 6.8 Hz, 3H). 13C NMR (176 MHz, CDCl3) δ 169.1, 157.2, 150.9, 132.3 
(d, J = 36 Hz), 131.7, (d, J = 40 Hz) 130.4, 129.7, 123.0, 119.3, 118.4, 117.9, 116.9, 112.8, 
112.1, 74.5, 49.3, 49.0, 44.8, 42.2, 17.9. 
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1-(4-(3,5-bis(Trifluoromethyl)phenyl)piperazin-1-yl)-2-(3-
(trifluoromethyl)phenoxy)propan-1-one (3.138) 
 
To a stirring solution of 2-(3-(trifluoromethyl)phenoxy)propanoic acid (30 mg, 0.12 mmol, 
1 equiv) in DCM (5 mL) was added EDC (40 mg, 0.24 mmol, 2.0 equiv) and DMAP (1.59 
mg, 0.1 mmol, 2.0 equiv). This solution was stirred for 10 min before addition of 1-(3,5-
bistrifluoromethylphenyl)-piperazine (57 mg, 0.18 mmol, 1.5 equiv). The reaction slurry 
was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics 
were separated and the solvent was removed under reduced pressure. Column 
chromatography (0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient amounts 
of the target molecule for biological testing and characterization. LRMS (APCI - quad) m/z 
cal’d for C22H20F9N2O2+ [M+H+] 515.40, found 515. 1H NMR (400 MHz, CDCl3) δ 7.42 
(t, J = 8.4 Hz, 1H), 7.34 (s, 1H), 7.25 (obscured doublet, 1H), 7.21 (s, 1H), 7.16 (br, 1H), 
7.11 (d, J = 8.4 Hz, 1H), 5.05 (q, J = 7.1 Hz, 1H), 3.93 - 3.77 (m, 4H), 3.33 - 3.25 (m, 2H), 
3.22 - 3.14 (m, 1H), 3.13 - 3.04 (m, 1H), 1.68 (d, J = 6.8 Hz, 3H). 
 
3-(4-(2-(3-(Trifluoromethyl)phenoxy)propanoyl)piperazin-1-yl)benzonitrile (3.139) 
 
To a stirring solution of 2-(3-(trifluoromethyl)phenoxy)propanoic acid (30 mg, 0.16 mmol, 
1 equiv) in DCM (5 mL) was added EDC (40 mg, 0.24 mmol, 1.5 equiv) and DMAP (31 
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mg, 0.24 mmol, 1.5 equiv). This solution was stirred for 10 min before addition of 1-
(cyanophenyl)-piperazine (35 mg, 0.24 mmol, 1.5 equiv). The reaction slurry was brought 
to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics were separated 
and the solvent was removed under reduced pressure. Column chromatography (0 to 45% 
(EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for C21H21F3N3O2+ 
[M+H+] 404.41, found 404. 1H NMR (400 MHz, CDCl3) δ 7.41 (t, J = 8.2 Hz, 1H), 7.33 
(dd, J1 = 7.6, J2, = 9.2 Hz, 1H), 7.25 (obscured doublet, 1H), 7.17 - 7.13 (m, 2H), 7.12 - 
7.06 (m, 3H), 5.04 (q, J = 6.9 Hz, 1H), 3.91 - 3.75 (m, 4H), 3.24 - 3.16 (m, 2H), 3.16 - 3.05 
(m, 1H), 3.05 - 2.79 (m, 1H), 1.67 (d, J = 6.8 Hz, 3H). 
 
2-Methyl-2-(3-(trifluoromethyl)phenoxy)-1-(4-(3-(trifluoromethyl)phenyl)piperazin-
1-yl)propan-1-one (3.140) 
 
To a stirring solution of 2-methyl-2-(3-(trifluoromethyl)phenoxy)propanoic acid (30 mg, 
0.12 mmol, 1 equiv) in DCM (5 mL) was added EDC (40 mg, 0.24 mmol, 2.0 equiv) and 
DMAP (31 mg, 0.24 mmol, 2.0 equiv). This solution was stirred for 10 min before addition 
of 1-(3-trifluoromethylphenyl)-piperazine (48 mg, 0.18 mmol, 1.5 equiv). The reaction 
slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). 
Organics were separated and the solvent was removed under reduced pressure. Column 
chromatography (0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient amounts 
of the target molecule for biological testing and characterization. LRMS (APCI - quad) m/z 
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cal’d for C22H23F6N2O2+ [M+H+] 461.63, found 462. 1H NMR (400 MHz, CDCl3) δ 7.46 
- 7.39 (m, 2H), 7.35 (s, 1H), 7.30 (d, J = 7.8 Hz, 1H), 7.23 - 7.17 (m, 2H), 7.12 - 7.04 (m, 
3H), 4.08 (br, 2H), 3.92 (br, 2H), 3.22 (br, 2H), 2.95 (br, 2H), 1.78 (s, 6H). 13C NMR (176 
MHz, CDCl3) δ 171.2, 155.5, 150.8, 132.2 (d, J = 32 Hz), 131.6 (d, J = 33 Hz), 130.0, 
129.7, 124.9, 123.3, 119.7, 119.1, 118.3, 116.7, 114.5, 112.6, 81.4, 49.0, 48.8, 45.6, 42.8, 
26.0. 
 
1-(4-(3,5-bis(Trifluoromethyl)phenyl)piperazin-1-yl)-2-methyl-2-(3-
(trifluoromethyl)phenoxy)propan-1-one (3.141) 
 
To a stirring solution of 2-methyl-2-(3-(trifluoromethyl)phenoxy)propanoic acid (30 mg, 
0.12 mmol, 1 equiv) in DCM (5 mL) was added EDC (40 mg, 0.24 mmol, 2.0 equiv) and 
DMAP (31 mg, 0.24 mmol, 2.0 equiv). This solution was stirred for 10 min before addition 
of 1-(3,5-bistrifluoromethylphenyl)-piperazine (48 mg, 0.18 mmol, 1.5 equiv). The 
reaction slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 
mL). Organics were separated and the solvent was removed under reduced pressure. 
Column chromatography (0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient 
amounts of the target molecule for biological testing and characterization. LRMS (APCI - 
quad) m/z cal’d for C23H22F9N2O2+ [M+H+] 529.43, found 529. 1H NMR (400 MHz, 
CDCl3) δ 7.35 (t, J = 7.8 Hz, 1H), 7.30 (s, 1H), 7.22 (td, J1 = 0.7 Hz, J2 = 7.0 Hz, 1H), 7.15 
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- 7.11 (m, 3H), 7.01 (dd, J1 = 2.6, J2 = 8.3 Hz, 1H), 4.01 (br, 2H), 3.84 (br, 2H), 3.20 (br, 
2H), 2.92 (br, 2H), 1.70 (s, 6H).  
 
3-(4-(2-Methyl-2-(3-(trifluoromethyl)phenoxy)propanoyl)piperazin-1-yl)benzonitrile 
(3.142) 
 
To a stirring solution of 2-methyl-2-(3-(trifluoromethyl)phenoxy)propanoic acid (30 mg, 
0.12 mmol, 1 equiv) in DCM (5 mL) was added EDC (40 mg, 0.24 mmol, 2.0 equiv) and 
DMAP (31 mg, 0.24 mmol, 2.0 equiv). This solution was stirred for 10 min before addition 
of 1-(3-cyanophenyl)-piperazine (48 mg, 0.18 mmol, 1.5 equiv). The reaction slurry was 
brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics were 
separated and the solvent was removed under reduced pressure. Column chromatography 
(0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target 
molecule for biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C22H23F3N3O2+ [M+H+] 418.44, found 419. 1H NMR (400 MHz, CDCl3) δ 7.36 (t, J = 7.8 
Hz, 1H), 7.33 - 7.28 (m, 1H), 7.23 (J1, = 0.7, J2 = 7.0 Hz, 1H), 7.14 - 7.10 (m, 2H), 7.04 - 
7.00 (m, 3H), 4.00 (br, 2H), 3.83 (br, 2H), 3.12 (br, 2H), 2.84 (br, 2H), 1.70 (s, 6H). 
 
2-((3-(Trifluoromethyl)phenyl)amino)-1-(4-(3-(trifluoromethyl)phenyl)piperazin-1-
yl)ethan-1-one (3.143) 
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To a stirring solution of (3-(trifluoromethyl)phenyl)glycine (40 mg, 0.17 mmol, 1 equiv) 
in DCM (5 mL) was added EDC (56 mg, 0.34 mmol, 2.0 equiv) and DMAP (2.2 mg, 0.17 
mmol, 0.1 equiv). This solution was stirred for 10 min before addition of 1-(3-
trifluoromethylphenyl)-piperazine (63 mg, 0.25 mmol, 1.5 equiv). The reaction slurry was 
brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics were 
separated and the solvent was removed under reduced pressure. Column chromatography 
(0 to 45% (EtOAc/Hex)) on silica gel was used to purify sufficient amounts of the target 
molecule for biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C20H20F6N3O+ [M+H+] 432.39, found 434. 1H NMR (400 MHz, CDCl3) δ 7.41 (t, J = 7.9 
Hz, 1H), 7.28 (t, J = 7.8 Hz, 1H), 7.21 - 7.12 (m, 3H), 6.68 (d, J = 7.6 Hz, 1H), 6.84 - 6.80 
(m, 2H), 3.96 (s, 1H), 3.90 (t, J = 5.3 Hz, 2H), 3.69 (t, J = 5.2, 2H), 3.31 (t, J = 5.2 Hz, 
2H), 3.28 (t, J = 5.2 Hz, 2H). 13C NMR (176 MHz, CDCl3) δ 167.0, 150.9, 147.3, 131.8, 
(d, J = 11), 131.6, (d, J = 11 Hz), 129.8, 129.7, 125.1, (d, J = 37 Hz), 123.6 (d, J = 37 Hz), 
119.6, 117.1, 116.5, 114.1, 113.0, 108.5, 49.1, 49.0, 44.8, 44.1, 41.9. 
 
1-(4-(3,5-bis(Trifluoromethyl)phenyl)piperazin-1-yl)-2-((3-
(trifluoromethyl)phenyl)amino)ethan-1-one (3.144) 
 
To a stirring solution of (3-(trifluoromethyl)phenyl)glycine (40 mg, 0.13 mmol, 1 equiv) 
in DCM (5 mL) was added EDC (56 mg, 0.26 mmol, 2.0 equiv) and DMAP (2.2 mg, 0.013 
mmol, 0.1 equiv). This solution was stirred for 10 min before addition of 1-(3,5-
bistrifluoromethylphenyl)-piperazine (63 mg, 0.19 mmol, 1.5 equiv). The reaction slurry 
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was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics 
were separated and the solvent was removed under reduced pressure. Column 
chromatography (0 to 45% (EtOAc/Hex) on silica gel was used to purify sufficient amounts 
of the target molecule for biological testing and characterization. LRMS (APCI - quad) m/z 
cal’d for C21H19F9N3O+ [M+H+] 500.39, found 501. 1H NMR (400 MHz, CDCl3) δ 7.37 
(s, 1H), 7.32 - 7.27 (m, 3H), 7.00 (d, J = 7.4 Hz, 1H), 6.87 - 6.81 (m, 2H), 3.98 (s, 2H), 
3.89 (t, J = 5.3 Hz, 2H), 3.69 (t, J = 4.7 Hz, 2H), 3.38 (t, J = 5.4 Hz, 2H), 3.34 (t, J = 5.6 
Hz, 2H). 13C NMR (176 MHz, CDCl3) δ 167.1, 151.7, 147.2, 132.6 (q, J = 40 Hz), 131.6 
(d, J = 38 Hz), 121.7, 124.1 (d, J = 272 Hz), 123.4 (d, J = 272 Hz), 116.5, 115.4, 114.1 (d, 
J = 4 Hz), 113.2 (d, J = 3 Hz), 108.5 (d, J = 4 Hz), 48.3, 44.8, 43.8, 41.6. 
 
2-((2,4-Difluorophenyl)amino)-1-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethan-
1-one (3.145)  
 
To a stirring solution of (2,4-difluorophenyl)glycine (16 mg, 0.07 mmol, 1 equiv) in DCM 
(5 mL) was added EDC (27 mg, 0.14 mmol, 2.0 equiv) and DMAP (0.10 mg, 0.007 mmol, 
0.01 equiv). This solution was stirred for 10 min before addition of 1-(3-
(trifluoromethyl)phenyl)piperazine (30 mg, 0.011 mmol, 1.5 equiv). The reaction slurry 
was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics 
were separated and the solvent was removed under reduced pressure. Column 
chromatography (0 to 100% (EtOAc/Hex) on silica gel was used to purify sufficient 
amounts of the target molecule for biological testing and characterization. LRMS (APCI - 
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quad) m/z cal’d for C19H19F5N3O+ [M+H+], 400.37 found 401. 1H NMR (400 MHz, 
CDCl3) δ 7.39 (t, J = 8.0 Hz, 1H), 7.20 - 7.07 (m, 3H), 6.85 - 6.71 (m, 2H), 6.55 (dd, J1 = 
5.3, J2 = 9.3 Hz, 1H), 3.95 (s, 2H), 3.89 - 3.82 (m, 4H), 3.73 - 3.60 (m, 4H), 3.34 - 3.21 (m, 
4H). 
 
2-((4-Chlorophenyl)amino)-1-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethan-1-
one (3.146)  
 
To a stirring solution of (4-chlorophenyl)glycine (16 mg, 0.07 mmol, 1 equiv) in DCM (5 
mL) was added EDC (27 mg, 0.14mmol, 2.0 equiv) and DMAP (0.10 mg, 0.007 mmol, 
0.01 equiv). This solution was stirred for 10 min before addition of 1-(3-
(trifluoromethyl)phenyl)piperazine (30 mg, 0.10 mmol, 1.5 equiv). The reaction slurry was 
brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics were 
separated and the solvent was removed under reduced pressure. Column chromatography 
(0 to 100% (EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target 
molecule for biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C19H20ClF3N3O+ [M+H+], 398.83 found 399.1H NMR (400 MHz, CDCl3) δ 7.39 (t, J = 7.9 
Hz, 1H), 7.19 - 7.11 (m, 4H), 7.09 (d, J = 8.3 Hz, 1H), 6.59 (d, J = 8.7 Hz, 2H), 3.91 (s, 
2H), 3.88 - 3.84 (m, 2H), 3.66 - 3.61 (m, 2H), 3.31 - 3.22 (m, 4H). 13C NMR (101 MHz, 
CDCl3) δ 167.3, 150.9, 145.8, 131.6 (q, J = 32 Hz), 129.8, 129.2, 120.7 (q, J = 315 Hz), 
117.1 (d, J = 4 Hz), 114.0, 113.0 (d, J = 4 Hz), 49.1, 49.0, 45.2, 44.1, 41.9.  
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2-((2-Fluorophenyl)amino)-1-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethan-1-
one (3.147)  
 
To a stirring solution of (2-fluorophenyl)glycine (15 mg, 0.07 mmol, 1 equiv) in DCM (5 
mL) was added EDC (27 mg, 0.14 mmol,2.0 equiv) and DMAP (0.10 mg, 0.007 mmol, 
0.01 equiv). This solution was stirred for 10 min before addition of 1-(3-
(trifluoromethyl)phenyl)piperazine (30 mg,  0.1 mmol, 1.5 equiv). The reaction slurry was 
brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics were 
separated and the solvent was removed under reduced pressure. Column chromatography 
(0 to 100% (EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target 
molecule for biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C19H20F4N3O+ [M+H+], 382.38 found 383. 1H NMR (400 MHz, CDCl3) δ 7.40 (t, J = 7.9 
Hz, 1H), 7.20 - 7.09 (m, 3H), 7.03 - 6.96 (m, 2H), 6.72 - 6.59 (m, 2H), 3.98 (s, 2H), 3.92 - 
3.85 (m, 2H), 3.70 - 3.64 (m, 2H), 3.31 - 3.24 (m, 4H). 
 
2-((4-Fluorophenyl)amino)-1-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethan-1-
one (3.148)  
 
To a stirring solution of (4-fluorophenyl)glycine (15 mg, 0.07 mmol, 1 equiv) in DCM (5 
mL) was added EDC (27 mg, 0.14 mmol, 2.0 equiv) and DMAP (0.10 mg, 0.007, 0.01 
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equiv). This solution was stirred for 10 min before addition of 1-(3-
(trifluoromethyl)phenyl)piperazine (30 mg, 0.11 mmol, 1.5 equiv). The reaction slurry was 
brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics were 
separated and the solvent was removed under reduced pressure. Column chromatography 
(0 to 100% (EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target 
molecule for biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C19H20F4N3O+ [M+H+], 382.38 found 382. 1H NMR (400 MHz, CDCl3) δ 7.39 (t, J = 7.9 
Hz, 1H), 7.14 (d, J = 7.7 Hz, 1H), 7.13 (s, 1H), 7.08 (d, J = 8.2 Hz, 1H), 6.92 (t, J = 8.7 
Hz, 2H), 6.67 - 6.58 (m, 2H), 3.92 (s, 2H), 3.89 - 3.82 (m, 2H), 3.67 - 3.61 (m, 2H), 3.31 - 
3.22 (m, 4H). 
 
2-((2,4-Difluorophenyl)amino)-1-(4-(m-tolyl)piperazin-1-yl)ethan-1-one (3.149)  
 
To a stirring solution of (4-fluorophenyl)glycine (21 mg, 0.12 mmol, 1 equiv) in DCM (5 
mL) was added EDC (35 mg, 0.24 mmol, 2.0 equiv) and DMAP (0.13 mg, 0.012 mmol, 
0.01 equiv). This solution was stirred for 10 min before addition of 1-(m-tolyl)piperazine 
(30 mg, 0.16 mmol, 1.5 equiv). The reaction slurry was brought to 37 ˚C for 12 h before 
quenching with 1 N HCl solution (3 mL). Organics were separated and the solvent was 
removed under reduced pressure. Column chromatography (0 to 100% (EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C19H22F2N3O+ [M+H+], 346.40 
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found 346. 1H NMR (400 MHz, CDCl3) δ 7.19 (t, J = 7.7 Hz, 1H), 6.87 - 6.69 (m, 5H), 
6.54 (dt, J1 = 5.3, J2 = 9.2 Hz, 1H), 4.95 (br, 1H), 3.94 (s, 2H), 3.89 - 3.83 (m, 2H), 3.67 - 
3.60 (m, 2H), 3.26 - 3.16 (m, 4H), 2.34 (s, 3H). 
 
2-((4-Chlorophenyl)amino)-1-(4-(m-tolyl)piperazin-1-yl)ethan-1-one (3.150)  
 
To a stirring solution of (4-chlorophenyl)glycine (21 mg, 0.12 mmol, 1 equiv) in DCM (5 
mL) was added EDC (35 mg, 0.24 mmol, 2.0 equiv) and DMAP (0.13 mg, 0.012 mmol, 
0.01 equiv). This solution was stirred for 10 min before addition of 1-(m-tolyl)piperazine 
(30 mg, 0.16 mmol, 1.5 equiv). The reaction slurry was brought to 37 ˚C for 12 h before 
quenching with 1 N HCl solution (3 mL). Organics were separated and the solvent was 
removed under reduced pressure. Column chromatography (0 to 100% (EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C19H23ClN3O+ [M+H+], 344.86 
found 345. 1H NMR (400 MHz, CDCl3) δ 7.21 (t, J = 7.7 Hz, 1H), 7.15 (d, J = 8.3 Hz, 
2H), 6.89 - 6.80 (m, 3H), 6.56 (d, J = 8.4 Hz, 2H), 3.94 - 3.88 (m, 4H), 3.69 (br, 2H), 3.28 
- 3.19 (m, 4H), 2.35 (s, 3H). 
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2-((2-Fluorophenyl)amino)-1-(4-(m-tolyl)piperazin-1-yl)ethan-1-one (3.151)  
 
To a stirring solution of (2-fluorophenyl)glycine (19 mg, 0.12 mmol, 1 equiv) in DCM (5 
mL) was added EDC (35 mg, 0. 24 mmol, 2.0 equiv) and DMAP (0.13 mg, 0.012 mmol, 
0.01 equiv). This solution was stirred for 10 min before addition of 1-(m-tolyl)piperazine 
(30 mg, 0.16 mmol, 1.5 equiv). The reaction slurry was brought to 37 ˚C for 12 h before 
quenching with 1 N HCl solution (3 mL). Organics were separated and the solvent was 
removed under reduced pressure. Column chromatography (0 to 100% (EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C19H23FN3O+ [M+H+], 328.41 
found 329. 1H NMR (400 MHz, CDCl3) δ 7.19 (t, J = 7.6 Hz, 1H), 7.04 - 6.95 (m, 2H), 
6.82 - 6.72 (m, 3H), 6.71 - 6.58 (m, 2H), 5.12 (br, 1H), 3.97 (s, 2H), 3.88 - 3.82 (m, 2H), 
3.66 - 3.60 (m, 2H), 3.25 - 3.16 (m, 4H), 2.34 (s, 3H). 13C NMR (176 MHz, CDCl3) δ 
167.3, 152.7 (dd, J1 = 11, J2 = 238 Hz), 151.0 (dd, J1 = 11, J2 = 238 Hz), 150.4, 132.6 (dd, 
J1 = 3, J2 = 12 Hz), 131.6 (q, J = 33 Hz), 129.8, 124.2 (q, J = 273 Hz), 119.5, 116.9 (d, J = 
4 Hz), 112.9 (d, J = 4 Hz), 112.3 (dd, J1 = 5, J2 = 9 Hz), 110.5 (dd, J1 = 4, J2 = 22 Hz), 
103.7 (dd, J1 = 23, J2 = 27 Hz), 49.0, 48.9, 45.4, 44.1, 41.8. 
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2-((4-Fluorophenyl)amino)-1-(4-(m-tolyl)piperazin-1-yl)ethan-1-one (3.152)  
 
To a stirring solution of (4-fluorophenyl)glycine (19 mg, 0.11 mmol, 1 equiv) in DCM (5 
mL) was added EDC (35 mg, 0.22 mmol, 2.0 equiv) and DMAP (0.13 mg, 0.011 mmol, 
0.01 equiv). This solution was stirred for 10 min before addition of 1-(m-tolyl)piperazine 
(30 mg, 0.15 mmol, 1.5 equiv). The reaction slurry was brought to 37 ˚C for 12 h before 
quenching with 1 N HCl solution (3 mL). Organics were separated and the solvent was 
removed under reduced pressure. Column chromatography (0 to 100% (EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C19H23FN3O+ [M+H+], 328.41 
found 330. 1H NMR (400 MHz, CDCl3) δ 7.19 (t, J = 7.6 Hz, 1H), 6.91 (t, J = 8.5 Hz, 2H), 
6.82 - 6.74 (m, 3H), 6.62 - 6.54 (m, 2H), 3.90 (s, 2H), 3.87 - 3.82 (m, 2H), 3.66 - 3.60 (m, 
2H), 3.25 - 3.16 (m, 4H), 2.34 (s, 3H). 
 
3-(Phenylamino)-1-(4-phenylpiperazin-1-yl)propan-1-one (3.153)  
 
To a stirring solution of 3-(phenylamino)propanoic acid (50 mg, 0.30 mmol, 1 equiv) in 
DCM (5 mL) was added EDC (94 mg, 0.6 mmol, 2.0 equiv) and DMAP (92 mg, 0.75 
mmol, 2.5 equiv). This solution was stirred for 10 min before addition of 1-
phenylpiperazine (73 mg, 0.45 mmol, 1.5 equiv). The reaction slurry was brought to 37 ˚C 
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for 12 h before quenching with 1 N HCl solution (3 mL). Organics were separated and the 
solvent was removed under reduced pressure. Column chromatography (0 to 100% 
(EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for C19H24N3O+ 
[M+H+], 310.42 found 310. 1H NMR (400 MHz, CDCl3) δ 7.28 (t, J = 7.5 Hz, 2H), 7.18 
(t, J = 7.3 Hz, 2H), 6.95 - 6.87 (m, 3H), 6.71 (t, J = 7.3 Hz, 1H), 6.65 (d, J = 8.0 Hz, 2H), 
4.45 (br, 1H), 3.82 - 3.75 (m, 2H), 3.61 - 3.54 (m, 2H), 3.53 (t, J = 6.8 Hz, 2H), 3.19 - 3.09 
(m, 4H), 2.66 (t, J = 6.0 Hz, 2H) 
 
3-(Phenylamino)-1-(4-(m-tolyl)piperazin-1-yl)propan-1-one (3.154)  
 
To a stirring solution of 3-(phenylamino)propanoic acid (50 mg, 0.29 mmol, 1 equiv) in 
DCM (5 mL) was added EDC (94 mg, 0.58 mmol, 2.0 equiv) and DMAP (92 mg, 0.75 
mmol, 2.5 equiv). This solution was stirred for 10 min before addition of 1-(m-
tolyl)piperazine (80 mg, 0.45 mmol, 1.5 equiv). The reaction slurry was brought to 37 ˚C 
for 12 h before quenching with 1 N HCl solution (3 mL). Organics were separated and the 
solvent was removed under reduced pressure. Column chromatography (0 to 100% 
(EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for C20H26N3O+ 
[M+H+], 324.45 found 325. 1H NMR (400 MHz, CDCl3) δ 7.22 - 7.13 (m, 3H), 6.77 - 6.67 
(m, 4H), 6.64 (d, J = 8.4 Hz, 2H), 4.34 (br, 1H), 3.81 - 3.75 (m, 2H), 3.60 - 3.50 (m, 4H), 
3.17 - 3.08 (m, 4H), 2.65 (t, J = 6.0 Hz, 2H), 2.33 (s, 3H). 
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3-(Phenylamino)-1-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)propan-1-one 
(3.155) 
 
To a stirring solution of 3-(phenylamino)propanoic acid (50 mg, 0.22 mmol, 1 equiv) in 
DCM (5 mL) was added EDC (94 mg, 0.44 mmol, 2.0 equiv) and DMAP (92 mg, 0.51 
mmol, 2.5 equiv). This solution was stirred for 10 min before addition of 1-(3-
(trifluoromethyl)phenyl)piperazine (104 mg, 0.33 mmol, 1.5 equiv). The reaction slurry 
was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics 
were separated and the solvent was removed under reduced pressure. Column 
chromatography (0 to 100% (EtOAc/Hex) on silica gel was used to purify sufficient 
amounts of the target molecule for biological testing and characterization. LRMS (APCI - 
quad) m/z cal’d for C20H23F3N3O+ [M+H+], 378.42 found 379. 1H NMR (400 MHz, 
CDCl3) δ 7.37 (t, J = 8.0 Hz, 1H), 7.18 (t, J = 7.3 Hz, 2H), 7.13 (d, J = 7.7 Hz, 1H), 7.10 
(s, 1H), 7.05 (d, J = 8.3 Hz, 1H), 6.72 (t, J = 7.3 Hz, 1H), 6.65 (d, J = 8.6 Hz, 2H), 4.45 
(br, 1H), 3.83 - 3.76 (m, 2H), 3.61 - 3.57 (m, 2H), 3.54 (t, J = 6.0 Hz, 2H), 3.24 - 3.13 (m, 
4H), 2.66 (t, J = 6.0 Hz, 2H).  
 
3-((2-Nitro-4-(trifluoromethyl)phenyl)amino)-1-(4-phenylpiperazin-1-yl)propan-1-
one (3.156)  
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To a stirring solution of 3-((2-nitro-4-(trifluoromethyl)phenyl)amino)propanoic acid (50 
mg, 0.6 mmol, 1 equiv) in DCM (5 mL) was added EDC (55 mg, 1.2 mmol, 2.0 equiv) and 
DMAP (54 mg, 1.5 mmol, 2.5 equiv). This solution was stirred for 10 min before addition 
of 1-phenylpiperazine (43 mg, 0.9 mmol, 1.5 equiv). The reaction slurry was brought to 37 
˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics were separated and 
the solvent was removed under reduced pressure. Column chromatography (0 to 100% 
(EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for C20H22F3N4O3+ 
[M+H+], 423.42 found 424. 1H NMR (400 MHz, CDCl3) δ 8.52 (t, J = 6.5 Hz, 1H), 8.47 
(d, J = 2.1 Hz, 1H), 7.64 (dd, J1 = 2.2, J2 = 9.0 Hz, 1H), 7.29 (t, J = 7.1 Hz, 2H), 7.03 (d, J 
= 9.0 Hz, 1H), 6.96 - 6.90 (m, 2H), 3.85 - 3.73 (m, 4H), 3.67 - 3.60 (m, 2H), 3.22 - 3.14 
(m, 4H), 2.77 (t, J = 6.6 Hz, 2H). 
 
3-((2-Nitro-4-(trifluoromethyl)phenyl)amino)-1-(4-(m-tolyl)piperazin-1-yl)propan-1-
one (3.157)  
 
To a stirring solution of 3-((2-nitro-4-(trifluoromethyl)phenyl)amino)propanoic acid (50 
mg, 0.29 mmol, 1 equiv) in DCM (5 mL) was added EDC (55 mg, 0.6 mmol, 2.0 equiv) 
and DMAP (54 mg, 0.75 mmol, 2.5 equiv). This solution was stirred for 10 min before 
addition of 1-(m-tolyl)piperazine (47 mg, 0.45 mmol, 1.5 equiv). The reaction slurry was 
brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics were 
separated and the solvent was removed under reduced pressure. Column chromatography 
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(0 to 100% (EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target 
molecule for biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C21H24F3N4O3+ [M+H+], 437.44 found 438. 1H NMR (400 MHz, CDCl3) δ 8.51 (br, 1H), 
8.48 (s, 1H), 7.64 (dd, J1 = 2.2, J2 = 9.1 Hz, 1H), 7.18 (t, J = 7.7 Hz, 1H), 7.03 (d, J = 9.0 
Hz, 1H), 6.78 - 6.73 (m, 2H), 3.84 - 3.73 (m, 4H), 3.65 - 3.60 (m, 2H), 3.20 - 3.14 (m, 4H), 
2.77 (t, J = 6.6 Hz, 2H), 2.33 (s, 3H). 
 
3-((2-Nitro-4-(trifluoromethyl)phenyl)amino)-1-(4-(3-
(trifluoromethyl)phenyl)piperazin-1-yl)propan-1-one (3.158)  
 
To a stirring solution of 3-((2-nitro-4-(trifluoromethyl)phenyl)amino)propanoic acid (50 
mg, 0.17 mmol, 1 equiv) in DCM (5 mL) was added EDC (55 mg, 0.34 mmol, 2.0 equiv) 
and DMAP (54 mg, 0.42 mmol, 2.5 equiv). This solution was stirred for 10 min before 
addition of 1-(3-(trifluoromethyl)phenyl)piperazine (62 mg, 0.26 mmol, 1.5 equiv). The 
reaction slurry was brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 
mL). Organics were separated and the solvent was removed under reduced pressure. 
Column chromatography (0 to 100% (EtOAc/Hex) on silica gel was used to purify 
sufficient amounts of the target molecule for biological testing and characterization. LRMS 
(APCI - quad) m/z cal’d for C21H21F6N4O3+ [M+H+], 491.41 found 492. 1H NMR (400 
MHz, CDCl3) δ 8.52 (t, J = 5.8 Hz, 1H), 8.47 (d, J = 2.1 Hz, 1H), 7.64 (dd, J1 = 2.2, J2 = 
9.1 Hz, 1H), 7.38 (t, J = 7.9 Hz, 1H), 7.14 (d, J = 7.8 Hz, 1H), 7.11 (s, 1H), 7.70 (d, J = 8.3 
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Hz, 1H), 7.03 (d, J = 9.0 Hz, 1H), 3.84 - 3.76 (m, 4H), 3.68 - 3.62 (m, 2H), 3.28 - 3.19 (m, 
4H), 2.78 (t, J = 6.6 Hz, 2H). 
 
3-((2-Fluorophenyl)amino)-1-(4-phenylpiperazin-1-yl)propan-1-one (3.159) 
 
To a stirring solution of 3-((2-fluorophenyl)amino)propanoic acid (50 mg, 0.26 mmol, 1 
equiv) in DCM (5 mL) was added EDC (85 mg, 0.52 mmol, 2.0 equiv) and DMAP (83 mg, 
0.63 mmol, 2.5 equiv). This solution was stirred for 10 min before addition of 1-
phenylpiperazine (66 mg, 0.40 mmol, 1.5 equiv). The reaction slurry was brought to 37 ˚C 
for 12 h before quenching with 1 N HCl solution (3 mL). Organics were separated and the 
solvent was removed under reduced pressure. Column chromatography (0 to 100% 
(EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for C19H23FN3O+ 
[M+H+], 328.41 found 329. 1H NMR (400 MHz, CDCl3) δ 7.32 - 7.26 (m, 2H), 7.08 (q, J 
= 6.9 Hz, 1H), 6.94 - 6.89 (m, 3H), 6.42 - 6.36 (m, 2H), 6.32 (td, J1 = 2.4, J2 = 11.6 Hz, 
1H), 3.81 - 3.77 (m, 2H), 3.61 - 3.56 (m, 2H), 3.50 (t, J = 5.9 Hz, 2H), 3.18 - 3.11 (m, 4H), 
2.64 (t, J = 5.9 Hz, 2H). 
 
3-((2-Fluorophenyl)amino)-1-(4-(m-tolyl)piperazin-1-yl)propan-1-one (3.160)  
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To a stirring solution of 3-((2-fluorophenyl)amino)propanoic acid (50 mg, 0.28 mmol, 1 
equiv) in DCM (5 mL) was added EDC (85 mg, 0.54 mmol, 2.0 equiv) and DMAP (83 mg, 
0.69 mmol, 2.5 equiv). This solution was stirred for 10 min before addition of 1-(m-
tolyl)piperazine (72 mg, 0.42 mmol, 1.5 equiv). The reaction slurry was brought to 37 ˚C 
for 12 h before quenching with 1 N HCl solution (3 mL). Organics were separated and the 
solvent was removed under reduced pressure. Column chromatography (0 to 100% 
(EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for C20H25FN3O+ 
[M+H+], 342.44 found 343. 1H NMR (400 MHz, CDCl3) δ 7.17 (t, J = 7.7 Hz, 1H), 7.08 
(q, J = 7.9 Hz, 1H), 6.77 - 7.60 (m, 3H), 6.42 - 6.27 (m, 3H), 4.51 (br, 1H), 3.81 - 3.75 (m, 
2H), 3.61 - 3.54 (m, 2H), 3.50 (t, J = 5.8 Hz, 2H), 3.18 - 3.09 (m, 4H), 2.64 (t, J = 5.9 Hz, 
2H), 2.32 (s, 3H). 13C NMR (176 MHz, CDCl3) δ 169.9, 164.0 (d, J = 243 Hz), 150.9, 
149.6 (d, J = 10 Hz), 139.0, 130.4 (d, J = 10 Hz), 129.1, 121.7, 117.6, 113.8, 109.0, 103.7 
(d, J = 22 Hz), 99.4 (d, J = 25 Hz), 49.8, 49.5, 45.4, 41.6, 39.3, 31.9, 21.7.  
 
3-((2-Fluorophenyl)amino)-1-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)propan-
1-one (3.161)  
 
To a stirring solution of 3-((2-fluorophenyl)amino)propanoic acid (50 mg, 0.26 mmol, 1 
equiv) in DCM (5 mL) was added EDC (85 mg, 0.52 mmol, 2.0 equiv) and DMAP (83 mg, 
0.69 mmol, 2.5 equiv). This solution was stirred for 10 min before addition of 1-(3-
(trifluoromethyl)phenyl)piperazine (94 mg, 0.40 mmol, 1.5 equiv). The reaction slurry was 
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brought to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics were 
separated and the solvent was removed under reduced pressure. Column chromatography 
(0 to 100% (EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target 
molecule for biological testing and characterization. LRMS (APCI - quad) m/z cal’d for 
C20H22F4N3O+ [M+H+], 396.41 found 397. 1H NMR (400 MHz, CDCl3) δ 7.37 (t, J = 7.9 
Hz, 1H), 7.16 - 7.02 (m, 4H), 6.42 - 6.64 (m, 2H), 6.31 (td, J1 = 2.4, J2 = 11.6 Hz, 1H), 
4.50 (br, 1H), 3.83 - 3.77 (m, 2H), 3.63 - 3.57 (m, 2H), 3.51 (t, J = 5.9 Hz, 2H), 3.24 - 3.16 
(m, 4H), 2.65 (t, J = 5.9 Hz, 2H). 13C NMR (176 MHz, CDCl3) δ 170.0, 164.0 (d, J = 
243), 150.9, 149.5 (d, J = 11 Hz), 131.5 (d, J = 32 Hz), 130.4 (d, J = 11 Hz), 129.8,  124.1 
(d, J = 273 Hz), 119.4, 117.0, 112.8 (d, J = 4 Hz), 109.0 (d, J = 2 Hz), 103.9 (d, J = 21 Hz), 
99.4 (d, J = 25 Hz), 49.0, 48.9, 45.1, 41.3, 39.3, 31.9. 
 
1-(4-(Pyrimidin-2-yl)piperazin-1-yl)-2-((3-(trifluoromethyl)phenyl)amino)ethan-1-
one (3.162)  
 
To a stirring solution of (3-(trifluoromethyl)phenyl)glycine (27 mg, 0.11 mmol, 1 equiv) 
in DCM (5 mL) was added EDC (37 mg, 0.22 mmol, 2.0 equiv) and DMAP (0.14mg, 
0.01mmol, 0.01 equiv). This solution was stirred for 10 min before addition of 2-
(piperazin-1-yl)pyrimidine (30 mg, 0.15 mmol, 1.5 equiv). The reaction slurry was brought 
to 37 ˚C for 12 h before quenching with 1 N HCl solution (3 mL). Organics were separated 
and the solvent was removed under reduced pressure. Column chromatography (0 to 100% 
(EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
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biological testing and characterization. LRMS (APCI - quad) m/z cal’d for C17H19F3N5O+ 
[M+H+], 366.37 found 367. 1H NMR (400 MHz, CDCl3) δ 8.30 (d, J = 4.8 Hz, 2H), 7.25 
- 7.19 (m, 1H), 6.91 (d, J = 7.6 Hz, 1H), 6.78 - 6.71 (m, 2H), 6.53 (t, J = 4.8 Hz, 1H), 3.93 
- 3.87 (m, 4H), 3.86 - 3.80 (m, 2H), 3.77 - 3.70 (m, 2H), 3.53 - 3.46 (m, 2H).  
 
2-((2,4-Difluorophenyl)amino)-1-(4-(pyrimidin-2-yl)piperazin-1-yl)ethan-1-one 
(3.163)  
 
To a stirring solution of (2,4-difluorophenyl)glycine (23 mg, 0.11 mmol, 1 equiv) in DCM 
(5 mL) was added EDC (37 mg, 0.22 mmol, 2.0 equiv) and DMAP (0.14 mg, 0.01mmol, 
0.01 equiv). This solution was stirred for 10 min before addition of 2-(piperazin-1-
yl)pyrimidine (30 mg, 0.16 mmol, 1.5 equiv). The reaction slurry was brought to 37 ˚C for 
12 h before quenching with 1 N HCl solution (3 mL). Organics were separated and the 
solvent was removed under reduced pressure. Column chromatography (0 to 100% 
(EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for C16H18F2N5O+ 
[M+H+], 334.35 found 335. 1H NMR (400 MHz, CDCl3) δ 8.35 (d, J = 4.8 Hz, 2H), 6.85 
- 6.71 (m, 2H), 6.61 - 6.52 (m, 2H), 3.97 - 3.86 (m, 6H), 3.81 - 3.74 (m, 2H), 3.58 - 3.50 
(m, 2H). 
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2-((4-Chlorophenyl)amino)-1-(4-(pyrimidin-2-yl)piperazin-1-yl)ethan-1-one (3.164)  
 
To a stirring solution of 4-chlorophenyl)glycine (22 mg, 0.11mmol, 1 equiv) in DCM (5 
mL) was added EDC (37 mg, 0.22 mmol, 2.0 equiv) and DMAP (0.14 mg, 0.011 mmol, 
0.01 equiv). This solution was stirred for 10 min before addition of 2-(piperazin-1-
yl)pyrimidine (30 mg, 0.16 mmol, 1.5 equiv). The reaction slurry was brought to 37 ˚C for 
12 h before quenching with 1 N HCl solution (3 mL). Organics were separated and the 
solvent was removed under reduced pressure. Column chromatography (0 to 100% 
(EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for C16H19ClN5O+ 
[M+H+], 332.81 found 333. 1H NMR (400 MHz, CDCl3) δ 8.47 (d, J = 5.0 Hz, 2H), 7.16 
(d, J = 8.6 Hz, 2H), 6.74 (t, J = 5.0 Hz, 1H), 6.62 (d, J = 8.5 Hz, 2H), 4.16 - 4.08 (m, 2H), 
4.04 - 3.98 (m, 2H), 3.39 (s, 2H), 3.85 - 3.78 (m, 2H), 3.67 - 3.60 (m, 2H). 
 
2-((2-Fluorophenyl)amino)-1-(4-(pyrimidin-2-yl)piperazin-1-yl)ethan-1-one (3.165)  
 
To a stirring solution of (2-fluorophenyl)glycine (22 mg, 0.11 mmol, 1 equiv) in DCM (5 
mL) was added EDC (37 mg, 0.22 mmol, 2.0 equiv) and DMAP (0.14 mg, 0.011 mmol,  
0.01 equiv). This solution was stirred for 10 min before addition of 2-(piperazin-1-
yl)pyrimidine (30 mg, 0.16 mmol, 1.5 equiv). The reaction slurry was brought to 37 ˚C for 
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12 h before quenching with 1 N HCl solution (3 mL). Organics were separated and the 
solvent was removed under reduced pressure. Column chromatography (0 to 100% 
(EtOAc/Hex) on silica gel was used to purify sufficient amounts of the target molecule for 
biological testing and characterization. LRMS (APCI - quad) m/z cal’d for C16H19FN5O+ 
[M+H+], 316.36 found 317. 1H NMR (400 MHz, CDCl3) δ 8.36 (d, J = 4.8 Hz, 2H), 7.04 
- 6.95 (m, 2H), 6.69 - 6.57 (m, 3H), 4.00 - 3.87 (m, 6H), 3.82 - 3.75 (m, 2H), 3.59 - 3.52 
(m, 2H). 
 
2-((4-Fluorophenyl)amino)-1-(4-(pyrimidin-2-yl)piperazin-1-yl)ethan-1-one (3.166)  
 
To a stirring solution of (4-fluorophenyl)glycine (22 mg, 0.11 mmol, 1 equiv) in DCM (5 
mL) was added EDC (37 mg, 0.22 mmol, 2.0 equiv) and DMAP (0.14 mg, 0.01 mmol, 0.01 
equiv). This solution was stirred for 10 min before addition of 2-(piperazin-1-yl)pyrimidine 
(30 mg, 0. 16 mmol, 1.5 equiv). The reaction slurry was brought to 37 ˚C for 12 h before 
quenching with 1 N HCl solution (3 mL). Organics were separated and the solvent was 
removed under reduced pressure. Column chromatography (0 to 100% (EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C16H19FN5O+ [M+H+], 316.36 
found 318. 1H NMR (400 MHz, CDCl3) δ 8.36 (d, J = 4.8 Hz, 2H), 6.92 (t, J = 8.7 Hz, 
2H), 6.65 - 6.56 (m, 3H), 3.98 - 3.86 (m, 6H), 3.80 - 3.73 (m, 2H), 3.61 - 3.50 (m, 2H). 
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N,4-bis(3-(Trifluoromethyl)phenyl)piperidine-1-carboxamide (3.167)  
 
To a stirring solution of 4-(3-(trifluoromethyl)phenyl)piperidine (30 mg, 0.13 mmol, 1.0 
equiv), triethylamine (1.8 µL, 0.013 mmol, 0.1 equiv) in DCM (5 mL) was added 1-
isocyanato-3-(trifluoromethyl)benzene (29 mg, 0.16 mmol, 1.2 equiv) and the solution was 
stirred for 30 min at RT. After confirming consumption of limiting reagent by TLC, 3 mL 
of distilled water was added to the reaction vial. The organic layer was separated and 
removed under reduced atmosphere. Column chromatography (0 to 50% EtOAc/Hex) on 
silica gel was used to purify sufficient amounts of the target molecule for biological testing 
and characterization. LRMS (APCI - quad) m/z cal’d for C20H19F6N2O+ [M+H+], 417.37 
found 419. 1H NMR (400 MHz, CDCl3) δ 7.67 (s, 1H), 7.58 (d, J = 8.2 Hz, 1H), 7.52 - 
7.37 (m, 5H), 7.29 (d, J = 7.8 Hz, 1H), 6.59 (s, 1H), 4.25 (d, J = 13.4 Hz, 2H), 3.04 (t, J = 
12.9 Hz, 2H), 2.82 (tt, J1 = 3.3, J2 = 6.9 Hz, 1H), 1.96 (d, J = 15.0 Hz, 2H), 1.75 (dq, J1 = 
4.1, J2 = 12.7 Hz, 2H), 13C NMR (101 MHz, CDCl3) δ 154.4, 145.9, 139.7, 131.1 (quint, 
J = 32 Hz), 130.1, 129.4, 129.1, 124.1 (dq, J1 = 16, J2 = 272), 123.5 (sext, J = 4 Hz), 122.9, 
119.6 (q, J = 4 Hz), 116.4 (q, J = 4 Hz), 44.9, 42.5, 32.9. 
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GPHR-00213869 Analogs 
6-Chloro-3-phenyl-[1,2,4]triazolo[4,3-b]pyridazine (3.168) 
 
To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and benzoic 
anhydride (313 mg, 1.38 mmol, 2 equiv). The resulting suspension was heated to reflux 
and stirred for 12 h. After confirmation of consumption of starting material by TLC, the 
reaction was cooled to rt and the toluene was removed under reduced pressure. DCM (50 
mL) was added and reaction was washed with a saturated NaHCO3 solution (3 x 25 mL). 
The organic layer was then dried over Na2SO4, filtered and solvent removed under reduced 
pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used to purify 
sufficient amounts of target molecule for biological testing and characterization.  
LRMS (CI-quad) m/z cal’d for C11H8N4Cl+ [M+H+] 231.65, found 232.  
1H NMR (400 MHz, CDCl3) δ 10.29 (s, 1H), 8.19 (d, J = 9.2 Hz, 1H), 7.65 (d, J = 7.1 Hz, 
2H), 7.56 (d, J = 7.7 Hz, 2H), 7.48 (d, J = 9.2 Hz, 1H), 7.42 (dd, J1 = 7.6, J2 = 15.0 Hz, 
1H), 7.38 - 7.30 (m, 3H), 7.20 (t, J1 = 7.7 Hz, 2H). 
 
6-Chloro-3-(m-tolyl)-[1,2,4]triazolo[4,3-b]pyridazine (3.169) 
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To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and 3-
methylbenzoic anhydride (261 mg, 1.38 mmol, 2 equiv). The resulting suspension was 
heated to reflux and stirred for 12 h. After confirmation of consumption of starting material 
by TLC, the reaction was cooled to rt and the toluene was removed under reduced pressure. 
DCM (50 mL) was added and reaction was washed with a saturated NaHCO3 solution (3 x 
25 mL). The organic layer was then dried over Na2SO4, filtered and solvent removed under 
reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used 
to purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C12H10N4Cl+ [M+H+] 246.69, found 247. 1H NMR (400 
MHz, CDCl3) δ 9.05 (s, 1H), 8.21 (d, J = 9.3 Hz, 1H), 7.54 (d, J = 9.2 Hz, 1H), 7.50 (d, J 
= 11.0 Hz, 1H), 7.44 (d, J = 7.5 Hz, 1H), 7.33 - 7.27 (m, 1H), 2.35 (s, 3H).  
 
6-Chloro-3-(3-(trifluoromethyl)phenyl)-[1,2,4]triazolo[4,3-b]pyridazine (3.170) 
 
To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and 3-
(trifluoromethyl)benzoic anhydride (247 mg, 1.38 mmol, 2 equiv). The resulting 
suspension was heated to reflux and stirred for 12 h. After confirmation of consumption of 
starting material by TLC, the reaction was cooled to rt and the toluene was removed under 
reduced pressure. DCM (50 mL) was added and reaction was washed with a saturated 
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NaHCO3 solution (3 x 25 mL). The organic layer was then dried over Na2SO4, filtered and 
solvent removed under reduced pressure. Column chromatography (0 to 10% 
MeOH/DCM) on silica gel was used to purify sufficient amounts of target molecule for 
biological testing and characterization. LRMS (CI-quad) m/z cal’d for C12H7N4F3Cl+ 
[M+H+] 300.66, found 300. 1H NMR (400 MHz, CDCl3) δ 8.79 (s, 1H) 8.70 (d, J = 7.9 
Hz, 1H), 8.19 (d, J = 9.6 Hz, 1H), 7.79 (J = 7.8 Hz, 1H), 7.71 (t, J = 7.9 Hz, 1H), 7.21 (d, 
J = 9.6 Hz, 1H). 
 
6-Chloro-3-(p-tolyl)-[1,2,4]triazolo[4,3-b]pyridazine (3.171) 
 
To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and 4-
methylbenzoic anhydride (175 mg, 1.38 mmol, 2 equiv). The resulting suspension was 
heated to reflux and stirred for 12 h. After confirmation of consumption of starting material 
by TLC, the reaction was cooled to rt and the toluene was removed under reduced pressure. 
DCM (50 mL) was added and reaction was washed with a saturated NaHCO3 solution (3 x 
25 mL). The organic layer was then dried over Na2SO4, filtered and solvent removed under 
reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used 
to purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C12H10N4Cl+ [M+H+] 246.69, found 247. 1H NMR (400 
MHz, CDCl3) δ 8.35 (d, J = 8.3 Hz, 2H), 8.16 (d, J = 9.6 Hz, 1H), 7.38 (d, J = 8.0 Hz, 2H), 
7.14 (d, J = 9.6, 2H), 2.45 (s, 3H). 
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6-Chloro-3-(4-(trifluoromethyl)phenyl)-[1,2,4]triazolo[4,3-b]pyridazine (3.172) 
 
To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and 4-
(trifluoromethyl)benzoic anhydride (249 mg, 1.38 mmol, 2 equiv). The resulting 
suspension was heated to reflux and stirred for 12 h. After confirmation of consumption of 
starting material by TLC, the reaction was cooled to rt and the toluene was removed under 
reduced pressure. DCM (50 mL) was added and reaction was washed with a saturated 
NaHCO3 solution (3 x 25 mL). The organic layer was then dried over Na2SO4, filtered and 
solvent removed under reduced pressure. Column chromatography (0 to 10% 
MeOH/DCM) on silica gel was used to purify sufficient amounts of target molecule for 
biological testing and characterization. LRMS (CI-quad) m/z cal’d for C12H7N4F3Cl+ 
[M+H+] 300.66, found 300. 1H NMR (400 MHz, CDCl3) δ 8.62 (d, J = 7.8 Hz, 2H), 8.19 
(d, J = 9.6 Hz, 1H), 7.83 (d, J = 8.0 Hz, 2H), 7.21 (d, J = 9.6 Hz, 1H).  
 
6-Chloro-3-(4-methoxyphenyl)-[1,2,4]triazolo[4,3-b]pyridazine (3.173) 
 
To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and 4-
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methoxybenzoic anhydride (294 mg, 1.38 mmol, 2 equiv). The resulting suspension was 
heated to reflux and stirred for 12 h. After confirmation of consumption of starting material 
by TLC, the reaction was cooled to rt and the toluene was removed under reduced pressure. 
DCM (50 mL) was added and reaction was washed with a saturated NaHCO3 solution (3 x 
25 mL). The organic layer was then dried over Na2SO4, filtered and solvent removed under 
reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used 
to purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C12H10N4OCl+ [M+H+] 262.69, found 263. 1H NMR (400 
MHz, CDCl3) δ 9.06 (s, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.83 (d, J = 8.9 Hz, 2H), 6.97 (d, J 
= 8.9 Hz, 2H), 3.87 (s, 3H). 
 
6-Chloro-3-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine (3.174) 
 
To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and 4-
fluorobenzoic anhydride (180 mg, 1.38 mmol, 2 equiv). The resulting suspension was 
heated to reflux and stirred for 12 h. After confirmation of consumption of starting material 
by TLC, the reaction was cooled to rt and the toluene was removed under reduced pressure. 
DCM (50 mL) was added and reaction was washed with a saturated NaHCO3 solution (3 x 
25 mL). The organic layer was then dried over Na2SO4, filtered and solvent removed under 
reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used 
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to purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C11H7N4FCl+ [M+H+] 250.65, found 251. 1H NMR (400 
MHz, CDCl3) δ 8.49 (dddd, J1 = 3.0, J2 = 5.1, J3 = 8.4, J4 = 10.1 Hz, 2H), 8.16 (d, J = 9.6 
Hz, 1H), 7.27 (dddd, J1 = 3.0, J2 = 5.1, J3 = 10.1 Hz, 2H), 7.16 (d, J = 9.6 Hz, 1H). 
 
6-Chloro-3-(4-chlorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine (3.175) 
 
To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and 4-
chlorobenzoic anhydride (203 mg, 1.38 mmol, 2 equiv). The resulting suspension was 
heated to reflux and stirred for 12 h. After confirmation of consumption of starting material 
by TLC, the reaction was cooled to rt and the toluene was removed under reduced pressure. 
DCM (50 mL) was added and reaction was washed with a saturated NaHCO3 solution (3 x 
25 mL). The organic layer was then dried over Na2SO4, filtered and solvent removed under 
reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used 
to purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C11H7N4Cl2+ [M+H+] 267.11, found 267. 1H NMR (400 
MHz, CDCl3) δ 8.43 (d, J = 8.7 Hz, 2H), 8.16 (d, J = 9.6 Hz, 1H) 7.54 (d, J = 8.6 Hz, 2H), 
7.17 (d, J = 9.6 Hz, 1H). 
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6-Chloro-3-(pyridin-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine (3.176) 
 
To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and nicotinic 
anhydride (157 mg, 1.38 mmol, 2 equiv). The resulting suspension was heated to reflux 
and stirred for 12 h. After confirmation of consumption of starting material by TLC, the 
reaction was cooled to rt and the toluene was removed under reduced pressure. DCM (50 
mL) was added and reaction was washed with a saturated NaHCO3 solution (3 x 25 mL). 
The organic layer was then dried over Na2SO4, filtered and solvent removed under reduced 
pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used to purify 
sufficient amounts of target molecule for biological testing and characterization. LRMS 
(CI-quad) m/z cal’d for C10H7N5Cl+ [M+H+] 233.65, found 234. 1H NMR (400 MHz, 
CDCl3) δ 9.72 (d, J1 = 2.0 Hz, 1H), 8.80 - 8.72 (m, 2H), 8.19 (d, J1 = 9.6 Hz, 1H), 7.52 
(dd, J1 = 4.9, J2 = 8.0 Hz, 1H), 7.21 (d, J1 = 9.6 Hz, 1H). 
 
6-Chloro-3-(3,4-dichlorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine (3.177) 
 
To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and 3,4-
dichlorobenzoic anhydride (251 mg, 1.38 mmol, 2 equiv). The resulting suspension was 
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heated to reflux and stirred for 12 h. After confirmation of consumption of starting material 
by TLC, the reaction was cooled to rt and the toluene was removed under reduced pressure. 
DCM (50 mL) was added and reaction was washed with a saturated NaHCO3 solution (3 x 
25 mL). The organic layer was then dried over Na2SO4, filtered and solvent removed under 
reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used 
to purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C11H6N4Cl3+ [M+H+] 301.55, found 302. 1H NMR (400 
MHz, CDCl3) δ 8.64 (d, J1 = 2.0 Hz, 1H), 8.38 (dd, J1 = 2.0, J2 = 8.5 Hz, 1H), 8.18 (d, J = 
9.6 Hz, 1H), 7.65 (d, J = 8.5 Hz, 1H), 7.20 (d, J = 9.6 Hz, 1H). 
 
3-(4-(tert-Butyl)phenyl)-6-chloro-[1,2,4]triazolo[4,3-b]pyridazine (3.178) 
 
To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and 4-(tert-
butyl)benzoic anhydride (233 mg, 1.38 mmol, 2 equiv). The resulting suspension was 
heated to reflux and stirred for 12 h. After confirmation of consumption of starting material 
by TLC, the reaction was cooled to rt and the toluene was removed under reduced pressure. 
DCM (50 mL) was added and reaction was washed with a saturated NaHCO3 solution (3 x 
25 mL). The organic layer was then dried over Na2SO4, filtered and solvent removed under 
reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used 
to purify sufficient amounts of target molecule for biological testing and characterization. 
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LRMS (CI-quad) m/z cal’d for C15H16N4Cl+ [M+H+] 289.77, found 290. 1H NMR (400 
MHz, CDCl3) δ 8.39 (dd, J1 = 2.0, J2 = 2.4 Hz, 1H), 8.37 (dd, J1 = 1.5, J2 = 1.9 Hz, 1H), 
8.14 (d, J = 9.6 Hz, 1H), 7.61 (dd, J1 = 2.1, J2 = 2.6 Hz, 1H), 7.59 (dd, J1 = 1.7, J2 = 2.1 
Hz, 1H), 7.13 (d, J = 9.6 Hz, 1H), 1.39 (s, 9H).  
 
6-Chloro-3-methyl-[1,2,4]triazolo[4,3-b]pyridazine (3.179) 
 
To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and acetic 
anhydride (70 mg, 1.38 mmol, 2 equiv). The resulting suspension was heated to reflux and 
stirred for 12 h. After confirmation of consumption of starting material by TLC, the 
reaction was cooled to rt and the toluene was removed under reduced pressure. DCM (50 
mL) was added and reaction was washed with a saturated NaHCO3 solution (3 x 25 mL). 
The organic layer was then dried over Na2SO4, filtered and solvent removed under reduced 
pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used to purify 
sufficient amounts of target molecule for biological testing and characterization. LRMS 
(CI-quad) m/z cal’d for C6H6N4Cl+ [M+H+] 170.59, found 170. 1H NMR (400 MHz, 
CDCl3) δ 8.03 (d, J = 9.6 Hz, 1H), 7.08 (d, J = 9.6 Hz, 1H), 2.80 (s, 3H). 
 
6-Chloro-3-propyl-[1,2,4]triazolo[4,3-b]pyridazine (3.180) 
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To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and butyric 
anhydride (107 mg, 1.38 mmol, 2 equiv). The resulting suspension was heated to reflux 
and stirred for 12 h. After confirmation of consumption of starting material by TLC, the 
reaction was cooled to rt and the toluene was removed under reduced pressure. DCM (50 
mL) was added and reaction was washed with a saturated NaHCO3 solution (3 x 25 mL). 
The organic layer was then dried over Na2SO4, filtered and solvent removed under reduced 
pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used to purify 
sufficient amounts of target molecule for biological testing and characterization. LRMS 
(CI-quad) m/z cal’d for C8H10N4Cl+ [M+H+] 198.64, found 198. 1H NMR (400 MHz, 
CDCl3) δ 8.04 (d, J = 9.6 Hz, 1H), 7.07 (d, J = 9.6 Hz, 1H), 3.15 (t, J = 7.4 Hz, 2H), 1.95 
(sext, J = 7.5 Hz, 2H), 1.05 (t, J = 7.4 Hz, 3H).   
 
3-(tert-Butyl)-6-chloro-[1,2,4]triazolo[4,3-b]pyridazine (3.181) 
 
To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and pivalic 
anhydride (128 mg, 1.38 mmol, 2 equiv). The resulting suspension was heated to reflux 
and stirred for 12 h. After confirmation of consumption of starting material by TLC, the 
reaction was cooled to rt and the toluene was removed under reduced pressure. DCM (50 
mL) was added and reaction was washed with a saturated NaHCO3 solution (3 x 25 mL). 
The organic layer was then dried over Na2SO4, filtered and solvent removed under reduced 
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pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used to purify 
sufficient amounts of target molecule for biological testing and characterization. LRMS 
(CI-quad) m/z cal’d for C9H13N4Cl+ [M+H+] 213.68, found 214. 1H NMR (400 MHz, 
CDCl3) δ 8.05 (d, J = 9.6 Hz, 1H), 7.06 (d, J = 9.7, 1H), 1.61 (s, 9H). 
 
6-Chloro-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazine (3.182) 
 
To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and 2,2,2-
trifluoroacetic anhydride (144 mg, 1.38 mmol, 2 equiv). The resulting suspension was 
heated to reflux and stirred for 12 h. After confirmation of consumption of starting material 
by TLC, the reaction was cooled to rt and the toluene was removed under reduced pressure. 
DCM (50 mL) was added and reaction was washed with a saturated NaHCO3 solution (3 x 
25 mL). The organic layer was then dried over Na2SO4, filtered and solvent removed under 
reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used 
to purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C6H3N4F3Cl+ [M+H+], 224.56, found 224. 1H NMR (400 
MHz, CDCl3) δ 8.22 (d, J = 10.0 Hz, 1H), 7.34 (d, J = 9.7, 1H). 
 
6-Chloro-3-(trichloromethyl)-[1,2,4]triazolo[4,3-b]pyridazine (3.183) 
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To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and 2,2,2-
trichloroacetic anhydride (213 mg, 1.38 mmol, 2 equiv). The resulting suspension was 
heated to reflux and stirred for 12 h. After confirmation of consumption of starting material 
by TLC, the reaction was cooled to rt and the toluene was removed under reduced pressure. 
DCM (50 mL) was added and reaction was washed with a saturated NaHCO3 solution (3 x 
25 mL). The organic layer was then dried over Na2SO4, filtered and solvent removed under 
reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used 
to purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C6H3N4Cl4+ [M+H+] 273.93, found 274. 1H NMR (400 
MHz, CDCl3) δ 8.21 (d, J = 9.7 Hz, 1H), 7.33 (d, J = 9.5 Hz, 1H). 
 
6-Bromo-3-phenyl-[1,2,4]triazolo[4,3-a]pyridine (3.184) 
 
To a stirring suspension of 5-bromo-2-hydrazinylpyridine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added benzoic anhydride (54 mg, 0.69 mmol, 1 equiv). The 
resulting suspension was heated to reflux and stirred for 24 h. After confirmation of 
consumption of starting material by TLC, the reaction was cooled to rt and the toluene was 
removed under reduced pressure. DCM (50 mL) was added and reaction was washed with 
a saturated NaHCO3 solution (3 x 25 mL). The organic layer was then dried over Na2SO4, 
filtered and solvent removed under reduced pressure. Column chromatography (0 to 10% 
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MeOH/DCM) on silica gel was used to purify sufficient amounts of target molecule for 
biological testing and characterization. LRMS (CI-quad) m/z cal’d for C12H9N3Br+ [M+H+] 
276.12, found 276. 1H NMR (400 MHz, CDCl3) δ 8.15 (d, J = 2.2 Hz, 1H), 7.89 (d, J = 
7.5 Hz, 2H), 7.62 (dd, J1 = 2.3, J2 = 8.9 Hz, 1H), 7.56 (t, J = 7.2 Hz, 1H), 7.47 (d, J = 7.8 
Hz, 2H), 6.74 (d, J = 8.9 Hz, 1H). 
 
6-Bromo-3-(m-tolyl)-[1,2,4]triazolo[4,3-a]pyridine (3.185) 
 
To a stirring suspension of 5-bromo-2-hydrazinylpyridine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added 3-methylbenzoic anhydride (134 mg, 0.69 mmol, 1 equiv). 
The resulting suspension was heated to reflux and stirred for 24 h. After confirmation of 
consumption of starting material by TLC, the reaction was cooled to rt and the toluene was 
removed under reduced pressure. DCM (50 mL) was added and reaction was washed with 
a saturated NaHCO3 solution (3 x 25 mL). The organic layer was then dried over Na2SO4, 
filtered and solvent removed under reduced pressure. Column chromatography (0 to 10% 
MeOH/DCM) on silica gel was used to purify sufficient amounts of target molecule for 
biological testing and characterization. LRMS (CI-quad) m/z cal’d for C13H11N3Br+ 
[M+H+] 290.15, found 290. 1H NMR (400 MHz, CDCl3) δ 8.18 (d, J = 2.1 Hz, 1H), 7.68 
(s, 1H), 7.65 (d, J = 6.7 Hz, 1H), 7.59 (dd, J1 = 2.3, J2 = 8.8 Hz, 1H), 7.38 - 7.33 (m, 2H), 
6.70 (d, J = 8.8 Hz, 1H), 2.40 (s, 3H).  
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6-Bromo-3-(3-(trifluoromethyl)phenyl)-[1,2,4]triazolo[4,3-a]pyridine (3.186) 
 
To a stirring suspension of 5-bromo-2-hydrazinylpyridine (100 mg, 0.53 mmol, 1 equiv) 
in toluene (20 mL) was added 3-(trifluoromethyl)benzoic anhydride (191 mg, 0.53 mmol, 
1 equiv). The resulting suspension was heated to reflux and stirred for 24 h. After 
confirmation of consumption of starting material by TLC, the reaction was cooled to rt and 
the toluene was removed under reduced pressure. DCM (50 mL) was added and reaction 
was washed with a saturated NaHCO3 solution (3 x 25 mL). The organic layer was then 
dried over Na2SO4, filtered and solvent removed under reduced pressure. Column 
chromatography (0 to 10% MeOH/DCM) on silica gel was used to purify sufficient 
amounts of target molecule for biological testing and characterization. LRMS (CI-quad) 
m/z cal’d for C13H8N3F3Br+ [M+H+] 344.12, found 344. 1H NMR (400 MHz, CDCl3) δ 
8.21 (d, J = 2.1 Hz, 1H), 8.14 (s, 1H), 8.05 (d, J = 7.8 Hz, 1H), 7.81 (d, J = 7.8 Hz, 1H), 
7.60 (t, J = 6.7 Hz, 1H), 6.69 (d, J = 8.8 Hz, 1H). 
 
6-Bromo-3-(p-tolyl)-[1,2,4]triazolo[4,3-a]pyridine (3.187) 
 
To a stirring suspension of 5-bromo-2-hydrazinylpyridine (100 mg, 0.53 mmol, 1 equiv) 
in toluene (20 mL) was added 4-methylbenzoic anhydride (134 mg, 0.53 mmol, equiv). 
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The resulting suspension was heated to reflux and stirred for 24 h. After confirmation of 
consumption of starting material by TLC, the reaction was cooled to rt and the toluene was 
removed under reduced pressure. DCM (50 mL) was added and reaction was washed with 
a saturated NaHCO3 solution (3 x 25 mL). The organic layer was then dried over Na2SO4, 
filtered and solvent removed under reduced pressure. Column chromatography (0 to 10% 
MeOH/DCM) on silica gel was used to purify sufficient amounts of target molecule for 
biological testing and characterization. LRMS (CI-quad) m/z cal’d for C13H11N3Br+ 
[M+H+] 290.15, found 290. 1H NMR (400 MHz, CDCl3) δ 8.16 (d, J = 2.3 Hz, 1H), 7.76 
(d, J = 8.1 Hz, 2H), 7.58 (dd, J1 = 2.4, J2 = 8.8 Hz, 1H), 7.25 (d, J = 7.9 Hz, 2H), 6.70 (d, 
J = 9.6 Hz, 1H), 2.41 (s, 3H). 
 
6-Bromo-3-(4-(trifluoromethyl)phenyl)-[1,2,4]triazolo[4,3-a]pyridine (3.188) 
 
To a stirring suspension of 5-bromo-2-hydrazinylpyridine (100 mg, 0.53 mmol, 1 equiv) 
in toluene (20 mL) was added 4-(trifluoromethyl)benzoic anhydride (191 mg, 0.53 mmol, 
equiv). The resulting suspension was heated to reflux and stirred for 24 h. After 
confirmation of consumption of starting material by TLC, the reaction was cooled to rt and 
the toluene was removed under reduced pressure. DCM (50 mL) was added and reaction 
was washed with a saturated NaHCO3 solution (3 x 25 mL). The organic layer was then 
dried over Na2SO4, filtered and solvent removed under reduced pressure. Column 
chromatography (0 to 10% MeOH/DCM) on silica gel was used to purify sufficient 
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amounts of target molecule for biological testing and characterization. LRMS (CI-quad) 
m/z cal’d for C13H8N3F3Br+ [M+H+] 344.12, found 344. 1H NMR (400 MHz, CDCl3) δ 
8.23 (d, J = 2.0 Hz, 1H), 7.99 (d, J = 8.0 Hz, 2H), 7.75 (d, J = 8.0 Hz, 2H), 7.65 (dd, J1 = 
2.3, J2 = 8.8 Hz, 1H), 6.71 (d, J = 8.8 Hz, 1H). 
 
6-Bromo-3-(4-methoxyphenyl)-[1,2,4]triazolo[4,3-a]pyridine (3.189) 
 
To a stirring suspension of 5-bromo-2-hydrazinylpyridine (100 mg, 0.53 mmol, 1 equiv) 
in toluene (20 mL) was added 4-methoxybenzoic anhydride (151 mg, 0.53 mmol, equiv). 
The resulting suspension was heated to reflux and stirred for 24 h. After confirmation of 
consumption of starting material by TLC, the reaction was cooled to rt and the toluene was 
removed under reduced pressure. DCM (50 mL) was added and reaction was washed with 
a saturated NaHCO3 solution (3 x 25 mL). The organic layer was then dried over Na2SO4, 
filtered and solvent removed under reduced pressure. Column chromatography (0 to 10% 
MeOH/DCM) on silica gel was used to purify sufficient amounts of target molecule for 
biological testing and characterization. LRMS (CI-quad) m/z cal’d for C13H11ON3Br+ 
[M+H+] 306.15, found 306. 1H NMR (400 MHz, CDCl3) δ 8.15 (d, J = 2.2 Hz, 1H), 7.83 
(dt, J1 = 2.8, J2 = 4.8 Hz, 2H), 7.55 (dd, J1 = 2.4, J2, = 8.8 Hz, 1H), 6.92 (dt, J1 = 2.8, J2 = 
4.7 Hz, 2H), 6.67 (d, J = 8.8, 1H), 3.85 (s, 3H). 
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6-Bromo-3-(4-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyridine (3.190) 
 
To a stirring suspension of 5-bromo-2-hydrazinylpyridine (100 mg, 0.53 mmol, 1 equiv) 
in toluene (20 mL) was added 4-fluorobenzoic anhydride (138 mg, 0.53 mmol, equiv). The 
resulting suspension was heated to reflux and stirred for 24 h. After confirmation of 
consumption of starting material by TLC, the reaction was cooled to rt and the toluene was 
removed under reduced pressure. DCM (50 mL) was added and reaction was washed with 
a saturated NaHCO3 solution (3 x 25 mL). The organic layer was then dried over Na2SO4, 
filtered and solvent removed under reduced pressure. Column chromatography (0 to 10% 
MeOH/DCM) on silica gel was used to purify sufficient amounts of target molecule for 
biological testing and characterization. LRMS (CI-quad) m/z cal’d for C12H8N3FBr+ 
[M+H+] 294.11, found 294. 1H NMR (400 MHz, CDCl3) δ 8.24 (d, J = 2.3 Hz, 1H), 7.89 
(dd, J1 = 5.3, J2 = 8.4 Hz, 2H), 7.64 (dd, J1 = 2.3, J2 = 8.8 Hz, 1H), 7.17 (t, J = 8.5 Hz, 2H), 
6.69 (d, J = 8.7 Hz, 1H).   
 
6-Bromo-3-(4-chlorophenyl)-[1,2,4]triazolo[4,3-a]pyridine (3.191) 
 
To a stirring suspension of 5-bromo-2-hydrazinylpyridine (100 mg, 0.53 mmol, 1 equiv) 
in toluene (20 mL) was added 4-chlorobenzoic anhydride (156 mg, 0.53 mmol, equiv). The 
 284 
resulting suspension was heated to reflux and stirred for 24 h. After confirmation of 
consumption of starting material by TLC, the reaction was cooled to rt and the toluene was 
removed under reduced pressure. DCM (50 mL) was added and reaction was washed with 
a saturated NaHCO3 solution (3 x 25 mL). The organic layer was then dried over Na2SO4, 
filtered and solvent removed under reduced pressure. Column chromatography (0 to 10% 
MeOH/DCM) on silica gel was used to purify sufficient amounts of target molecule for 
biological testing and characterization. LRMS (CI-quad) m/z cal’d for C12H8N3ClBr+ 
[M+H+] 310.57, found 310. 1H NMR (400 MHz, CDCl3) δ 8.08 (d, J = 2.3 Hz, 1H), 7.75 
(d, J = 8.4 Hz, 2H), 7.54, (dd, J1 = 2.4, J2 = 8.8 Hz, 1H), 7.36 (d, J = 8.5, 2H), 6.63 (d, J = 
8.8 Hz, 1H).  
 
6-Bromo-3-(3,4-dichlorophenyl)-[1,2,4]triazolo[4,3-a]pyridine (3.192) 
 
To a stirring suspension of 5-bromo-2-hydrazinylpyridine (100 mg, 0.53 mmol, 1 equiv) 
in toluene (20 mL) was added 3,4-dichlorobenzoic anhydride (192 mg, 0.53 mmol, equiv). 
The resulting suspension was heated to reflux and stirred for 24 h. After confirmation of 
consumption of starting material by TLC, the reaction was cooled to rt and the toluene was 
removed under reduced pressure. DCM (50 mL) was added and reaction was washed with 
a saturated NaHCO3 solution (3 x 25 mL). The organic layer was then dried over Na2SO4, 
filtered and solvent removed under reduced pressure. Column chromatography (0 to 10% 
MeOH/DCM) on silica gel was used to purify sufficient amounts of target molecule for 
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biological testing and characterization. LRMS (CI-quad) m/z cal’d for C12H7N3Cl2Br+ 
[M+H+] 345.01, found 345. 1H NMR (400 MHz, CDCl3) δ 8.23 (d, J = 2.3 Hz, 1H), 7.97 
(d, 2.04 Hz, 1H), 7.69 (dd, J1 = 1.8, J2 = 8.3 Hz, 1H), 7.64 (dd, J1 = 2.3, J2 = 4.8 Hz, 1H), 
7.57 (d, J = 8.3 Hz, 1H), 6.68 (d, J = 8.8 Hz, 1H). 
 
6-Bromo-3-(pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine (3.193) 
 
To a stirring suspension of 5-bromo-2-hydrazinylpyridine (100 mg, 0.53 mmol, 1 equiv) 
in toluene (20 mL) was added nicotinic anhydride (120 mg, 0.53 mmol, equiv). The 
resulting suspension was heated to reflux and stirred for 24 h. After confirmation of 
consumption of starting material by TLC, the reaction was cooled to rt and the toluene was 
removed under reduced pressure. DCM (50 mL) was added and reaction was washed with 
a saturated NaHCO3 solution (3 x 25 mL). The organic layer was then dried over Na2SO4, 
filtered and solvent removed under reduced pressure. Column chromatography (0 to 10% 
MeOH/DCM) on silica gel was used to purify sufficient amounts of target molecule for 
biological testing and characterization. LRMS (CI-quad) m/z cal’d for C11H8N4Br+ [M+H+] 
277.11, found 277. 1H NMR (400 MHz, CDCl3) δ 9.08 (s, 1H), 8.70 (d, J = 4.7 Hz, 1H), 
8.15 (d, J = 7.9 Hz, 1H), 8.11 (d, J = 2.1 Hz, 1H), 7.50 (dd, J1 = 2.3, J2 = 8.9 Hz, 1H), 7.33 
(dd, J1 = 4.9, J2 = 8.1 Hz, 1H), 6.63 (d, J = 8.8 Hz, 1H). 
 
 286 
6-Bromo-3-propyl-[1,2,4]triazolo[4,3-a]pyridine (3.194) 
 
To a stirring suspension of 5-bromo-2-hydrazinylpyridine (100 mg, 0.53 mmol, 1 equiv) 
in toluene (20 mL) was added butyric anhydride (83 mg, 0.53 mmol, equiv). The resulting 
suspension was heated to reflux and stirred for 24 h. After confirmation of consumption of 
starting material by TLC, the reaction was cooled to rt and the toluene was removed under 
reduced pressure. DCM (50 mL) was added and reaction was washed with a saturated 
NaHCO3 solution (3 x 25 mL). The organic layer was then dried over Na2SO4, filtered and 
solvent removed under reduced pressure. Column chromatography (0 to 10% 
MeOH/DCM) on silica gel was used to purify sufficient amounts of target molecule for 
biological testing and characterization. LRMS (CI-quad) m/z cal’d for C9H11N3Br+ [M+H+] 
242.11, found 242. 1H NMR (400 MHz, CDCl3) δ 8.17 (d, J = 2.3 Hz, 1H), 7.60 (dd, J1 = 
2.4, J2 = 8.9 Hz, 1H), 6.61 (d, J = 8.8 Hz, 1H, 2.27 (t, J = 7.4 Hz, 2H), 1.73 (sext, J = 7.5 
Hz, 2H), 0.99 (t, J = 7.4 Hz, 3H).  
 
6-Bromo-3-(tert-butyl)-[1,2,4]triazolo[4,3-a]pyridine (3.195) 
 
To a stirring suspension of 5-bromo-2-hydrazinylpyridine (100 mg, 0.53 mmol, 1 equiv) 
in toluene (20 mL) was added pivalic anhydride (98 mg, 0.53 mmol, equiv). The resulting 
suspension was heated to reflux and stirred for 24 h. After confirmation of consumption of 
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starting material by TLC, the reaction was cooled to rt and the toluene was removed under 
reduced pressure. DCM (50 mL) was added and reaction was washed with a saturated 
NaHCO3 solution (3 x 25 mL). The organic layer was then dried over Na2SO4, filtered and 
solvent removed under reduced pressure. Column chromatography (0 to 10% 
MeOH/DCM) on silica gel was used to purify sufficient amounts of target molecule for 
biological testing and characterization. LRMS (CI-quad) m/z cal’d for C10H13N3Br+ 
[M+H+] 256.13, found 257. 1H NMR (400 MHz, CDCl3) δ 8.17 (d, J = 2.1 Hz, 1H), 8.06 
(s, 1H), 7.56 (dd, J1 = 2.2 Hz, J2 = 8.8, 1H), 6.54 (d, J = 8.8 Hz, 1H), 1.26 (s, 9H). 
 
6-Bromo-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine (3.196) 
 
To a stirring suspension of 5-bromo-2-hydrazinylpyridine (100 mg, 0.53 mmol, 1 equiv) 
in toluene (20 mL) was added 2,2,2-trifluoroacetic anhydride (111 mg, 0.53 mmol, equiv). 
The resulting suspension was heated to reflux and stirred for 24 h. After confirmation of 
consumption of starting material by TLC, the reaction was cooled to rt and the toluene was 
removed under reduced pressure. DCM (50 mL) was added and reaction was washed with 
a saturated NaHCO3 solution (3 x 25 mL). The organic layer was then dried over Na2SO4, 
filtered and solvent removed under reduced pressure. Column chromatography (0 to 10% 
MeOH/DCM) on silica gel was used to purify sufficient amounts of target molecule for 
biological testing and characterization. LRMS (CI-quad) m/z cal’d for C7H4N3F3Br+ 
[M+H+] 268.03, found 268. 1H NMR (400 MHz, CDCl3) δ 8.25 (d, J = 2.4 Hz, 1H), 7.69 
(dd, J1 = 2.4, J2 = 8.8 Hz, 1H), 6.65 (d, J = 8.8 Hz, 1H). 
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6-Bromo-3-phenylimidazo[1,5-a]pyridine (3.197) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (100 mg, 0.69 mmol, 1 
equiv) in dichloroethane (20 mL) was added benzoic anhydride (131 mg, 0.76 mmol, 1.1 
equiv). The resulting suspension was stirred at rt for 30 min before dropwise addition of 
POCl3 (88 mg, 0.76 mmol, 1.1 equiv) as a solution in ca 3 mL DCM. The reaction was 
then heated to reflux for 3 hr. After confirmation of consumption of starting material by 
TLC, the reaction was cooled to rt and the reaction was stirred with 5 mL of 0.1 N HCl 
(caution:exothermic reaction) for 15 mins to hydrolyze excess POCl3. Post stirring, the 
reaction was washed with a saturated NaHCO3 solution (3 x 25 mL, caution:gas evolution). 
The organic layer was then dried over Na2SO4, filtered and solvent removed under reduced 
pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used to purify 
sufficient amounts of target molecule for biological testing and characterization. LRMS 
(CI-quad) m/z cal’d for C13H10N2Br+ [M+H+] 276.14, found 276. 1H NMR (400 MHz, 
CDCl3) δ 8.40 (s, 1H), 7.78 (d, J = 7.6 Hz, 2H), 7.60 (s, 1H), 7.56 (t, J = 7.5 Hz, 2H), 7.48 
(t, J = 7.4 Hz, 1H), 7.41 (d, J = 9.6 Hz, 1H), 6.80 (d, J = 9.6 Hz, 1H). 
 
6-Bromo-3-(m-tolyl)imidazo[1,5-a]pyridine (3.198) 
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To a stirring suspension of (5-bromopyridin-2-yl)methanamine (100 mg, 0.69 mmol, 1 
equiv) in dichloroethane (20 mL) was added 3-methylbenzoic anhydride (141 mg, 1.58 
mmol, 2.3 equiv). The resulting suspension was stirred at rt for 30 min before dropwise 
addition of POCl3 (88 mg, 1.12 mmol, 1.7 equiv) as a solution in ca 3 mL DCM. The 
reaction was then heated to reflux for 3 hr. After confirmation of consumption of starting 
material by TLC, the reaction was cooled to rt and the reaction was stirred with 5 mL of 
0.1 N HCl (caution:exothermic reaction) for 15 mins to hydrolyze excess POCl3. Post 
stirring, the reaction was washed with a saturated NaHCO3 solution (3 x 25 mL, caution:gas 
evolution). The organic layer was then dried over Na2SO4, filtered and solvent removed 
under reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel 
was used to purify sufficient amounts of target molecule for biological testing and 
characterization. LRMS (CI-quad) m/z cal’d for C11H8N2Br+ [M+H+] 249.10, found 249. 
1H NMR (400 MHz, CDCl3) δ 8.38 (s, 1H), 7.60 (s, 1H), 7.57 (s, 1H), 7.55 (d, J = 7.7 Hz, 
1H), 7.43 (t, J = 7.6 Hz, 1H), 7.38 (d, J = 9.5 Hz, 1H), 7.28 (d, J = 7.6, 1H), 6.77 (dd, J1 = 
1.5, J2 = 10.9 Hz, 1H), 2.45 (s, 3H). 
 
6-Bromo-3-(3-(trifluoromethyl)phenyl)imidazo[1,5-a]pyridine (3.199) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (100 mg, 0.69 mmol, 1 
equiv) in dichloroethane (20 mL) was added 3-(trifluoromethyl)benzoic anhydride (210 
mg, 0.76 mmol, 1.1 equiv). The resulting suspension was stirred at rt for 30 min before 
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dropwise addition of POCl3 (105 mg, 0.89 mmol, 1.3 equiv) as a solution in ca 3 mL DCM. 
The reaction was then heated to reflux for 3 hr. After confirmation of consumption of 
starting material by TLC, the reaction was cooled to rt and the reaction was stirred with 5 
mL of 0.1 N HCl (caution:exothermic reaction) for 15 mins to hydrolyze excess POCl3. 
Post stirring, the reaction was washed with a saturated NaHCO3 solution (3 x 25 mL, 
caution:gas evolution). The organic layer was then dried over Na2SO4, filtered and solvent 
removed under reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on 
silica gel was used to purify sufficient amounts of target molecule for biological testing 
and characterization. LRMS (CI-quad) m/z cal’d for C14H9N2F3Br+ [M+H+] 343.13, found 
343. 1H NMR (400 MHz, CDCl3) δ 8.35 (s, 1H), 8.08 (s, 1H), 7.96 (d, J = 7.5 Hz, 1H), 
7.73 - 7.67 (m, 2H), 7.63 (s, 1H), 7.43 (d, J = 9.6 Hz, 1H), 6.85 (d, J = 9.6 Hz, 1H).  
 
6-Bromo-3-(p-tolyl)imidazo[1,5-a]pyridine (3.200) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (100 mg, 0.69 mmol, 1 
equiv) in dichloroethane (20 mL) was added nicotinic anhydride (147 mg, 0.76 mmol, 1.1 
equiv). The resulting suspension was stirred at rt for 30 min before dropwise addition of 
POCl3 (105 mg, 0.89 mmol, 1.3 equiv) as a solution in ca 3 mL DCM. The reaction was 
then heated to reflux for 3 hr. After confirmation of consumption of starting material by 
TLC, the reaction was cooled to rt and the reaction was stirred with 5 mL of 0.1 N HCl 
(caution:exothermic reaction) for 15 mins to hydrolyze excess POCl3. Post stirring, the 
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reaction was washed with a saturated NaHCO3 solution (3 x 25 mL, caution:gas evolution). 
The organic layer was then dried over Na2SO4, filtered and solvent removed under reduced 
pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used to purify 
sufficient amounts of target molecule for biological testing and characterization. LRMS 
(CI-quad) m/z cal’d for C14H12N2Br+ [M+H+] 289.16, found 289. 1H NMR (400 MHz, 
CDCl3) δ 8.36 (s, 1H), 7.65 (d, J = 7.9 Hz, 2H), 7.56 (s, 1H), 7.39 - 7.32 (m, 3H), 6.76 (d, 
J = 9.5 Hz, 1H), 2.44 (s, 3H). 
 
6-Bromo-3-(4-(trifluoromethyl)phenyl)imidazo[1,5-a]pyridine (3.201) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (100 mg, 0.69 mmol, 1 
equiv) in dichloroethane (20 mL) was added 4-(trifluoromethyl)benzoic anhydride (210 
mg, 0.76 mmol, 1.1 equiv). The resulting suspension was stirred at rt for 30 min before 
dropwise addition of POCl3 (105 mg, 0.89 mmol, 1.3 equiv) as a solution in ca 3 mL DCM. 
The reaction was then heated to reflux for 3 hr. After confirmation of consumption of 
starting material by TLC, the reaction was cooled to rt and the reaction was stirred with 5 
mL of 0.1 N HCl (caution:exothermic reaction) for 15 mins to hydrolyze excess POCl3. 
Post stirring, the reaction was washed with a saturated NaHCO3 solution (3 x 25 mL, 
caution:gas evolution). The organic layer was then dried over Na2SO4, filtered and solvent 
removed under reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on 
silica gel was used to purify sufficient amounts of target molecule for biological testing 
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and characterization. LRMS (CI-quad) m/z cal’d for C14H9N2F3Br+ [M+H+] 343.13, found 
343. 1H NMR (400 MHz, CDCl3) δ 8.40 (s, 1H), 7.93 (d, J = 8.1 Hz, 2H), 7.81 (d, J = 8.2 
Hz, 2H), 7.64 (s, 1H), 7.44 (d, J = 9.5 Hz, 1H), 6.85 (d, J = 9.5 Hz, 1H). 
 
6-Bromo-3-(4-fluorophenyl)imidazo[1,5-a]pyridine (3.202) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (100 mg, 0.69 mmol, 1 
equiv) in dichloroethane (20 mL) was added 4-fluorobenzoic anhydride (322 mg, 1.58 
mmol, 2.3 equiv). The resulting suspension was stirred at rt for 30 min before dropwise 
addition of POCl3 (140 mg, 1.12 mmol, 1.7 equiv) as a solution in ca 3 mL DCM. The 
reaction was then heated to reflux for 3 hr. After confirmation of consumption of starting 
material by TLC, the reaction was cooled to rt and the reaction was stirred with 5 mL of 
0.1 N HCl (caution:exothermic reaction) for 15 mins to hydrolyze excess POCl3. Post 
stirring, the reaction was washed with a saturated NaHCO3 solution (3 x 25 mL, caution:gas 
evolution). The organic layer was then dried over Na2SO4, filtered and solvent removed 
under reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel 
was used to purify sufficient amounts of target molecule for biological testing and 
characterization. LRMS (CI-quad) m/z cal’d for C13H9N2FBr+ [M+H+] 293.13, found 293. 
1H NMR (400 MHz, CDCl3) δ 8.24 (s, 1H), 7.69 (dd, J1 = 5.4, J2 = 8.2 Hz, 2H), 7.51 (s, 
1H), 7.33 (d, J = 9.5 Hz, 1H), 7.17 (d, J = 8.6 Hz, 1H), 6.73 (d, J = 9.6 Hz, 1H). 
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6-Bromo-3-(4-chlorophenyl)imidazo[1,5-a]pyridine (3.203) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (100 mg, 0.69 mmol, 1 
equiv) in dichloroethane (20 mL) was added 4-chlorobenzoic anhydride (361 mg, 1.58 
mmol, 2.3 equiv). The resulting suspension was stirred at rt for 30 min before dropwise 
addition of POCl3 (141 mg, 1.12 mmol, 1.7 equiv) as a solution in ca 3 mL DCM. The 
reaction was then heated to reflux for 3 hr. After confirmation of consumption of starting 
material by TLC, the reaction was cooled to rt and the reaction was stirred with 5 mL of 
0.1 N HCl (caution:exothermic reaction) for 15 mins to hydrolyze excess POCl3. Post 
stirring, the reaction was washed with a saturated NaHCO3 solution (3 x 25 mL, caution:gas 
evolution). The organic layer was then dried over Na2SO4, filtered and solvent removed 
under reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel 
was used to purify sufficient amounts of target molecule for biological testing and 
characterization. LRMS (CI-quad) m/z cal’d for C13H8N2ClBr+ [M+H+] 293.13, found 293. 
1H NMR (400 MHz, CDCl3) δ 8.27 (s, 1H), 7.66 (d, J = 8.3 Hz, 1H), 7.54 (s, 1H), 7.46 
(d, J = 8.2 Hz, 1H), 7.35 (d, J = 9.7 Hz, 1H), 6.75 (d, J = 9.6 Hz, 1H). 
 
6-Bromo-3-(pyridin-3-yl)imidazo[1,5-a]pyridine (3.204) 
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To a stirring suspension of (5-bromopyridin-2-yl)methanamine (100 mg, 0.69 mmol, 1 
equiv) in dichloroethane (20 mL) was added nicotinic anhydride (132 mg, 0.76 mmol, 1.1 
equiv). The resulting suspension was stirred at rt for 30 min before dropwise addition of 
POCl3 (105 mg, 0.89 mmol, 1.3 equiv) as a solution in ca 3 mL DCM. The reaction was 
then heated to reflux for 3 hr. After confirmation of consumption of starting material by 
TLC, the reaction was cooled to rt and the reaction was stirred with 5 mL of 0.1 N HCl 
(caution:exothermic reaction) for 15 mins to hydrolyze excess POCl3. Post stirring, the 
reaction was washed with a saturated NaHCO3 solution (3 x 25 mL, caution:gas evolution). 
The organic layer was then dried over Na2SO4, filtered and solvent removed under reduced 
pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used to purify 
sufficient amounts of target molecule for biological testing and characterization. LRMS 
(CI-quad) m/z cal’d for C12H9N3Br+ [M+H+] 276.12, found 276. 1H NMR (400 MHz, 
CDCl3) δ 9.07 (d, J = 2.3 Hz, 1H) 8.70 (d, J = 5.0 Hz, 1H), 8.38 (s, 1H), 8.13 (d, J = 8.1 
Hz, 1H), 7.63 (s, 1H), 7.50 (dd, J1 = 4.8, J2 = 7.9 Hz,1H), 7.44 (d, J = 9.6 Hz, 1H), 6.85 (d, 
J = 9.5 Hz, 1H).  
 
6-Bromo-3-methylimidazo[1,5-a]pyridine (3.205) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (100 mg, 0.69 mmol, 1 
equiv) in dichloroethane (20 mL) was added acetic anhydride (59 mg, 0.76 mmol, 1.1 
equiv). The resulting suspension was stirred at rt for 30 min before dropwise addition of 
POCl3 (105 mg, 0.89 mmol, 1.3 equiv) as a solution in ca 3 mL DCM. The reaction was 
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then heated to reflux for 3 hr. After confirmation of consumption of starting material by 
TLC, the reaction was cooled to rt and the reaction was stirred with 5 mL of 0.1 N HCl 
(caution:exothermic reaction) for 15 mins to hydrolyze excess POCl3. Post stirring, the 
reaction was washed with a saturated NaHCO3 solution (3 x 25 mL, caution:gas evolution). 
The organic layer was then dried over Na2SO4, filtered and solvent removed under reduced 
pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used to purify 
sufficient amounts of target molecule for biological testing and characterization. LRMS 
(CI-quad) m/z cal’d for C8H8N2Br+ [M+H+] 213.07, found 213. 1H NMR (400 MHz, 
CDCl3) δ 7.76 (s, 1H), 7.29 (s, 1H), 7.22 (t, J = 11.8 Hz, 1H), 6.63 (d, J = 10.1 Hz, 1H), 
2.57 (s, 3H). 
 
6-Bromo-3-propylimidazo[1,5-a]pyridine (3.206) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (100 mg, 0.69 mmol, 1 
equiv) in dichloroethane (20 mL) was added butyric anhydride (91 mg, 0.76 mmol, 1.1 
equiv). The resulting suspension was stirred at rt for 30 min before dropwise addition of 
POCl3 (105 mg, 0.89 mmol, 1.3 equiv) as a solution in ca 3 mL DCM. The reaction was 
then heated to reflux for 3 hr. After confirmation of consumption of starting material by 
TLC, the reaction was cooled to rt and the reaction was stirred with 5 mL of 0.1 N HCl 
(caution:exothermic reaction) for 15 mins to hydrolyze excess POCl3. Post stirring, the 
reaction was washed with a saturated NaHCO3 solution (3 x 25 mL, caution:gas evolution). 
The organic layer was then dried over Na2SO4, filtered and solvent removed under reduced 
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pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used to purify 
sufficient amounts of target molecule for biological testing and characterization. LRMS 
(CI-quad) m/z cal’d for C10H12N2Br+ [M+H+] 242.12, found 242. 1H NMR (400 MHz, 
CDCl3) δ 7.88 (s, 1H), 7.39 (s, 1H), 7.30 (t, J = 9.6 Hz, 1H), 6.70 (d, J = 9.6 Hz, 1H), 2.93 
(t, J = 7.6 Hz, 2H), 1.90 (sext, J = 7.4 Hz, 2H), 1.05 (t, J = 7.4 Hz, 3H).  
 
N-((5-Bromopyridin-2-yl)methyl)benzamide (3.207) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (20 mg, 0.106 mmol, 1 
equiv) in dichloroethane (20 mL) was added benzoic anhydride (26 mg, 0.76 mmol, 1.1 
equiv). The resulting suspension was stirred at rt for 30 min. After confirmation of 
consumption of starting material by TLC, reaction solvent was removed under reduced 
pressure and column chromatography (0 to 10% MeOH/DCM) on silica gel was used to 
purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C13H12ON2Br+ [M+H+] 294.15, found 294. 1H NMR (400 
MHz, CDCl3) δ 8.62 (d, J = 1.9 Hz, 1H), 7.85 (d, J = 7.0 Hz, 2H), 7.81 (dd, J1 = 2.3, J2 = 
8.3 Hz, 1H), 7.51 (t, J = 7.4 Hz, 1H), 7.45 (t, J = 7.6 Hz, 2H), 7.27 (t, J = 6.6 Hz, 1H), 4.72 
(d, J = 5.0 Hz, 2H). 
 
N-((5-Bromopyridin-2-yl)methyl)-3-methylbenzamide (3.208) 
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To a stirring suspension of (5-bromopyridin-2-yl)methanamine (20 mg, 0.106 mmol, 1 
equiv) in dichloroethane (20 mL) was added 3-methylbenzoic anhydride (30 mg, 0.76 
mmol, 1.1 equiv). The resulting suspension was stirred at rt for 30 min. After confirmation 
of consumption of starting material by TLC, reaction solvent was removed under reduced 
pressure and column chromatography (0 to 10% MeOH/DCM) on silica gel was used to 
purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C14H14ON2Br+ [M+H+] 307.18, found 307. 1H NMR (400 
MHz, CDCl3) δ 8.63 (d, J = 2.0 Hz, 1H), 7.81 (dd, J1 = 2.2, J2 = 8.3 Hz, 1H), 7.67 (s, 1H), 
7.66 - 7.59 (m, 1H), 7.37 - 7.29 (m, 2H), 7.26 (t, J = 4.8 Hz, 1H), 4.71 (d, J = 5.1 Hz, 2H), 
2.40 (s, 3H). 
 
N-((5-Bromopyridin-2-yl)methyl)-4-methylbenzamide (3.209) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (20 mg, 0.106 mmol, 1 
equiv) in dichloroethane (20 mL) was added 4-methylbenzoic anhydride (30 mg, 0.76 
mmol, 1.1 equiv). The resulting suspension was stirred at rt for 30 min. After confirmation 
of consumption of starting material by TLC, reaction solvent was removed under reduced 
pressure and column chromatography (0 to 10% MeOH/DCM) on silica gel was used to 
purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C14H14ON2Br+ [M+H+] 307.18, found 308. 1H NMR (400 
MHz, CDCl3) δ 8.62 (d, J = 2.1 Hz, 1H), 7.80 (dd, J1 = 2.3, J2 = 8.4 Hz, 1H), 7.75 (d, J = 
8.2 Hz, 2H), 7.36 (br, 1H), 7.29 - 7.20 (m, 3H), 4.71 (d, J = 5.1 Hz, 2H), 2.40 (s, 3H). 
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N-((5-Bromopyridin-2-yl)methyl)-4-(trifluoromethyl)benzamide (3.210) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (20 mg, 0.106 mmol, 1 
equiv) in dichloroethane (20 mL) was added 4-(trifluoromethyl)benzoic anhydride (42 mg, 
0.76 mmol, 1.1 equiv). The resulting suspension was stirred at rt for 30 min. After 
confirmation of consumption of starting material by TLC, reaction solvent was removed 
under reduced pressure and column chromatography (0 to 10% MeOH/DCM) on silica gel 
was used to purify sufficient amounts of target molecule for biological testing and 
characterization. LRMS (CI-quad) m/z cal’d for C14H11ON3F3Br+ [M+H+] 375.16, found 
375. 1H NMR (400 MHz, CDCl3) δ 8.65 (d, J = 2.2 Hz, 1H), 7.99 (d, J = 8.1 Hz, 2H), 7.87 
(dd, J1 = 2.3, J2 = 8.4 Hz, 1H), 7.74 (d, J = 8.1 Hz, 2H), 7.57 (br, 1H), 7.29 (d, J = 8.3, 1H), 
4.75 (d, J = 4.9 Hz, 2H).   
 
N-((5-Bromopyridin-2-yl)methyl)-4-methoxybenzamide (3.211) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (20 mg, 0.106 mmol, 1 
equiv) in dichloroethane (20 mL) was added 4-methoxybenzoic anhydride (34 mg, 0.76 
mmol, 1.1 equiv). The resulting suspension was stirred at rt for 30 min. After confirmation 
of consumption of starting material by TLC, reaction solvent was removed under reduced 
 299 
pressure and column chromatography (0 to 10% MeOH/DCM) on silica gel was used to 
purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C14H14O2N2Br+ [M+H+] 323.18, found 323. 1H NMR (400 
MHz, CDCl3) δ 8.63 (d, J = 2.2 Hz, 1H), 7.88 - 7.77 (m, 3H), 7.35 (br, 1H), 7.28 (d, J = 
8.8 Hz, 2H), 4.72 (d, J = 5.1 Hz, 2H), 3.86 (s, 3H). 
 
N-((5-Bromopyridin-2-yl)methyl)-4-fluorobenzamide (3.212) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (20 mg, 0.106 mmol, 1 
equiv) in dichloroethane (20 mL) was added 4-fluorobenzoic anhydride (31 mg, 0.76 
mmol, 1.1 equiv). The resulting suspension was stirred at rt for 30 min. After confirmation 
of consumption of starting material by TLC, reaction solvent was removed under reduced 
pressure and column chromatography (0 to 10% MeOH/DCM) on silica gel was used to 
purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C13H11ON2FBr+ [M+H+] 311.14, found 311. 1H NMR (400 
MHz, CDCl3) δ 8.65 (d, J = 2.3 Hz, 1H), 7.89 (ddd, J1 = 2.8, J2 = 3.3, J3 = 5.4 Hz, 2H), 
7.85 (dd, J1 = 2.4, J2 = 8.3 Hz, 1H), 7.41 (br, 1H), 7.28 (d, J = 8.4 Hz, 2H), 7.14 (ddd, J1 = 
3.0, J2 = 4.8, J3 = 11.5 Hz, 2H), 4.73 (d, J = 5.0 Hz, 2H).  
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N-((5-Bromopyridin-2-yl)methyl)-4-chlorobenzamide (3.213) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (20 mg, 0.106 mmol, 1 
equiv) in dichloroethane (20 mL) was added 4-fluorobenzoic anhydride (34 mg, 0.76 
mmol, 1.1 equiv). The resulting suspension was stirred at rt for 30 min. After confirmation 
of consumption of starting material by TLC, reaction solvent was removed under reduced 
pressure and column chromatography (0 to 10% MeOH/DCM) on silica gel was used to 
purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C13H11ON2ClBr+ [M+H+] 327.60, found 327. 1H NMR (400 
MHz, CDCl3) δ 8.63 (d, J = 2.4 Hz, 1H), 7.85 (dd, J1 = 2.6, J2 = 8.6 Hz, 1H), 7.80 (d, J = 
8.3 Hz, 2H), 7.43 (d, J = 8.7 Hz, 2H), 7.27 (d, J = 7.4 Hz, 1H),  4.71 (d, J = 5.0 Hz, 2H). 
 
N-((5-Bromopyridin-2-yl)methyl)-3,4-dichlorobenzamide (3.214) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (20 mg, 0.106 mmol, 1 
equiv) in dichloroethane (20 mL) was added 3,4-dichlorobenzoic anhydride (42 mg, 0.76 
mmol, 1.1 equiv). The resulting suspension was stirred at rt for 30 min. After confirmation 
of consumption of starting material by TLC, reaction solvent was removed under reduced 
pressure and column chromatography (0 to 10% MeOH/DCM) on silica gel was used to 
purify sufficient amounts of target molecule for biological testing and characterization. 
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LRMS (CI-quad) m/z cal’d for C13H10ON2Cl2Br+ [M+H+] 362.04, found 362. H1 NMR 
(400 MHz, CDCl3) 8.64 (d, J = 2.2 Hz, 1H), 7.96 (d, J = 2.0 Hz, 1H), 7.85 (dd, J1 = 2.3, 
J2 = 8.4 Hz, 1H), 7.68 (dd, J1 = 2.0, J2 = 8.4 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.50 (br, 
1H), 7.28 (s, 1H), 4.71 (d, J = 4.9 Hz, 2H). 
 
N-((5-Bromopyridin-2-yl)methyl)-4-(tert-butyl)benzamide (3.215) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (20 mg, 0.106 mmol, 1 
equiv) in dichloroethane (20 mL) was added 4-(tert-butyl)benzoic anhydride (39 mg, 0.76 
mmol, 1.1 equiv). The resulting suspension was stirred at rt for 30 min. After confirmation 
of consumption of starting material by TLC, reaction solvent was removed under reduced 
pressure and column chromatography (0 to 10% MeOH/DCM) on silica gel was used to 
purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C17H16ON2Br+ [M+H+] 345.23, found 345. 1H NMR (400 
MHz, CDCl3) δ 8.61 (d, J = 2.1 Hz, 1H), 7.83 - 7.77 (m, 3H), 7.46 (d, J = 8.6 Hz, 2H), 
7.27 (d, J = 8.3 Hz, 1H), 4.71 (d, J = 5.1 Hz, 2H), 1.34 (s, 9H).  
 
N-((5-Bromopyridin-2-yl)methyl)nicotinamide (3.216) 
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To a stirring suspension of (5-bromopyridin-2-yl)methanamine (20 mg, 0.106 mmol, 1 
equiv) in dichloroethane (20 mL) was added nicotinic anhydride (27 mg, 0.76 mmol, 1.1 
equiv). The resulting suspension was stirred at rt for 30 min. After confirmation of 
consumption of starting material by TLC, reaction solvent was removed under reduced 
pressure and column chromatography (0 to 10% MeOH/DCM) on silica gel was used to 
purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C12H11ON3Br+ [M+H+] 294.14, found 294. 1H NMR (400 
MHz, CDCl3) δ 9.14 (d, J = 2.2 Hz, 1H), 8.76 (dd, J1 = 1.6, J2 = 5.0 Hz, 1H), 8.64 (d, J = 
2.2 Hz, 1H), 8.23 (td, J1 = 2.0, J2 = 4.0 Hz, 1H), 7.84 (dd, J1 = 2.5, J2 = 8.4 Hz, 1H), 7.68 
(br, 1H), 7.46 (dd, J1 = 4.9, J2 = 8.0 Hz, 1H), 7.28 (d, J = 8.4 Hz, 1H), 4.74 (d, J = 4.9 Hz, 
2H). 
 
N-((5-Bromopyridin-2-yl)methyl)acetamide (3.217) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (20 mg, 0.106 mmol, 1 
equiv) in dichloroethane (20 mL) was added 4-chlorobenzoic anhydride (12 mg, 0.76 
mmol, 1.1 equiv). The resulting suspension was stirred at rt for 30 min. After confirmation 
of consumption of starting material by TLC, reaction solvent was removed under reduced 
pressure and column chromatography (0 to 10% MeOH/DCM) on silica gel was used to 
purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C8H10ON2Br+ [M+H+] 231.08, found 231. 1H NMR (400 
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MHz, CDCl3) δ 8.60 (d, J = 2.1 Hz, 1H), 7.80 (dd, J1 = 2.2, J2 = 8.3 Hz, 1H), 7.20 (d, J = 
7.9 Hz, 1H), 6.60 (s (b), 1H), 2.07 (s, 3H). 
 
N-((5-Bromopyridin-2-yl)methyl)butyramide (3.218) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (20 mg, 0.106 mmol, 1 
equiv) in dichloroethane (20 mL) was added butyric anhydride (18 mg, 0.76 mmol, 1.1 
equiv). The resulting suspension was stirred at rt for 30 min. After confirmation of 
consumption of starting material by TLC, reaction solvent was removed under reduced 
pressure and column chromatography (0 to 10% MeOH/DCM) on silica gel was used to 
purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C10H14ON2Br+ [M+H+] 259.13, found 259. 1H NMR (400 
MHz, CDCl3) δ 8.59 (d, J = 2.1 Hz, 1H), 7.79, (dd, J1 = 2.3, J2 = 8.3 Hz, 1H), 7.19 (d, J = 
8.3 Hz, 1H), 6.58 (s, 1H), 4.51 (d, J = 5.2 Hz, 2H), 2.25 (t, J = 7.4 Hz, 2H). 1.69 (sext, 7.44 
Hz, 2H), 0.96 (t, J = 7.4 Hz, 3H). 
 
3-Phenyl-[1,2,4]triazolo[4,3-a]pyridine (3.218) 
 
To a stirring suspension of 2-hydrazinylpyridine (100 mg, 0.91 mmol, 1 equiv) in toluene 
(20 mL) was added benzoic anhydride (208 mg, 0.91 mmol, 1 equiv). The resulting 
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suspension was heated to reflux and stirred for 24 h. After confirmation of consumption of 
starting material by TLC, the reaction was cooled to rt and the toluene was removed under 
reduced pressure. DCM (50 mL) was added and reaction was washed with a saturated 
NaHCO3 solution (3 x 25 mL). The organic layer was then dried over Na2SO4, filtered and 
solvent removed under reduced pressure. Column chromatography (0 to 10% 
MeOH/DCM) on silica gel was used to purify sufficient amounts of target molecule for 
biological testing and characterization. LRMS (CI-quad) m/z cal’d for C12H10N3+ [M+H+] 
197.26, found 197. 1H NMR (400 MHz, CDCl3) δ 8.14 (dd, J1 = 1.6, J2 = 5.6 Hz, 1H), 
7.90 (d, J = 7.3 Hz, 2H), 7.58 - 7.50 (m, 2H), 7.47 (t, J = 7.7 Hz, 2H), 6.80 (t, J = 4.2 Hz, 
1H). 
 
3-Phenyl-[1,2,4]triazolo[4,3-b]pyridazine (3.219) 
 
To a stirring suspension of 3-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) in toluene 
(20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and benzoic anhydride (205 
mg, 1.38 mmol, 2 equiv). The resulting suspension was heated to reflux and stirred for 12 
h. After confirmation of consumption of starting material by TLC, the reaction was cooled 
to rt and the toluene was removed under reduced pressure. DCM (50 mL) was added and 
reaction was washed with a saturated NaHCO3 solution (3 x 25 mL). The organic layer was 
then dried over Na2SO4, filtered and solvent removed under reduced pressure. Column 
chromatography (0 to 10% MeOH/DCM) on silica gel was used to purify sufficient 
 305 
amounts of target molecule for biological testing and characterization. LRMS (CI-quad) 
m/z cal’d for C11H9N4+ [M+H+] 198.22, found 198. 1H NMR (400 MHz, CDCl3) δ 8.51 - 
8.44 (m, 3H), 8.21 (dd, J1 = 1.6, J2 = 9.5 Hz, 1H), 7.59 - 7.52 (m, 3H), 7.16 (dd, J1 = 4.1, 
J2 = 9.5 Hz, 1H).  
 
6-Bromo-3-(m-tolyl)imidazo[1,5-a]pyridine (3.220) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (100 mg, 0.69 mmol, 1 
equiv) in dichloroethane (20 mL) was added 3-methylbenzoic anhydride (314 mg, 1.58 
mmol, 2.3 equiv). The resulting suspension was stirred at rt for 30 min before dropwise 
addition of POCl3 (141 mg, 1.12 mmol, 1.7 equiv) as a solution in ca 3 mL DCM. The 
reaction was then heated to reflux for 3 hr. After confirmation of consumption of starting 
material by TLC, the reaction was cooled to rt and the reaction was stirred with 5 mL of 
0.1 N HCl (caution:exothermic reaction) for 15 mins to hydrolyze excess POCl3. Post 
stirring, the reaction was washed with a saturated NaHCO3 solution (3 x 25 mL, caution:gas 
evolution). The organic layer was then dried over Na2SO4, filtered and solvent removed 
under reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel 
was used to purify sufficient amounts of target molecule for biological testing and 
characterization. LRMS (CI-quad) m/z cal’d for C14H12N2Br+ [M+H+] 289.16, found 289. 
1H NMR (400 MHz, CDCl3) δ 8.36 (s, 1H), 7.59 (s, 1H), 7.57 (s, 1H), 7.54 (d, J = 7.9 Hz, 
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1H), 7.43 (d, J = 7.6 Hz, 1H), 7.38 (d, J = 9.5, 1H), 7.28 (d, J = 8.8 Hz, 1H), 6.77 (d, J = 
9.5 Hz, 1H), 2.45 (s, 3H). 
 
6-Bromo-3-(3-(trifluoromethyl)phenyl)imidazo[1,5-a]pyridine (3.221) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (100 mg, 0.69 mmol, 1 
equiv) in dichloroethane (20 mL) was added 3-(trifluoromethyl)benzoic anhydride (448 
mg, 1.58 mmol, 2.3 equiv). The resulting suspension was stirred at rt for 30 min before 
dropwise addition of POCl3 (141 mg, 1.12 mmol, 1.7 equiv) as a solution in ca 3 mL DCM. 
The reaction was then heated to reflux for 3 hr. After confirmation of consumption of 
starting material by TLC, the reaction was cooled to rt and the reaction was stirred with 5 
mL of 0.1 N HCl (caution:exothermic reaction) for 15 mins to hydrolyze excess POCl3. 
Post stirring, the reaction was washed with a saturated NaHCO3 solution (3 x 25 mL, 
caution:gas evolution). The organic layer was then dried over Na2SO4, filtered and solvent 
removed under reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on 
silica gel was used to purify sufficient amounts of target molecule for biological testing 
and characterization. LRMS (CI-quad) m/z cal’d for C14H7N2F3Br+ [M+H+] 341.12, found 
341. 1H NMR (400 MHz, CDCl3) δ 8.27 (s, 1H), 8.00 (s, 1H), 7.88 (d, J = 7.5 Hz, 1H), 
7.65 - 7.57 (m, 2H), 7.54 (s, 1H), 7.35 (d, J = 9.5 Hz, 1H), 6.76 (d, J = 9.5 Hz, 1H). 
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6-Bromo-3-(p-tolyl)imidazo[1,5-a]pyridine (3.222) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (100 mg, 0.69 mmol, 1 
equiv) in dichloroethane (20 mL) was added 4-methylbenzoic anhydride (314 mg, 1.58 
mmol, 2.3 equiv). The resulting suspension was stirred at rt for 30 min before dropwise 
addition of POCl3 (141 mg, 1.12 mmol, 1.7 equiv) as a solution in ca 3 mL DCM. The 
reaction was then heated to reflux for 3 hr. After confirmation of consumption of starting 
material by TLC, the reaction was cooled to rt and the reaction was stirred with 5 mL of 
0.1 N HCl (caution:exothermic reaction) for 15 mins to hydrolyze excess POCl3. Post 
stirring, the reaction was washed with a saturated NaHCO3 solution (3 x 25 mL, caution:gas 
evolution). The organic layer was then dried over Na2SO4, filtered and solvent removed 
under reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel 
was used to purify sufficient amounts of target molecule for biological testing and 
characterization. LRMS (CI-quad) m/z cal’d for C14H12N2Br+ [M+H+] 289.16, found 289. 
1H NMR (400 MHz, CDCl3) δ 8.28 (s, 1H), 7.58 (d, J = 7.7 Hz, 2H), 7.49 (s, 1H), 7.33 - 
7.25 (m, 3H), 6.68 (d, J = 9.5 Hz, 1H), 2.37 (s, 3H). 
 
6-Chloro-3-phenyl-[1,2,4]triazolo[4,3-b]pyridazine (3.223) 
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To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and benzoic 
anhydride (78 mg, 0.69 mmol, 1 equiv). The resulting suspension was heated to reflux and 
stirred for 12 h. After confirmation of consumption of starting material by TLC, the 
reaction was cooled to rt and the toluene was removed under reduced pressure. DCM (50 
mL) was added and reaction was washed with a saturated NaHCO3 solution (3 x 25 mL). 
The organic layer was then dried over Na2SO4, filtered and solvent removed under reduced 
pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used to purify 
sufficient amounts of target molecule for biological testing and characterization. LRMS 
(CI-quad) m/z cal’d for C11H7N4Cl+ [M+H+] 231.65, found 232. 1H NMR (400 MHz, 
CDCl3) δ 8.45 (d, J = 7.9 Hz, 2H), 8.15 (d, J = 9.6 Hz, 1H), 7.59 - 7.49 (m, 3H), 7.15 (d, 
J = 9.6 Hz, 1H). 
 
6-Chloro-3-(m-tolyl)-[1,2,4]triazolo[4,3-b]pyridazine (3.224) 
 
To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and 3-
methylbenzoic anhydride (87 mg, 0.69 mmool, 1 equiv). The resulting suspension was 
heated to reflux and stirred for 12 h. After confirmation of consumption of starting material 
by TLC, the reaction was cooled to rt and the toluene was removed under reduced pressure. 
DCM (50 mL) was added and reaction was washed with a saturated NaHCO3 solution (3 x 
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25 mL). The organic layer was then dried over Na2SO4, filtered and solvent removed under 
reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used 
to purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C12H10N4Cl+ [M+H+] 246.69, found 247. 1H NMR (400 
MHz, CDCl3) δ 8.29 - 8.20 (m, 2H), 8.17 (d, J = 9.6 Hz, 1H), 7.46 (t, J = 7.9 Hz, 1H), 7.36 
(d, J = 7.7 Hz, 1H), 7.17 (d, J = 9.6 Hz, 1H), 2.48 (s, 3H). 
 
6-Chloro-3-(p-tolyl)-[1,2,4]triazolo[4,3-b]pyridazine (3.225) 
 
To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and 4-
methylbenzoic anhydride (87 mg, 0.69 mmol, 1 equiv). The resulting suspension was 
heated to reflux and stirred for 12 h. After confirmation of consumption of starting material 
by TLC, the reaction was cooled to rt and the toluene was removed under reduced pressure. 
DCM (50 mL) was added and reaction was washed with a saturated NaHCO3 solution (3 x 
25 mL). The organic layer was then dried over Na2SO4, filtered and solvent removed under 
reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used 
to purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C12H10N4Cl+ [M+H+] 246.69, found 247. 1H NMR (400 
MHz, CDCl3) δ 8.35 (d, J = 8.0 Hz, 2H), 8.17 (d, J = 9.6 Hz, 1H), 7.39 (d, J = 8.0 Hz, 2H), 
7.16 (d, J = 9.6 Hz, 1H), 2.45 (s, 3H).  
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6-Chloro-3-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine (3.226) 
 
To a stirring suspension of 3-chloro-6-hydrazinylpyridazine (100 mg, 0.69 mmol, 1 equiv) 
in toluene (20 mL) was added DIPEA (0.2 mL, 0.069 mmol, 0.01 equiv) and 4-
fluorobenzoic anhydride (87 mg, 0.69 mmol, 1 equiv). The resulting suspension was heated 
to reflux and stirred for 12 h. After confirmation of consumption of starting material by 
TLC, the reaction was cooled to rt and the toluene was removed under reduced pressure. 
DCM (50 mL) was added and reaction was washed with a saturated NaHCO3 solution (3 x 
25 mL). The organic layer was then dried over Na2SO4, filtered and solvent removed under 
reduced pressure. Column chromatography (0 to 10% MeOH/DCM) on silica gel was used 
to purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C11H7N4FCl+ [M+H+] 250.65, found 251. 1H NMR (400 
MHz, CDCl3) δ 8.49 (dd, J1 = 5.4, J2 = 8.6 Hz, 2H), 8.17 (d, J = 9.6 Hz, 1H), 7.26 (t, J = 
8.5 Hz, 2H), 7.17 (d, J = 9.6 Hz, 1H).  
 
N-((5-Bromopyridin-2-yl)methyl)-4-(trifluoromethyl)benzamide (3.227) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (50 mg, 0.27 mmol, 1 
equiv) in dichloroethane (20 mL) was added 4-(trifluoromethyl)benzoic anhydride (193 
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mg, 0.54 mmol, 2 equiv). The resulting suspension was stirred at rt for 30 min. After 
confirmation of consumption of starting material by TLC, reaction solvent was removed 
under reduced pressure and column chromatography (0 to 10% MeOH/DCM) on silica gel 
was used to purify sufficient amounts of target molecule for biological testing and 
characterization. LRMS (CI-quad) m/z cal’d for C14H11ON2F3Br+ [M+H+] 361.15, found 
361. 1H NMR (400 MHz, CDCl3) δ 8.63 (d, J = 2.2 Hz, 1H), 7.97 (d, J = 8.0 Hz, 2H), 7.84 
(dd, J1 = 2.3, J2 = 8.3 Hz, 1H), 7.72 (d, J = 8.1 Hz, 2H), 7.58 (br, 1H), 7.27 (d, J = 7.2 Hz, 
1H), 4.73 (d, J = 4.9 Hz, 2H). 
 
N-((5-Bromopyridin-2-yl)methyl)-4-(tert-butyl)benzamide (3.228) 
 
To a stirring suspension of (5-bromopyridin-2-yl)methanamine (50 mg, 0.27 mmol, 1 
equiv) in dichloroethane (20 mL) was added 4-(tert-butyl)benzoic anhydride (193 mg, 0.27 
mmol, 2 equiv). The resulting suspension was stirred at rt for 30 min. After confirmation 
of consumption of starting material by TLC, reaction solvent was removed under reduced 
pressure and column chromatography (0 to 10% MeOH/DCM) on silica gel was used to 
purify sufficient amounts of target molecule for biological testing and characterization. 
LRMS (CI-quad) m/z cal’d for C17H20ON2Br+ [M+H+] 349.26, found 349. 1H NMR (400 
MHz, CDCl3) δ 8.61 (d, J = 2.2 Hz, 1H), 7.82 - 7.77 (m, 3H), 7.46 (d, J = 8.6 Hz, 2H), 
7.39 (br, 1H), 7.25 (d, J = 8.4 Hz, 1H), 4.70 (d, J = 5.1 Hz, 2H), 1.33 (s, 9H).  
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Aminocyclopentitol Synthesis 
(2R,3S,4S,5R,6S)-2-(((tert-Butyldimethylsilyl)oxy)methyl)-6-methoxytetrahydro-2H-
pyran-3,4,5-triol (4.9).  
 
Methyl-α-D-glucopyranoside (5.10 g, 26.3 mmol) was dissolved in anhydrous DMF (60 
mL) and cooled to 0 °C. Imidazole (4.40 g, 64.6 mmol) and tert-butyldimethylsilyl chloride 
(4.70 g, 31.0 mmol) were added to the solution in sequence. The mixture was allowed to 
stir at room temperature overnight. Upon the consumption of starting material, monitored 
by TLC, the solvent was removed under high vacuum and the residue was dissolved in 
EtOAc (400 mL). The solution was washed with water (2 x 200 mL) and brine (2 x 200 
mL), dried over MgSO4, and concentrated in vacuo. The residue was purified by flash 
column chromatography on silica gel, using 100% EtOAc as the eluent. After 
chromatographic purification, an amorphous solid was obtained (7.3 g, 24 mmol, 98%). 1H 
NMR (CDCl3, 400 MHz): δ 4.75 (d, J = 3.9 Hz, 1H), 3.89 (dd, J = 4.9, 10.6 Hz, 1H), 3.82 
(dd, J = 5.2, 10.6 Hz, 1H), 3.74 (t, J = 9.1 Hz, 1H), 3.61 (dd, J = 5.0, 9.7 Hz, 1H), 3.53 (t, 
J = 9.0 Hz, 1H), 3.51 (m, 1H), 3.42 (s, 3H), 3.14 (s, 1H), 2.82 (s, 1H), 2.19 (d, J = 7.6 Hz, 
1H), 0.91 (s, 9H), 0.10 (s, 6H); 13C NMR (CDCl3, 100 MHz): δ 100.0, 75.6, 73.3, 73.1, 
71.2, 65.2, 56.2, 26.7, 19.1, -4.6; ESI-HRMS: calc’d m/e for [M+Na+] C13H28NaO6Si: 
309.1733, found 309.2209; IR (neat, NaCl, cm-1): 3474, 2954, 2929, 2858, 1655, 1472, 
1464, 1361, 1253, 1194, 1152, 1112, 1045, 1002, 903, 854, 837, 777, 749; [α]25  D +98 (c 
1.0, CHCl3). 
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tert-Butyldimethyl(((2R,3R,4S,5R,6S)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-
2H-pyran-2-yl)methoxy)silane (4.10).  
 
The starting pyranoside (7.00 g, 22.7 mmol) was dissolved in anhydrous DMF (100 mL) 
and cooled to 0 °C. Sodium hydride (3.30 g, 82.5 mmol) was added to the solution. After 
the evolution of H2 ceased, benzyl bromide (12.2 mL, 103 mmol) was added to the reaction. 
The mixture was stirred under an atmosphere of nitrogen overnight. Upon the consumption 
of the starting material, monitored by TLC, the reaction was quenched with MeOH (10 
mL), then poured into water (500 mL) and extracted with EtOAc (5 x 100 mL). The 
combined organic layers were washed with water (2 x×200 mL) and brine (2 x 200 mL), 
dried over MgSO4, and concentrated in vacuo. The residue was purified by flash column 
chromatography on silica gel, using 10% EtOAc:hexanes (v/v) as the eluent. After 
chromatographic purification, a colorless oil was obtained (11.2 g, 19.3 mmol, 85%). 1H 
NMR (CDCl3, 400 MHz): δ 7.32 - 7.21 (m, 15H), 4.93 (d, J = 10.8 Hz, 1H), 4.84 (d, J = 
10.9 Hz, 1H), 4.78 (d, J = 10.9 Hz, 1H), 4.76 (d, J = 12.1 Hz, 1H), 4.64 (d, J = 12.1 Hz, 
1H), 4.60 (d, J = 11.0 Hz, 1H), 4.57 (d, J = 3.6 Hz, 1H), 3.96 (t, J = 9.3 Hz, 1H), 3.75 (d, 
J = 3.2 Hz, 1H), 3.58 (dt, J = 3.7, 10.0 Hz, 1H), 3.50 (d, J = 9.1 Hz, 1H), 3.48 (d, J = 3.6 
Hz, 1H), 3.46 (d, J = 3.6 Hz, 1H), 3.33 (s, 3H), 0.85 (s, 9H), 0.00 (d, J = 2.0 Hz, 6H); 13C 
NMR (CDCl3, 100 MHz): δ 139.2, 138.9, 138.6, 128.8, 128.7, 128.4, 128.39, 128.2, 128.0, 
127.9, 98.2, 82.5, 80.6, 78.1, 76.2, 75.3, 73.7, 71.9, 62.6, 55.2, 26.3, 18.7, -4.8, -5.0; ESI-
HRMS: calc’d m/e for [M+Na+] C34H46NaO6Si: 601.2961, found 601.2932; IR (neat, NaCl, 
cm-1): 3065, 3031, 2928, 2856, 1606, 1497, 1455, 1361, 1252, 1201, 1193, 1160, 1136, 
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1092, 1072, 910, 836, 778, 735, 697; [α]25  D  +130 (c 0.89, CHCl3). 
 
((2R,3R,4S,5R,6S)-3,4,5-tris(Benzyloxy)-6-methoxytetrahydro-2H-pyran-2-
yl)methanol (4.11).  
 
The starting pyranoside (11.5 g, 19.9 mmol) was dissolved in acetonitrile (120 mL). H2O 
(25 mL) was added, and the pH of the solution adjusted to pH = 3 by the addition of p-
toluenesulphonic acid. The reaction mixture was stirred at room temperature overnight. 
Upon the consumption of the starting material, monitored by TLC, EtOAc (300 mL) was 
added to the reaction mixture. The mixture was washed with saturated aqueous sodium 
bicarbonate (2 x 150 mL) and brine (150 mL). The organic layers were combined, dried 
over MgSO4, and concentrated in vacuo. The residue was purified by flash column 
chromatography on silica gel, using 30% EtOAc:hexanes (v/v) as the eluent. After 
chromatographic purification, a colorless oil was obtained (6.00 g, 12.9 mmol, 65%). 1H 
NMR (CDCl3, 400 MHz): δ 7.37 - 7.28 (m, 15H), 4.99 (d, J = 10.9 Hz, 1H), 4.88 (d, J = 
11.1 Hz, 1H), 4.84 (d, J = 10.9 Hz, 1H), 4.80 (d, J = 12.1 Hz, 1H), 4.65 (t, J = 12.2 Hz, 
2H), 4.57 (d, J = 3.6 Hz, 1H), 4.00 (t, J = 9.3 Hz, 1H), 3.77 (m, 1H), 3.69 (m, 1H), 3.65 
(m, 1H), 3.53 (d, J = 9.2 Hz, 1H), 3.50 (dd, J = 3.6, 6.1 Hz, 1H), 3.37 (s, 3H), 1.60 (dd, J 
= 5.3, 7.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz): δ 139.1, 138.5, 128.8, 128.8, 128.5, 
128.4, 128.3, 128.3, 128.2, 128.0, 98.6, 82.3, 80.4, 76.1, 75.4, 73.8, 71.0, 62.3, 55.6.; ESI-
HRMS: calc’d m/e for [M+Na+] C28H32NaO6: 487.2097, found 487.2104; IR (neat, NaCl, 
cm-1): 3486, 3063, 3034, 2921, 1732, 1606, 1497, 1454, 1360, 1260, 1192, 1076, 1072, 
 315 
1068, 911, 802, 737, 697; [α]25  D  +23 (c 0.99, CHCl3). 
 
(2S,3S,4S,5R,6S)-3,4,5-Tris(benzyloxy)-2-(iodomethyl)-6-methoxytetrahydro-2H-
pyran (4.12).  
 
Triphenylphosphine (5.10 g, 19.4 mmol) and imidazole (1.80 g, 26.4 mmol) were 
successively dissolved in THF (150 mL). The resultant mixture was cooled to 0 °C, and 
iodine (4.90 g, 19.3 mmol) was added in portions over 30 min. A solution of starting 
pyranoside (6.00 g, 12.9 mmol) in THF (50 mL) was cannulated into the reaction flask. 
The reaction was then heated to 66 °C and stirred at that temperature for 1 h. The reaction 
was then cooled to room temperature and quenched with H2O (25 mL); the aqueous layer 
was extracted with EtOAc (250 mL x 2). The organic layers were combined, washed with 
10% sodium thiosulfate, dried over MgSO4, and concentrated in vacuo. The crude material 
was purified by flash column chromatography on silica gel, using 10% EtOAc:hexanes 
(v/v) as the eluent. After chromatographic purification, a light yellow, oil was obtained 
(10.8 g, 18.8 mmol, 97%). 1H NMR (CDCl3, 400 MHz): δ 7.37 - 7.27 (m, 15H), 4.99 (d, J 
= 10.8 Hz, 1H), 4.94 (d, J = 11.0 Hz, 1H), 4.81 (d, J = 2.0 Hz, 1H), 4.79 (d, J = 3.3 Hz, 
1H), 4.67 (t, J = 11.0 Hz, 2H), 4.61 (d, J = 3.6 Hz, 1H), 4.01 (t, J = 9.0 Hz, 1H), 3.54 (dd, 
J = 3.6 Hz, 1H), 3.46 (m, 2H), 3.42 (s, 3H), 3.34 (t, J = 9.0 Hz, 1H), 3.29 (dd, J = 6.7, 11.0 
Hz, 1H); 13C NMR (CDCl3, 100 MHz): δ 138.9, 138.4, 138.36, 128.9, 128.85, 128.8, 128.4, 
128.35, 128.3, 128.1, 98.5, 81.9, 81.9, 80.4, 76.1, 75.7, 73.8, 69.7, 55.9, 8.0; ESI-HRMS: 
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calc’d m/e for [M+Na+] C28H31INaO5: 597.1114, found 597.1162; IR (neat, NaCl, cm-1): 
3062, 3030, 2909, 1496, 1454, 1359, 1260, 1196, 1120, 1102, 1088, 1048, 1028, 736, 697; 
[α]25  D  +32 (c 1.1, CHCl3). 
 
(2R,3S,4R)-2,3,4-Tris(benzyloxy)hex-5-enal (4.13). 
 
The starting Iodo-compound (4.6 g, 8.0 mmol) was dissolved in a mixture of THF/H2O 
(9:1, 200 mL) and then activated zinc (5.20 g, 79.5 mmol) was added. The flask was placed 
in an ultrasonic cleaner and sonicated overnight. The reaction progress was monitored by 
mass spectroscopy due to the fact that the Rf value of the product is identical to that of the 
starting material on TLC. Upon the consumption of the starting material, the reaction was 
diluted with EtOAc (50 mL), and the aqueous layer was extracted with EtOAc (50 mL x 
2). The organic layers were combined, washed with sodium bicarbonate (20 mL), brine (20 
mL) and dried over MgSO4. The solvent was removed in vacuo and the residue was purified 
by flash column chromatography on silica gel, using 10% EtOAc:hexanes (v/v) as the 
eluent. After chromatographic purification, a colorless oil was obtained (3.1 g, 7.5 mmol, 
96%). 1H NMR (CDCl3, 400 MHz): 9.63 (dd, J = 1.6, 2.2 Hz, 0.6 H), 9.57 (d, J = 1.0 Hz, 
0.4H), 7.29 - 7.21 (m, 15H), 5.84 - 5.76 (m, 1H), 5.29 (dt, J = 1.0, 4.3 Hz, 1H), 5.20 (dd, J 
= 1.0, 7.0 Hz, 1H), 4.64 (dd, J = 2.2, 10.0 Hz, 1H), 4.60 (t, J = 13.1 Hz, 1H), 4.54 (m, 1H), 
4.50 (m, 1H), 4.44 (dd, J = 8.0, 19.8 Hz, 1H), 4.30 (dd, J = 3.3, 11.9 Hz, 1H), 4.04 (m, 1H), 
3.91 (t, J = 6.8 Hz, 1H), 3.78 (m, 1H); 13C NMR (CDCl3, 100 MHz): δ 201.6, 201.0, 138.1, 
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138.07, 137.8, 137.7, 137.2, 134.8, 134.4, 128.6, 128.5, 128.4, 128.4, 128.34, 128.31, 
128.26, 128.2, 128.1, 128.0, 127.9, 127.8, 127.79, 127.7, 127.6, 127.0, 119.5, 119.4, 82.4, 
81.8, 80.9, 80.0, 75.9, 74.5, 73.3, 73.1, 71.0 70.7, 45.2; ESI-HRMS: calc’d m/e for 
[M+Na+] C27H28NaO4: 439.1885, found 439.1954; IR (neat, NaCl, cm-1): 3064, 3031, 
2866, 1727, 1497, 1454, 1393, 1352, 1208, 1071, 1027, 932, 735, 697; [α]25  D  +4.5 (c 0.85, 
CHCl3). 
 
(3aR,4R,5S,6S,6aR)-4,5,6-Tris(benzyloxy)hexahydro-1H-cyclopenta[c]isoxazole 
(4.14). 
 
The starting aldehyde (3.8 g, 9.1 mmol) was dissolved in MeOH (40 mL). To the stirring 
solution, hydroxylamine hydrochloride (2.50 g, 36.0 mmol) was added. The suspension 
was neutralized with sodium bicarbonate (4.30 g, 40.6 mmol). The solution was then stirred 
under refluxing conditions for 6 h. After the consumption of the starting material, the 
solvent was removed in vacuo. The residue was dissolved in EtOAc, washed with 10% 
HCl solution, saturated sodium bicarbonate, and brine in sequence, and dried over MgSO4. 
The solvent was removed to yield an oily residue which was passed through a silica plug 
with 25% EtOAc:hexanes (v/v) as the eluent, giving a mixture of inseparable E/Z isomers 
as a light green oil. The resulting oxime (970 mg, 2.20 mmol) was then dissolved in dry 
toluene (35 mL) and heated at reflux for 15 h under nitrogen. Upon the consumption of the 
starting material, monitored by TLC, the reaction was cooled; and the solvent was removed 
in vacuo. The crude product was purified by flash column chromatography on silica gel, 
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using 40% EtOAc in hexanes as the eluent. After chromatographic purification, a yellow 
oil was obtained (2.7 g, 6.4 mmol, 70%). 1H NMR (CDCl3, 400 MHz): δ 7.38 - 7.28 (m, 
15 H), 4.85 (d, J = 11.8 Hz, 1H), 4.79 (d, J = 11.9 Hz, 2H), 4.71 (d, J = 5.9 Hz, 2H), 4.58 
(d, J = 11.8 Hz, 1H), 3.94 (t, J = 8.4 Hz, 1H), 3.87 (t, J = 5.8 Hz, 2H), 3.83 (t, J = 6.6 Hz, 
1H), 3.68 (t, J = 7.4 Hz, 1H), 3.46 (t, J = 6.9 Hz, 1H), 2.91 (dd, J = 5.5, 7.0 Hz, 1H); 13C 
NMR (CDCl3, 100 MHz): δ 138.5, 138.3, 138.1, 128.5, 128.4, 128.3, 127.9, 127.8, 127.75, 
127.7, 127.6, 127.5, 86.0, 85.6, 84.7, 76.0, 72.7, 72.4, 72.3, 66.3, 49.6; ESI-HRMS: calc’d 
m/e for [M+Na+] C27H29NNaO4: 454.1994, found 454.1996; IR (neat, NaCl, cm-1): 3435, 
3031, 2922, 2863, 1742, 1724, 1497, 1454, 1364, 1208, 1094, 1072, 736, 697; [α]25  D  +25 
(c 0.54, CHCl3). 
 
((1R,2R,3S,4S,5R)-2,3,4-Tris(benzyloxy)-5-amino-cyclopentyl)methanol (4.15). 
 
To a stirring solution of starting isoxazole (675 mg, 1.60 mmol) in 85% acetic acid in H2O 
(25 mL), active zinc dust (510 mg, 8.00 mmol) was added. The reaction was then stirred at 
55 °C for 2 h. After the consumption of the starting material, monitored by TLC, the 
mixture was cooled to room temperature and the zinc dust was filtered off. The filtrate was 
diluted with H2O (25 mL) and basified with 1M NaOH. The resultant solution was 
extracted with CH2Cl2 (3 x 25 mL); the organic layers were combined, dried over MgSO4, 
and concentrated in vacuo. The crude product was purified by flash column 
chromatography on silica gel, using 10% MeOH/CH2Cl2 + 1% NH4OH as the eluent. After 
chromatographic purification, a colorless oil was obtained (0.97 g, 2.2 mmol, 87%). 1H 
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NMR (CDCl3, 400 MHz): δ 7.30 - 7.28 (m, 15 H), 5.56 - 5.23 (br s, 3H), 4.68 (d, J = 12.0 
Hz, 2H), 4.64 (d, J = 11.1 Hz, 2H), 4.54 (m, 2H), 4.53 (d, J = 11.6 Hz, 1H), 4.48 (d, J = 
11.6 Hz, 1H), 4.02 (t, J = 5.7 Hz, 1H), 3.92 (t, J = 4.4 Hz, 1H), 3.87 (t, J = 5.0 Hz, 1H), 
3.82 (m, 1H), 3.69 (t, J = 6.7 Hz, 1H), 2.02 (m, 1H); 13C NMR (CDCl3, 100 MHz): δ 138.2, 
138.18, 138.0, 128.8, 128.3, 128.2, 128.16, 87.6, 85.6, 83.0, 72.8, 72.4, 72.3, 61.1, 55.8, 
45.3; ESI-HRMS: calc’d m/e for [M+H+] C27H32NO4: 434.2326, found 434.2295; IR (neat, 
NaCl, cm-1): 3308, 3063, 3030, 2927, 2871, 1496, 1454, 1363, 1207, 1091, 1071, 1028, 
735, 697.  
 
5-Hydroxypentyl 4-methylbenzenesulfonate (4.16). 
 
To a stirring solution of 1,5-pentanediol (3 g, 28 mmol, 1 equiv) in DCM (50 mL) was 
added DMAP (342 mg, 2.8 mmol, 0.1 equiv) followed by p-toluenesulfonyl chloride 
(pTsCl, 5.49 g, 28 mmol, 1 equiv). The pTsCl was added as a solution in DCM over 10 
mins. After the addition was complete the reaction was left to stir overnight at room 
temperature under nitrogen. After confirming consumption of starting materials, the 
reaction was transferred to a separatory funnel and was successively with water (2x100 
mL) and brine (2X100 mL). The remaining organics were dried over Na2SO4, filtered and 
concentrated en vacuo. The crude product was purified by flash column chromatography 
on silica gel, using 10% to 30% EtOAc/Hexanes (v/v) as the eluent. After purification a 
colorless, viscous oil was obtained whose spectra matched reported literature. (1.41 g, 
19%). 1H NMR (CDCl3, 400 MHz): δ 7.78 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 
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4.03 (t, J = 6.4 Hz, 2H), 3.60 (t, J = 6.3 Hz, 2H), 2.45 (s, 3H), 1.67 (q, J = 7.2 Hz, 2H), 
1.55 – 1.48 (m, 2H), 1.44 – 1.35 (m, 2H). 
 
5-Oxopentyl 4-methylbenzenesulfonate (4.17)  
 
The starting tosyl compound (1.41 g, 5.45 mmol, 1 equiv) was dissoved in 50 mL of a 4:1 
mix of DCM to DMSO. To this was incrementally added sulfur trioxide pyridine complex 
(3.4 g, 21.8 mmol, 4 equiv) over 10 min. The reaction was stirred at room temperature for 
30 min and after confirming consumption of starting material, it was quenched with 50 mL 
water. The mixture was transferred to a separatory funnel and washed once with brine (50 
mL) followed by a saturated solution of citric acid (50 mL). The organics were dried over 
Na2SO4, filtered and concentrated en vacuo to afford 1.28 g of crude product which was 
purified via flash chromatographing using 20 to 50% EtOAc/Hexanes (v/v) as the eluent. 
A viscous, colorless oil was obtained after purification. (464 mg, 1.81 mmol, 33%). 1H 
NMR (CDCl3, 400 MHz): δ 9.72 (s, 1H), 7.78 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.1 Hz, 2H), 
4.03 (t, J = 5.6 Hz, 2H), 2.48 – 2.37 (m, 5H), 1.74 – 1.61 (m, 4H). 
 
4-(1,3-Dioxolan-2-yl)butyl 4-methylbenzenesulfonate (4.18). 
 
An excess of ethylene glycol (7 mL, 125 mmol, 100 equiv) and para-toluene sulfonic acid 
(31 mg, 0.18 mmol, 0.1 equiv) were dissolved in 20 mL of toluene. To this flask was 
attached a Dean-Stark apparatus and the flask was refluxed for 1 h, cooled, and to it was 
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added the starting aldehyde (464 mg, 1.8 mmol, 1 equiv) as a solution in anhydrous toluene 
(10 mL). The reaction was brought to reflux again for 4 hr after which time starting material 
was no longer observed by TLC. The reaction was cooled, transferred to a separatory 
funnel and washed with sat. NaHCO3 until neutralized. The organics were dried over 
Na2SO4, filtered and collected en vacuo. The crude product was purified using flash column 
chromatography to afford target acetal as a colorless, very viscous oil. (398 mg, 1.33 mmol, 
74%). 1H NMR (CDCl3, 400 MHz): δ 7.80 (d, J = 8.2 Hz, 2H), 7.35 (d, J = 7.9 Hz, 2H), 
4.81 (t, J = 4.63 Hz, 1H), 4.03 (t, J = 6.4 Hz, 2H), 3.99 – 3.79 (m, 4H), 2.46 (s, 3H), 1.75 
– 1.66 (m, 2H), 1.65 – 1.58 (m, 2H), 1.50 – 1.41 (m, 2H). 
 
2-(4-((Adamantan-1-yl)methoxy)butyl)-1,3-dioxolane (4.19) 
 
To a stirring solution of 1-adamantane methanol (615 mg, 3.87 mmol, 1.5 equiv) in DMF 
(15 mL) was added sodium hydride (300 mg, 7.5 mmol, 3 equiv) incrementally over 20 
min after which the reaction was heated to 40 °C for 1 hr. At this time, the starting acetal 
(EJC-4-114, 775 mg, 2.5 mmol, 1 equiv) was added to the reaction as a solution in DMF 
(10 mL). The reaction was stirred for a further 3.5 hr until starting material was confirmed 
consumed. At which time the reaction was cooled to room temperature, diluted with 100 
mL water and transferred to a separatory funnel. The organics were extracted 2X150 mL 
EtOAc, then the combined organics were washed 2X100 mL brine, dried over Na2SO4, 
filtered and concentrated en vacuo. The crude product was purified by flash colum 
chromatography using 15 to 45% EtOAc/Hex (v/v) as the eluent. Pure product was 
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obtained as a colorless, viscous oil. (543 mg, 1.8 mmol, 74%) 1H NMR (CDCl3, 400 MHz): 
δ 4.86 (br, 1H), 3.98 – 3.82 (m, 4H), 3.38 (t, J = 6.1 Hz, 2H), 2.95 (s, 2H), 1.95 (s, 3H), 
1.72 – 1.57 (m, 11H), 1.52 (br, 6H), 1.49 – 1.46 (m, 2H). 
 
5-((Adamantan-1-yl)methoxy)pentanal (4.20)  
 
Starting acetal (540 mg, 1.8 mmol, 1 equiv) was dissolved in a 1:1 mixture of 6 M HCl and 
acetone. The reaction was heated to 40 °C for 2 hr. Upon confirmation of consumption of 
starting material, the reaction was neutralized with a 0 °C slurry of 6 mL of a 1:1 mix of 3 
N NaOH and diethyl ether. Ensuring the pH of the reaction was raised above 7, the reaction 
was then transferred to a separatory funnel and the layers separated. The aqueous layer was 
extracted twice more with 30 mL diethyl ether. The combined organic layers were then 
washed with brine (2X50 mL), dried over Na2SO4, filtered and concentrated en vacuo. The 
crude product was purified by flash column chromatography using 3 to 10% 
EtOAc/Hexanes (v/v) as the eluent. The colorless, viscous oil recovered from the column 
was verified as target molecule and used within 3 days. (324 mg, 1.3 mmol, 71%). 1H NMR 
(CDCl3, 400 MHz): δ 9.77 (s, 1H), 3.39 (t, J = 6.4 Hz, 2H), 2.95 (s, 2H), 2.47 (t, J = 7.4 
Hz, 2H), 1.95 (br, 3H), 1.74 – 1.58 (m, 12H), 1.52 (s, 6H). 
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((1R,2R,3S,4S,5R)-2,3,4-tris(Benzyloxy)-5-(dibutylamino)cyclopentyl)methanol 
(4.21) 
 
To a solution of the free amine (288 mg, 0.666 mmol, 1 equiv) in DCE (15 mL) was added 
butanal (191.8 mg, 2.66 mmol, 4 equiv). After 10 min, sodium triacetoxyborohydride (705 
mg, 3.33 mmol, 5 equiv) was added to the mixture, and the reaction was stirred at room 
temperature for 15 h. After the consumption of the starting material, monitored by TLC, 
the reaction was quenched with a saturated sodium bicarbonate solution and extracted with 
CH2Cl2 (2 x 50 mL). The organic layers were combined, dried over MgSO4, and 
concentrated in vacuo. The crude product was purified by flash column chromatography 
on silica gel, using 5% MeOH/CH2Cl2 + 1% NH4OH as the eluent. Product was isolated as 
a colorless oil (119.2 mg, 33%). 1H NMR (CDCl3, 400 MHz): δ 7.38 – 7.25 (m, 15H), 4.68 
(t, J`= 11.9 Hz, 2H), 4.62 – 4.52 (m, 4H), 4.15 (dd, J1 = 6.0 Hz, J2 = 8.3 Hz, 1H), 3.99 (t, J 
= 5.4 Hz, 1H), 3.8 (m, 2H), 3.56 (t, J = 5.2 Hz, 1H), 3.51 (t, J = 8.6 Hz, 1H), 2.60 – 2.53 
(m, 5H), 1.57 (b, 1H), 1.48 – 1.42 (m, 4H), 1.27 – 1.21 (m, 4H), 0.89 (t, J = 7.0 Hz, 6H); 
13C NMR (CDCl3, 100 MHz) δ 138.0, 128.5, 128.4, 128.35, 128.30, 128.2, 127.9, 127.83, 
127.77, 127.6, 89.3, 88.5, 87.6, 83.0, 82.8, 81.2, 77.2, 72.3, 71.8, 71.1, 68.1, 65.2, 63.4, 
63.1, 52.5, 46.9, 44.7, 35.0, 33.4, 31.7, 29.7, 20.7, 19.2, 14.12, 14.05.; ESI-HRMS: calc’d 
m/e for [M+] C35H47NO4: 545.3505, found 545.3495. [α]25  D  +50 (c 0.100, MeOH). 
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(1R,2S,3S,4R,5R)-2,3,4-tris(Benzyloxy)-5-((benzyloxy)methyl)-N,N-
dinonylcyclopentan-1-amine (4.22) 
 
To a solution of the free amine (287 mg, 0.666 mmol, 1 equiv) in DCE (15 mL) was added 
nonanal (472.7 mg, 3.32 mmol, 5 equiv). After 10 min, sodium triacetoxyborohydride (844 
mg, 3.98 mmol, 6 equiv) was added to the mixture, and the reaction was stirred at room 
temperature for 15 h. After the consumption of the starting material, monitored by TLC, 
the reaction was quenched with a saturated sodium bicarbonate solution and extracted with 
CH2Cl2 (2 x 50 mL). The organic layers were combined, dried over MgSO4, and 
concentrated in vacuo. The crude product was purified by flash column chromatography 
on silica gel, using 5% MeOH/CH2Cl2 + 1% NH4OH as the eluent. Product was isolated as 
a colorless oil (157 mg, 39%). 1H NMR (CDCl3, 400 MHz): δ 7.37 – 7.25 (m, 15H), 5.62 
(b, 1H), 4.69 (d, J = 11.2 Hz, 1H), 4.64 (t, J = 11.9 Hz, 1H), 4.61 – 4.52 (m, 4H), 4.14 (t, 
J = 7.6 Hz, 1H), 3.99 (t, J = 5.4 Hz, 1H), 3.80 – 3.70 (m, 2H), 3.56 (t, J = 5.2 Hz, 1H), 3.50 
(t, J = 8.6 Hz, 1H), 2.6 – 2.49 (m, 5H), 1.50 – 1.40 (m, 4H), 1.31 – 1.17 (m, 24H), 0.88 (t, 
J = 6.5 Hz, 6H). 13C NMR (CDCl3, 100 MHz) δ 138.27, 138.26, 138.1, 128.55, 128.54, 
128.52, 128.51, 128.39, 128.38, 127.99, 127.98, 127.92, 127.89, 127.88, 127.87, 127.86, 
127.85, 127.7, 89.4, 83.1, 83.06, 83.05, 72.4, 71.91, 71.88, 65.3, 63.4, 63.0, 52.80, 52.79, 
44.8, 32.93, 32.92, 32.0, 29.69, 29.67, 29.56, 29.55, 29.38, 29.37, 27.6, 27.5, 25.9, 22.8, 
14.2; ESI-HRMS: calc’d m/e for [M+H+] C45H67NO4:686.5143, found 686.5135. [α]25  D  
+62 (c 0.81, MeOH). 
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((1R,2R,3S,4S,5R)-2-((6-(Adamantan-1-ylmethoxy)hexyl)amino)-3,4,5-
tris(benzyloxy)cyclopentyl)methanol (4.23) 
 
To a solution of the free amine (200 mg, 0.463 mmol, 1 equiv) in MeOH (15 mL) was 
added aldehyde 4.20 (130 mg, 0.522 mmol, 1.12 equiv). After 10 min, sodium 
triacetoxyborohydride (294 mg, 1.39 mmol, 3 equiv) was added to the mixture, and the 
reaction was stirred at room temperature for 15 h. After the consumption of the starting 
material, monitored by TLC, the reaction was quenched with a saturated sodium 
bicarbonate solution and extracted with CH2Cl2 (2 x 50 mL). The organic layers were 
combined, dried over MgSO4, and concentrated in vacuo. The crude product was purified 
by flash column chromatography on silica gel, using 5% MeOH/CH2Cl2 + 1% NH4OH as 
the eluent. Product was isolated as a colorless oil (119 mg, 33%). %). 1H NMR (CDCl3, 
400 MHz): δ 7.38 – 7.27 (m, 15H), 4.69 (d, J1 = 12 Hz, 1H), 4.63 – 4.50 (m, 5H), 3.97 (t, 
J1 = 4.5 Hz, 1H), 3.85 – 3.94 (m, 4H), 3.34 (t, J1 = 6.5 Hz, 2H), 3.24 (t, J1 = 7.0 Hz, 1H), 
2.94 (s, 2H), 2.59 (t, J1 = 6.9 Hz, 2H), 2.36 (dd, J1 = 5.9 Hz, J2 = 12 Hz, 1H), 1.95 (bs, 3H), 
1.74 – 1.61 (m, 7H), 1.60 – 1.25 (m, 14H). 13C NMR (CDCl3, 100 MHz) δ 137.5, 128.6, 
128.6, 127.8, 127.4, 86.5, 82.8, 81.8, 78.5, 73.3, 73, 71.3, 57.5, 48.3, 46.4, 40, 36.8, 34, 
31.6, 30.8, 30.2, 28.4, 27, 25.6; ESI-HRMS: calc’d m/e for [M+H+] C44H59NO5: 681.4393, 
found 681.4400. 
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(1R,2S,3S,4R,5R)-4-(Dibutylamino)-5-(hydroxymethyl)cyclopentane-1,2,3-triol 
(4.24). 
 
A mixture of the tri-benzyl precursor (119 mg, 0.22 mmol, 1 equiv), ammonium formate 
(138 mg, 1.94 mmol, 10 equiv) and 10% palladium on carbon (0.3 g per mmol of O-benzyl 
group) was refluxed in MeOH in a sealed reaction vessel for 5 h. Thereafter, the catalyst 
was filtered off by passing the reaction mixture through a Celite pad. The solvent was 
subsequently removed under vacuum. The neutral residue was purified by flash column 
chromatography on silica gel, using 10% MeOH/ CH2Cl2 + 1% NH4OH (v/v) as the eluent. 
Compound was obtained as a colorless oil (39.5 mg, 51%). 1H NMR (CDCl3, 400 MHz): 
δ 5.05 (br, 4H), 4.01 (m, 1H), 3.85 (m, 1H), 3.69 (m, 3H), 3.32 (t, J = 9.25 Hz, 1H), 2.61 
(m, 4H), 2.26 (b, 1H), 1.48 (m, 4H), 1.29 (m, 4H), 0.92 (t, J = 7.15 Hz, 6H); 13C NMR 
(CDCl3, 100 MHz): δ 81.5, 75.5, 75.4, 64.4, 62.4, 52.8, 45.2, 29.7, 20.6, 14.1; ESI-HRMS: 
calc’d m/e for [M+H+] C14H30NO4: 276.2169, found 276.2180. [α]25  D  +18 (c 0.36, MeOH). 
 
(1R,2S,3S,4R,5R)-4-((5-((Adamantan-1-yl)methoxy)pentyl)amino)-5-
(hydroxymethyl)cyclopentane-1,2,3-triol (4.25). 
 
A mixture of the tri-benzyl precursor (129.7 mg, 0.194 mmol, 1 equiv), ammonium formate 
(122 mg, 1.94 mmol, 10 equiv) and 10% palladium on carbon (0.3 g per mmol of O-benzyl 
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group) was refluxed in MeOH in a sealed reaction vessel for 5 h. Thereafter, the catalyst 
was filtered off by passing the reaction mixture through a Celite pad. The solvent was 
subsequently removed under vacuum. The neutral residue was purified by flash column 
chromatography on silica gel, using 10% MeOH/ CH2Cl2 + 1% NH4OH (v/v) as the eluent. 
Compound was obtained as a colorless oil (39.5 mg, 51%).  1H NMR (CDCl3, 400 MHz): 
δ 3.97 (t, J = 7.3 Hz, 1H), 3.88 (d, J = 10.9 Hz, 1H), 3.73 (q, J = 8.2 Hz, 2H), 3.65 (t, J = 
8.1 Hz, 1H), 3.37 (t, J = 6.5 Hz, 2H), 3.11 (t, J = 8.7 Hz, 1H), 2.95 (s, 2H), 2.66 (m, 2H), 
2.05 (m, 1H), 1.96 (m, 3H), 1.68 (app. q, 6H), 1.54 (m, 10H), 1.36 (m, 2H); 13C NMR 
(CDCl3, 100 MHz): δ 82.0, 81.0, 75.1, 71.5, 61.9, 49.8, 45.0, 39.8, 37.3, 34.1, 30.0, 29.5, 
28.3, 23.9.; ESI-HRMS: calc’d m/e for [M+H+] C22H40NO5: 398.2901, found 
398.2912;[𝑎𝑎] 25
𝐷𝐷
 +11 (c 0.46, MeOH). 
 
(1R,2S,3S,4R,5R)-4-(Dinonylamino)-5-(hydroxymethyl)cyclopentane-1,2,3-triol 
(4.26)  
 
A fask, fitted with a dry ice condenser, was charged with anhydrous liquid ammonia (8.0 
mL) and then an amount of lithium was added piecewise so as to cause to persist the blue 
color within the flask. A solutin of tri-benzyl compound (0.157 g, 0.229 mmol, 1 equiv) 
was dissolved in THF and added dropwise into the flask over 5 min. After an additional 10 
min, ammonium chloride was added to the solution until the blue color faded. The dry ice 
condenser was removed and the ammonia was allowed to evaporate. The residue was 
extracted with EtOAc (2 X 20 mL). The organic layers were combined, dried over Mg2SO4 
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and concentrated en vacuo. The crude product was purified by flash column 
chromatography on silica gel with 10% MeOH/DCM + 1% NH4OH (v/v) as the eluent. 
After chromatographic purification, a colorless, viscous oil was obtained (88 mg, 92%). 1H 
NMR (CDCl3, 400 MHz): δ 4.90 (b, 2H), 3.98 (t, J = 7.8 Hz, 1H), 3.85 (dd, J1 = 4.8 Hz, J2 
= 11.7 Hz, 1H), 3.7 (p, J = 8.1 Hz, 2H), 3.64 (dd, J1 = 6.3 Hz, J2 = 12 Hz 1H), 3.28 (t, J = 
10 Hz, 1H), 2.56 (t, J = 7.6 Hz, 4H), 2.22 (m, 1H), 1.48 (m, 4H), 1.27 (m, 26H), 0.88 (t, J 
= 6.3 Hz, 6H); 13C NMR (CDCl3, 100 MHz): δ 81.5, 75.7, 75.5, 64.3, 62.5, 53.0, 45.4, 
31.9, 29.7, 29.4, 27.6, 22.7, 14.1; ESI-HRMS: calc’d m/e for [M+H+] C24H50NO4: 
416.3734, found 416.3783. [α]25  D  +23 (c 1.00, MeOH).  
 
(1R,2S,3S,4R,5R)-4-Amino-5-(hydroxymethyl)cyclopentane-1,2,3-triol (4.27).  
 
A mixture of the tribenzyl precursor (0.155 g, 0.358 mmol, 1 equiv), ammonium formate 
(225 mg, 3.58 mmol, 10 equiv) and 10% palladium on carbon (0.3 g per mmol of O-benzyl 
group, 430 mg) was refluxed in MeOH in a sealed reaction vessel for 3 h. Thereafter, the 
catalyst was filtered off by passing the reaction mixture through a Celite pad. The solvent 
was subsequently removed under vacuum, yielding the product as a tan solid. This solid 
was taken up in MeOH and shaken with MP-TMT resin (Biotage, cat#801469, 0.3 g per 
mmol of Pd used in reaction) for 24 hr. After this, the contents of the vial were filtered 
through a celite pad and the solvent was removed under vacuum to afford an off-white 
solid of suitable purity to carry on to the final step (50.6 mg, 0.31 mmol, 87%). 1H NMR 
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(CD3OD, 400 MHz) 3.83 – 3.77 (ddd, J1 = 3.9 Hz, J2 = 11 Hz, 2H), 3.76 – 3.71 (m, 2H), 
3.62 (t, J = 7.8 Hz, 1H), 3.43 (t, J = 9.2 Hz, 1H), 2.18 – 2.11 (m, 1H); 13C NMR (CD3OD, 
100 MHz) δ 81.8, 79.2, 75.8, 59.9, 56.3, 45.9; ESI-HRMS: calc’d m/e for [M+] C6H13NO4: 
163.0845, found 163.0865; [𝑎𝑎] 25
𝐷𝐷
 +8 (c 0.61, MeOH). 
 
(2S,3R,4S,5R)-2,3,4,6-tetrakis(Benzyloxy)hexane-1,5-diol (4.29). 
 
To a 0 °C solution of commercially available 2,3,4,6-tetra-O-benzyl-α-galactopyranose 
(5.25 g, 9.71 mmol, 1 equiv) in anhydrous THF (150 mL), LiAlH4 (1.25 g, 33 mmol, 3.43 
equiv) was added carefully in small portions.  The mixture was stirred overnight at room 
temperature and then cooled to 0 °C.  After the excess of LiAlH4 was destroyed by the 
careful addition of ethyl acetate (20 mL), additional ethyl acetate (500 mL) was added.  
Then 2 N aq HCl (250 mL) was added and the reaction mixture was stirred for 10 minutes. 
The organic layer was separated, washed successively with sat. aq. NaHCO3 (150 mL), 
dried with Na2SO4, and evaporated affording 4.22 g (80%) of 1.19 as a colorless viscous 
syrup.  
1H NMR (400 MHz, CDCl3): δ = 7.27 (m, 20H), 4.6 (m, 8H), 4.02 (m, 1H), 3.89 (dd, J = 
3.6, 6.2 Hz, 1H), 3.75 (m, 3H), 3.63 (d, J = 3.8 Hz, 2H), 3.55 (dd, J = 4.5, 11.9 Hz, 1H). 
13C NMR (100 MHz, CDCl3): δ = 138.27, 138.01, 128.59, 128.28, 128.14, 128.06, 127.98, 
127.09, 79.62, 79.22, 77.47, 74.66, 73.60, 73.41, 73.23, 71.27, 70.84, 61.95. [𝛼𝛼] 25
𝐷𝐷
 +14.7 
(c = 1.12, CHCl3). ESI-HRMS: calc’d m/z for [M+H+] C22H40NO5: 543.2741, found 
543.2771. 
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(2R,3S,4R,5S)-3,4,5-tris(Benzyloxy)-2-((benzyloxy)methyl)-1-butylpiperidine (4.30).  
 
To a -78 °C mixture of dry CH2Cl2 (12 mL) and anhydrous DMSO (3.65 g, 3.32 mL, 46.9 
mmol, 6 equiv) under an inert gas atmosphere was added dropwise a solution of oxalyl 
chloride (4.04 g, 2.73 mL, 31 mmol, 4 equiv) in CH2Cl2 (25 mL) over 15 min. After the 
mixture was stirred for 1.5 h at -78 °C, a solution of 1.19 (4.22 g, 7.78 mmol, 1 equiv) in 
CH2Cl2 (15 mL) was added dropwise while maintaining the temperature of the reaction 
mixture below -78 °C during the addition. The mixture was stirred for an additional 2 h at 
–78°C and then a solution of Et3N (6.29 g, 8.68 mL, 8 equiv) in CH2Cl2 (10 mL) was added 
slowly dropwise at -78 °C. After that, the mixture was allowed to warm to room 
temperature and the solvents were removed under reduced pressure at 40 °C. The residue 
containing the crude ketoaldehyde 2 was used in the next step without purification. 
The ketoaldehyde was dissolved in anhydrous methanol (150 mL) and then 
powdered 4 Å molecular sieves (0.3g per mmol limiting reagent) were added.  A solution 
of n-butylamine (1.71 g, 2.31 mL, 23.3 mmol, 3 equiv) in anhydrous methanol (25 mL) 
was added, followed by sodium cyanoborohydride (1.46 g, 23.34 mmol, 3 equiv). The pH 
should be maintained below 7 during this reaction. If needed, acetic acid is added to the 
mix. After the mixture was stirred at 50 °C overnight, the mixture was made alkaline via 
addition of 1.0 M NaOH. The mixture was filtered through Celite and the filtrate was 
diluted with water (50 mL), extracted twice with CH2Cl2 (100 mL) and dried over Na2SO4.  
Silica gel column chromatography, employing hexanes/ethyl acetate (80:20) furnished 
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1.21 as a pale yellow solid (696 mg, 15% over two steps). 1H NMR (400 MHz, CDCl3) δ 
= 7.3 (m, 20H), 4.95 (d, J = 11.1 Hz, 1H), 4.87 (d, J = 10.9 Hz, 1H), 4.80 (d, J = 11.1 Hz, 
1H), 4.68 (d, J = 11.6 Hz, 1H), 4.64 (d, J = 11.6 Hz, 1H), 4.48 (d, J = 12.3 Hz, 1H), 4.45 
(d, J = 12.3 Hz, 1H), 4.42 (d, J = 10.9 Hz, 1H), 3.60 (m, 4H), 3.45 (t, J = 9.0 Hz, 1H), 3.10 
(dd, J = 4.8, 11.1 Hz, 1H), 2.60 (m, 2H), 2.30 (d, J = 9.5Hz, 1H), 2.25 (t, J = 10.8 Hz, 1H), 
1.35 (m, 2H), 1.19 (m, 2H), 0.86 (t, J = 7.2 Hz, 3H), 13C NMR (100 MHz, CDCl3): δ = 
138.24, 138.79, 138.00, 128.59, 128.53, 128.48, 128.02, 127.78, 127.67, 127.57, 87.57, 
78.81, 78.77, 75.46, 75.34, 73.64, 72.91, 63.95, 54.66, 52.29, 25.92, 20.84, 14.71. [𝛼𝛼] 25
𝐷𝐷
 -
14.0 (c = 1.23, CHCl3). ESI-HRMS: calc’d m/z for [M+H+] C38H45NO4: 580.3421, found 
580.3341. 
 
N-Butyl-1-deoxynojirimycin (4.31).  
 
To a solution containing 4.30 (696 mg, 1.2 mmol, 1 equiv) dissolved in methanol (50 mL) 
and H2O (15 mL) was added palladium chloride (851 mg, 4.8 mmol, 1.1 equiv per benzyl 
group).  The reaction was stirred under hydrogen gas until the uptake of hydrogen stopped. 
The reaction mixture was filtered through Celite and solvent was removed en vacuo. The 
crude product was purified using flash column chromatography (10% MeOH in DCM) to 
afford 248 mg (94%) of target compound. Mp = 129-130 °C Optical rotation [α]D25 -15 (c 
= 1.23, H2O). 1H NMR (D2O, 400 MHz): δ 3.91 (dd, J = 2.3, 12.8 Hz, 1H), 3.83 (dd, J = 
2.7, 12.8 Hz, 1H), 3.54 (ddd, J = 4.9, 10.2, 14.3 Hz, 1H), 3.38 (d,d, J = 9.4 Hz, 1H), 3.25 
 332 
(d,d, J = 9.3 Hz, 1H), 3.03 (dd, J = 5.0, 11.4 Hz, 1H), 2.74 (m, 1H), 2.60 (m, 1H), 2.30 (d, 
J = 11.1 Hz, 1H), 2.24 (dd, J = 2.7, 12.5 Hz, 1H), 1.46 (m, 2H), 1.28 (m, 2H), 0.90 (t, J = 
7.3 Hz, 3H). 13C NMR (100 MHz, D2O): δ 74.7, 70.0, 66.7, 62.6, 60.2, 55.5, 52.1, 24.8, 
20.0, 13.1; ESI-HRMS: calc’d m/z for [M+H+] C38H45NO4: 219.1471, found 220.1521. 
HRMS calc’d for C10H22NO4 (M+1)+; found 220.1521. 
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